

Antioxidants for preventing and reducing muscle soreness after exercise

RANCHORDAS, Mayur http://orcid.org/0000-0001-7995-9115, ROGERSON, David http://orcid.org/0000-0001-9611-6777 and COSTELLO, Joseph T

Available from Sheffield Hallam University Research Archive (SHURA) at:

https://shura.shu.ac.uk/17745/

This document is the Published Version [VoR]

Citation:

RANCHORDAS, Mayur, ROGERSON, David, SOLTANI, Hora and COSTELLO, Joseph T (2017). Antioxidants for preventing and reducing muscle soreness after exercise. Cochrane Database of Systematic Reviews, 2017 (12). [Article]

Copyright and re-use policy

See http://shura.shu.ac.uk/information.html



Antioxidants for preventing and reducing muscle soreness after exercise (Review)

Ranchordas MK, Rogerson D, Soltani H, Costello JT

Ranchordas MK, Rogerson D, Soltani H, Costello JT. Antioxidants for preventing and reducing muscle soreness after exercise. *Cochrane Database of Systematic Reviews* 2017, Issue 12. Art. No.: CD009789. DOI: 10.1002/14651858.CD009789.pub2.

www.cochranelibrary.com



TABLE OF CONTENTS

HEADER	1
ABSTRACT	1
PLAIN LANGUAGE SUMMARY	2
SUMMARY OF FINDINGS FOR THE MAIN COMPARISON	4
BACKGROUND	9
OBJECTIVES	9
METHODS	9
RESULTS	12
Figure 1	13
Figure 2	18
Figure 3	19
Figure 4	22
Figure 5	23
DISCUSSION	25
Figure 6	28
Figure 7	29
AUTHORS' CONCLUSIONS	31
ACKNOWLEDGEMENTS	31
REFERENCES	31
CHARACTERISTICS OF STUDIES	41
DATA AND ANALYSES	131
Analysis 1.1. Comparison 1 Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies),	
Outcome 1 Muscle soreness up to 6 hours; random-effects model	134
Analysis 1.2. Comparison 1 Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies),	
Outcome 2 Muscle soreness at 24 hours; random-effects model.	136
Analysis 1.3. Comparison 1 Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies),	
Outcome 3 Muscle soreness at 48 hours; random-effects model.	138
Analysis 1.4. Comparison 1 Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies),	
Outcome 4 Muscle soreness at 72 hours; random-effects model.	140
Analysis 1.5. Comparison 1 Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies),	
Outcome 5 Muscle soreness at 96 hours; random-effects model.	142
Analysis 1.6. Comparison 1 Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies),	
Outcome 6 Muscle soreness (follow-ups: 120, 144 and 168 hours); random-effects model.	143
Analysis 1.7. Comparison 1 Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies),	0
Outcome 7 Muscle soreness up to 6 hours - all at same scale (0 to 10; worst pain).	144
Analysis 1.8. Comparison 1 Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies),	
Outcome 8 Muscle soreness at 24 hours - all at same scale (0 to 10; worst pain).	145
Analysis 1.9. Comparison 1 Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies),	11)
Outcome 9 Muscle soreness at 48 hours - all at same scale (0 to 10; worst pain).	147
Analysis 1.10. Comparison 1 Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies),	14/
Outcome 10 Muscle soreness at 72 hours - all at same scale (0 to 10; worst pain).	150
Analysis 1.11. Comparison 1 Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies),	1)0
Outcome 11 Muscle soreness at 96 hours - all at same scale (0 to 10; worst pain).	150
	152
Analysis 1.12. Comparison 1 Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies),	
Outcome 12 Muscle soreness at 24 hours. Subgroup analysis by type of exercise (whole body aerobic vs. mechanically	150
induced)	153
Analysis 1.13. Comparison 1 Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies),	
Outcome 13 Muscle soreness at 48 hours. Subgroup analysis by type of exercise (whole body aerobic vs. mechanically	155
induced)	155
Antioxidants for preventing and reducing muscle soreness after exercise (Review)	i

Analysis 1.14. Comparison 1 Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies),	
Outcome 14 Muscle soreness at 24 hours. Subgroup analysis by funding sources (funded by food company or provider	
of antioxidant supplements vs. not funded by food company or provider of antioxidant supplements).	158
Analysis 1.15. Comparison 1 Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies),	
Outcome 15 Muscle soreness at 48 hours. Subgroup analysis by funding sources (funded by food company or provider	
of antioxidant supplements vs. not funded by food company or provider of antioxidant supplements).	160
Analysis 1.16. Comparison 1 Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies),	
Outcome 16 Muscle tenderness measured in Newtons (all follow-up times).	163
Analysis 1.17. Comparison 1 Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies),	
Outcome 17 Muscle tenderness measured in kg (all follow-up times).	164
Analysis 1.18. Comparison 1 Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies),	
Outcome 18 30-second Wingate average peak power output (W/kg) (post 7 days of intervention).	165
Analysis 1.19. Comparison 1 Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies),	
Outcome 19 20 m Sprint time (s)	165
Analysis 1.20. Comparison 1 Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies),	
Outcome 20 Maximal oxygen consumption (mL/kg/min) (post 42 days of supplementation).	166
Analysis 1.21. Comparison 1 Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies),	
Outcome 21 Agility (seconds).	166
Analysis 1.22. Comparison 1 Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies),	
Outcome 22 6 second sprint maximal power (Watts) (all follow-up times).	167
Analysis 1.23. Comparison 1 Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies),	
Outcome 23 Maximal voluntary isometric contraction measured as percentage change from baseline	168
Analysis 1.24. Comparison 1 Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies),	
Outcome 24 Maximal voluntary isometric contraction measured in Newton metres.	172
Analysis 1.25. Comparison 1 Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies),	
Outcome 25 Maximal voluntary isometric contraction measured in Newtons	174
Analysis 1.26. Comparison 1 Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies),	
Outcome 26 Maximal voluntary isometric contraction measured in Newton metres per kg of body mass	176
Analysis 1.27. Comparison 1 Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies),	
Outcome 27 Maximal voluntary isometric contraction measured in kg	177
Analysis 1.28. Comparison 1 Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies),	
Outcome 28 Range of motion (all follow-up times).	178
ADDITIONAL TABLES	182
APPENDICES	194
CONTRIBUTIONS OF AUTHORS	198
DECLARATIONS OF INTEREST	198
SOURCES OF SUPPORT	198
DIFFERENCES BETWEEN PROTOCOL AND REVIEW	199

[Intervention Review]

Antioxidants for preventing and reducing muscle soreness after exercise

Mayur K Ranchordas¹, David Rogerson¹, Hora Soltani², Joseph T Costello³

¹Department of Sport, Sheffield Hallam University, Sheffield, UK. ²Centre for Health and Social Care Research, Sheffield Hallam University, Sheffield, UK. ³Department of Sport and Exercise Science, University of Portsmouth, Portsmouth, UK

Contact address: Mayur K Ranchordas, Department of Sport, Sheffield Hallam University, Collegiate Crescent Campus, A221 Collegiate Hall, Ecclesall Road, Sheffield, South Yorkshire, S10 2BP, UK. m.ranchordas@shu.ac.uk, m.ranchordas@gmail.com.

Editorial group: Cochrane Bone, Joint and Muscle Trauma Group. **Publication status and date:** New, published in Issue 12, 2017.

Citation: Ranchordas MK, Rogerson D, Soltani H, Costello JT. Antioxidants for preventing and reducing muscle soreness after exercise. *Cochrane Database of Systematic Reviews* 2017, Issue 12. Art. No.: CD009789. DOI: 10.1002/14651858.CD009789.pub2.

Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

ABSTRACT

Background

Muscle soreness typically occurs after intense exercise, unaccustomed exercise or actions that involve eccentric contractions where the muscle lengthens while under tension. It peaks between 24 and 72 hours after the initial bout of exercise. Many people take antioxidant supplements or antioxidant-enriched foods before and after exercise in the belief that these will prevent or reduce muscle soreness after exercise.

Objectives

To assess the effects (benefits and harms) of antioxidant supplements and antioxidant-enriched foods for preventing and reducing the severity and duration of delayed onset muscle soreness following exercise.

Search methods

We searched the Cochrane Bone, Joint and Muscle Trauma Group Specialised Register, the Cochrane Central Register of Controlled Trials, MEDLINE, Embase, SPORTDiscus, trial registers, reference lists of articles and conference proceedings up to February 2017.

Selection criteria

We included randomised and quasi-randomised controlled trials investigating the effects of all forms of antioxidant supplementation including specific antioxidant supplements (e.g. tablets, powders, concentrates) and antioxidant-enriched foods or diets on preventing or reducing delayed onset muscle soreness (DOMS). We excluded studies where antioxidant supplementation was combined with another supplement.

Data collection and analysis

Two review authors independently screened search results, assessed risk of bias and extracted data from included trials using a prepiloted form. Where appropriate, we pooled results of comparable trials, generally using the random-effects model. The outcomes selected for presentation in the 'Summary of findings' table were muscle soreness, collected at times up to 6 hours, 24, 48, 72 and 96 hours post-exercise, subjective recovery and adverse effects. We assessed the quality of the evidence using GRADE.

Main results

Fifty randomised, placebo-controlled trials were included, 12 of which used a cross-over design. Of the 1089 participants, 961 (88.2%) were male and 128 (11.8%) were female. The age range for participants was between 16 and 55 years and training status varied from sedentary to moderately trained. The trials were heterogeneous, including the timing (pre-exercise or post-exercise), frequency, dose, duration and type of antioxidant supplementation, and the type of preceding exercise. All studies used an antioxidant dosage higher than the recommended daily amount. The majority of trials (47) had design features that carried a high risk of bias due to selective reporting and poorly described allocation concealment, potentially limiting the reliability of their findings.

We tested only one comparison: antioxidant supplements versus control (placebo). No studies compared high-dose versus low-dose, where the low-dose supplementation was within normal or recommended levels for the antioxidant involved.

Pooled results for muscle soreness indicated a small difference in favour of antioxidant supplementation after DOMS-inducing exercise at all main follow-ups: up to 6 hours (standardised mean difference (SMD) -0.30, 95% confidence interval (CI) -0.56 to -0.04; 525 participants, 21 studies; low-quality evidence); at 24 hours (SMD -0.13, 95% CI -0.27 to 0.00; 936 participants, 41 studies; moderate-quality evidence); at 48 hours (SMD -0.24, 95% CI -0.42 to -0.07; 1047 participants, 45 studies; low-quality evidence); at 72 hours (SMD -0.19, 95% CI -0.38 to -0.00; 657 participants, 28 studies; moderate-quality evidence), and little difference at 96 hours (SMD -0.05, 95% CI -0.29 to 0.19; 436 participants, 17 studies; low-quality evidence). When we rescaled to a 0 to 10 cm scale in order to quantify the actual difference between groups, we found that the 95% CIs for all five follow-up times were all well below the minimal important difference of 1.4 cm: up to 6 hours (MD -0.52, 95% CI -0.95 to -0.08); at 24 hours (MD -0.17, 95% CI -0.42 to 0.07); at 72 hours (MD -0.29, 95% CI -0.59 to 0.02); and at 96 hours (MD -0.03, 95% CI -0.43 to 0.37). Thus, the effect sizes suggesting less muscle soreness with antioxidant supplementation were very unlikely to equate to meaningful or important differences in practice. Neither of our subgroup analyses to examine for differences in effect according to type of DOMS-inducing exercise (mechanical versus whole body aerobic) or according to funding source confirmed subgroup differences. Sensitivity analyses excluding cross-over trials showed that their inclusion had no important impact on results.

None of the 50 included trials measured subjective recovery (return to previous activities without signs or symptoms).

There is very little evidence regarding the potential adverse effects of taking antioxidant supplements as this outcome was reported in only nine trials (216 participants). From the studies that did report adverse effects, two of the nine trials found adverse effects. All six participants in the antioxidant group of one trial had diarrhoea and four of these also had mild indigestion; these are well-known side effects of the particular antioxidant used in this trial. One of 26 participants in a second trial had mild gastrointestinal distress.

Authors' conclusions

There is moderate to low-quality evidence that high dose antioxidant supplementation does not result in a clinically relevant reduction of muscle soreness after exercise at up to 6 hours or at 24, 48, 72 and 96 hours after exercise. There is no evidence available on subjective recovery and only limited evidence on the adverse effects of taking antioxidant supplements. The findings of, and messages from, this review provide an opportunity for researchers and other stakeholders to come together and consider what are the priorities, and underlying justifications, for future research in this area.

PLAIN LANGUAGE SUMMARY

Antioxidants for preventing and reducing muscle soreness after exercise

Background and aim of the review

Muscle soreness typically occurs after intense or unaccustomed exercise. It peaks between 24 and 72 hours after the initial bout of exercise. Many people take antioxidant supplements such as vitamin C and/or E or antioxidant-enriched foods such as tart cherry or pomegranate juice before and after exercise in the belief that these will prevent or reduce muscle soreness after exercise.

Results of the search

We searched medical databases up to February 2017 for studies that compared antioxidant supplementation with a control intervention such as a placebo (a dummy pill or drink that had no antioxidant) or no treatment. We found 50 studies, all of which compared antioxidant supplementation with a placebo. These reported results for a total of 1089 participants. Of these, nearly 9 out of 10 were male. The age range for participants was between 16 and 55 years and their training status varied from sedentary to moderately trained.

The studies were very varied such as in the type and dosage of the antioxidant supplement and the type of exercises used to cause muscle soreness. All studies used an antioxidant dosage higher than the recommended daily amount.

Key results

There is evidence that high dose antioxidant supplementation may slightly reduce muscle soreness at up to 6 hours and at 24, 48 and 72 hours follow-up but not at 96 hours. However, these reductions were so small that they were unlikely to make any difference. None of the trials reported on outcomes related to subjective recovery, such as return to previous activities without signs or symptoms.

Only nine studies reported on adverse effects and only two found adverse effects. All six participants in the antioxidant group of one trial had diarrhoea and four of these also had mild indigestion; these are well-known side effects of the particular antioxidant used in this study. One of 26 participants in a second trial had mild gastrointestinal distress.

Quality of the evidence

We considered the evidence for muscle soreness to be 'moderate' or 'low' quality. This was mainly because the majority of studies had aspects that could have affected the reliability of their results and in some cases because of variation in the results of the studies. This means there is some uncertainty about the findings and further research may provide evidence that could change our conclusions.

Authors' conclusions

Antioxidant supplementation does not appear to reduce muscle soreness early on or at one, two, three or four days after exercise.

SUMMARY OF FINDINGS FOR THE MAIN COMPARISON [Explanation]

Antioxidants compared with placebo or no treatment for preventing and reducing muscle soreness after exercise

Patient or population: mainly physically active individuals¹ partaking in exercise² designed to produce delayed onset muscle soreness Settings: controlled laboratory studies and field-based studies

Intervention: antioxidant supplements³. These fell into 3 main categories: whole natural food source (e.g. bilberry juice, cherry, pomegranate juice); antioxidant extract or mixed antioxidants (e.g. black tea extract, curcumin); and vitamin C or E or both combined

Comparison: all were placebo controls

Outcomes	Illustrative comparative	erisks (95% CI)	Relative effect (95% Cl)	No of participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Control (placebo or no antioxidants)	Antioxidant supple- mentation				
	cle soreness in the con- trol group ranged from	The mean level of mus- cle soreness after an- tioxidant supplementa- tion was 0.30 standard deviations lower (0.56 to 0.04 lower)		525 (21 studies ⁴)	⊕⊕⊖⊖ low⁵	One 'rule of thumb' is that 0.2 represents a small difference, 0.5 a moderate difference and 0.8 a large differ- ence Based on this 'rule of thumb', this result equates to a small to moderate difference in favour of antioxidant supplementation However, when we rescaled the data to a 0 to 10 cm scale, the MD was lower by 0.52 cm (0.95 to 0.08 cm lower) . These are all under the typical MID for pain (taken here as 1.4 cm)

ھ

Muscle soreness Follow-up: 24 hours	cle soreness in the con- trol group ranged from	The mean level of mus- cle soreness after an- tioxidant supplementa- tion was 0.13 standard deviations lower (0.27 to 0.00 lower)	•	936 (41 studies ⁴)	⊕⊕⊕ moderate ⁶	Based on the above 'rule of thumb', this re- sult equates to a small difference in favour of antioxidant supplemen- tation However, when we rescaled the data to a 0 to 10 cm scale, the MD was lower by 0.17 cm (0.42 lower to 0.07 higher). These are all under the typical MID for pain (taken here as 1.4 cm)
Muscle soreness Follow-up: 48 hours	cle soreness in the con- trol group ranged from	The mean level of mus- cle soreness after an- tioxidant supplementa- tion was 0.24 standard deviations lower (0.42 to 0.07 lower)	• •	1047 (45 studies ⁷)	⊕⊕⊖⊖ low ⁸	Based on the above 'rule of thumb', this re- sult equates to a small difference in favour of antioxidant supplemen- tation However, when we rescaled the data to a 0 to 10 cm scale, the MD was lower by 0.41 cm (0.69 to 0.12 lower) . These are all under the typical MID for pain (taken here as 1.4 cm)
Muscle soreness Follow-up: 72 hours	cle soreness in the con- trol group ranged from	The mean level of mus- cle soreness after an- tioxidant supplementa- tion was 0.19 standard deviations lower (0.38 to 0.00 lower)		657 (28 studies ⁴)	⊕⊕⊕⊖ moderate ⁶	Based on the above 'rule of thumb', this re- sult equates to a small difference in favour of antioxidant supplemen- tation

						When we rescaled th data to a 0 to 10 cr scale, the MD was lowe by 0.29 cm (0.59 lowe to 0.02 higher). Thes are all under the typica MID for pain (taken her as 1.4 cm)
Muscle soreness Follow-up: 96 hours	cle soreness in the con- trol group ranged from	The mean level of mus- cle soreness after an- tioxidant supplementa- tion was 0.05 standard deviations lower (0.29 lower to 0.19 higher)		436 (17 studies ⁴)	⊕⊕⊖⊖ low ⁸	Based on the above 'rule of thumb', this re- sult equates to a smat difference in favour of antioxidant supplement tation but also include a small effect in favour of placebo or no antiox idants However, when we rescaled the data to 0 to 10 cm scale, the MD was lower by 0.00 cm (0.43 lower to 0.33 higher). These are a under the typical MI for pain (taken here a 1.4 cm)
Subjective recovery	See comment	See comment	-	See comment		None of the 50 stud ies included in this re view measured subjed tive recovery (return t previous activities with out signs or symptoms

Adverse events	See comment	See comment		See comment 9 studies (216 participants)	⊕ooo very low ⁹	Adverse effects were considered in only 9 studies and actual events reported in 2 studies. One study re- ported that all 6 par- ticipants in the an- tioxidant supplementa- tion group ¹⁰ had diar- rhoea (5 mild, 1 se- vere); 4 participants also reported mild in- digestion. One placebo group participant also had mild indigestion. The second study re- ported mild gastroin- testinal distress in 1 of 26 participants taking the antioxidant supple- ment
GRADE Working Group High quality: Further r research Moderate quality: Furt	grades of evidence esearch is very unlikel ther research is likely t	y to change our confidence	e in the estimate of e et on our confidence i		nat the true effect lies	s close to what was found in the ate. Thus, the true effect is likely

Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Thus, the true effect may be substantially different from what was found

Very low quality: We are very uncertain about the estimate.

¹Although some participants were sedentary, the majority of participants were recreationally active or moderately trained athletes. No data were included from highly trained elite athletes. Most trial participants were male.

²Muscle damage was induced either mechanically (e.g. resistance-based exercise) or through whole body aerobic exercise

(e.g. running, cycling, bench stepping).

7

³Typically, supplementation was taken before, the day of and after exercise for up to several days. The supplements were all taken orally, either as capsules, powders or drinks. All studies used an antioxidant dosage higher than the recommended daily amount.

⁴In this analysis, one study tested two antioxidants compared with placebo control.

⁵We downgraded the quality of evidence one level for serious study limitations (high/unclear risk of bias) and one level for serious inconsistency.

⁶We downgraded the quality of evidence one level for serious study limitations (high/unclear risk of bias).

⁷In this analysis, two studies tested two antioxidants compared with placebo control.

⁸We downgraded the quality of evidence one level for serious study limitations (high/unclear risk of bias) and one level for serious inconsistency.

⁹We downgraded the quality of evidence three levels for very serious study limitations, in particular reflecting bias relating failure to record or report on adverse events by the majority of trials.

¹⁰Notably the antioxidant used was NAC (N-acetylcysteine), which is a prescription medicine with antioxidant properties. Listed side effects of NAC include nausea, vomiting and diarrhoea or constipation.

œ

BACKGROUND

Description of the condition

Muscle soreness after exercise is commonly referred to as delayed onset muscle soreness (DOMS) (Cheung 2003). DOMS is common in individuals who engage in strenuous and unaccustomed exercise and physical activity. It is classified as a grade 1 muscle strain injury and is characterised by localised tenderness and soreness (Cheung 2003). DOMS typically peaks between 24 to 72 hours after a bout of exercise but eventually disappears after five to seven days (Armstrong 1984; Bieuzen 2013; Bleakley 2012; Byrnes 1986; Cleak 1992; Costello 2015).

DOMS is particularly associated with exercise involving eccentric muscle action, such as in downhill running. An eccentric action is where a muscle generates tension to control the rate it lengthens (Close 2005), and it can cause significant muscle damage. DOMS could be detrimental for athletes who are returning to training from a prolonged period of inactivity. In addition, DOMS could deter individuals from adhering to an exercise programme. For some individuals, DOMS could result from excessive physical activity associated with daily living, particularly if repeated eccentric movements or unaccustomed physical activity are involved.

Several theories have been proposed to explain the mechanisms underlying DOMS. These include lactate accumulation (Asmussen 1953), inflammation (Smith 1991), muscle spasm (De Vries 1966), muscle damage (Hough 1900), connective tissue damage (Weinstock 1997), and increased muscle temperature (Davies 1972). A common feature of several of these proposed mechanisms is an increased production of free radicals (Maughan 1989), and reactive oxygen species. Indeed, it has been shown that reactive oxygen species are produced in nearly every biological process and that they also play a crucial role as signalling molecules for translating the exercise signals to appropriate adaptations (Margaritelis 2016).

Description of the intervention

Taking dietary antioxidants in the form of supplements (e.g. tablets, capsules, powders) or antioxidant-enriched foods (e.g. food concentrates) in doses much higher than the recommended amounts (up to 10 times the recommended daily amounts) several days before and after exercise has been proposed as a way to prevent or reduce muscle soreness after exercise. Two sources of antioxidants exist: exogenous (i.e. from dietary sources) and endogenous (i.e. produced by the body) (Watson 2010). Exogenous antioxidants include vitamin C, vitamin E, polyphenols, glutathione, carotenoids and coenzyme Q_{10} . These are typically found in plant sources such as dark-coloured vegetables, citrus fruits, legumes, nuts, grains, seeds and oils. Endogenous antioxidants include plasma proteins, bilirubin, uric acid and the en-

zymes superoxide dismutase, glutathione peroxidase and catalase (Watson 2010).

How the intervention might work

It has been reported that although physical activity is beneficial to health, any type of exercise causes oxidative stress, partly due to increased oxygen consumption, and could deplete the body's antioxidant defences and increase the rate of free radical production (Powers 2008; Ramel 2004; Witt 1992). Moreover, unaccustomed, eccentric or exhaustive exercise may also induce inflammatory reactions that can contribute to increased reactive oxygen species production and reduced antioxidant defences (Tsai 2001), causing exercise-induced muscle damage and resulting in DOMS (Cheung 2003). Dietary antioxidants may counteract oxidative stress by reducing the concentration of free radicals and reactive oxygen species associated with exercise (Powers 2008). Reducing DOMS could be beneficial to athletes when returning to training from injury (i.e. after a period of inactivity), and it could help sedentary and older individuals recover from unaccustomed physical activity.

Why it is important to do this review

The ease of taking antioxidant supplements to prevent and reduce muscle soreness after exercise and enhance recovery makes this an attractive option for physically active individuals. Moreover, antioxidant supplements are available to buy from supermarkets and health food stores and some are marketed to enhance recovery. However, our initial look at the evidence based on a small sample of the trials testing antioxidants for reducing DOMS showed that the evidence to support these claims was mixed (Bryer 2006; Howatson 2010; Mastaloudis 2006). There is conflicting evidence, too, on the potential for adverse effects of taking antioxidant supplements including impairment of post-exercise adaptations both acutely (Gomez-Cabrera 2008; Ristow 2009) and chronically (Paulsen 2014). All these pointed to the need for a systematic review of all the available trials.

OBJECTIVES

To assess the effects (benefits and harms) of antioxidant supplements and antioxidant-enriched foods for preventing and reducing the severity and duration of delayed onset muscle soreness following exercise.

METHODS

Criteria for considering studies for this review

Types of studies

All randomised controlled trials and quasi-randomised controlled trials (a method of allocating participants to groups that is not truly random; e.g. allocation by date of birth, day of the week, medical record number) investigating the effects of dietary antioxidants on preventing or reducing delayed onset muscle soreness. Only studies that measured muscle soreness and/or muscle tenderness were included in this study.

Types of participants

People of any age and level of physical or sports activity, performing exercise (i.e. eccentric, high-intensity, unaccustomed exercise) that is likely to induce DOMS. We included studies that used any type of exercise protocol.

Types of interventions

All forms of antioxidant supplementation including specific antioxidant supplements (i.e. tablets, powders, concentrates) and antioxidant-enriched foods or diets. No restrictions were placed on timing (pre-exercise or post-exercise), frequency, dose or duration, or type of antioxidant supplementation. Interventions that used more than one antioxidant (e.g. a combination of vitamins C and E) were also included.

We set out two comparisons.

• Antioxidant supplementation versus placebo or no supplementation.

High-dose versus low-dose, where the low-dose

supplementation is within normal or recommended levels for the antioxidant involved.

Types of outcome measures

Trials that did not record muscle soreness (pain) were not included in the review.

Primary outcomes

1. Muscle soreness (pain) - typically measured by a visual analogue scale (i.e. subjective)

2. Subjective recovery (return to previous activities without signs or symptoms)

3. Adverse effects (e.g. intestinal discomfort, diarrhoea)

Secondary outcomes

1. Muscle tenderness - typically measured using a handheld algometer

2. Performance variables (e.g. vertical jump, speed, agility)

3. Muscle force production (objective measures of muscle strength or power)

4. Range of motion

Timing of outcome measurement

Where appropriate, we extracted outcome data for the following time periods: the day of exercise, and daily up to seven days postexercise.

Search methods for identification of studies

Electronic searches

We searched the Cochrane Bone, Joint and Muscle Trauma Group Specialised Register (6 February 2017), the Cochrane Central Register of Controlled Trials (CENTRAL) (2017, Issue 2), MED-LINE (including Epub Ahead of Print, In-Process & Other Non-Indexed Citations and Ovid MEDLINE Daily) (1946 to 3 February 2017), Embase (1980 to 2017 Week 5) and SPORTDiscus (1949 to 20 April 2017). We also searched ClinicalTrials.gov and the World Health Organization Clinical Trials Registry Platform for ongoing and recently completed studies (to 6 February 2017). In MEDLINE, we combined a subject-specific search with the sensitivity-maximising version of the Cochrane Highly Sensitive Search Strategy for identifying randomised trials (Lefebvre 2011). The search strategies for MEDLINE, CENTRAL, Embase and SPORTDiscus are shown in Appendix 1. We applied no language restrictions.

Searching other resources

We contacted experts in the field (identified by the lead authors in published studies) to find unpublished trials. We checked the bibliographies of included studies and relevant reviews for further references to relevant trials.

Data collection and analysis

Selection of studies

Two authors (MR and DR) independently screened the titles, abstracts and descriptors of the studies retrieved from the searches. Studies that appeared meet the inclusion criteria were selected and the above two authors independently reviewed the full-text articles. Any disagreements about study selection were resolved by consultation with the third and fourth author (HS and JC). If required, we contacted study authors for further information; this, however, did not include contacting authors to check whether DOMS had been measured where not stated in the trial reports.

Data extraction and management

Two authors (MR and DR) independently extracted data using a pre-piloted data extraction form. We resolved any discrepancies that could not be settled by discussion by consultation with the third and fourth authors (HS and JC). Where necessary, we contacted primary authors of selected studies for additional information and data.

Assessment of risk of bias in included studies

Two authors (MR and DR) independently assessed the risk of bias in the included studies using the guidelines and criteria outlined in the *Cochrane Handbook for Systematic Reviews of Interventionss* (Higgins 2011). We assessed the included studies for selection bias (random sequence generation and allocation concealment), performance bias (blinding of participants and personnel), detection bias (blinding of outcome assessment), attrition bias (incomplete outcome data), reporting bias (selective reporting) and any other sources of bias. We resolved any disagreement by discussion and, where necessary, consultation with the third author and forth author (HS and JC).

Measures of treatment effect

We calculated mean differences with 95% confidence intervals for continuous data. We calculated standardised mean differences and 95% confidence intervals when combining results from studies using different ways of measuring a continuous outcome. Where possible, we used follow-up scores in preference to change scores. Should dichotomous data have been available, we planned to calculate risk ratios with 95% confidence intervals.

Unit of analysis issues

The unit of randomisation in the included trials was the individual participant. Some trials reported the same outcomes at more than one time point (e.g. soreness measured immediately after exercise, one day post-exercise, two days post-exercise, three days post-exercise and so on). As planned, we extracted and presented data for the above listed time points up to seven days post-exercise. We consulted a statistician to discuss the appropriate use and processing of data from cross-over trials that were included in the review. For these, we extracted data at each time point and analysed the data as if a parallel design was employed (Deeks 2011). We judged that there was an adequate washout period in each of the trials.

Dealing with missing data

Where there were missing data for an included study, we contacted the primary study author via email. We ignored data missing at random and focused only on the available data. Where appropriate, we conducted intention-to-treat analyses in which all randomised participants are analysed in the groups to which they were originally assigned. While planned, there were insufficient data (often missing denominators) to conduct worst-case and bestcase scenario sensitivity analyses to examine the potential effects of dropouts and exclusions. We contacted authors for missing mean and standard deviations. Where data were not available in the manuscript and the authors did not respond we extracted data from graphs using Graphclick 2010.

Assessment of heterogeneity

We visually evaluated heterogeneity between comparable trials using forest plots, and the Chi² test and I² statistic, with the level of significance for the Chi² test being set at P = 0.1 (Deeks 2011). Thus, we considered a P value for Chi² of < 0.1 to indicate statistically significant heterogeneity between studies. We interpreted values of I² as follows: 0% to 40% might not be important; 30% to 60% may represent moderate heterogeneity; 50% to 90% may represent substantial heterogeneity; and 75% to 100% may represent considerable heterogeneity.

Assessment of reporting biases

In view of the difficulty of detecting and correcting for publication bias and other reporting biases, we aimed to minimise their potential impact by ensuring a comprehensive search for eligible studies and by being alert for duplication of data. Where there were 10 or more studies in an analysis, we planned to use a funnel plot to explore the possibility of small-study effects (a tendency for estimates of the intervention effect to be more beneficial in smaller studies). (We restricted these to DOMS at 24 and 48 hours given these were the time periods for which the majority of data were available.)

Data synthesis

If considered appropriate, we pooled the results of comparable groups of trials. Initially we used the fixed-effect model and 95% confidence intervals but then selected the random-effects model, again with 95% confidence intervals, because of the substantial clinical and statistically significant heterogeneity.

Subgroup analysis and investigation of heterogeneity

As described in Differences between protocol and review, we modified our list of planned subgroup analyses, which involved the removal of one (antioxidant supplement versus antioxidant-enriched food) and the merging of two subgroups relating to type of exercise (normal sporting activities versus laboratory-induced DOMS; exercise that requires high oxygen consumption (e.g. running, cycling) versus exercise that requires low oxygen consumption (e.g. eccentric exercise in one arm). We also added in a subgroup analysis relating to source of funding.

Our revised list of planned subgroup analyses is as follows.

• Treatment intervention

 Timing of administration (pre-exercise or postexercise)

• Type of exercise

• Mechanically induced damage (e.g. resistance exercise) versus whole body aerobic exercise (e.g. running)

• Funding source

 Trials funded by food company or provider of antioxidant supplements versus those not funded by food company or provider of antioxidant supplements

To test whether subgroups were statistically significantly different from one another, we used the test for subgroup differences available in the Review Manager 5 software (RevMan 2014).

Sensitivity analysis

Where sufficient data were available, we performed sensitivity analyses to investigate the effects of various aspects of trial and review methodology. We performed limited sensitivity analyses to explore the effects of inclusion of trials at high or unclear risk of selection bias, principally from lack of or unclear allocation concealment, the effects of including cross-over trials, and from the choice of model for data synthesis (fixed-effect compared with random-effects). We did not conduct our other planned sensitivity analyses to explore the effects of inclusion of trials at high risk of selection bias specifically because of lack of allocation concealment, or for which only abstracts were obtained, or the effects of missing data.

'Summary of findings' table

We prepared a 'Summary of findings' table for the main comparison (antioxidant supplementation versus a placebo intervention) (Schünemann 2011). We summarised the quality of evidence by applying the principles of the GRADE framework and following the recommendations and worksheets of the Cochrane Effective Practice and Organisation of Care Group for creating 'Summary of findings' tables (EPOC 2013). We assessed the quality of the evidence according to four levels (high, moderate, low and very low). We selected muscle soreness up to 6 hours after exercise, 24, 48, 72 and 96 hours; subjective recovery and adverse events for presentation in a 'Summary of findings' table.

RESULTS

Description of studies

Results of the search

The search was completed in February 2017. We screened a total of 1558 records from the following databases: Cochrane Bone, Joint and Muscle Trauma Group Specialised Register (25 records), CENTRAL (194), MEDLINE (302), Embase (476), SPORTDiscus (117), ClinicalTrials.gov (162) and the WHO International Clinical Trials Registry Platform (282). We also identified 12 potentially eligible studies from ongoing searches and through contacting experts in the field.

The search resulted in the identification of 128 potentially eligible studies, for which we obtained full reports. Upon study selection, we included 50 (*see* Included studies) and excluded 77 (*see* Excluded studies). One study is ongoing (NCT02281981). A flow diagram summarising the study selection process is presented in Figure 1.




Figure I. Study flow diagram

Included studies

We included 50 studies with a total of 1089 participants of which 48 studies with 1043 participants were included in the quantitative synthesis (meta-analysis) for muscle soreness. All the studies were reported in English in peer-reviewed journals, in articles published between 1992 to 2016. Details of the individual studies are provided in Characteristics of included studies.

We contacted the authors of 33 studies to request for raw data for delayed onset muscle soreness (DOMS), maximal voluntary isometric contraction (MVIC), range of motion (ROM) and performance measures. Nineteen authors responded to our request (Bell 2015; Bell 2016; Bloomer 2004; Bloomer 2005; Bloomer 2007; Close 2006; Cobley 2011; Drobnic 2014; He 2015; Howatson 2009; Kaminski 1992; Kerksick 2009; Laupheimer 2014; Nicol 2015; O'Fallon 2012; Tanabe 2015; Thompson 2004; Trombold 2010; Trombold 2011); and 14 did not (Arent 2010; Avery 2003; Beaton 2002a; Bryer 2006; Connolly 2006; Connolly 2006a; Goldfarb 2011; Herrlinger 2015; Krotkiewski 1994; McFarlin 2016; Michailidis 2013; Phillips 2003; Peschek 2014; Su 2008). With the exception of Herrlinger 2015, we successfully extracted data from graphs for the other 13 studies in the second category using GraphClick, Arizona (version 3.0.2, 2010).

The two studies not included in the quantitative analyses for DOMS were Herrlinger 2015 and McCormick 2016. This resulted in the loss of 37 participants for whom DOMS data were missing for Herrlinger 2015 and of nine participants for McCormick 2016. We only included the data for McCormick 2016 in the qualitative analysis because the exercise paradigm was completely different to all the other studies included in this review. The other studies used an exercise paradigm where mechanical or whole body aerobic exercise was used to cause muscle damage and then a range of outcomes such as muscle soreness, muscle function, range of motion and performance were measured at various time points up to several days after exercise. However, participants in McCormick 2016 had a fixed daily training regimen for five continuous days performance, with outcomes being measured at the start and then throughout the trial. Thus the severity of muscle damage caused by the daily training regimen was not controlled.

Design

All 50 studies were randomised controlled trials; no quasi-randomised controlled trials met the inclusion criteria. Thirty-eight trials (with a total of 901 participants) employed a parallel design. The other 12 trials (with a total of 188 participants) employed a cross-over design (Arent 2010; Connolly 2006a; Kaminski 1992; McCormick 2016; McLeay 2012; Michailidis 2013; Nicol 2015; Peschek 2014; Tanabe 2015; Thompson 2001; Trombold 2010; Trombold 2011). The time between intervention arms in the crossover trials was five days in Arent 2010; 14 days in Connolly 2006a, Nicol 2015, Thompson 2001, Trombold 2010 and Trombold 2011; 21 days in Kaminski 1992 and Peschek 2014; 28 days in Tanabe 2015; 30 days in McLeay 2012; 35 days in McCormick 2016 and 42 days in Michailidis 2013.

Three studies had three groups: Herrlinger 2015 compared lowdose phenolic blend (12 participants) versus high-dose phenolic blend (12 participants) versus placebo (13 participants); Kerksick 2009 compared epigallocatechin gallate supplementation (10 participants) versus N-acetyl cysteine supplementation (10 participants) versus placebo (10 participants); and Silva 2008 compared N-acetyl cysteine (nine participants) versus N-acetyl cysteine plus placebo (eight participants) versus placebo (eight participants).

Sample sizes

The 50 trials included a total of 1089 participants with 901 participants in the parallel-group trials (range 7 to 54) and 188 participants in the cross-over trials (range 8 to 24).

Setting

Twenty-four studies were conducted in the USA (Arent 2010; Avery 2003; Beaton 2002a; Bloomer 2004; Bloomer 2005; Bloomer 2007; Bryer 2006; Connolly 2006; Connolly 2006a; Goldfarb 2011; He 2015; Herrlinger 2015; Hutchinson 2016; Kaminski 1992; Kerksick 2009; Kuehl 2010; McBride 1997; McFarlin 2016; O'Connor 2013; O'Fallon 2012; Peschek 2014; Phillips 2003; Trombold 2010; Trombold 2011); 12 studies were carried out in the UK (Bailey 2011; Bell 2015; Bell 2016; Close 2006; Cobley 2011; Howatson 2009; Laupheimer 2014; Lynn 2015; Thompson 2001; Thompson 2001a; Thompson 2003; Thompson 2004); two studies were conducted in Australia (McCormick 2016; Nicol 2015); two studies in Brazil (Silva 2008; Silva 2010); two studies in China (Nie 2004; Su 2008); two studies in Greece (Michailidis 2013; Theodorou 2011); one study in Iran (Meamarbashi 2011); one study in Ireland (Shafat 2004); one study in Japan (Tanabe 2015); one study in New Zealand (McLeay 2012); one study in Poland (Krotkiewski 1994); and one study in Spain (Drobnic 2014).

Seven trials were designed to produce DOMS under field-based conditions (Bailey 2011; Cobley 2011; Howatson 2009; Kuehl 2010; Laupheimer 2014; Lynn 2015; McCormick 2016), and the other 43 studies were designed to produce DOMS under laboratory-based conditions.

Funding source

Details of the funding of individual studies are given in Characteristics of included studies. In all, 21 studies were industry funded either by a food company or a provider of antioxidant supplements (Arent 2010; Bailey 2011; Beaton 2002a; Bell 2015; Bell 2016; Bloomer 2005; Bloomer 2007; Connolly 2006a; Herrlinger 2015; Kerksick 2009; Kuehl 2010; McFarlin 2016; O'Connor 2013; Peschek 2014; Phillips 2003; Tanabe 2015; Thompson 2001; Thompson 2001a; Thompson 2003; Trombold 2010; Trombold 2011). Of the 28 other studies reporting on funding, 15 declared "none" in their report (Avery 2003; Bloomer 2004; Bryer 2006; Close 2006; Cobley 2011; Connolly 2006; Drobnic 2014; Hutchinson 2016; Kaminski 1992; Laupheimer 2014; McBride 1997; Nie 2004; Shafat 2004; Theodorou 2011; Thompson 2004); the other 13 referring to various sources of university and public body research funding sources (Goldfarb 2011; He 2015; Howatson 2009; Krotkiewski 1994; Lynn 2015; McCormick 2016; McLeay 2012; Meamarbashi 2011; Michailidis 2013; Nicol 2015; O'Fallon 2012; Silva 2008; Silva 2010). We were unsuccessful in obtaining information on funding from the only trial that did not report on this (Su 2008).

Participants

Of the 1089 participants, 961 (88.2%) were male and 128 (11.8%) were female. Two studies recruited females only (Bloomer 2004; McLeay 2012). The age range of participants was between 16 (Nie 2004) and 55 years (Laupheimer 2014). The majority of the studies recruited recreationally active or moderately trained participants with the exception of seven studies (Bryer 2006; Kerksick 2009; Meamarbashi 2011; O'Connor 2013; O'Fallon 2012; Phillips 2003; Tanabe 2015), which included a total of 193 sedentary participants. One study had a sample of 16 semi-professional soccer players (Bell 2016) and one study (Laupheimer 2014) had seven well-trained distance runners. Only McCormick 2016 had participants (nine in all) who were classed as highly-trained elite athletes.

Details of exercise

There was a range of different exercise models used to induce muscle damage. Twenty-eight studies used mechanically induced exercise (i.e. resistance-based exercise) and 22 studies used whole body aerobic exercise (i.e. running, cycling, bench stepping). The majority of the studies that used mechanically induced exercise employed some form of resistance training protocol using weights or an isokinetic dynamometer to induce delayed onset muscle damage and soreness with large variances on number of repetitions, sets and percentage of load used. One study used a circuit training session where participants rotated round a circuit of cycling and stepping exercises (Krotkiewski 1994). Two studies used a repeated maximal sprint protocol on a cycle ergometer (Arent 2010; Bell 2016), one study used a repeated bench stepping protocol (Meamarbashi 2011), and one study used a repeated squat jump protocol using a weighted jacket (Nie 2004). Sixteen studies used a running model: seven trials used a downhill running protocol on a treadmill (Close 2006; Drobnic 2014; He 2015; Herrlinger 2015 Peschek 2014; Su 2008; Thompson 2004); four trials used the 90 minute Loughborough Intermittent Shuttle Running Test (LIST) (Bailey 2011; Thompson 2001; Thompson 2001a; Thompson 2003); one study used the Yo-Yo IR 1 repeated sprint test (Cobley 2011), and three trials used a competitive running race to induce damage. Howatson 2009 and Laupheimer 2014 used the London marathon, one study used the ultra-endurance Hood Coast Relay, which is based in the United States (Kuehl 2010), and one study used a half marathon run (Lynn 2015).

The majority of the studies asked the participants to refrain from strenuous exercise, refrain from taking any form of anti-inflammatory medication or other supplements, and not use any other form of analgesic activity that would reduce or relieve soreness, such as an ice bath or massage, for the duration of the study. Participants were typically excluded if they took any form of supplementation regularly or had any type of chronic inflammatory condition.

Interventions

In all trials, an antioxidant supplement was compared with a placebo. A summary of the antioxidant supplement regimens tested in the individual trials is presented in Table 1.

In all, 13 trials used antioxidants from a whole natural food source (Bell 2015; Bell 2016; Connolly 2006a; Howatson 2009; Hutchinson 2016; Kuehl 2010; Lynn 2015; McCormick 2016; McLeay 2012; O'Connor 2013; Peschek 2014; Trombold 2010; Trombold 2011), 19 used an antioxidant extract or mixed antioxidants (Arent 2010; Bailey 2011; Bloomer 2005; Cobley 2011; Drobnic 2014; Goldfarb 2011; Herrlinger 2015; Kerksick 2009; Krotkiewski 1994; Laupheimer 2014; McFarlin 2016; Meamarbashi 2011; Michailidis 2013; Nicol 2015; O'Fallon 2012; Phillips 2003; Silva 2008; Su 2008; Tanabe 2015), and 18 provided either vitamin C or vitamin E or both together (Avery 2003; Beaton 2002a; Bloomer 2004; Bloomer 2007; Bryer 2006; Close 2006; Connolly 2006; He 2015; Kaminski 1992; McBride 1997; Nie 2004; Shafat 2004; Silva 2010; Theodorou 2011; Thompson 2001; Thompson 2001a; Thompson 2003; Thompson 2004). All studies used a placebo either as a powder, capsule or drink; however, three studies did not provide details of what the placebo comprised (Arent 2010; McBride 1997; Nie 2004).

No trials compared high-dose versus low-dose antioxidant supplements, where the low-dose supplementation is within normal or recommended levels for the antioxidant involved.

Antioxidants used

Whole foods tested were:

- Bilberry juice (n = 19) (Lynn 2015)
- Blackcurrant nectar (n = 16) (Hutchinson 2016)
- Blueberry smoothie (n =10) (McLeay 2012)
- Cherry (n = 127) (Bell 2015, n = 16; Bell 2016, n = 16;

Connolly 2006a, n = 16; Howatson 2009, n = 16; Kuehl 2010, n = 54; McCormick 2016, n = 9)

- Cocoa (n = 8) (Peschek 2014)
- Mixed grape drink (n = 40) (O'Connor 2013)
- Pomegranate juice (n = 33) (Trombold 2010, n = 16; Trombold 2011, n = 17)

Antioxidant extract or mixed or other antioxidants tested were:

- Allicin (n = 16) (Su 2008)
- Astaxanthin extract (n = 20) (Bloomer 2005)
- Black tea extract (n = 18) (Arent 2010)
- Curcumin (n = 79) (Drobnic 2014, n = 20; McFarlin 2016,
- n = 28; Nicol 2015, n = 17; Tanabe 2015, n = 14)
- Fruit and vegetable powder (Juice Plus) (N = 44) (Goldfarb 2011)
 - Green and black tea extract (n = 37) (Herrlinger 2015)
 - Mixed antioxidants (vitamin C, E, B6, B9, B12 and zinc)
- (n = 38) (Bailey 2011)
 - Mixed flavanoid antioxidants (N = 40) (Phillips 2003)
- N-acetylcysteine (NAC) with epigallocatechin gallate (EGCG) (n = 30) (Kerksick 2009)
- N-acetylcysteine (NAC) (n = 53) (Cobley 2011, n = 14; Michailidis 2013, n = 10; Silva 2008, n = 29)
 - Pollen extract (n = 50) (Krotkiewski 1994)
 - Purslane extract (n = 20) (Meamarbashi 2011)
 - Quercetin (n = 30) (O'Fallon 2012)
 - Resveratrol (n = 7) (Laupheimer 2014)

Vitamin C or E or both combined were:

Vitamin C (n = 158) (Bryer 2006, n = 18; Close 2006, n = 20; Connolly 2006, n = 24; Kaminski 1992, n = 25; Nie 2004, n = 16; Thompson 2001, n = 9; Thompson 2001a, n = 16; Thompson 2003, n = 16; Thompson 2004, n = 14)

- Vitamin C and E co-ingestion (n = 134) (Beaton 2002a, n
- = 18; Bloomer 2004, n = 18; Bloomer 2007, n = 36; He 2015, n
- = 22; Shafat 2004, n = 12; Theodorou 2011, n = 28)

• Vitamin E (n = 57) (Avery 2003, n =18; McBride 1997, n = 12; Silva 2010, n = 27)

There was a large variation across the studies regarding the duration of supplementation: the shortest period was under one day (Tanabe 2015; Thompson 2001) and the longest period was 91 days (Herrlinger 2015). Although the form of supplement was varied, including capsules, powders and drinks, every study used an antioxidant dosage higher than the recommended daily amount. Every study required the participant to ingest the supplement orally either once daily or up to three times per day.

Supplementation was taken before, the day of and after exercise for up to several days in all the studies except for three studies where supplements were post-exercise only (Michailidis 2013; Peschek 2014; Thompson 2003).

Outcomes

Primary outcomes

Muscle pain

All 50 trials included muscle soreness as an outcome measure, the recording of which was an inclusion criterion of this review. Details of the measurement of muscle soreness in the individual trials are presented in Table 2.

Thirty-three trials measured muscle soreness using a 0 to 10 cm (or 0 to 100 mm) visual analogue scale (VAS). Of the 17 other trials, seven measured soreness using a 1 to 10 cm scale (Bailey 2011; Bryer 2006; Goldfarb 2011; Kaminski 1992; Michailidis 2013; Thompson 2001; Thompson 2003); four trials used the 0 to 20 cm (or 0 to 200 mm) scale (Bell 2015; Bell 2016; Howatson 2009; Lynn 2015); two studies (He 2015; Meamarbashi 2011) used a 0- to 6-point scale, Herrlinger 2015 used a 0 to 7 Likert scale, Drobnic 2014 used a 0- to 4-point scale; Cobley 2011 used a 0 to 12 cm scale and Su 2008 used the Borg CR-10 scale (Borg 1998). The Borg CR-10 scale ranges from 0 (no soreness) to 10 (maximal soreness). In the included studies, participants were asked to rate a muscle soreness on the soreness scales by either carrying out a squat using body weight, self palpitation of muscle or based on muscle soreness at rest.

There was considerable variation on the timing of the soreness measurement after the damaging exercise occurred. Whilst all the trials measured soreness at baseline, 18 studies measured muscle soreness immediately after exercise, two studies measured soreness two hours after exercise (Trombold 2010; Trombold 2011), and one study measured soreness six hours after exercise (Kerksick 2009). Due to this variation, we grouped these studies into the 'up to 6 hours post-exercise' category. In addition to measuring soreness immediately after exercise, a few trials also measured soreness 2, 4, 6 or 10 hours post-exercise although the earliest follow-up time point to immediately post-exercise was used. Forty-one trials measured muscle soreness at 24 hours, 45 trials at 48 hours, 28 trials at 72 hours and 17 trials at 96 hours post-exercise. Only six trials measured muscle soreness subsequently: four trials measured soreness at 120 hours post-exercise (Krotkiewski 1994; Michailidis 2013; O'Fallon 2012; Theodorou 2011), one study at 144 hours (Michailidis 2013), and three studies at 168 hours after exercise (Michailidis 2013; Phillips 2003; Silva 2008).

Antioxidants for preventing and reducing muscle soreness after exercise (Review) Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Subjective recovery

None of the 50 included trials measured the primary outcome of subjective recovery.

Adverse effects

Only nine studies reported information on adverse effects, seven of which reported no adverse effects of antioxidant supplementation (Kerksick 2009; Laupheimer 2014; Lynn 2015; McLeay 2012; Michailidis 2013; O'Connor 2013; Phillips 2003), and two which reported specific adverse effects (Cobley 2011; Kuehl 2010). The remaining 41 studies failed to report adverse effects.

Secondary outcomes

Muscle tenderness

Muscle tenderness (or pressure pain threshold, PPT) was measured in four trials using a handheld algometer where the cylindrical metal probe was placed on the belly of the muscle and the investigator applied pressure gradually to the point where the participant felt discomfort (Close 2006; Connolly 2006; Connolly 2006a; Peschek 2014).

Performance variables

Performance variables were measured in five trials: Arent 2010 used the 30-second Wingate to measure power output in Watts per kg of body weight (W/kg); Bell 2015 measured cycling efficiency; Bell 2016 used a battery of tests including the 20 m sprint, 505 Agility test and counter-movement jump; Cobley 2011 used the 20 m sprint and Yo-Yo test; and O'Connor 2013 examined the effects of antioxidant supplementation on maximal oxygen consumption.

Muscle force

Muscle force production was measured in 30 trials using a dynamometer or an isokinetic dynamometer in the muscle where damage was caused (Bailey 2011; Beaton 2002a; Bell 2015; Bell 2016; Bloomer 2004; Bloomer 2005; Bloomer 2007; Bryer 2006; Close 2006; Cobley 2011; Connolly 2006; Connolly 2006a; Goldfarb 2011; Herrlinger 2015; Howatson 2009; Kerksick 2009; McLeay 2012; Meamarbashi 2011; Michailidis 2013; O'Connor 2013; O'Fallon 2012; Peschek 2014; Shafat 2004; Tanabe 2015; Theodorou 2011; Thompson 2001; Thompson 2001a; Thompson 2003; Trombold 2010; Trombold 2011). The main variable measured in these trials was peak isometric force.

Range of motion

Range of motion was assessed in 13 trials using a goniometer and units were reported in degrees (Bailey 2011; Beaton 2002a; Bloomer 2004; Bryer 2006; Connolly 2006; Goldfarb 2011; Howatson 2009; McLeay 2012; Meamarbashi 2011; O'Connor 2013; O'Fallon 2012; Tanabe 2015; Theodorou 2011). Flexion range was determined either in the elbow or the knee by using universal landmarks to ensure consistency on subsequent measures.

Excluded studies

We excluded 77 studies, 73 because delayed onset muscle soreness was not measured (Characteristics of excluded studies). One study was excluded because the supplement used is not classed as an antioxidant (Kingsley 2006). We excluded one study because the antioxidant supplement was co-ingested with a fish oil supplement and therefore the effect of antioxidant-only supplementation was not examined (Lenn 2002). We excluded one study because the antioxidant was combined with a protein supplement (Romano-Ely 2006), and we excluded one study because antioxidants were combined with ibuprofen, cold water immersion and whey protein at the same time (Al-Nawaiseh 2016).

Studies awaiting classification

There are no studies awaiting classification.


Ongoing trials


Details of one ongoing trial testing curcumin supplementation are available in the Characteristics of ongoing studies table (NCT02281981).


Risk of bias in included studies

Details of the 'Risk of bias' assessment, including methods of randomisation, for individual trials are provided in Characteristics of included studies and the assessments are summarised in Figure 2 and Figure 3.

Figure 2. 'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.







Allocation

Random sequence generation

We judged 30 studies, all of which gave details of random sequence generation, at low risk of bias. We rated 15 studies at unclear risk of bias because they did not specify how the random sequence was generated and attempts obtain clarification from authors were unsuccessful. Clarification received from the authors of Tanabe 2015 did not confirm effective random sequence generation and so we judged this at unclear risk of bias too.

Four studies were at high risk of bias (Howatson 2009; Kerksick 2009; Su 2008; Theodorou 2011). Howatson 2009 matched on sex and predicted finishing time. Participants were matched in clusters according to age and body weight for assignment in Kerksick 2009. Su 2008 randomly assigned participants into an allicin or control group according to sex and sports participation and in Theodorou 2011, participants were allocated based on age, body mass index (BMI) and maximum isometric torque into equal groups then a computer generator was used for the assignment into groups.

Concealment of treatment allocation

We deemed that 20 studies had a low risk of bias because allocation concealment was very likely (Bailey 2011; Bell 2015; Bell 2016; Bloomer 2004; Bloomer 2005; Bloomer 2007; Close 2006; Cobley 2011; He 2015; Herrlinger 2015; Kerksick 2009; Laupheimer 2014; McCormick 2016; Meamarbashi 2011; Nicol 2015; O'Connor 2013; Peschek 2014; Silva 2008; Silva 2010; Theodorou 2011). We rated 23 studies at unclear risk as there were no details specified in the manuscripts and authors did not respond to our request for clarification. The authors of a further six studies responded to our query but their response was unclear thus they were assessed also at unclear risk of bias (Drobnic 2014; Howatson 2009; Lynn 2015; Nie 2004; Shafat 2004; Tanabe 2015). We considered McLeay 2012 at high risk of bias because safeguards to ensure allocation concealment were absent and the treatment for the second stage of this cross-over trial would have been predictable.

Blinding

Overall, 36 studies were double-blind or blinding was reported and therefore we assessed them at low risk of performance and detection bias.

We assessed eight studies at high risk of performance bias because of the lack of blinding of personnel (Drobnic 2014; Howatson 2009; Lynn 2015; McLeay 2012; Peschek 2014; Shafat 2004; Silva 2008; Tanabe 2015). We rated five studies at unclear risk of performance bias as there were no details specified in the trial reports and the authors did not respond to our request for clarification (Bryer 2006; Connolly 2006a; Herrlinger 2015; McBride 1997;

Su 2008). We assessed only one study at high risk of detection bias, with a clear possibility of a lack of participant blinding (McLeay 2012). Of the nine six studies assessed at unclear risk of detection bias, six provided no details of whether there was blinding (Bryer 2006; Connolly 2006a; Herrlinger 2015; McBride 1997; Su 2008; Tanabe 2015), and there were reasons for some doubts about whether blinding was assured in three others (Drobnic 2014; Lynn 2015; Shafat 2004).

Incomplete outcome data

We judged 38 studies at low risk of attrition bias. We assessed one study at unclear risk of attrition bias since there were no details on participant flow and the authors did not reply to our request for data (Krotkiewski 1994). We rated 11 studies at high risk of attrition bias as dropouts ranged between 12.5% to 50% either overall or in a trial arm (Arent 2010; Bloomer 2007; Connolly 2006a; Hutchinson 2016; Kaminski 1992; Lynn 2015; McFarlin 2016; Michailidis 2013; Phillips 2003; Silva 2008; Silva 2010). In Arent 2010, out of the six participants who dropped out, five withdrew of their own volition due to the inability to tolerate the physical demands of the testing protocol. Six participants did not complete all aspects of the study for personal reasons in Bloomer 2007. Two participants withdrew from another cross-over study for personal reasons (Connolly 2006a). In Hutchinson 2016, eight participants withdrew due to illness and injury unrelated to the study protocol. In Kaminski 1992, six participants withdrew for a variety of reasons (loss of capsule integrity, failure to properly maintain records, non-compliance with the experimental protocol), and one was removed for failure to develop DOMS in either stage of the cross-over trial. In Lynn 2015, data were missing from two participants of the intervention group; however, as this was a cross-over trial, attrition was balanced across groups. McFarlin 2016 had a 30% attrition/non-compliance rate, probably with an uneven dropout rate between the two groups. One cross-over study stated in a published protocol that 20 individuals were enrolled and 12 completed although the manuscript stated that 10 males completed the study (Michailidis 2013). Phillips 2003 excluded five participants due to complications with blood-drawing procedures; however, it is unclear which group they were from. Four participants withdrew from Silva 2008 and six participants from Silva 2010 for personal reasons not associated with the exercise or the supplementation; it was not specified to which group the loses applied in either study.

Selective reporting

Three studies were registered with ClinicalTrials.gov and as all the outcomes were reported in the published studies we initially judged these at low risk of selective reporting (Kuehl 2010; Michailidis 2013; Theodorou 2011). However, Theodorou 2011 did not record adverse effects and we thus judged it at unclear risk of

bias. We also judged all nine studies that reported on adverse effects from antioxidant supplementation, as well as fully reporting outcomes listed in their methods sections, at low risk of selective reporting bias (Cobley 2011; Kerksick 2009; Kuehl 2010; Laupheimer 2014; Lynn 2015; McLeay 2012; Michailidis 2013; O'Connor 2013; Phillips 2003). We rated the remaining 40 studies at high risk of selective reporting. As well as the lack of reporting of adverse effects, this reflected the lack of response from the authors of 16 studies to requests for mean and standard deviation data. Three studies rated at high risk of selective reporting bias because of other deficiencies in reporting were Bell 2015, Bell 2016 and Thompson 2003: the first two studies did not report muscle soreness data immediately post-exercise and Thompson 2003 did not report data for all the time points.

Other potential sources of bias

We deemed 16 studies at unclear risk of other potential sources of bias such as dietary control or avoiding medication or supplements that could reduce muscle soreness. Of these, we judged seven studies at unclear risk of other bias because no details regarding dietary control or instructing participants to avoid nonsteroidal anti-inflammatory drugs (NSAIDs) or other supplements were provided in the trial report (Bailey 2011; Bloomer 2005; McBride 1997; Nicol 2015; Shafat 2004; Silva 2008; Silva 2010). The nine other studies controlled the participants' diets but provided no details regarding dietary control or instructing participants to avoid NSAIDs or other supplements and we therefore judged them at unclear risk of bias (Bell 2016; Krotkiewski 1994; McCormick 2016; McLeay 2012; Michailidis 2013; Nie 2004; Theodorou 2011; Thompson 2001; Thompson 2004). We rated 34 studies at low risk of other bias as diet, intake of supplements and medication were controlled.

Effects of interventions

See: Summary of findings for the main comparison Summary of findings: antioxidants versus placebo

Evidence from the 50 trials included in this review applied to only one comparison: antioxidant supplements versus control (placebo).

Antioxidant supplementation versus placebo or no supplementation

All 50 included studies made this comparison. Muscle soreness data were not available for pooling from one trial (Herrlinger 2015), and no data were pooled from McCormick 2016 because of its protracted exercise regimen.

Primary outcomes

Delayed onset muscle soreness (DOMS) (visual analogue scale, various scales or scores; highest values = worst pain)

Forty-eight studies presented data on muscle soreness at various different time points based on various visual analogue scale (VAS) scores. Results are presented at eight follow-up times after exercise: up to 6 hours, and at 24, 48, 73, 96, 120, 144 and 168 hours. As there was considerable clinical heterogeneity we used the random-effects model. Both Kerksick 2009 and Silva 2008 tested two antioxidants: in the analyses, Kerksick 2009 appears twice for the first four follow-up times and Silva 2008 appears twice at 48, 96 and 168 hours.

Antioxidant supplementation reduced muscle soreness in comparison with placebo intervention when measured up to 6 hours postexercise (standardised mean difference (SMD) -0.30, 95% confidence interval (CI) -0.56 to -0.04; participants = 525; studies = 21; $I^2 = 53\%$; low-quality evidence); Analysis 1.1); at 24 hours after exercise (SMD -0.13, 95% CI -0.27 to 0.00; participants = 936; studies = 41; I^2 = 5%; moderate-quality evidence; Analysis 1.2; Figure 4); at 48 hours after exercise (SMD -0.24, 95% CI -0.42 to -0.07; participants = 1047; studies = 45; I² = 47%; lowquality evidence; Analysis 1.3; Figure 5) and at 72 hours after exercise (SMD -0.19, 95% CI -0.38 to -0.00; participants = 657; studies = 28; $I^2 = 27\%$; moderate-quality evidence; Analysis 1.4). (It is notable that the heterogeneity in this analysis is solely related to the inclusion of Michailidis 2013). There was little effect of antioxidants on muscle soreness at 96 hours after exercise (SMD -0.05, 95% CI -0.29 to 0.19; participants = 436; studies = 17; I 2 = 31%; low-quality evidence; Analysis 1.5). Far fewer trials provided data at five days or subsequently. There was very low-quality evidence of little effect of antioxidants on muscle soreness at 120 hours (SMD 0.21, 95% CI -0.26 to 0.69; participants = 128; studies = 4; I² = 39%), at 144 hours (SMD -0.23, 95% CI -1.11 to 0.65; participants = 20; studies = 1) or at 168 hours (SMD -0.04, 95% CI -0.48 to 0.41; participants = 80; studies = 4; I^2 = 0%); Analysis 1.6).

	Ar	ntioxidant		I	Placebo		1	Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl
Arent 2010	1.12	1.4425	18	2.09	1.6971	18	3.8%	-0.60 [-1.27, 0.07]	
Avery 2003	5.9	3.6	9	6	3.9	9	2.0%	-0.03 [-0.95, 0.90]	
Bailey 2011	5	2	20	5	2	18	4.1%	0.00 [-0.64, 0.64]	
Bell 2015	20.67	27.6	8	25	19.7	8	1.8%	-0.17 [-1.15, 0.81]	
Bell 2016	60	32.47	8	93	50.79	8	1.7%	-0.73 [-1.75, 0.29]	
Bloomer 2004	3.54	2.25	9	4.2	2.25	9	2.0%	-0.28 [-1.21, 0.65]	
Bloomer 2005	5.7	0.9487	10	4.8	0.9487	10	2.0%	0.91 [-0.02, 1.84]	
Bloomer 2007	7.35	1.217	7	5.75	2.4324	8	1.6%	0.77 [-0.30, 1.83]	+
Bryer 2006	4.2	2.2136	10	6.2	2.2627	8	1.8%	-0.85 [-1.83, 0.13]	
Close 2006	4.49	2.29	10	4.54	2.83	10	2.3%	-0.02 [-0.90, 0.86]	
Cobley 2011	3.2	1	6	3.1	2.3	6	1.4%	0.05 [-1.08, 1.18]	
Connolly 2006	2.54	2.46	12	2.75	2.14	12	2.7%	-0.09 [-0.89, 0.71]	
Connolly 2006a	3.7	4.49	14	4.3	4.8642	14	3.1%	-0.12 [-0.87, 0.62]	
Goldfarb 2011	2.6	1.3748	21	2.3	1.7889	20	4.4%	0.19 [-0.43, 0.80]	- -
He 2015 (1)	1.82	1.25	11	3.64	2.01	11	2.1%	-1.05 [-1.95, -0.14]	
Howatson 2009	91	39	10	82	45	10	2.1%	0.20 [-0.67, 1.08]	_
Hutchinson 2016	2.44	1.8385	8	3	1.7819	8	1.8%	-0.29 [-1.28, 0.69]	
Kerksick 2009 (2)	2.84	1.0303	10	3.58	2.3	5	1.5%	-0.37 [-1.45, 0.72]	
Kerksick 2009 (2) Kerksick 2009 (3)	2.04	3.83	10	3.58	2.3	5	1.5%	-0.39 [-1.48, 0.69]	
Krotkiewski 1994	3.9	1.8	36	2.7	1.1225	14	4.2%	0.72 [0.08, 1.35]	
Laupheimer 2014	3.5	2.96	30	6.25	4.44	4	4.2 %	-0.48 [-2.03, 1.06]	
Lynn 2015	52.27	37.57	11	53	36.38	10	2.4%	-0.02 [-0.88, 0.84]	
		1.9596	6	3.25		6			
McBride 1997	2.33				2.1556		1.3%	-0.41 [-1.56, 0.74]	
McFarlin 2016	7.4	3.6	16	9.9	3.1177	12	2.9%	-0.71 [-1.49, 0.06]	
McLeay 2012 (4)	2.14	1.73	10	2.45	2	10	2.3%	-0.16 [-1.04, 0.72]	
Meamarbashi 2011	1.8	1.8	10	3.2	1.8	10	2.1%	-0.74 [-1.66, 0.17]	
Michailidis 2013	8.4	0.4	10	8.8	0.4	10	2.0%	-0.96 [-1.89, -0.02]	
Nicol 2015 (5)	3.7	1.32	17	4.3	1.98	17	3.7%	-0.35 [-1.03, 0.33]	
Nie 2004	6.2	1.7	8	6.7	1.2	8	1.8%	-0.32 [-1.31, 0.67]	
O'Connor 2013	19.9	21.4	20	18.5	14.3	20	4.3%	0.08 [-0.54, 0.70]	
O'Fallon 2012	36.03	16.27	15	39	15.67	15	3.3%	-0.18 [-0.90, 0.54]	
Peschek 2014	41	18	8	46	17	8	1.8%	-0.27 [-1.26, 0.72]	
Shafat 2004	9.5	1.2	6	10	1.4	6	1.3%	-0.35 [-1.50, 0.79]	
Bu 2008	6.2	3.1113	8	7.5	1.6971	8	1.8%	-0.49 [-1.49, 0.51]	
Tanabe 2015	4.3	2.5	14	4.7	1.9	14	3.1%	-0.17 [-0.92, 0.57]	
Theodorou 2011	3.36	2.06	14	2.79	1.42	14	3.1%	0.31 [-0.43, 1.06]	
Thompson 2001	4	3	9	3	3	9	2.0%	0.32 [-0.61, 1.25]	
Thompson 2001a (6)	50	16.9706	8	58	16.9706	8	1.8%	-0.45 [-1.44, 0.55]	
Thompson 2003	6	2.8284	8	3	2.8284	8	1.6%	1.00 [-0.06, 2.06]	<u> </u>
Thompson 2004	50.4	20.37	7	46.7	24.07	7	1.6%	0.16 [-0.89, 1.21]	
Trombold 2010	8	2	16	8.2	1.9	16	3.5%	-0.10 [-0.79, 0.59]	- _
Trombold 2011 (7)	3.59	2.03	17	4.17	1.62	17	3.7%	-0.31 [-0.99, 0.37]	
Fotal (95% CI)			488			448	100.0%	-0.13 [-0.27, 0.00]	•
Heterogeneity: Tau² = 0 Test for overall effect: Z			df = 41	(P = 0.3	9); I ² = 5%				-4 -2 0 2 Favours antioxidant Favours placebo

Figure 4. Forest plot of comparison: I Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies), outcome: 1.2 Muscle soreness at 24 hours; random-effects model.

Footnotes (1) Soreness at the thigh muscle (2) EGCG vs placebo (3) NAC vs placebo (4) 12 hrs post exercise (5) Single leg squat (6) General soreness (0-100mm)

(7) Soreness at elbow

Figure 5.	Forest plot of comparison: I Antioxidant supplementation vs. placebo for delayed onset muscle
S	oreness (all studies), outcome: 1.3 Muscle soreness at 48 hours; random-effects model.

Study of Cul		ntioxidant	T - 1 - 1		Placebo	T-4-1		Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean			Mean			Weight	IV, Random, 95% Cl	IV, Random, 95% Cl
Arent 2010	0.88	1.3576	18	1.94	1.9516	18	2.8%	-0.62 [-1.29, 0.05]	
Avery 2003	4.9	3.3	9	5.1	4.2	9	2.1%	-0.05 [-0.97, 0.87]	
Bailey 2011	5	2	20	5	2	18	2.9%	0.00 [-0.64, 0.64]	
Beaton 2002a	8.8	3.1	9	7.5	2	7	1.9%	0.46 [-0.55, 1.46]	
Bell 2015	14.92	22.51	8	21.8	18.72	8	1.9%	-0.31 [-1.30, 0.67]	
Bell 2016	45	27.82	8	91	56.08	8	1.8%	-0.98 [-2.04, 0.07]	
Bloomer 2004	3.04	2.4	9	5.46	3	9	1.9%	-0.85 [-1.82, 0.13]	
Bloomer 2005	5.8	2.5298	10	4.8	1.8974	10	2.2%	0.43 [-0.46, 1.32]	
Bloomer 2007	7.07	0.926	7	6.25	2.7436	8	1.8%	0.37 [-0.66, 1.39]	
Bryer 2006	6.1	2.2136	10	7.5	2.2627	8	2.0%	-0.60 [-1.55, 0.36]	
Close 2006	4.34	2.74	10	5.59	2.6	10	2.1%	-0.45 [-1.34, 0.44]	
Cobley 2011	2.9	1.1	6	2.4	0.8	6	1.6%	0.48 [-0.68, 1.64]	
Connolly 2006	2.25	1.92	12	2.75	2.07	12	2.4%	-0.24 [-1.05, 0.56]	
Connolly 2006a	3.3	4.1158	14	5	4.49	14	2.6%	-0.38 [-1.13, 0.37]	
Drobnic 2014	23.3	7.9	9	30.6	7.9	10	2.0%	-0.88 [-1.84, 0.07]	
Goldfarb 2011	2.8	2.7495	21	3	1.3416	20	3.0%	-0.09 [-0.70, 0.52]	
He 2015 (1)	1.91	1.14	11	3.09	1.58	11	2.2%	-0.82 [-1.70, 0.05]	
Howatson 2009	58	39	10	46	28	10	2.2%	0.34 [-0.55, 1.22]	
Hutchinson 2016	2.75	2.4324	8	3.38	2.1213	8	1.9%	-0.26 [-1.25, 0.72]	
Kaminski 1992	3.7	2.6	19	5.4	2.2	19	2.9%	-0.69 [-1.35, -0.03]	
Kerksick 2009 (2)	3.49	2.15	10	5.51	1.64	5	1.6%	-0.95 [-2.09, 0.20]	
Kerksick 2009 (3)	3.3	2.08	10	5.51	1.64	5	1.6%	-1.06 [-2.23, 0.10]	
Krotkiewski 1994	2.95	1.8	36	1.1	0.7483	14	2.8%	1.15 [0.49, 1.81]	<u> </u>
Lynn 2015	24.6	22.53	10	17.7	12.99	10	2.2%	0.36 [-0.53, 1.24]	
McBride 1997	2	2.1311	6	2.75	2.278	6	1.6%	-0.31 [-1.46, 0.83]	
McFarlin 2016	11.4	3.2	16	12.5	2.7713	12	2.5%	-0.35 [-1.11, 0.40]	
McLeay 2012 (4)	3.79	1.88	10	3.35	2.25	10	2.2%	0.20 [-0.68, 1.08]	
Meamarbashi 2011	1.2	0.7	10	3.3	1.6	10	1.8%	-1.63 [-2.67, -0.59]	
Michailidis 2013	8.9	0.2	10	9.5	0.2	10	1.3%	-2.87 [-4.20, -1.55]	
Nicol 2015 (5)	3.32	1.15	17	4	2.14	17	2.8%	-0.39 [-1.07, 0.29]	
Nie 2004	5.1	1.2	8	4.9	1.3	8	1.9%	0.15 [-0.83, 1.13]	
O'Connor 2013	18.6	18.7	20	17.7	13.9	20	3.0%	0.05 [-0.57, 0.67]	
O'Fallon 2012	39.6	21.86	15	43.43	17.7	15	2.7%	-0.19 [-0.90, 0.53]	
Peschek 2014	45	20	8	34	24	8	1.9%	0.47 [-0.53, 1.47]	_
Shafat 2004	10	1.5	6	10.3	1.4	6	1.6%	-0.19 [-1.33, 0.94]	
Silva 2008 (6)	5.83	1	8	5.43	0.8	4	1.5%	0.39 [-0.82, 1.61]	<u> </u>
Silva 2008 (7)	3.86	0.7	9	5.43	0.8	4	1.1%	-2.00 [-3.50, -0.51]	
Silva 2010	3.8	2.6533	11	6.2	1.5811	10	2.1%	-1.04 [-1.97, -0.12]	
Su 2008	6.2	4.5255	8	8	4.2426	8	1.9%	-0.39 [-1.38, 0.60]	
Tanabe 2015	5.5	2.1	14	6	2.2	14	2.6%	-0.23 [-0.97, 0.52]	<u> </u>
Theodorou 2011	6.07	2.4	14	5.57	1.5	14	2.6%	0.24 [-0.50, 0.99]	
Thompson 2001	3	3	. 9	3	3	9	2.1%	0.00 [-0.92, 0.92]	
Thompson 2001a (8)	33	11.3137	8	47	22.6274	8	1.8%	-0.74 [-1.76, 0.28]	
Thompson 2003	4	2.8284	8	3	2.8284	8	1.9%	0.33 [-0.65, 1.32]	
Thompson 2004	64.3	16.4	7	48.6	27.24	7	1.7%	0.65 [-0.43, 1.74]	
Trombold 2010	8.1	1.6	16	10.0	2.2	16	2.7%	0.05 [-0.64, 0.74]	
Trombold 2011 (9)	2.71	2.11	17	3.76	1.68	17	2.8%	-0.54 [-1.22, 0.15]	+
Total (95% CI)			549			498	100.0%	-0.24 [-0.42, -0.07]	•
Heterogeneity: Tau ² = 0	117: Chi ^a	= 86.34 0		(P = 0.0	(003): $P = 4$. ,	+ + + +
Test for overall effect: Z		•		. 0.0					-4 -2 Ó 2

(1) Soreness at the thigh muscle
(2) NAC vs placebo
(3) EGCG vs placebo

(4) 36 hours post exercise

(5) Single leg squat(6) 14 days supplementation

(7) 21 days supplementation(8) General soreness (0-100mm)

(9) Soreness at elbow

As there was considerable variation in the units used to measured muscle soreness, we rescaled all trials to the 0 to 10 scale at the first five time points in order to explore the actual difference between groups on a standard scale. The results are as follows: up to 6 hours (mean difference (MD) -0.52, 95% CI -0.95 to -0.08; participants = 525; studies = 21; I^2 = 66%; Analysis 1.7); at 24 hours (MD -0.17, 95% CI -0.42 to 0.07; participants = 936; studies = 41; I² = 29%; Analysis 1.8); at 48 hours (MD -0.41, 95% CI -0.69 to -0.12; participants = 1047; studies = 45; I² = 64%; Analysis 1.9); at 72 hours (MD -0.29, 95% CI -0.59 to 0.02; participants = 657; studies = 28; I² = 27%; Analysis 1.10); and at 96 hours (MD -0.03, 95% CI -0.43 to 0.37; participants = 436; studies = 17; I² = 51%; Analysis 1.11). This rescaling also allows us to examine whether the antioxidant supplement produces a clinically important difference. For consistency with Bleakley 2012, we considered 1.4 cm as the minimal important difference (MID) for pain reduction on a 10 cm visual analogue scale; this was based on an estimated MID for musculoskeletal conditions of the shoulder by Tashjian 2009. It is notable that all of the upper limits of the 95% CIs of these five analyses are lower that this MID and hence all quantitative differences do not appear to represent person-relevant differences in muscle soreness.

Subgroup and sensitivity analyses

We performed only a few subgroup and sensitivity analyses. We selected the 24 and 48 hours analyses for subgroup analyses given that these were the categories with the largest number of trials. We did not use the up to 6 hours time period because of the variation in the timing of measurement: i.e. some studies measured this outcome immediately after exercise whereas other studies measured this up to 2 hours or up to 6 hours after exercise.

A sensitivity analysis exploring the use of the fixed-effect model for all eight follow-up times produced similar results to that of random-effects model (Table 3; analysis not shown).

A subgroup analysis could not be performed on timing of administration (i.e. pre-exercise and post-exercise versus post-exercise only) because there were very few trials (one or two studies depending on the time of follow-up) in the post-exercise group. We performed a subgroup analysis on the type of exercise, that is, mechanically induced versus whole body aerobic exercise for the 24 and 48 hour follow-up times (see Analysis 1.12; Analysis 1.13). There is no evidence of subgroup differences for muscle soreness for type of exercise at 24 hours (Chi² = 0.44, df = 1; P = 0.51, I² = 0%) or at 48 hours (Chi² = 0.88, df = 1; P = 0.35, I² = 0%). Our second subgroup analysis was based on source of funding where we compared studies that were funded by a food company or provider of antioxidant supplements versus studies that there were not (see Analysis 1.14; Analysis 1.15). There is no evidence of subgroup differences for muscle soreness according to source of funding at 24 hours (Chi² = 0.03, df = 1, P = 0.87, I² = 0%) or 48 hours (Chi² = 0.10, df = 1, P = 0.875 I² = 0%); no information on funding was available for Su 2008.

We conducted a sensitivity analysis testing trials at unclear risk of bias, relating to random sequence generation, allocation concealment or both, which included 19 trials (Bailey 2011; Bell 2015; Bell 2016; Bloomer 2004; Bloomer 2005; Bloomer 2007; Close 2006; Cobley 2011; He 2015; Herrlinger 2015; Howatson 2009; Laupheimer 2014; McCormick 2016; Meamarbashi 2011; O'Connor 2013; Peschek 2014; Silva 2008; Silva 2010; Tanabe 2015). This analysis made little difference to the overall effect at either 24 hours post-exercise (SMD -0.10, 95% CI -0.37 to 0.17; participants = 280; studies = 14; I² = 19%) or at 48 hours (SMD -0.31, 95% CI -0.66 to 0.04; participants = 327; studies = 16; I² = 57%).

Also presented are sensitivity analyses testing the effects of excluding cross-over studies; these provide reassurance that the inclusion of such trials did not have an important effect on the results (Table 4).

Subjective recovery

No study measured subjective recovery (return to previous activities without signs or symptoms).

Adverse effects

Nine studies, reporting on a total of 216 participants, reported on this outcome (very low-quality evidence). One study reported that all six participants in the NAC (N-acetylcysteine) supplementation group had diarrhoea, which was mild in five participants and severe diarrhoea in one (Cobley 2011). The same study reported mild indigestion in four participants (67%) in the NAC group and one of six participants in the placebo group. Another study reported that tart cherry juice caused mild gastrointestinal distress in one of 26 participants taking the antioxidant supplement (Kuehl 2010). Seven studies reported no adverse effects of taking the antioxidant supplementation (Kerksick 2009; Laupheimer 2014; Lynn 2015; McLeay 2012; Michailidis 2013; O'Connor 2013; Phillips 2003). The remaining 41 studies failed to report adverse effects.

Secondary outcomes

Muscle tenderness

Only four studies measured muscle tenderness using a handheld algometer (Close 2006; Connolly 2006; Connolly 2006a; Peschek 2014) (and Analysis 1.17). Two studies measured tenderness using pressure algometry and reported the results in Newtons (Connolly 2006; Connolly 2006a), and two studies measured tenderness and reported in kg (Close 2006; Peschek 2014). There was very lowquality evidence of little difference between antioxidant supplementation versus placebo in tenderness (a greater pressure exerted means less tenderness) at the four time points (24, 48, 72 and 96 hours) for the pooled data from the two studies (52 participants) reporting the results in Newtons (Analysis 1.16); nor for five time points (up to 6 hours, 24, 48, 72 and 96 hours) for the data from the two studies (36 participants) reporting the results in kg (Analysis 1.17).

Performance variables

The quality of the evidence for all performance variables was very low; each variable presented here being reported by only one of the five studies reporting these outcomes (Arent 2010; Bell 2015; Bell 2016; Cobley 2011; O'Connor 2013). Arent 2010 (18 participants; cross-over trial) found no effect of antioxidant supplementation on the 30-second Wingate performed on a cycle ergometer (the DOMS-provoking exercise) seven days after supplementation (MD 0.30 W/kg, 95% CI -2.74 to 3.34; Analysis 1.18). Cobley 2011 (12 participants) found antioxidant supplementation (NAC) enhanced sprint time over 20 metres at three followup times (lower values = better performance): 24 hours (MD -0.41 seconds, 95% CI -0.63 to -0.19), 48 hours (MD -0.30 seconds, 95% CI -0.52 to -0.08) and 120 hours (MD -0.30, 95% CI -0.54 to -0.06; Analysis 1.19). O'Connor 2013 (40 participants) found no improvements in maximal oxygen consumption when measured after 42 days after antioxidant supplementation (higher values = better performance) (MD 0.20 mL/kg/min, 95% CI -5.66 to 6.06; Analysis 1.20). Bell 2016 (16 participants) found no effect of antioxidant supplementation on agility (5-0-5 agility: lower values = better performance) at any of the three time points measured: 24 hours (MD 0.01 seconds, 95% CI -0.16 to 0.18), 48 hours (MD -0.05 seconds, 95% CI -0.19 to 0.09) or 72 hours (MD -0.02 seconds, 95% CI -0.17 to 0.13) (Analysis 1.21). Bell 2015 (16 participants) found no effect of antioxidant supplementation on six-second sprint power (higher values = better performance) at any of the three time points measured: 24 hours (MD 39.00 W, 95% CI -182.33 to 260.33), 48 hours (MD 50.00 W, 95% CI -195.44 to 295.44) or 72 hours (MD 53.00 W, 95% CI -174.56 to 280.56) (Analysis 1.22).

Muscle force production (maximal voluntary contraction)

Thirty studies measured muscle function at various different time points. Muscle force production was measured in different ways and we pooled results only from studies using the same outcome measure: 15 trials reported the percentage change in force production from baseline; six reported Newton metres, six reported Newtons, two reported Newton metres per kg of body mass and one reported kg. We rated the quality of evidence as very low for all findings. When muscle force production was measured as a percentage change from baseline, antioxidant supplementation appeared to increase force production to a small extent (all under 6%) in comparison with placebo across the first five time points: up to 6 hours after exercise (MD 5.86%, 95% CI 3.29 to 8.42; participants = 255; studies = 11; I² = 3%), at 24 hours (MD 2.51%, 95% CI 0.99 to 4.04; participants = 375; studies = 15; I^2 = 75%), at 48 hours (MD 4.46%, 95% CI 2.94 to 5.98; participants = 375; studies = 15; $I^2 = 59\%$), at 72 hours (MD 3.92%, 95% CI 0.88 to 6.96; participants = 277; studies = 11; I^2 = 51%), and at 96 hours after exercise (MD 5.29, 95% CI 3.65 to 6.92; participants = 252; studies = 9; I^2 = 72%) (Analysis 1.23). (Although in the results for 168 hours after exercise, the antioxidant showed a harmful effect on muscle force production, only two studies measured this outcome at this time point and the results were statistically heterogeneous (MD -7.96, 95% CI -15.96 to 0.05; participants = 36; studies = 2; $I^2 = 68\%$). Where data were pooled, for up to six studies for force production measured in Newton metres, or for up to five studies for force production measured in Newtons, there were no differences found between the antioxidant supplementation and placebo groups across all of the time points measured (see Analysis 1.24 and Analysis 1.25). For completeness, the non-pooled results for the two trials reporting the strength in Newton metres per kg of body mass are shown in Analysis 1.26 and those for the trial reporting strength in kg in Analysis 1.27. The former are dominated by those of Michailidis 2013, which favour antioxidants in the first five follow-ups but placebo in the last two follow-ups.

Range of motion

There was very low-quality evidence that range of motion, which was measured in 10 studies (Bailey 2011; Bloomer 2004; Bryer 2006 Connolly 2006a; Goldfarb 2011; Meamarbashi 2011; O'Connor 2013; Phillips 2003; Tanabe 2015; Theodorou 2011), did not differ importantly between the two groups (antioxidant versus placebo) at any of the follow-up times (see Analysis 1.28). All differences (higher values = better range of motion) were small and unlikely to relate to a clinically important difference at either the elbow or knee. The first five follow-up time results are presented here: up to 6 hours after exercise (MD -0.25 degrees, 95% CI -3.31 to 2.81; participants = 163; studies = 6; I² = 0%), at 24 hours (MD 1.03 degrees, 95% CI -0.91 to 2.96; participants = 259; studies = 9; I² = 0%), at 48 hours (MD 2.71 degrees, 95%) CI 0.39 to 5.04; participants = 259; studies = 9; $I^2 = 61\%$), at 72 hours (MD 2.93 degrees, 95% CI -0.02 to 5.87; participants = 196; studies = 7; I^2 = 0%) and at 96 hours (MD 0.79 degrees, 95% CI -1.26 to 2.84; participants = 158; studies = 6; I² = 0%).

High-dose versus low-dose, where the low-dose supplementation is within normal or recommended levels for the antioxidant involved

None of the included studies made this comparison.

DISCUSSION

Summary of main results

This review examined the effectiveness of antioxidants for preventing and treating muscle soreness after exercise. Fifty randomised placebo-controlled studies were included, 12 of which used a crossover design. The 50 studies involved a total of 1089 participants

(961 male; 128 female; age range 16 to 55 years). The studies were heterogeneous, including the timing (pre-exercise or postexercise), frequency, dose or duration, and type of antioxidant supplementation, and the type of preceding delayed onset muscle soreness (DOMS)-producing exercise. All studies used an antioxidant dosage higher than the recommended daily amount. No studies compared high-dose versus low-dose, where the low-dose supplementation was within normal or recommended levels for the antioxidant involved.

The included studies made only one comparison: antioxidant supplements versus control (placebo). Our main outcomes were muscle soreness (up to 6 hours post-exercise and at 24, 48, 72 and 96 hours), subjective recovery and adverse events.

Antioxidant supplementation versus placebo or no supplementation

A summary of the evidence available for the main outcomes for this comparison is presented in Summary of findings for the main comparison. The assessment of the quality of the evidence varied between moderate quality, where the effect is probably true but there is a possibility that it could be substantially different, low quality, where the effect may be true but it may also be substantially different from what was found, and very low quality, where we are very uncertain about the estimate.

Pooled standardised mean difference (SMD) results for muscle soreness indicated a small difference in favour of antioxidant supplementation after DOMS-inducing exercise at all main followups: up to 6 hours (525 participants; 21 studies; low-quality evidence); at 24 hours (936 participants; 41 studies; moderate-quality evidence), at 48 hours (1047 participants; 45 studies; low-quality evidence); at 72 hours (657 participants; 28 studies; moderate-quality evidence), and little difference at 96 hours (436 participants; 17 studies; low-quality evidence). When, however, we rescaled all the trial results to the 0 to 10 cm scale in order to compare the actual difference between groups, we found that the 95% confidence intervals (CIs) for all five follow-up times were all below 1.0 cm, and thus all below the minimal important difference of 1.4 cm that we used in this review. Thus, all statistical differences in DOMS favouring antioxidant supplementation were unlikely to equate to meaningful or important differences in practice. Neither of our subgroup analyses to examine for differences in effect according to type of DOMS-inducing exercise (mechanical versus whole body aerobic) or according to funding source confirmed subgroup differences. Sensitivity analyses to test the selection of the statistical model for pooling (fixed-effect instead of randomeffects) and the exclusion of cross-over studies all showed similar results to the main analyses.

None of the 50 studies reported on subjective recovery (return to previous activities without signs or symptoms).

Only nine studies (216 participants) reported on adverse effects, with actual events reported in two studies. One study (12 participants) reported that all six participants in the NAC (N-acetylcysteine) supplementation group had diarrhoea, which was mild in five participants and severe in one (Cobley 2011). The same study reported mild indigestion in four participants (67%) in the NAC group and one of six participants in the placebo group. It should be noted that NAC supplementation is usually prescribed and it has been found to cause uncomfortable side effects including nausea and diarrhoea in other studies. Another study reported that tart cherry juice caused mild gastrointestinal distress in one of 26 participants taking the antioxidant supplement (Kuehl 2010). The other seven studies reported no adverse effects of taking the antioxidant supplementation; this included 10 participants having NAC supplementation in one study. Overall, the available evidence for adverse events is very low-quality.

Overall completeness and applicability of evidence

Data for muscle soreness, the primary outcome, were available from 48 of the 50 small placebo-controlled randomised trials, with pooled data available at 24 hours after the exercise from 41 trials (one of which tested two antioxidants), involving 936 participants and from 45 (two of which tested two antioxidants), involving 1047 participants. In contrast there were no data for subjective recovery and few data for adverse effects.

We consider the applicability of the evidence in terms of the population characteristics, the exercise used to induce muscle damage and trial settings, the antioxidants used and outcomes. In particular, the 50 trials included in this review varied regarding dosages of antioxidants, the muscle damage model and adequate control of extraneous variables.

The majority of the 1089 participants included in this review were male (961; 88.2%) and so arguably the findings of the review are mainly applicable to males but there is no biological basis for why antioxidants should have a different effect in the two sexes. These sex differences are typical of what is observed in the athletic recovery literature (Bieuzen 2013; Bleakley 2012; Costello 2014). More noteworthy is that no data from highly-trained elite athletes were included in the analyses; the data pertaining to nine elite athletes tested in McCormick 2016 were not included in the metaanalyses because the exercise paradigm was completely different to all the other studies included in this review. As the majority of the participants were either college students or relatively young and active, these findings cannot be generalised in the elite athlete population who have a different physiological and training status. Some reservations in terms of applicability also apply to older individuals due to their anatomical and physiological characteristics as there were no older participants included in this review (age range of participants: 16 to 55 years).

There were large variations regarding the mode of exercise used to induce muscle damage in the studies, with some studies using exhaustive high-intensity exercise such as downhill running (i.e. whole body aerobic exercise) and other studies using a resistance training protocol (i.e. mechanically induced exercise). Thus the level of muscle damage experienced by the participants will have varied. In addition, the intensity of the exercise used to illicit muscle damage also varied greatly amongst studies: some studies used an extremely demanding and intense exercise protocol such as 10 sets of 10 repetitions knee extensions performed at 80% of one repetition maximum or a marathon run, whereas others used less exhaustive protocols such as a bench stepping exercise. The amount of muscle damage and oxidative stress caused depends on the type, intensity and duration of physical exercise performed (Castrogiovanni 2012). Paulsen 2012 found exercise that has a greater eccentric component that involves a greater range of motion and high force generation is more likely to cause greater levels of damage. Moreover, Bleakley 2012 reported that resistance exercises performed under laboratory conditions are associated with high levels of muscle damage and soreness, particularly in the untrained population. Our subgroup analysis that compared type of exercise at 24 and 48 hours did not show subgroup differences between whole body aerobic exercise and mechanically induced exercise. Despite the variation, the key point for this review is that the exercise protocols, whether in the laboratory or field setting, were all sufficient to induce muscle damage that would result in DOMS in people undergoing sport activities.

There was large variation in the dose and duration of the antioxidants used, with three trials testing supplements started only after exercise. The variation was too great to enable meaningful indirect comparisons (subgroup analyses) and no trial compared highversus low-dose supplementation, where the low-dose supplementation was within normal or recommended levels for the antioxidant involved. Nonetheless, all studies used an antioxidant dosage higher than the recommended daily amount. The timing for assessment of muscle soreness, with the majority of evidence available for 24 and 48 hours after exercise, was appropriate. However, the timing of measurement for up to 6 hours varied greatly amongst the studies where some studies measured muscle soreness immediately after exercise and some studies measured this several hours after exercise. There was considerable variation in the measurement of muscle soreness, which meant that we pooled SMDs for the main analyses. Exploratory analyses, where all results were on a 10 cm scale, allowed an assessment of whether the between-group differences were clinically relevant. Crucially, the upper limits of the 95% CIs at all five time points were much less than a typical minimal important difference (MID) for pain.

Quality of the evidence

We assessed the quality of evidence using the GRADE framework, which com-

bines considerations of *risk of bias,indirectness,inconsistency (heterogeneity),imprecision* and *publication bias*. The findings for the main outcomes are shown in Summary of findings for the main comparison. We downgraded all outcomes one level for serious risk of bias, due mainly to selective reporting bias (the majority of the trials failed to report on adverse effects) and, to a lesser degree, attrition biases. We did not downgrade for indirectness in relation to muscle soreness. We downgraded two outcomes for serious inconsistency reflecting heterogeneity that could not be traced to the inclusion of just one outlier trial. Pooled evidence did not support downgrading for imprecision. Our tests for publication bias did not reveal a serious concern (Figure 6; Figure 7), although all were small studies. Thus, we did not downgrade for publication bias. We concluded that the quality of the evidence ranged from moderate to very low.

Figure 6. Funnel plot of comparison: I Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies), outcome: 1.2 Muscle soreness at 24 hours; random-effects model.





Figure 7. Funnel plot of comparison: I Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies), outcome: I.3 Muscle soreness at 48 hours; random-effects model.



Potential biases in the review process

We used the standard methods described in the *Cochrane Handbook for Systematic Reviews of Interventions* (Higgins 2011). Although our search was extensive, we cannot exclude the possibility that we have missed relevant evidence. For studies where we required the raw data, we contacted authors via email. The authors of 14 studies did not respond to several emails requesting mean and standard deviation data (Avery 2003; Beaton 2002a; Bryer 2006; Connolly 2006; Connolly 2006a; Goldfarb 2011; Krotkiewski 1994; McFarlin 2016; Michailidis 2013; Peschek 2014; Phillips 2003; Su 2008; Trombold 2010; Trombold 2011). We therefore extracted these data from graphs using Graphclick 2010 Arizona (version 3.0.2, 2010). Whilst this is not ideal, we tried to minimise error by having two review authors (MR and DR) independently extract the data, with any discrepancies resolved by consultation with the third and fourth authors (HS and JC).

One potential source of bias is the post-hoc exclusion of trials not reporting our primary outcomes (see Types of outcome measures). However, none of the excluded studies were aimed at the prevention, reduction or treatment of DOMS.

We set out "to assess the effects (benefits and harms) of antioxidant supplements and antioxidant-enriched foods for preventing and reducing the severity and duration of delayed onset muscle soreness following exercise" (Objectives). To achieve this, we decided to pool data from clearly heterogeneous trials; for instance varying in their study design, populations, the exercise protocols, the antioxidant dosage, start and length of supplementation, their accounting for extraneous variables that could affect recovery and to a lesser degree in their timing of measuring muscle soreness (DOMS). In the light of this clinical heterogeneity, the statistical heterogeneity was not extreme and sometimes the heterogeneity could be sourced to a very few outliers (e.g. Michailidis 2013 for muscle soreness at 72 hours (Analysis 1.4)). Subgroup analysis by type of exercise proved reassuring. Keeping the focus on the main characteristic of the intervention (i.e. oral antioxidant supplementation at dosage above the recommended daily dosage) appears justified.

Publication bias is a threat to any systematic review or meta-analysis and publication bias among nutrition-related scientific articles remains a problem. Lesser 2007 investigated financial sponsorship of scientific articles addressing the health effects of three commonly consumed beverages to determine how sponsorship affects published conclusions and found that industry funding of nutritionrelated studies may bias conclusions in favour of sponsors' prod-

ucts. However, funnel plots for the outcomes of muscle soreness at 24 hours and 48 hours were not suggestive of publication bias (Figure 6; Figure 7). Moreover, we performed a subgroup analysis on studies that were funded by a food company or provider of antioxidant supplements and compared them with studies that were not funded by a food company or provider of antioxidant supplements and we found no evidence of subgroup differences and thus sponsorship bias (Analysis 1.14; Analysis 1.15).

Our inclusion of cross-over studies and our analysis of their data as if from a parallel group trial, thus without adjustment for the cross-over design, are other potential sources of bias. With one exception, the cross-over studies included in this review used a washout period of two to six weeks, which is sufficient to allow the muscles to recover. The exception used a washout period of only five days between treatments and therefore carries some risk of a carry-over effect (Arent 2010); sensitivity analysis to check on the effect of excluding the data from this trial did not result in important changes. Further sensitivity analyses checking the effects of excluding the cross-over trials from the muscle soreness analyses showed that our inclusion and handling of the cross-over studies did not have an important impact on the review results.

Agreements and disagreements with other studies or reviews

Several narrative reviews have been written on antioxidant supplementation and recovery (e.g. Gross 2011; Howatson 2008b; McGinley 2009; Peternelj 2011). However, to our knowledge this is the first systematic review that has examined the effects of antioxidant supplements for preventing and reducing muscle soreness after exercise. Our review also includes more recently published evidence. For example, of the 45 trials contributing evidence to the 48 hours muscle soreness analysis (Analysis 1.3), 14 were published in 2012 or subsequently, and 14 more were published between 2009 and 2011.

The observations by Howatson 2008b on the large variations in type of, dosage used and duration of antioxidant and exercise modality are consistent with our findings. McGinley 2009, which reviewed the effects of vitamin C, vitamin E and both combined on muscle damage and oxidative stress, also attributed the mixed findings to variations in dosage, timing and duration of antioxidant and exercise modality. McGinley 2009 suggested that there was some evidence to show that both vitamin C and vitamin E antioxidants can reduce oxidative stress but there was poor evidence to show any positive effects on protecting against muscle damage and soreness. It is also notable that there has been some indication that long-term antioxidant supplementation in high doses, in particular vitamin E, may increase mortality (Bjelakovic 2007). Peternelj 2011 concluded that antioxidant supplementation attenuates exercise-induced oxidative stress but had no effects on exercise-induced muscle damage, soreness and performance. Although Peternelj 2011 did not perform a meta-analysis, they suggested

that there is a growing body of evidence indicating that antioxidant supplements may have a detrimental effect as they may interfere with the beneficial effects of exercise training. Gross 2011 in their narrative review on antioxidant supplementation and endurance training noted that the use of antioxidants in sport by amateur and professional athletes was common and that some studies had suggested that these may actually be counterproductive (in particular vitamin C and E supplements) as they may impair and weaken some of the desired signalling roles played by free radicals during training adaptations. The latter, however, was not investigated by Gross 2011. Nonetheless, over the last few years there has been an emergence of studies showing that chronic antioxidant supplementation may actually be counterproductive, particularly in interfering with exercise-induced cell-signalling in skeletal muscle thus having an overall detrimental effect of exercise training on both performance and health (Gomez-Cabrera 2008; Paulsen 2014; Ristow 2009). More specifically, several studies have shown that antioxidant supplements promote exercise-induced oxidative stress (Avery 2003; Bailey 2011; Beaton 2002; Childs 2001; Knez 2007; Lamprecht 2009; Malm 1996; Nieman 2004), hinder cell adaptation to exercise-induced oxidative stress (Gomez-Cabrera 2008; Ristow 2009; Paulsen 2014), and delay healing and recovery from exercise (Close 2006; Teixeira 2009), and long-term antioxidant supplementation in high doses may increase mortality (Bjelakovic 2014; Slatore 2008).

The risk of adverse effects is likely to be dependent of the type of antioxidant. One of the two trials in the review reporting on adverse effects was testing NAC supplementation and reported that all six participants in the antioxidant group had diarrhoea (Cobley 2011). As well as being a listed side effect of this prescription drug, uncomfortable side effects such as nausea and diarrhoea from NAC supplementation have also been reported elsewhere (Ferreira 2011).

As well as random errors relating to small trials and bias, there are numerous factors that can explain why there are differences between trials and in the antioxidant literature on whether antioxidants are beneficial or not for recovery. The recovery process is complex, and there are many extraneous variables that could interfere or accelerate the recovery process. Factors such as differences in antioxidant dosage, length of supplementation, and accounting for extraneous variables that could affect recovery could explain differences between trials (Close 2014). Second, there are large variations in the type of participants with most studies recruiting untrained, sedentary and relatively young and healthy individuals and far fewer studies recruiting well-trained athletes. Participants will vary in size, body weight, body composition and they may respond differently to antioxidant supplementation due to metabolic differences; these may also be some reasons that can explain the differences in findings. Nonetheless, as argued above, retaining the focus on the broad question asked in this review has helped to us to examine and summarise the evidence for the overall question of whether antioxidants prevent or reduce muscle soreness after exercise.

AUTHORS' CONCLUSIONS

Implications for practice

There is moderate- to low-quality evidence that antioxidant supplementation does not result in a clinically relevant reduction of muscle soreness after exercise at any of the five follow-up times: up to 6 hours and at 24, 48, 72 and 96 hours after exercise. There is no evidence available on subjective recovery and only limited evidence on adverse effects of taking antioxidant supplements. Some antioxidant supplements such as N-acetylcysteine may cause unwanted side effects including gastrointestinal discomfort and diarrhoea.

Implications for research

The findings of, and messages from, this review provide an opportunity for researchers and other stakeholders to come together and consider what are the priorities, and underlying justifications, for future research in this area. Should there be a continuing focus on antioxidants, in preference to other interventions used for reducing muscle soreness, the area would benefit from standardisation of methods and antioxidant protocols. Future randomised controlled trials should ensure that the rationale for the antioxidant protocol is considered and specified, and attention given to dietary control and other factors that may affect recovery as these are important confounders when investigating the impact of antioxidant supplementation on exercise performance and recovery. The rationale for selection of populations different from those covered in the review should also be given. We suggest that a case could be made for elite athletes, not included in this review, as this particular group have a different physiological and training status. As recently noted, future studies should employ a parallel design with larger sample sizes as when investigating muscle recovery cross-over trials may have a risk regarding carry-over effects between treatment periods (Bleakley 2012; Costello 2015).

A C K N O W L E D G E M E N T S

We would like to thank Joanne Elliott for her assistance with developing and running the search strategies. We would also like to thank Helen Handoll, Joanne Elliott, Lindsey Elstub and Zipporah Iheozor-Ejiofor for their comments and feedback on drafts of the review. We thank the external referee, Michalis Nikolaidis, for his feedback.

We thank the Cochrane Editorial Unit for feedback received during editorial screening, including the preparation by Newton Opiyo of an additional table documenting sensitivity analyses testing the effects of excluding cross-over studies.

This project was supported by the National Institute for Health Research via Cochrane Infrastructure funding to the Cochrane Bone, Joint and Muscle Trauma Group. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, NHS or the Department of Health.

REFERENCES

References to studies included in this review

Arent 2010 *{published data only (unpublished sought but not used)}* Arent SM, Senso M, Golem DL, McKeever KH. The effects

of theaflavin-enriched black tea extract on muscle soreness, oxidative stress, inflammation, and endocrine responses to acute anaerobic interval training: a randomized, doubleblind, crossover study. *Journal of the International Society of Sports Nutrition* 2010;7(1):7.

Avery 2003 {published data only}

Avery NG, Kaiser JL, Sharman MJ, Scheett TP, Barnes DM, Gómez AL, et al. Effects of vitamin E supplementation on recovery from repeated bouts of resistance exercise. *Journal* of Strength and Conditioning Research 2003;**17**(4):801–9.

Bailey 2011 {published data only}

Bailey DM, Williams C, Betts JA, Thompson D, Hurst TL. Oxidative stress, inflammation and recovery of muscle function after damaging exercise: effect of 6-week mixed antioxidant supplementation. *European Journal of Applied Physiology* 2011;**111**(6):925–36.

Beaton 2002a {published data only}

Beaton LJ, Allan DA, Tarnopolsky MA, Tiidus PM, Phillips SM. Contraction-induced muscle damage is unaffected by vitamin E supplementation. *Medicine and Science in Sports and Exercise* 2002;**34**(5):798–805.

Bell 2015 {published and unpublished data}

* Bell PG, Walshe IH, Davison GW, Stevenson EJ, Howatson G. Recovery facilitation with Montmorency cherries following high-intensity, metabolically challenging exercise. *Applied Physiology, Nutrition, and Metabolism* 2016;**40**(4):414–23.

Ranchordas MK. Raw data for DOMS and MVIC [personal communication]. Email to: P Bell 3 February 2017.

Bell 2016 {published and unpublished data}

* Bell PG, Stevenson E, Davison GW, Howatson G. The effects of Montmorency tart cherry concentrate

supplementation on recovery following prolonged, intermittent exercise. *Nutrients* 2016;**8**(7):441. PUBMED: 27455316]

Ranchordas MK. Request for raw data for DOMS and MVIC [personal communication]. Email to: P Bell 3 February 2017.

Bloomer 2004 {published and unpublished data}

* Bloomer RJ, Goldfarb AH, McKenzie MJ, You T, Nguyen L. Effects of antioxidant therapy in women exposed to eccentric exercise. *International Journal of Sport Nutrition and Exercise Metabolism* 2004;14(4):377–88. Ranchordas MK. Raw data for DOMS and MVIC [personal communication]. Email to: AH Goldfarb 3 October 2013.

Bloomer 2005 {published and unpublished data}

* Bloomer RJ, Fry A, Schilling B, Chiu L, Hori N, Weiss L. Astaxanthin supplementation does not attenuate muscle injury following eccentric exercise in resistance-trained men. *International Journal of Sport Nutrition and Exercise Metabolism* 2005;**15**(4):401–12.

Ranchordas MK. Raw data for DOMS and MVIC [personal communication]. Email to: RJ Bloomer 3 October 2013.

Bloomer 2007 {published and unpublished data}

* Bloomer RJ, Falvo MJ, Schilling BK, Smith WA. Prior exercise and antioxidant supplementation: effect on oxidative stress and muscle injury. *Journal of the International Society of Sports Nutrition* 2007;**3**(10):1–10. Ranchordas MK. Raw data for DOMS and MVIC [personal communication]. Email to: RJ Bloomer 3 October 2013.

Bryer 2006 {published data only}

Bryer SC, Goldfarb AH. Effect of high dose vitamin C supplementation on muscle soreness, damage, function, and oxidative stress to eccentric exercise. *International Journal of Sport Nutrition and Exercise Metabolism* 2006;**16**(3): 270–80.

Close 2006 {published and unpublished data}

* Close GL, Ashton T, Cable T, Doran D, Holloway C, McArdle F, et al. Ascorbic acid supplementation does not attenuate post-exercise muscle soreness following muscledamaging exercise but may delay the recovery process. *British Journal of Nutrition* 2006;**95**(5):976–81. PUBMED: 16611389]

Ranchordas MK. Raw data for PPT, DOMS and MVIC [personal communication]. Email to: CL Close 3 October 2013.

Cobley 2011 {published and unpublished data}

* Cobley JN, McGlory C, Morton JP, Close GL. Nacetylcysteine's attenuation of fatigue after repeated bouts of intermittent exercise: practical implications for tournament situations. *International Journal of Sport Nutrition and Exercise Metabolism* 2011;**21**(6):451–61. Ranchordas MK. Raw data for DOMS, performance variables and MVIC [personal communication]. Email to: J Cobley 3 December 2013.

Connolly 2006 {published data only}

Connolly DA, Lauzon C, Agnew J, Dunn M, Reed B. The effects of vitamin C supplementation on symptoms of

delayed onset muscle soreness. *Sports Medicine and Physical Fitness* 2006;**46**(3):462–7.

Connolly 2006a {published data only}

Connolly DA, McHugh MP, Padilla-Zakour OI, Carlson L, Sayers SP. Efficacy of a tart cherry juice blend in preventing the symptoms of muscle damage. *British Journal of Sports Medicine* 2006;**40**(8):679–83.

Drobnic 2014 {published and unpublished data}

* Drobnic F, Riera J, Appendino G, Togni S, Franceschi F, Valle X, et al. Reduction of delayed onset muscle soreness by a novel curcumin delivery system (Meriva): a randomised placebo controlled trial. *Journal of the International Society of Sport Nutrition* 2014;**11**(31):1–10.

Ranchordas MK. Raw data for DOMS [personal communication]. Email to: F Drobnic 18 February 2016.

Goldfarb 2011 {published data only}

Goldfarb AH, Garten RS, Cho C, Chee PD, Chambers LA. Effects of a fruit/berry/vegetable supplement on muscle function and oxidative stress. *Medicine and Science in Sports and Exercise* 2011;**43**(3):501–8.

He 2015 {published and unpublished data}

* He F, Hockemeyer AK, Sedlock D. Does combined antioxidant vitamin supplementation blunt repeated bout effect?. *International Journal of Sports Medicine* 2015;**36**: 407–13.

Ranchordas MK. Raw data for DOMS [personal communication]. Email to: F He 24 February 2016.

Herrlinger 2015 {published data only}

Herrlinger KA, Chirouzes DM, Ceddia MA. Supplementation with a polyphenolic blend improves postexercise strength recovery and muscle soreness. *Food and Nutrition Research* 2015;**59**:30034.

Howatson 2009 {published data only}

Howatson G, McHugh MP, Hill JA, Brouner J, Jewell AP, van Someren KA, et al. Influence of tart cherry juice on indices of recovery following marathon running. *Scandinavian Journal of Medicine and Science in Sports* 2010; **20**(6):843–52.

Hutchinson 2016 {published data only}

Hutchinson AT, Flieller EB, Dillon KJ, Leverett BD. Black currant nectar reduces muscle damage and inflammation following a bout of high-intensity eccentric contractions. *Journal of Dietary Supplements* 2016;**13**(1):1–15.

Kaminski 1992 {published and unpublished data}

* Kaminski M, Boal R. An effect of ascorbic acid on delayed-onset muscle soreness. *Pain* 1992;**50**(3):317–21. Ranchordas MK. Raw data for DOMS [personal communication]. Email to: M Kaminski 3 December 2013.

Kerksick 2009 {published and unpublished data}

* Kerksick CM, Kreider RB, Willoughby DS. Intramuscular adaptations to eccentric exercise and antioxidant supplementation. *Amino Acids* 2010;**39**(1):219–32. Ranchordas MK. Raw data for DOMS and MVIC [personal communication]. Email to DS Willoughby 2 November 2013.

Krotkiewski 1994 {published data only}

Krotkiewski M, Brzezinska Z, Liu B, Grimby G, Palm S. Prevention of muscle soreness by pretreatment with antioxidants. *Scandinavian Journal of Science Medicine and Sport* 1994;**4**(3):191–9.

Kuehl 2010 {published data only}

Kuehl KS. Hood to coast injury study. https:// clinicaltrials.gov/ct2/show/NCT00733395?term= NCT00733395&rank=1 (accessed 20 April 2017). * Kuehl KS, Perrier ET, Elliot DL, Chesnutt JC. Efficacy of tart cherry juice in reducing muscle pain during running: a randomized controlled trial. *Journal if the International Society of Sports Nutrition* 2010;7(7):17.

Laupheimer 2014 {published and unpublished data}

* Laupheimer MW, Perry M, Benton S, Malliaras P, Maffulli N. Resveratrol exerts no effect on inflammatory response and delayed onset muscle soreness after a marathon in male athletes. *Translational Medicine* 2014;**10**(8):38–42. Ranchordas MK. Raw data for DOMS [personal communication]. Email to: MW Laupheimer 18 February 2016.

Lynn 2015 {published data only}

Lynn A, Garner S, Nelson N, Simper T, Hall A, Ranchordas MK. Effect of bilberry juice on muscle damage and inflammation in runners completing a half marathon. *Proceedings of the Nutrition Society* 2015;74(OCE5):E287.

McBride 1997 {published data only}

McBride JM, Kraemer WJ, Triplett-McBride T, Sebastianelli W. Effect of resistance exercise on free radical production. *Medicine and Science in Sports and Exercise* 1998;**30**(1): 67–72.

McCormick 2016 {published data only}

McCormick R, Peeling P, Binnie M, Dawson B, Sim M. Effect of tart cherry juice on recovery and next day performance in well-trained Water Polo players. *Journal of the International Society of Sports Nutrition* 2016;**13**:41.

McFarlin 2016 {published data only}

McFarlin BK, Venable AS, Henning AL, Sampson JNB, Pennel K, Vingren J, et al. Reduced inflammatory and muscle damage biomarkers following oral supplementation with bioavailable curcumin. *BBA Clinical* 2016;**5**:72–8.

McLeay 2012 {published data only}

McLeay Y, Barnes MJ, Mundel T, Hurst SM, Hurst RD, Stannard SR. Effect of New Zealand blueberry consumption on recovery from eccentric exercise-induced muscle damage. *Journal of the International Society of Sports Nutrition* 2012;**9** (1):9–19.

Meamarbashi 2011 {published data only}

Meamarbashi A, Abedini F. Preventative effects of purslane extract on delayed onset muscle soreness induced by one session bench stepping exercise. *Isokinetics and Exercise Science* 2011;**19**(3):199–206.

Michailidis 2013 {published data only}

Fatouros IF. NAC supplementation and skeletal muscle performance. https://clinicaltrials.gov/ct2/show/ NCT01778309 (accessed 20 April 2017).

* Michailidis Y, Karagounis LG, Terzis G, Jamurtas AZ, Spengos K, Tsoukas D, et al. Thiol-based antioxidant supplementation alters human skeletal muscle signaling and attenuates its inflammatory response and recovery after intense eccentric exercise. *American Journal of Clinical Nutrition* 2013;**98**(1):233–45.

Nicol 2015 {published and unpublished data}

* Nicol LM, Rowlands DS, Fazakerly R, Kellet J. Curcumin supplementation likely attenuates delayed onset muscle soreness (DOMS). *European Journal of Applied Physiology* 2015;**115**(8):1769–77.

Ranchordas MK. Raw data for DOMS and CMJ [personal communication]. Email to: DS Rowlands 15 March 2016.

Nie 2004 {published data only}

Nie J, Lin H. Effects of vitamin C supplementation on recovery from eccentric exercise-induced muscle soreness and damage in junior athletes. *Journal of Exercise Science and Fitness* 2004;**2**(2):94–8.

O'Connor 2013 {published data only}

O'Connor PJ, Caravalho AL, Freese EC, Cureton KJ. Grape consumption's effects on fitness, muscle injury, mood, and perceived health. *International Journal of Sport Nutrition and Exercise Metabolism* 2013;**23**(1):57–64.

O'Fallon 2012 {published and unpublished data}

* O'Fallon KS, Kaushik D, Michniak-Kohn B, Dunne CP, Zambraski EJ, Clarkson PM. Effects of quercetin supplementation on markers of muscle damage and inflammation after eccentric exercise. *International Journal* of Sport Nutrition and Exercise Metabolism 2012;**22**(6): 430–7.

Ranchordas MK. Raw data for DOMS, ROM and MVIC [personal communication]. Email to: KS O'Fallon 3 November 2013.

Peschek 2014 {published data only}

Peschek K, Pritchett R, Bergman E, Pritchett K. The effects of acute post exercise consumption of two cocoa-based beverages with varying flavanol content on indices of muscle recovery following downhill treadmill running. *Nutrients* 2013;6:50–62.

Phillips 2003 {published data only}

Phillips T, Childs AC, Dreon DM, Phinney S, Leeuwenburgh C. A dietary supplement attenuates IL-6 and CRP after eccentric exercise in untrained males. *Medicine and Science in Sports and Exercise* 2003;**35**(12):2032–7.

Shafat 2004 {published data only}

Shafat A, Butler P, Jensen RL, Donnelly AE. Effects of dietary supplementation with vitamins C and E on muscle function during and after eccentric contractions in humans. *European Journal of Applied Physiology* 2004;**93**(1-2): 196–202.

Silva 2008 {published data only}

Silva LA, Silveira PC, Pinho CA, Tuon T, Dal Pizzol F, Pinho RA. N-acetylcysteine supplementation and oxidative damage and inflammatory response after eccentric exercise. *International Journal of Sport Nutrition and Exercise Metabolism* 2008;**18**(4):379–88.

Silva 2010 {published data only}

Silva LA, Pinho CA, Silveira PC, Tuon T, De Souza CT, Dal-Pizzol F, et al. Vitamin E supplementation decreases muscular and oxidative damage but not inflammatory response induced by eccentric contraction. *Journal of Physiological Sciences* 2010;**60**(1):51–7.

Su 2008 {published data only}

Su QS, Tian Y, Zhang JG, Zhang H. Effects of allicin supplementation on plasma markers of exercise-induced muscle damage, IL-6 and antioxidant capacity. *European Journal of Applied Physiology* 2008;**103**(3):275–83.

Tanabe 2015 {published and unpublished data}

Ranchordas MK. Raw data for DOMS, ROM and MVIC [personal communication]. Email to: N Akazawa 8 December 2016.

* Tanabe Y, Maeda S, Akazawa N, Zempo-Miyaki A, Choi Y, Ra S, et al. Attenuation of indirect markers of eccentric exercise-induced muscle damage by curcumin. *European Journal of Applied Physiology* 2015;**115**(9):1949–57.

Theodorou 2011 {published data only}

Jamurtas AZ. The effect of antioxidant vitamin supplementation on muscle performance and redox status after eccentric training. https://clinicaltrials.gov/ct2/show/ NCT01290458 (accessed 20 April 2017).

* Theodorou AA, Nikolaidis MG, Paschalis V, Koutsias S, Panayiotou G, Fatouros IG, et al. No effect of antioxidant supplementation on muscle performance and blood redox status adaptations to eccentric training. *American Journal of Clinical Nutrition* 2011;**93**(6):1373–83.

Thompson 2001 {published data only}

Thompson D, Williams C, Kingsley M, Nicholas CW, Lakomy HK, McArdle F, et al. Muscle soreness and damage parameters after prolonged intermittent shuttle-running following acute vitamin C supplementation. *International Journal of Sports Medicine* 2001;**22**(1):68–75.

Thompson 2001a {published data only}

Thompson D, Williams C, McGregor SJ, Nicholas CW, McArdle F, Jackson MJ, et al. Prolonged vitamin C supplementation and recovery from demanding exercise. *International Journal of Sport Nutrition and Exercise Metabolism* 2001;**11**(4):466–81.

Thompson 2003 {published data only}

Thompson D, Williams C, Garcia-Roves P, McGregor SJ, McArdle F, Jackson MJ. Post-exercise vitamin C supplementation and recovery from demanding exercise. *European Journal of Applied Physiology* 2003;**89**(3-4): 393–400.

Thompson 2004 {published and unpublished data}

Ranchordas MK. Raw data for DOMS [personal communication]. Email to: D Thompson 3 November 2013.

* Thompson D, Bailey DM, Hill J, Hurst T, Powell JR, Williams C. Prolonged vitamin C supplementation and recovery from eccentric exercise. *European Journal of Applied Physiology* 2004;**92**(1-2):133–8.

Trombold 2010 {published and unpublished data}

Ranchordas MK. Raw data for DOMS and MVIC [personal communication]. Email to: JR Trombold 2 November 2013.

* Trombold JR, Barnes JN, Critchley L, Coyle EF. Ellagitannin consumption improves strength recovery 2-3 d after eccentric exercise. *Medicine Science in Sports Exercise* 2010;**42**(3):493–8.

Trombold 2011 {published and unpublished data}

Ranchordas MK. Raw data for DOMS and MVIC [personal communication]. Email to: JR Trombold 2 November 2013.

* Trombold JR, Reinfeld AS, Casler JR, Coyle EF. The effect of pomegranate juice supplementation on strength and soreness after eccentric exercise. *Journal of Strength and Conditioning Research* 2011;**25**(7):1782–8.

References to studies excluded from this review

Aalizadeh 2016 {published data only}

Aalizadeh A, Vispour Z, Changizi-Ashtiyani S, Hashemi G, Alvani J, Fatemikia H. Effects of oral administration of thyme (Thymus vulgaris) aqueous extract on delayed muscle soreness in inactive women. *De Pharma Chemica* 2016;**8**(3):225–30.

Al-Nawaiseh 2016 {published data only}

Al-Nawaiseh AM, Pritchett RC, Bishop PA. Enhancing short-term recovery after high-intensity anaerobic exercise. *Journal of Strength and Conditioning Research* 2016;**30**(2): 320–5. PUBMED: 26815173]

Ammar 2016 {published data only}

Ammar A. Pomegranate improve biological recovery kinetics in elite weightlifter. https://clinicaltrials.gov/ct2/show/ NCT02697903?term=NCT02697903&rank=1 (accessed 20 April 2017).

* Ammar A, Turki M, Chtourou H, Hammouda O, Trabelsi K, Kallel C, et al. Pomegranate supplementation accelerates recovery of muscle damage and soreness and inflammatory markers after a weightlifting training session. *PLoS One* 2016;**11**(10):e0160305.

Arent 2010a {published data only}

Arent SM, Pellegrino JK, Williams CA, Difabio DA, Greenwood JC. Nutritional supplementation, performance, and oxidative stress in college soccer players. *Journal of Strength and Conditioning Research* 2010;**24**(4):1117–24. PUBMED: 20300015]

Askari 2012 {published data only}

Askari G, Ghiasvand R, Karimian J, Feizi A, Paknahad Z, Sharifirad G, et al. Does quercetin and vitamin C

improve exercise performance, muscle damage, and body composition in male athletes?. *Journal of Research in Medical Sciences* 2012;**17**(4):328–31. PUBMED: 23267392]

Askari 2013 {published data only}

Askari G, Ghiasvand R, Paknahad Z, Karimian J, Rabiee K, Sharifirad G. The effects of quercetin supplementation on body composition, exercise performance and muscle damage indices in athletes. *International Journal of Preventive Medicine* 2013;4(1):21–6.

Babaei 2009 {published data only}

Babaei P, Rahmani-Nia F, Nakhostin B, Bohloolo SH. The effect of vitamin C on immunoendocrine and oxidative stress responses to exercise. *Journal of Clinical and Diagnotic Research* 2009;**3**:1627–32.

Bell 2014 {published data only}

Bell PG, Walshe IH, Davison GW, Stevenson E, Howatson G. Montmorency cherries reduce the oxidative stress and inflammatory responses to repeated days high-intensity stochastic cycling. *Nutrients* 2014;**6**(2):829–43.

Bloomer 2006 {published data only}

Bloomer RJ, Goldfarb AH, McKenzie MJ. Oxidative stress response to aerobic exercise: comparison of antioxidant supplements. *Medicine and Science in Sports and Exercise* 2006;**38**(6):1098–105. PUBMED: 16775552]

Bowtell 2011 {published data only}

Bowtell JL, Sumners DP, Dyer A, Fox P, Mileva KN. Montmorency cherry juice reduces muscle damage caused by intensive strength exercise. *Medicine and Science in Sports and Exercise* 2011;**43**(8):1544–51. PUBMED: 21233776]

Braakhuis 2014 {published data only}

Braakhuis AJ, Hopkins WG, Lowe TE. Effects of dietary antioxidants on training and performance in female runners. *European Journal of Sport Science* 2014;**14**(2):160–8.

Bunpo 2016 {published data only}

Bunpo P, Anthony TG. Ascorbic acid supplementation does not alter oxidative stress markers in healthy volunteers engaged in a supervised exercise program. *Applied Physiology, Nutrition, and Metabolism* 2016;**41**(2):175–80. PUBMED: 26789096]

Carvalho-Peixoto 2015 {published data only}

Carvalho-Peixoto J, Moura MR, Cunha FA, Lollo PC, Monteiro WD, Carvalho LM, et al. Consumption of acai (Euterpe oleracea Mart.) functional beverage reduces muscle stress and improves effort tolerance in elite athletes: a randomized controlled intervention study. *Applied Physiology, Nutrition, and Metabolism* 2015;**40**(7):725–33. PUBMED: 26140415]

Cavas 2004 {published data only}

Cavas L, Tarhan L. Effects of vitamin-mineral supplementation on cardiac marker and radical scavenging enzymes, and MDA levels in young swimmers. *International Journal of Sport Nutrition and Exercise Metabolism* 2004;**14** (2):133–46. PUBMED: 15118188]

Childs 2001a {published data only}

Childs A, Jacobs C, Kaminski T, Halliwell B, Leeuwenburgh C. Supplementation with vitamin C and N-acetyl-cysteine increases oxidative stress in humans after an acute muscle injury induced by eccentric exercise. *Free Radical Biology and Medicine* 2001;**31**(6):745–53. PUBMED: 11557312]

Clifford 2017 {published data only}

Clifford T, Bell O, West DJ, Howatson G, Stevenson EJ. Antioxidant-rich beetroot juice does not adversely affect acute neuromuscular adaptation following eccentric exercise. *Journal of Sports Sciences* 2017;**35**(8):812–9. PUBMED: 27267689]

Daneshvar 2013 {published data only}

Daneshvar P, Hariri M, Ghiasvand R, Askari G, Darvishi L, Mashhadi NS, et al. Effect of eight weeks of quercetin supplementation on exercise performance, muscle damage and body muscle in male badminton players. *International Journal of Preventative Medicine* 2013;4(Suppl 1):S53–7.

Dawson 2002 {published data only}

Dawson B, Henry GJ, Goodman C, Gillam I, Beilby JR, Ching S, et al. Effect of vitamin C and E supplementation on biochemical and ultrastructural indices of muscle damage after a 21 km run. *International Journal of Sports Medicine* 2002;**23**(1):10–5. PUBMED: 11774060]

Eichenberger 2010 {published data only}

Eichenberger P, Mettler S, Arnold M, Colombani PC. No effects of three-week consumption of a green tea extract on time trial performance in endurance-trained men. *International Journal for Vitamin and Nutrition Research* 2010;**80**(1):54–64. PUBMED: 20533245]

Fuster-Munoz 2016 {published data only}

Fuster-Munoz E, Roche E, Funes L, Martinez-Peinado P, Sempere JM, Vicente-Salar N. Effects of pomegranate juice in circulating parameters, cytokines, and oxidative stress markers in endurance-based athletes: a randomized controlled trial. *Nutrition* 2016;**32**(5):539–45. PUBMED: 26778544]

Gaeini 2006 {published data only}

Gaeini AA, Rahnama N, Hamedinia MR. Effects of vitamin E supplementation on oxidative stress at rest and after exercise to exhaustion in athletic students. *Journal of Sports Medicine and Physical Fitness* 2006;**46**(3):458–61. PUBMED: 16998452]

Gomez-Cabrera 2003 {published data only}

Gomez-Cabrera MC, Pallardo FV, Sastre J, Vina J, Garciadel-Moral L. Allopurinol and markers of muscle damage among participants in the Tour de France. *JAMA* 2003;**289** (19):2503–4. PUBMED: 12759321]

Hillman 2017 {published data only}

Hillman AR, Taylor BCR, Thompkins D. The effects of tart cherry juice with whey protein on the signs and symptoms of exercise-induced muscle damage following plyometric exercise. *Journal of Functional Foods* 2017;**29**:185–92.

Itoh 2000 {published data only}

Itoh H, Ohkuwa T, Yamazaki Y, Shimoda T, Wakayama A, Tamura S, et al. Vitamin E supplementation attenuates leakage of enzymes following 6 successive days of running training. *International Journal of Sports Medicine* 2000;**21** (5):369–74. PUBMED: 10950448]

Jakeman 1993 {published data only}

Jakeman P, Maxwell S. Effect of antioxidant vitamin supplementation on muscle function after eccentric exercise. *European Journal of Applied Physiology and Occupational Physiology* 1993;**67**(5):426–30. PUBMED: 8299614]

Jowko 2011 {published data only}

Jowko E, Sacharuk J, Balasinska B, Ostaszewski P, Charmas M, Charmas R. Green tea extract supplementation gives protection against exercise-induced oxidative damage in healthy men. *Nutrition Research* 2011;**31**(11):813–21. PUBMED: 22118751]

Jowko 2012 {published data only}

Jowko E, Sacharuk J, Balasinska B, Wilczak J, Charmas M, Ostaszewski P, et al. Effect of a single dose of green tea polyphenols on the blood markers of exercise-induced oxidative stress in soccer players. *International Journal of Sport Nutrition and Exercise Metabolism* 2012;**22**(6): 486–96. PUBMED: 22805286]

Jowko 2015 {published data only}

Jowko E, Dlugolecka B, Makaruk B, Cieslinski I. The effect of green tea extract supplementation on exercise-induced oxidative stress parameters in male sprinters. *European Journal of Nutrition* 2015;**54**(5):783–91. PUBMED: 25120110]

Kaikkonen 1998 {published data only}

Kaikkonen J, Kosonen L, Nyyssonen K, Porkkala-Sarataho E, Salonen R, Korpela H, et al. Effect of combined coenzyme Q10 and d-alpha-tocopheryl acetate supplementation on exercise-induced lipid peroxidation and muscular damage: a placebo-controlled double-blind study in marathon runners. *Free Radical Research* 1998;**29** (1):85–92. PUBMED: 9733025]

Keong 2006 {published data only}

Keong CC, Singh HJ, Singh R. Effects of palm vitamin E supplementation on exercise-induced oxidative stress and endurance performance in the heat. *Journal of Sport Science and Medicine* 2006;**5**(4):629–39.

Kim 2013 {published data only}

Kim H, Suzuki T, Saito K, Yoshida H, Kojima N, Kim M, et al. Effects of exercise and tea catechins on muscle mass, strength and walking ability in community-dwelling elderly Japanese sarcopenic women: a randomized controlled trial. *Geriatrics Gerontology International* 2013;**13**(2):458–65.

Kingsley 2006 {published data only}

Kingsley MI, Kilduff LP, McEneny J, Dietzig RE, Benton D. Phosphatidylserine supplementation and recovery following downhill running. *Medicine and Science in Sports and Exercise* 2006;**38**(9):1617–25. PUBMED: 16960523]

Kizaki 2015 {published data only}

Kizaki K, Terada T, Arikawa H, Tajima T, Imai H, Takahashi T, et al. Effect of reduced coenzyme Q10 (ubiquinol) supplementation on blood pressure and muscle damage during kendo training camp: a double-blind, randomized controlled study. *Journal of Sports Medicine and Physical Fitness* 2015;**55**(7-8):797–804. PUBMED: 25369277]

Kon 2008 {published data only}

Kon M, Tanabe K, Akimoto T, Kimura F, Tanimura Y, Shimizu K, et al. Reducing exercise-induced muscular injury in kendo athletes with supplementation of coenzyme Q10. *British Journal of Nutrition* 2008;**100**(4):903–9. PUBMED: 18284711]

Kraemer 2007 {published data only}

Kraemer WJ, Hatfield DL, Spiering BA, Vingren JL, Fragala MS, Ho JY, et al. Effects of a multi-nutrient supplement on exercise performance and hormonal responses to resistance exercise. *European Journal of Applied Physiology* 2007;**101** (5):637–46. PUBMED: 17701421]

Lafay 2009 {published data only}

Lafay S, Jan C, Nardon K, Lemaire B, Ibarra A, Roller M, et al. Grape extract improves antioxidant status and physical performance in elite male athletes. *Journal of Sports Science and Medicine* 2009;**8**(3):468–80. PUBMED: 24150013]

Lamprecht 2009a {published data only}

Lamprecht M, Hofmann P, Greilberger JF, Schwaberger G. Increased lipid peroxidation in trained men after 2 weeks of antioxidant supplementation. *International Journal of Sport Nutrition and Exercise Metabolism* 2009;**19**(4):385–99. PUBMED: 19827463]

Leelarungrayub 2011 {published data only}

Leelarungrayub D, Khansuwan R, Pothongsunun P, Klaphajone J. N-acetylcysteine supplementation controls total antioxidant capacity, creatine kinase, lactate, and tumor necrotic factor-alpha against oxidative stress induced by graded exercise in sedentary men. *Oxidative Medicine and Cellular Longevity* 2011;**329643**:1–6. [DOI: 10.1155/2011/329643

Lenn 2002 {published data only}

Lenn J, Uhl T, Mattacola C, Boissonneault G, Yates J, Ibrahim W, et al. The effects of fish oil and isoflavones on delayed onset muscle soreness. *Medicine and Science in Sports and Exercise* 2002;**34**(10):1605–13. PUBMED: 12370562]

Levers 2015 {published data only}

Levers K, Dalton R, Galvan E, Goodenough C, O'Connor A, Simbo S, et al. Effects of powdered Montmorency tart cherry supplementation on an acute bout of intense lower body strength exercise in resistance trained males. *Journal* of the International Society of Sports Nutrition 2015;**12**:41. PUBMED: 26578852]

Levers 2016 {published data only}

Levers K, Dalton R, Galvan E, O'Connor A, Goodenough C, Simbo S, et al. Effects of powdered Montmorency tart cherry supplementation on acute endurance exercise performance in aerobically trained individuals. *Journal of the International Society of Sports Nutrition* 2016;**13**:22. PUBMED: 27231439]

Louis 2010 {published data only}

Louis J, Hausswirth C, Bieuzen F, Brisswalter J. Vitamin and mineral supplementation effect on muscular activity and cycling efficiency in master athletes. *Applied Physiology*.

Nutrition, and Metabolism 2010;**35**(3):251–60. PUBMED: 20555368]

Margaritis 2003 {published data only}

Margaritis I, Palazzetti S, Rousseau AS, Richard MJ, Favier A. Antioxidant supplementation and tapering exercise improve exercise-induced antioxidant response. *Journal of the American College of Nutrition* 2003;**22**(2):147–56. PUBMED: 12672711]

Mastaloudis 2006 {published data only}

Mastaloudis A, Traber MG, Carstensen K, Widrick JJ. Antioxidants did not prevent muscle damage in response to an ultramarathon run. *Medicine and Science in Sports and Exercise* 2006;**38**(1):72–80. PUBMED: 16394956]

Matsumoto 2005 {published data only}

Matsumoto H, Takenami E, Iwasaki-Kurashige K, Osada T, Katsumura T, Hamaoka T. Effects of blackcurrant anthocyanin intake on peripheral muscle circulation during typing work in humans. *European Journal of Applied Physiology* 2005;**94**(1-2):36–45. PUBMED: 15605279]

McKenna 2006 {published data only}

McKenna MJ, Medved I, Goodman CA, Brown MJ, Bjorksten AR, Murphy KT, et al. N-acetylcysteine attenuates the decline in muscle Na+,K+-pump activity and delays fatigue during prolonged exercise in humans. *Journal of Physiology* 2006;**576**(Pt 1):279–88. PUBMED: 16840514]

Meamarbashi 2014 {published data only}

Meamarbashi A, Tavakoli AM. Ergogenic effect of a traditional natural powder: ghavoot. *Journal of Dietary Supplements* 2014;**11**(3):241–7. PUBMED: 25025852]

Meamarbashi 2016 {published data only}

Meamarbashi A, Rajabi A. Potential ergogenic effects of saffron. *Journal of Dietary Supplements* 2016;**13**(5):522–9. PUBMED: 26811090]

Medved 2004 {published data only}

Medved I, Brown MJ, Bjorksten AR, Murphy KT, Petersen AC, Sostaric S, et al. N-acetylcysteine enhances muscle cysteine and glutathione availability and attenuates fatigue during prolonged exercise in endurance-trained individuals. *Journal of Applied Physiology* 2004;**97**(4): 1477–85. PUBMED: 15194675]

Meydani 1993 {published data only}

Meydani M, Evans WJ, Handelman G, Biddle L, Fielding RA, Meydani SN, et al. Protective effect of vitamin E on exercise-induced oxidative damage in young and older adults. *American Journal of Physiology* 1993;**264**(5 Pt 2): R992–8. PUBMED: 8498608]

Mizuno 1997 {published data only}

Mizuno M, Quistorff B, Theorell H, Theorell M, Chance B. Effects of oral supplementation of coenzyme Q10 on 31P-NMR detected skeletal muscle energy metabolism in middle-aged post-polio subjects and normal volunteers. *Molecular Aspects of Medicine* 1997;**18 Suppl**:S291–8. PUBMED: 9266539]

Morillas-Ruiz 2005 {published data only}

Morillas-Ruiz J, Zafrilla P, Almar M, Cuevas MJ, Lopez FJ, Abellan P, et al. The effects of an antioxidant-supplemented beverage on exercise-induced oxidative stress: results from a placebo-controlled double-blind study in cyclists. *European Journal of Applied Physiology* 2005;**95**(5-6):543–9. PUBMED: 16132121]

NCT01555775 {published data only}

Sousa MV. Compared effect of a fruit milk shake with a protein-carbohydrate supplement on recovery after resistance exercise. https://clinicaltrials.gov/ct2/show/ NCT01555775?term=NCT01555775&rank=1 (accessed 20 April 2017).

Nieman 2010 {published data only}

Nieman DC, Williams AS, Shanely RA, Jin F, McAnulty SR, Triplett NT, et al. Quercetin's influence on exercise performance and muscle mitochondrial biogenesis. *Medicine and Science in Sports and Exercise* 2010;**42**(2): 338–45. PUBMED: 19927026]

Olesen 2013 {published data only}

Olesen J, Gliemann L, Bienso RS, Schmidt J, Hellsten Y, Pilegaard H. Exercise - but not resveratrol - increases performance and oxidative proteins in elderly human skeletal muscle. European Association for the Study of Diabetes (EASD) 49th Annual Meeting; 2013 Sep 23-7; Barcelona, Spain. 2013.

Ostman 2012 {published data only}

Ostman B, Sjodin A, Michaelsson K, Byberg L. Coenzyme Q10 supplementation and exercise-induced oxidative stress in humans. *Nutrition* 2012;**28**(4):403–17. PUBMED: 22079391]

Panza 2016 {published data only}

Panza VP, Diefenthaeler F, Tamborindeguy AC, Camargo C de Q, De Moura BM, Brunetta HS, et al. Effects of mate tea consumption on muscle strength and oxidative stress markers after eccentric exercise. *British Journal of Nutrition* 2016;**115**(8):1370–8. PUBMED: 26917157]

Passerieux 2015 {published data only}

Passerieux E, Hayot M, Jaussent A, Carnac G, Gouzi F, Pillard F, et al. Effects of vitamin C, vitamin E, zinc gluconate, and selenomethionine supplementation on muscle function and oxidative stress biomarkers in patients with facioscapulohumeral dystrophy: a double-blind randomized controlled clinical trial. *Free Radical Biology & Medicine* 2015;**81**:158–69. PUBMED: 25246239]

Paulsen 2014a {published data only}

Paulsen G, Cumming KT, Holden G, Hallén J, Rønnestad BR, Sveen O, et al. Vitamin C and E supplementation hampers cellular adaptation to endurance training in humans: a double-blind, randomised, controlled trial. *Journal of Physiology* 2014;**592**(8):1887–901.

Petersen 2001 {published data only}

Petersen EW, Ostrowski K, Ibfelt T, Richelle M, Offord E, Halkjaer-Kristensen J, et al. Effect of vitamin supplementation on cytokine response and on muscle damage after strenuous exercise. *American Journal*

of Physiology. Cell Physiology 2001;**280**(6):C1570–5. PUBMED: 11350752]

Pilaczynska-Szczesniak 2005 {published data only}

Pilaczynska-Szczesniak L, Skarpanska-Steinborn A, Deskur E, Basta P, Horoszkiewicz-Hassan M. The influence of chokeberry juice supplementation on the reduction of oxidative stress resulting from an incremental rowing ergometer exercise. *International Journal of Sport Nutrition and Exercise Metabolism* 2005;**15**(1):48–58. PUBMED: 15902989]

Roengrit 2014 {published data only}

Roengrit T, Wannanon P, Prasertsri P, Kanpetta Y, Sripanidkulchai BO, Leelayuwat N. Antioxidant and antinociceptive effects of Phyllanthus amarus on improving exercise recovery in sedentary men: a randomized crossover (double-blind) design. *Journal of the International Society of Sports Nutrition* 2014;**11**(1):9. PUBMED: 24636198]

Roengrit 2015 {published data only}

Roengrit T, Wannanon P, Prasertsri P, Kanpetta Y, Sripanidkulchai BO, Wattanathorn J, et al. Antioxidant effect of Phyllanthus amarus after moderate-intensity exercise in sedentary males: a randomized crossover (doubleblind) study. *Journal of Physical Therapy Science* 2015;**27**(4): 1181–6. PUBMED: 25995584]

Romano-Ely 2006 {published data only}

Romano-Ely BC, Todd MK, Saunders MJ, Laurent TS. Effect of an isocaloric carbohydrate-protein-antioxidant drink on cycling performance. *Medicine and Science in Sports and Exercise* 2006;**38**(9):1608–16. PUBMED: 16960522]

Sacheck 2003 {published data only}

Sacheck JM, Milbury PE, Cannon JG, Roubenoff R, Blumberg JB. Effect of vitamin E and eccentric exercise on selected biomarkers of oxidative stress in young and elderly men. *Free Radical Biology & Medicine* 2003;**34**(12): 1575–88. PUBMED: 12788477]

Sanchis-Gomar 2015 {published data only}

Sanchis-Gomar F, Pareja-Galeano H, Gomez-Cabrera MC, Candel J, Lippi G, Salvagno GL, et al. Allopurinol prevents cardiac and skeletal muscle damage in professional soccer players. *Scandinavian Journal of Medicine & Science in Sports* 2015;**25**(1):e110–5. PUBMED: 24690021]

Santos 2016 {published data only}

Santos SA, Silva ET, Caris AV, Lira FS, Tufik S, Dos Santos RV. Vitamin E supplementation inhibits muscle damage and inflammation after moderate exercise in hypoxia. *Journal of Human Nutrition and Dietetics* 2016;**29**(4): 516–22. PUBMED: 27062041]

Skarpanska-Stejnborn 2008 {published data only}

Skarpanska-Stejnborn A, Pilaczynska-Szczesniak L, Basta P, Deskur-Smielcka E, Horoszkiewicz-Hassan M. The influence of supplementation with artichoke (Cynara scolymus L.) extract on selected redox parameters in rowers. *International Journal of Sport Nutrition and Exercise Metabolism* 2008;**18**(3):313–27. PUBMED: 18562776]

Suzuki 2015 {published data only}

Suzuki K, Takahashi M, Li CY, Lin SP, Tomari M, Shing CM, et al. The acute effects of green tea and carbohydrate coingestion on systemic inflammation and oxidative stress during sprint cycling. *Applied Physiology, Nutrition, and Metabolism* 2015;**40**(10):997–1003. PUBMED: 26319564]

Taub 2015 {published data only}

Taub PR, Patel M, Higginbotham E, Ramon L, Moreno-Ulloa A, Ramirez-Sanchez I, el al. Effects of Dark Chocolate (DC) on exercise capacity in sedentary older adults (a double blind placebo controlled trial. American College of Cardiology (ACC) 64th Annual Scientific Session & Expo 2015 & i2 Summit; 2015 Mar 14-16;San Diego, California. 2015.

Teixeira 2009a {published data only}

Teixeira VH, Valente HF, Casal SI, Marques AF, Moreira PA. Antioxidants do not prevent postexercise peroxidation and may delay muscle recovery. *Medicine and Science in Sports and Exercise* 2009;**41**(9):1752–60. PUBMED: 19657294]

Toscano 2015 {published data only}

Toscano LT, Tavares RL, Toscano LT, Silva CS, Almeida AE, Biasoto AC, et al. Potential ergogenic activity of grape juice in runners. *Applied Physiology, Nutrition, and Metabolism* 2015;**40**(9):899–906. PUBMED: 26288392]

Yarahmadi 2014 {published data only}

Yarahmadi M, Askari G, Kargarfard M, Ghiasvand R, Hoseini M, Mohamadi H, et al. The effect of anthocyanin supplementation on body composition, exercise performance and muscle damage indices. *International Journal of Preventative Medicine* 2014;**5**(12):1594–600.

Yarahmadi 2014a {published data only}

Yarahmadi M, Askari G, Kargarfard M, Ghiasvand R, Hoseini M, Mohamadi H, et al. The effect of anthocyanin supplementation on body composition, exercise performance and muscle damage indices in athletes. *International Journal of Preventive Medicine* 2014;**5**(12): 1594–600. PUBMED: 25709796]

Yfanti 2010 {published data only}

Yfanti C, Akerstrom T, Nielsen S, Nielsen AR, Mounier R, Mortensen OH, et al. Antioxidant supplementation does not alter endurance training adaptation. *Medicine and Science in Sports and Exercise* 2010;**42**(7):1388–95. PUBMED: 20019626]

Yfanti 2012 {published data only}

Yfanti C, Fischer CP, Nielsen S, Akerström T, Nielsen AR, Veskoukis AS, et al. Role of vitamin C and E supplementation on IL-6 in response to training. *Journal of Applied Physiology* 2012;**112**(6):990–1000.

Zoppi 2006 {published data only}

Zoppi CC, Hohl R, Silva FC, Lazarim FL, Neto JM, Stancanneli M, et al. Vitamin C and E supplementation effects in professional soccer players under regular training. *Journal of the International Society of Sports Nutrition* 2006; **3**:37–44. PUBMED: 18500971]

References to ongoing studies

NCT02281981 {published data only}

Burr J. The effects of repeated bouts of downhill running and curcumin supplementation on arterial stiffness during recovery. https://clinicaltrials.gov/ct2/show/ NCT02281981?term=NCT02281981&rank=1 (accessed 20 April 2017).

Additional references

Armstrong 1984

Armstrong RB. Mechanisms of exercise-induced delayed onset muscular soreness: a brief review. *Medicine and Science in Sports and Exercise* 1984;**16**(6):529–38. [PUBMED: 6392811]

Asmussen 1953

Asmussen E. Positive and negative muscular work. *Acta Physiologica Scandinavica* 1953;**28**(4):364–82. [PUBMED: 13091912]

Beaton 2002

Beaton LJ, Allan DA, Tarnopolsky MA, Tiidus PM, Phillips SM. Contraction-induced muscle damage is unaffected by vitamin E supplementation. *Medicine and Science in Sports* and Exercise 2002;**34**(5):798–805. [PUBMED: 11984298]

Bieuzen 2013

Bieuzen F, Bleakley CM, Costello JT. Contrast water therapy and exercise induced muscle damage: a systematic review and meta-analysis. *PloS One* 2013;**8**(4):e62356. [DOI: 10.1371/journal.pone.0062356

Bjelakovic 2007

Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. *JAMA* 2007;**297**(8): 842–57. [PUBMED: 17327526]

Bjelakovic 2014

Bjelakovic G, Nikolova D, Gluud C. Antioxidant supplements and mortality. *Current Opinion in Clinical Nutrition and Metabolic Care* 2014;**17**(1):40–4. [PUBMED: 24241129]

Bleakley 2012

Bleakley C, McDonough S, Gardner E, Baxter GD, Hopkins JT, Davison GW. Cold-water immersion (cryotherapy) for preventing and treating muscle soreness after exercise. *Cochrane Database of Systematic Reviews* 2012, Issue 2. [DOI: 10.1002/14651858.CD008262.pub2

Borg 1998

Borg G. *Perceived Exertion and Pain Scale*. Champaign, IL: Human Kinetics, 1998.

Byrnes 1986

Byrnes WC, Clarkson PM. Delayed onset muscle soreness and training. *Clinics in Sports Medicine* 1986;**5**(3):605–14. [PUBMED: 3521903]

Castrogiovanni 2012

Castrogiovanni P, Imbesi R. Oxidative stress and skeletal muscle in exercise. *Italian Journal of Anatomy and Embryology* 2012;**117**(2):107–17. [PUBMED: 23420998]

Cheung 2003

Cheung K, Hume P, Maxwell L. Delayed onset muscle soreness: treatment strategies and performance factors. *Sports Medicine* 2003;**33**(2):145–64. [PUBMED: 12617692]

Childs 2001

Childs A, Jacobs C, Kaminski T, Halliwell B, Leeuwenburgh C. Supplementation with vitamin C and N-acetyl-cysteine increases oxidative stress in humans after an acute muscle injury induced by eccentric exercise. *Free Radical Biology and Medicine* 2001;**31**(6):745–53. [PUBMED: 11557312]

Cleak 1992

Cleak MJ, Eston RG. Delayed onset muscle soreness: mechanisms and management. *Journal of Sports Sciences* 1992;**10**(4):325–41. [PUBMED: 1518094]

Close 2005

Close GL, Ashton T, McArdle A, Maclaren DP. The emerging role of free radicals in delayed onset muscle soreness and contraction-induced muscle injury. *Comparative Biochemistry and Physiology. Part A, Molecular* & Integrative Physiology 2005;**142**(3):257–66. [PUBMED: 16153865]

Close 2014

Close GL, Jackson MJ. Antioxidants and exercise: a tale of the complexities of relating signalling processes to physiological function?. *Journal of Physiology* 2014;**592**(8): 1721–2. [PUBMED: 24737894]

Costello 2014

Costello JT, Bieuzen F, Bleakley CM. Where are all the female participants in Sports and Exercise Medicine research?. *European Journal of Sport Science* 2014;**14**(8): 847–51. [DOI: 10.1080/17461391.2014.911354

Costello 2015

Costello JT, Baker PRA, Minett GM, Bieuzen F, Stewart IB, Bleakley C. Whole-body cryotherapy (extreme cold air exposure) for preventing and treating muscle soreness after exercise in adults. *Cochrane Database of Systematic Reviews* 2015, Issue 9. [DOI: 10.1002/14651858.CD010789.pub2

Davies 1972

Davies CT, Barnes C. Negative (eccentric) work. II. Physiological responses to walking uphill and downhill on a motor-driven treadmill. *Ergonomics* 1972;**15**(2):121–31. [PUBMED: 5036082]

De Vries 1966

De Vries HA. Quantitative electromyographic investigation of the spasm theory of muscle pain. *American Journal of Physical Medicine* 1966;**45**(3):119–34. [PUBMED: 5938206]

Deeks 2011

Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins

JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.

EPOC 2013

Cochrane Effective Practice, Organisation of Care. EPOC Worksheets for preparing a Summary of Findings (SoF) table using GRADE 2013. http://epoc.cochrane.org/epocspecific-resources-review-authors (accessed 28 June 2016).

Ferreira 2011

Ferreira LF, Campbell KS, Reid MB. N-acetylcysteine in handgrip exercise: plasma thiols and adverse reactions. *International Journal of Sport Nutrition and Exercise Metabolism* 2011;**21**(2):146–54. [PUBMED: 21558576]

Gomez-Cabrera 2008

Gomez-Cabrera MC, Domenech E, Romagnoli M, Arduini A, Borras C, Pallardo FV, et al. Oral administration of vitamin C decreases muscle mitochondrial biogenesis and hampers training-induced adaptations in endurance performance. *American Journal of Clinical Nutrition* 2008; **87**(1):142–9. [PUBMED: 18175748]

Graphclick 2010 [Computer program]

Bovet J, Bovet S. Graphclick version 3.0.2. http:// www.arizona-software.ch/graphclick: Arizona, 2010.

Gross 2011

Gross M, Baum O, Hoppeler H. Antioxidant supplementation and endurance training: win or loss?. *European Journal of Sport Science* 2011;**11**(1):27–32.

Higgins 2011

Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.

Hough 1900

Hough T. Ergographic studies in muscular fatigue and soreness. *Journal of the Boston Society of Medical Sciences* 1900;**5**(3):81–92. [PUBMED: 19971340]

Howatson 2008b

Howatson G, van Someren KA. The prevention and treatment of exercise-induced muscle damage. *Sports Medicine* 2008;**38**(6):483–503. [PUBMED: 18489195]

Howatson 2010

Howatson G, McHugh MP, Hill JA, Brouner J, Jewell AP, van Someren KA, et al. Influence of tart cherry juice on indices of recovery following marathon running. *Scandinavian Journal of Medicine & Science in Sports* 2010; **20**(6):843–52. [PUBMED: 19883392]

Knez 2007

Knez WL, Jenkins DG, Coombes JS. Oxidative stress in half and full Ironman triathletes. *Medicine and Science in Sports and Exercise* 2007;**39**(2):283–8. [PUBMED: 17277592]

Lamprecht 2009

Lamprecht M, Hofmann P, Greilberger JF, Schwaberger G. Increased lipid peroxidation in trained men after 2 weeks of antioxidant supplementation. *International Journal of Sport Nutrition and Exercise Metabolism* 2009;**19**(4):385–99. [PUBMED: 19827463]

Lefebvre 2011

Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.

Lesser 2007

Lesser LI, Ebbeling CB, Goozner M, Wypij D, Ludwig DS. Relationship between funding source and conclusion among nutrition-related scientific articles. *PLoS Medicine* 2007;**4**(1):e5. [PUBMED: 17214504]

Malm 1996

Malm C, Svensson M, Sjoberg B, Ekblom B, Sjodin B. Supplementation with ubiquinone-10 causes cellular damage during intense exercise. *Acta Physiologica Scandinavica* 1996;**157**(4):511–2. [PUBMED: 8869734]

Margaritelis 2016

Margaritelis NV, Cobley JN, Paschalis V, Veskoukis AS, Theodorou AA, Kyparos A, et al. Principles for integrating reactive species into in vivo biological processes: examples from exercise physiology. *Cellular Signalling* 2016;**28**(4): 256–71. [PUBMED: 26721187]

Maughan 1989

Maughan RJ, Donnelly AE, Gleeson M, Whiting PH, Walker KA, Clough PJ. Delayed-onset muscle damage and lipid peroxidation in man after a downhill run. *Muscle & Nerve* 1989;**12**(4):332–6. [PUBMED: 2770784]

McGinley 2009

McGinley C, Shafat A, Donnelly AE. Does antioxidant vitamin supplementation protect against muscle damage? . *Sports Medicine* 2009;**39**(12):1011–32. [PUBMED: 19902983]

Nieman 2004

Nieman DC, Henson DA, McAnulty SR, McAnulty LS, Morrow JD, Ahmed A, et al. Vitamin E and immunity after the Kona Triathlon World Championship. Medicine and Science in Sports and Exercise 2004; Vol. 36, issue 8: 1328–35. [PUBMED: 15292740]

Paulsen 2012

Paulsen G, Mikkelsen UR, Raastad T, Peake JM. Leucocytes, cytokines and satellite cells: what role do they play in muscle damage and regeneration following eccentric exercise?. *Exercise Immunology Review* 2012;**18**:42–97. [PUBMED: 22876722]

Paulsen 2014

Paulsen G, Cumming KT, Holden G, Hallen J, Ronnestad BR, Sveen O, et al. Vitamin C and E supplementation hampers cellular adaptation to endurance training in humans: a double-blind, randomised, controlled trial. *Journal of Physiology* 2014;**592**(8):1887–901. [PUBMED: 24492839]

Peternelj 2011

Peternelj TT, Coombes JS. Antioxidant supplementation during exercise training: beneficial or detrimental?. *Sports Medicine* 2011;**41**(12):1043–69. [PUBMED: 22060178]

Powers 2008

Powers SK, Jackson MJ. Exercise-induced oxidative stress: cellular mechanisms and impact on muscle force production. *Physiological Reviews* 2008;**88**(4):1243–76. [PUBMED: 18923182]

Ramel 2004

Ramel A, Wagner KH, Elmadfa I. Plasma antioxidants and lipid oxidation after submaximal resistance exercise in men. *European Journal of Nutrition* 2004;**43**(1):2–6. [PUBMED: 14991263]

RevMan 2014 [Computer program]

The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.

Ristow 2009

Ristow M, Zarse K, Oberbach A, Kloting N, Birringer M, Kiehntopf M, et al. Antioxidants prevent health-promoting effects of physical exercise in humans. *Proceedings of the National Academy of Sciences of the United States of America* 2009;**106**(21):8665–70.

Schünemann 2011

Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al. Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.

Slatore 2008

Slatore CG, Littman AJ, Au DH, Satia JA, White E. Longterm use of supplemental multivitamins, vitamin C, vitamin E, and folate does not reduce the risk of lung cancer. *American Journal of Respiratory and Critical Care Medicine* 2008;**177**(5):524–30. [PUBMED: 17989343]

Smith 1991

Smith LL. Acute inflammation: the underlying mechanism in delayed onset muscle soreness?. *Medicine and Science*

in Sports and Exercise 1991;**23**(5):542–51. [PUBMED: 2072832]

Tashjian 2009

Tashjian RZ, Deloach J, Porucznik CA, Powell AP. Minimal clinically important differences (MCID) and patient acceptable symptomatic state (PASS) for visual analog scales (VAS) measuring pain in patients treated for rotator cuff disease. *Journal of Shoulder and Elbow Surgery* 2009;**18**(6): 927–32.

Teixeira 2009

Teixeira VH, Valente HF, Casal SI, Marques AF, Moreira PA. Antioxidants do not prevent postexercise peroxidation and may delay muscle recovery. *Medicine and Science in Sports and Exercise* 2009;**41**(9):1752–60. [PUBMED: 19657294]

Tsai 2001

Tsai K, Hsu TG, Hsu KM, Cheng H, Liu TY, Hsu CF, et al. Oxidative DNA damage in human peripheral leukocytes induced by massive aerobic exercise. *Free Radical Biology & Medicine* 2001;**31**(11):1465–72. [PUBMED: 11728819]

Watson 2010

Watson T. The science of antioxidants and exercise performance. In: Burke L, Deakin V editor(s). *Clinical Sports Nutrition.* 4th Edition. Sydney: McGraw-Hill, 2010: 295–303.

Weinstock 1997

Weinstock C, Konig D, Harnischmacher R, Keul J, Berg A, Northoff H. Effect of exhaustive exercise stress on the cytokine response. *Medicine and Science in Sports and Exercise* 1997;**29**(3):345–54. [PUBMED: 9139173]

Witt 1992

Witt EH, Reznick AZ, Viguie CA, Starke-Reed P, Packer L. Exercise, oxidative damage and effects of antioxidant manipulation. *Journal of Nutrition* 1992;**122**(3 Suppl): 766–73. [PUBMED: 1514950]

References to other published versions of this review

Ranchordas 2012

Ranchordas MK, Rogerson D, Soltani H. Antioxidants for preventing and reducing muscle soreness after exercise. *Cochrane Database of Systematic Reviews* 2012, Issue 4. [DOI: 10.1002/14651858.CD009789

* Indicates the major publication for the study

CHARACTERISTICS OF STUDIES

Characteristics of included studies [ordered by study ID]

Arent 2010

Methods	Randomised controlled trial (cross-over design) Separated by a 5-day washout	
Participants	Setting: laboratory; USA n = 24 college-aged males with at least 1 year of weightlifting experience; mean age 21. 3 (SE 0.4) years 18 participants completed the study; 1 participant dropped out due to training conflicts with his sport and the other 5 participants withdrew of their own volition due to the inability to tolerate the physical demands of the testing protocol Inclusion/exclusion criteria This study was limited to males in order to control for fluctuations in cortisol that occur during the menstrual cycle. At initial enrolment, all participants self-reported to be free from current injuries limiting their ability to train and complete physiological testing	
Interventions	Intervention Black tea extract: each 2-capsule serving contained 880 mg black tea extract and was standardised for 350 mg theaflavin 4 capsules per day - 2 in the morning and 2 in the afternoon Placebo Not specified Duration Supplements were taken 9 days before and 2 days after exercise (11 days)	
Outcomes	 PRIMARY Muscle soreness was assessed using a 10 cm visual analogue scale (VAS). The anchor at 0 corresponds to "no soreness" and at 10 to "too sore to move muscles". Participants were asked to perform one squat with hands on hips and then draw a line on the scale corresponding to their level of soreness SECONDARY Wingate 30-second sprint was performed on a Monark 894E Anaerobic Test Ergometer (Monark Exercise AB, Sweden). The load was set according to each participant's mass. The test was 30 seconds of all out cycling followed by 5 minutes of rest and then 8 x 10-second intervals of all out cycling. Each interval was separated by 2 minutes of rest. The resistance for the Wingate and intervals was set at 0.10 kP/kg body mass 	
Exercise type	30-second Wingate with 5 minutes rest followed by 8 x 10-second maximal sprints with 2 minutes recovery	
Sources of funding	The study was funded by WellGen, Inc USA through an unrestricted research	
Notes	Author was contacted via email on 27 May 2016 to request data for delayed onset muscle soreness but did not respond	
Risk of bias		

Arent 2010 (Continued)

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	No details specified in manuscript Author was contacted via email on 27 May 2016 but did not respond
Allocation concealment (selection bias)	Unclear risk	No details specified in manuscript Author was contacted via email on 27 May 2016 but did not respond
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double-blind
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Double-blind
Incomplete outcome data (attrition bias) All outcomes	High risk	6 participants withdrew from the study Attrition rate = 25%
Selective reporting (reporting bias)	High risk	No published protocol available All outcomes reported at all time points Adverse effects of antioxidant supplemen- tation were not reported
Other bias	Low risk	Participants were asked to refrain from using anti-inflammatory medication and other supplements for the duration of the study Participants were also asked to keep food records

Avery 2003

Methods	Randomised controlled trial (parallel design)	
Participants	Setting: laboratory; USA n = 18 healthy men who were active in endurance sports but not resistance trained (9 in each group) Mean age vitamin group: 22.7 ± 4.1 years Mean age placebo group: 22.3 ± 3.6 years Inclusion/exclusion criteria Participants were normally actively participating in endurance and sports activities but not resistance training to ensure the whole-body resistance exercise protocol resulted in detectable muscle soreness and muscle disruption. The participants had not lost or gained weight in the previous year, were not adhering to special diets and were not regular consumers of nutritional supplements including vitamin E. All participants were non-	

Avery 2003 (Continued)

	smokers and not currently taking any medication known to affect any of the dependant variables in the study	
Interventions	Intervention Vitamin E supplementation 992 mg per day (1200 IU) Number of capsules per day not specified Placebo Microcrystalline cellulose Duration 31 days	
Outcomes	PRIMARY Delayed onset muscle soreness of the shoulders, chest, quadriceps and hamstrings was evaluated using a visual analogue scale (0 to 10 cm) where 0 is "no pain" and 10 is "extreme pain" after performing shoulder abduction, shoulder horizontal adduction and hip flexion (unloaded squat)	
Exercise type	Whole body resistance exercise training protocol; 3 sets of 10 repetitions of 30% to 60% 1 RM	
Sources of funding	None	
Notes	Authors were contacted on 25 May 2016 to request data for delayed onset muscle soreness with no reply	

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Participants were matched according to physical characteristics and training history and then randomly assigned using a com- puter program
Allocation concealment (selection bias)	Unclear risk	No details in the manuscript Authors were contacted on 25 May 2016 with no reply
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double-blind
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Double-blind
Incomplete outcome data (attrition bias) All outcomes	Low risk	All participants completed the study

Avery 2003 (Continued)

Selective reporting (reporting bias)	High risk	No published protocol available All outcomes reported at all time points Adverse effects of antioxidant supplement were not reported
Other bias	Low risk	Participants were asked to refrain from using anti-inflammatory medication and other supplements for the duration of the study as well as any form of therapeutic in- tervention such as massage and ice Participants who were exposed to any form of resistance training were also excluded

Bailey 2011

Methods	Randomised controlled trial (parallel design)	
Participants	Setting: field and laboratory; UK n = 38 healthy young men (18 in the antioxidant group and 20 in the placebo group); mean age 22 (SD 1) years Inclusion/exclusion criteria All participants were non-smokers and habitually active in a variety of sports but were unfamiliar with the specific exercise protocol involved in the study	
Interventions	Intervention Mixed antioxidant supplement. 400 mg vitamin C, 268 mg vitamin E, 2 mg vitamin B6, 200 μg vitamin B9, 5 μg zinc sulphate, 1 μg vitamin B12 capsules 1 capsule daily Placebo Lactose capsules Duration 6 weeks	
Outcomes	PRIMARY Delayed onset muscle soreness using a visual analogue scale 1 to 10 with anchor terms ranging from 1 being "not sore" to 10 being "very very sore" SECONDARY Peak isometric torque of knee flexors Range of motion at the knee	
Exercise type	90-minute intermittent shuttle running	
Sources of funding	The study received financial support from Unilever R&D	
Notes	-	
Risk of bias		

Bailey 2011 (Continued)

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Randomised using a computer generator
Allocation concealment (selection bias)	Low risk	Identical capsules ingested twice daily with meals
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double-blind
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Double-blind
Incomplete outcome data (attrition bias) All outcomes	Low risk	All participants completed the study
Selective reporting (reporting bias)	High risk	No published protocol available All outcomes reported at all time points Adverse effects of antioxidant supplemen- tation were not reported
Other bias	Unclear risk	No details on whether participants were asked to refrain from using other supple- ments or anti-inflammatory medication

Beaton 2002a

Methods	Randomised controlled trial (parallel design)	
Participants	Setting: laboratory; USA n = 18 healthy men, mean age 20.3 (SD 1.70) years Inclusion/exclusion criteria Non-smokers, not taking vitamin E supplements(or any other antioxidant or related supplements) and had not participated in resistance training, or any other form of structured exercise for at least 6 months	
Interventions	Intervention 1200 IU vitamin E supplementation Placebo Safflower oil Duration 30 days	
Outcomes	PRIMARY Muscle soreness was assessed using the Descriptor Differential Scale (DDS) at the quadri-	

Beaton 2002a (Continued)

	ceps where 0 is "no pain" and 10 is "extreme pain" SECONDARY Peak isometric torque of knee flexors performed on the Biodex. Participants performed 3 maximal voluntary contraction repetitions each being of 5 seconds duration with 60 seconds rest in between
Exercise type	24 sets of 10 repetitions of eccentric knee flexion and extension contractions
Sources of funding	The authors acknowledged Quest vitamins (Vancouver, BC) for the gracious donation of the vitamin E used in the study. "This work was supported by NSERC (SMP). SMP is the recipient of a PREA and gratefully acknowledges that source of support in aiding in the completion of this research."
Notes	Supplements were given in the form of a capsule Authors were contacted on numerous occasions to request data for delayed onset muscle soreness, maximal voluntary isometric contraction and range of motion with the final email sent 25 May 2016 with no reply

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	No details in the manuscript Authors were contacted on numerous oc- casions with final email sent 25 May 2016 with no reply
Allocation concealment (selection bias)	Unclear risk	No details in the manuscript Authors were contacted on numerous oc- casions with final email sent 25 May 2016 with no reply
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double-blind
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Double-blind
Incomplete outcome data (attrition bias) All outcomes	Low risk	All participants completed the study
Selective reporting (reporting bias)	High risk	No published protocol available All outcomes reported at all time points Adverse effects of antioxidant supplemen- tation were not reported

Beaton 2002a (Continued)

Other bias	Low risk	Participants were non-resistance trained and were asked to refrain from using other supplements or anti-inflammatory medica- tion	
Bell 2015			
Methods	Double-blind randomised o	Double-blind randomised controlled trial (parallel design)	
Participants	n = 16 healthy men (8 in th Mean age 30 (SD 8) years Inclusion/exclusion criter Exclusion criteria for the s fruit products, currently tak	Setting: laboratory; England n = 16 healthy men (8 in the experimental group; 8 in the placebo group) Mean age 30 (SD 8) years Inclusion/exclusion criteria Exclusion criteria for the study included > 45 years of age, female, allergy to specific fruit products, currently taking any nutritional supplements or medication, and history of gastrointestinal, renal or cardiovascular disease	
Interventions	and 1800 hours) for 8 cons trial). Manuscript states "m UK), each 30 mL dose of M dent laboratory analysis sho 669.4 mg·mL–1 of carboh Placebo A commercially available m , mixed with 100 mL water	Participants were instructed to consume 30 mL of the supplement twice per day (0800 and 1800 hours) for 8 consecutive days (4 days pretrial, on the day of, and 3 days post- trial). Manuscript states "manufacturer's specification (Cherry Active Ltd, Hanworth, UK), each 30 mL dose of MC contained ~90-110 Montmorency tart cherries; indepen- dent laboratory analysis shows the juice to provide 9.2 mg·mL-1 of anthocyanins and 669.4 mg·mL-1 of carbohydrate (Atlas Biosciences, Tuscon, Ariz., USA)" Placebo A commercially available mixed berry cordial (less than 5% fruit in concentrate form), mixed with 100 mL water and maltodextrin (MyProtein Ltd., Northwich, UK) until matched for carbohydrate content Duration	
Outcomes	pain" and 200 is "pain/soren completing a squat to appro marked upon the scale to in SECONDARY Maximum voluntary isome mined using a strain gauge seated on a platform and th ternal joint angle of 80° (ver verbal encouragement for th Each contraction was separa	 PRIMARY Muscle soreness was assessed using a 0 to 200 mm visual analogue scale where 0 is "no pain" and 200 is "pain/soreness as bad as it could be". Participants rated their soreness after completing a squat to approximately a 90° knee flexion before standing and immediately marked upon the scale to indicate their level of soreness SECONDARY Maximum voluntary isometric contraction of the dominant knee extensors was determined using a strain gauge (MIE Medical Research Ltd., Leeds, UK). Participants were seated on a platform and the strain gauge was attached to the dominant ankle at an internal joint angle of 80° (verified by a goniometer). Participants were given standardised verbal encouragement for the duration of each of the 3 maximum 3-second contraction. Each contraction was separated by 1 minute Power: 6-second peak cycle power 	
Exercise type	-	A 109-minute cycling trial designed to replicate road race demands on an electromag- netically braked, cycle ergometer (Velotron Racer-Mate, Seattle, Wash., USA)	

Bell 2015 (Continued)

Sources of funding	Manuscript states: "The Cherry Marketing Institute (a not for profit organisation) pro- vided financial support for the analysis of inflammatory indices"
Notes	Authors were contacted on 3 February 2017 to request raw data for delayed onset muscle soreness and maximal voluntary isometric contraction and responded on 3 February 2017

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	No details in manuscript Authors confirmed via email on 3 February 2017 that stratified randomisation based on aerobic fitness and coin toss was em- ployed
Allocation concealment (selection bias)	Low risk	No details in manuscript Author confirmed via email on 3 February 2017 that opaque vessels used for all drink- ing bottles and this was prepared by an in- dependent member of the department
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double-blind
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Double-blind
Incomplete outcome data (attrition bias) All outcomes	Low risk	All participants completed the study
Selective reporting (reporting bias)	High risk	Delayed onset muscle soreness data im- mediately post-exercise not recorded or re- ported Adverse effects of antioxidant supplemen- tation were not reported
Other bias	Low risk	Participants did not complete any other ex- ercise or take supplements/medication over the course of the study

Bell 2016

Methods	Double-blind randomised controlled trial (parallel design)
Participants	Setting: laboratory; England n = 16 semi professional male soccer players (8 in the experimental group; 8 in the placebo group) Mean age 25 (SD 4) years Inclusion/exclusion criteria Inclusion criteria required participants to have trained in soccer consistently across the preceding 3 years and be free of any lower limb injury for the preceding 6 months
Interventions	 Intervention Participants were instructed to consume 30 mL of the supplement twice per day (0800 and 1800 hours) for 7 consecutive days (4 days pretrial and on each trial day). The supplement was a commercially available Montmorency cherry concentrate (CherryActive, Sunbury, UK); containing a total anthocyanin content of 73.5 mg·L-1 of cyanidin-3-glucoside, a total phenolic content of 178.8 gallic acid equivalent·L-1 and an antioxidant capacity (TEAC) of 0.58 trolox equivalents·L-1 Placebo A commercially available, less than 5% fruit, cordial, mixed with water and maltodextrin (MyProtein Ltd, Northwich, UK) until matched for energy content of the intervention (102 kcal) Duration 7 days
Outcomes	 PRIMARY Muscle soreness was assessed using a 0 to 200 mm visual analogue scale where 0 is "nopain" and 200 is "unbearably painful". Participants rated their soreness after completing a squat to approximately a 90° knee flexion before standing and immediately marked upon the scale to indicate their level of soreness SECONDARY Maximum voluntary isometric contraction of the dominant knee extensors was determined using a strain gauge (MIE Medical Research Ltd., Leeds, UK). Participants were given standardised verbal encouragement for the duration of each of the 3 maximum 3-second contractions. Each contraction was separated by 1 minute Sprint performance (20 m - infrared timing gates) Agility: 5-0-5 agility test (infrared timing gates) Power: counter movement jump (jump mat)
Exercise type	12 × 20 m run sprints, departing every 60 seconds followed by an adapted version of the Loughborough Intermittent Shuttle Test (LIST) (6 x 15-minute sections)
Sources of funding	The Cherry Marketing Institute (a not for profit organisation) provided financial support for the analysis of inflammatory indices
Notes	Authors were contacted on 3 February 2017 to request raw data for delayed onset muscle soreness and maximal voluntary isometric contraction and responded on 3 February

Bell 2016 (Continued)

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	No details in manuscript Authors confirmed via email on 3 February 2017 that stratified randomisation based on aerobic fitness and coin toss was em- ployed
Allocation concealment (selection bias)	Low risk	Manuscript states: "All supplements were prepared by an independent member of the department prepared in opaque bottles in order to maintain the double blind design"
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double-blind
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Double-blind
Incomplete outcome data (attrition bias) All outcomes	Low risk	No details in manuscript Authors confirmed via email on 3 Febru- ary 2017 that all participants completed the study
Selective reporting (reporting bias)	High risk	Delayed onset muscle soreness data im- mediately post-exercise not recorded or re- ported Adverse effects of antioxidant supplemen- tation were not reported
Other bias	Unclear risk	Manuscript states that participants "were also provided with a diet record diary and a list of foods to avoid throughout the 4 days prior to and during the trial period" No information on NSAIDs or medication

Bloomer 2004

Methods	Randomised controlled trial (parallel design)	
Participants	Setting: laboratory; USA n = 18 healthy women age range 19 to 31 years (9 in each group) Inclusion/exclusion criteria Participants provided a medical history and completed physical activity and diet and sup- plementation questionnaires to determine eligibility. None had orthopaedic or metabolic conditions that could have affected the variables of measurement. All participants were	

Bloomer 2004 (Continued)

	non-smokers, did not use oral contraceptives, anti-inflammatory drugs or dietary sup- plements (i.e. antioxidants for at least the past 3 months), and all were classified as non- resistance trained (i.e. had not performed resistance training in the past 12 months)	
Interventions	Intervention 268 mg vitamin E, 1 g vitamin C, 90 μg selenium Placebo Lactose placebo pill 3 capsules per day Duration 18 days	
Outcomes	PRIMARYDelayed onset muscle soreness in both arms using a visual analogue scale (0 to 10 cm) where 0 is "no pain" and 10 is "unbearable pain"Soreness was measured following active movement of elbow flexion or extension, as well as following light palpitation by the investigatorsSECONDARYMaximum isometric force was performed on the Biodex isokinetic dynamometer (Biodex Medical Systems, Ronkonkoma, NY). Participants were secured in the Biodex chair by shoulder and lap belts. Participants were asked to perform 3 maximal isometric unilateral contractions with their elbow flexors each lasting 3 seconds with 60 seconds rest in between each effort Range of motion was measured both relaxed and flexed at the elbow. Range of motion was calculated as relaxed minus flexed	
Exercise type	$4~{\rm sets}$ of $12~{\rm repetitions}$ of non-dominant elbow flexors at an angular velocity of $20^{\circ}/~{\rm second}$	
Sources of funding	None	
Notes	Authors were contacted on 3 October 2013 to request raw data for delayed onset muscle soreness and maximal voluntary isometric contraction and responded on 1 November 2013	

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	No details in manuscript Authors were contacted on 24 May 2016; response: "Likely via coin flip or random number selection"
Allocation concealment (selection bias)	Low risk	Response: "Blinding code retained by per- son not associated with research and/or provided in sealed envelope"

Bloomer 2004 (Continued)

Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double-blind
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Double-blind
Incomplete outcome data (attrition bias) All outcomes	Low risk	All participants completed the study with 100% compliance
Selective reporting (reporting bias)	High risk	No published protocol available All outcomes reported at all time points Adverse effects of antioxidant supplemen- tation were not reported
Other bias	Low risk	Participants were non-resistance trained and relatively inactive Participants were asked to refrain from us- ing other supplements or anti-inflamma- tory medication and oral contraceptives

Bloomer 2005

Methods	Randomised controlled trial (parallel design)	
Participants	Setting: laboratory; USA n = 20 weight-trained men (10 in the experimental group; 10 in the placebo group) Antioxidant group: mean age 24 (SEM 1.1) years Placebo group: mean age 26.2 (SEM 2.0) years Inclusion/exclusion criteria All participants had been weight training their lower body for a minimum of 12 months prior to testing and demonstrated a minimum strength of 1.5 times their body weight in the barbell back squat exercise. All participants were free of the orthopaedic and metabolic conditions that would have affected the variables of measurement	
Interventions	Intervention Astaxanthin - BioAstin; 1732 mg safflower oil; haematococcus algae extract (contains 4 mg astaxanthin and 480 mg lutein) Placebo 1732 mg safflower oil 2 capsules per day Duration 3 weeks before and 96 hours after	
Outcomes	PRIMARY Delayed onset muscle soreness in the dominant leg during knee extension using a 10 cm visual analogue scale where 0 is "no pain" and 10 is "unbearable pain"	

Bloomer 2005 (Continued)

	SECONDARY Muscle performance 1 RM concentric strength in the knee extension Isometric knee extensor action was performed using the modified York barbell (York, P. A. knee extension/flexion machine. The cable length was adjusted so that the knee was at 90 degrees flexion Mean dynamic force was determined in the knee extension exercise using a Body-Solid knee extension machine interfaced with a Fitrodyne dynamometer (Fitronic, Bratislava, Slovakia)
Exercise type	York knee extension machine 10 sets of 10 repetitions at 85% of 1 RM
Sources of funding	The study was supported by Cyanotech Corp. Kailua-Kona, HI, and IMAGINNutrition, Inc. Laguna Niguel, CA
Notes	Authors were contacted on 3 October 2013 to request raw data for delayed onset muscle soreness and maximal voluntary isometric contraction and responded on 1 November 2013

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	No details in manuscript Authors were contacted on 24 May 2016; response: "Likely via coin flip or random number selection"
Allocation concealment (selection bias)	Low risk	No details in manuscript Authors were contacted on 24 May 2016; response: "Blinding code retained by per- son not associated with research and/or provided in sealed envelope"
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double-blind
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Double-blind
Incomplete outcome data (attrition bias) All outcomes	Low risk	All participants successfully completed testing with 100% compliance
Selective reporting (reporting bias)	High risk	No published protocol available All outcomes reported at all time points Adverse effects of antioxidant supplemen- tation were not reported

Bloomer 2005 (Continued)

Other bias	Unclear risk	No details on whether participants were asked to refrain from using other supple- ments or anti-inflammatory medication	
Bloomer 2007			
Methods	Randomised controlled trial (parallel design)	
Participants	 18 participants had prior exer second group were included in "6 participants did not comp problems with blood donation Participants withdrew from the placebo; 2 participants from prior exercise placebo group; Inclusion/exclusion criteria No participant was vegetarian inflammatory drugs, or antiox during the study period. Eligith pressing a load greater or equ using dynamic (concentric/ec study participation (with no lated) 	 n = 36 men mean age 25 (SD 5) years 18 participants had prior exercise and 18 had no prior exercise; only the results for the second group were included in this review "6 participants did not complete the study due to personal reasons (e.g. lack of time, problems with blood donation, injury resulting from accident not to the study" Participants withdrew from the following groups: 1 participant from no prior exercise placebo; 2 participants from no prior exercise antioxidant group; 2 participants from prior exercise antioxidant group 	
Interventions	3 mg beta, 84 mg delta, 250 r alpha, 1.5 mg beta, 5 mg delta Placebo	Mixed antioxidant 1000 mg of vitamin C + 378 mg mixed tocopherols - 41 mg alpha, 3 mg beta, 84 mg delta, 250 mg gamma; and 39.5 mg mixed tocotrienols - 11 mg alpha, 1.5 mg beta, 5 mg delta, 22 mg gamma Placebo Soft gel (soybean oil) and powder (cellulose) placebos were identical in appearance to the antioxidants 2 capsules per day Duration	
Outcomes	of 2 (concentric-eccentric) rep 20 kg barbell. 0 represents "no SECONDARY Maximal isometric force in a plate and power rack design.	Delayed onset muscle soreness, visual analogue scale (0 to 10 cm) following performance of 2 (concentric-eccentric) repetitions of the barbell bench press exercise using a standard 20 kg barbell. 0 represents "no pain" and 10 represents "intense pain"	
Exercise type	Barbell bench press 10 sets, 10	Barbell bench press 10 sets, 10 reps of 70% 1 RM	

Bloomer 2007 (Continued)

Sources of funding	Supported in part by Jarrow Formulas and The National Strength and Conditioning Association Graduate Student Research Grant
Notes	Authors were contacted on 3 October 2013 to request raw data for delayed onset muscle soreness and maximal voluntary isometric contraction and responded on 1 November 2013 In our review, only the data from the no prior exercise group were used

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	No details in manuscript Authors were contacted on 24 May 2016; response: "Likely via coin flip or random number selection"
Allocation concealment (selection bias)	Low risk	No details in manuscript Authors were contacted on 24 May 2016; response: "Blinding code retained by per- son not associated with research and/or provided in sealed envelope"
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double-blind
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Double-blind
Incomplete outcome data (attrition bias) All outcomes	High risk	6 participants did not complete all aspects of the study for personal reasons Attrition rate: 17%
Selective reporting (reporting bias)	High risk	No published protocol available All outcomes reported at all time points Adverse effects of antioxidant supplemen- tation were not reported
Other bias	Low risk	Participants were asked to refrain from using anti-inflammatory medication and other supplements for the duration of the study

Bryer 2006

Methods	Randomised controlled trial (parallel design)	
Participants	Setting: laboratory, USA n = 18 young, untrained males who did not weight train for 6 months, mean age 24.4 (SEM 1.7) years Inclusion/exclusion criteria All participants were prescreened, in good health, abstained from vitamin or herba supplements for at least 6 months and were free of any muscular injuries	
Interventions	Intervention Vitamin C supplementation (3 g per day) Placebo Starch pills 3 capsules per day and participants were asked to keep food records Duration Supplementation given 2 weeks prior and 4 days after exercise	
Outcomes	 PRIMARY Delayed onset muscle soreness was assessed by means of a linear scale from 1 to 10 in a rested position and in response to palpation on the arms of the muscle where 1 is "no pain" and 10 is "extreme pain" SECONDARY Isometric force was conducted on an isokinetic dynamometer (Biodex System 3 Isokinetic Dynamometer, Biodex Medical Systems, Shirely, NY). Participants performed 3 concentric maximum voluntary contractions (MVC) and the forces were recorded for both the dominant and non-dominant arms through a full range of motion at a speed of 1.75 rad/second. The highest force obtained with no movement of the lever arm was accepted as the maximum isometric force Range of motion was assessed on both arms using a goniometer placed on markings from the medial aspect of th elbow of the humerus 	
Exercise type	70 eccentric actions using the elbow flexors	
Sources of funding	None	
Notes	Authors were contacted via email on 25 November 2013 to request data for delayed onset muscle soreness, maximal voluntary isometric contraction and range of motion, but did not respond	

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	No details in manuscript Authors were contacted via email on 25 November 2013 but no information was provided

Bryer 2006 (Continued)

Allocation concealment (selection bias)	Unclear risk	Participants were given numbered contain- ers for the 3 capsules per day Authors were contacted via email on 25 November 2013 but no information was provided
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	No details provided in the manuscript Authors were contacted via email on 25 November 2013 but no information was provided
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	No details provided
Incomplete outcome data (attrition bias) All outcomes	Low risk	All participants completed the study with no adverse outcomes
Selective reporting (reporting bias)	High risk	No published protocol available All outcomes reported at all time points Adverse effects of antioxidant supplemen- tation were not reported
Other bias	Low risk	Participants were asked to refrain from us- ing any supplements; medication and diet was controlled in both groups

Close 2006

Methods	Randomised controlled trial (parallel design)
Participants	Setting: laboratory; UK n = 20 physically active males naive to downhill running Placebo group mean age 22.1 (SEM 0.4) years (n = 10) Vitamin C group mean age 24.2 (SEM 1.5) years (n = 10) Inclusion/exclusion criteria All participants were non-smokers and free from any known illness as ascertained by questionnaire Participants taking any form of vitamin supplementation were excluded
Interventions	Intervention 1 g of vitamin C supplementation Placebo Lactose placebo Duration 14 days

Close 2006 (Continued)

Outcomes	 PRIMARY Delayed onset muscle soreness was measured at the gastrocnemius, anterior tibialis, hamstrings, quadriceps, gluteals (both sides) and lower back muscles using a 10-point visual analogue scale where 0 is "no pain" and 10 is "extreme pain" SECONDARY Muscle function was performed an isokinetic dynamometer. The test involved concentric quadriceps muscle torque assessment at 1.06 and 5.20 rad/second as well as eccentric quadriceps assessment at 2.6 rad/second Muscle tenderness was measurement using pressure algometry at the gastrocnemius, anterior tibialis, hamstrings, quadriceps, gluteals (both sides) and lower back muscles
Exercise type	30 minutes of downhill running on a treadmill at a grade of -15% at 60% VO2max
Sources of funding	None
Notes	No details on whether supplement was administered as a drink or a capsule or a powder Authors were contacted to request raw data for PPT, delayed onset muscle soreness and maximal voluntary isometric contraction on 3 October 2013 and responded on 3 December 2013

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	No details in manuscript Authors were contacted via email 17 May 2016 Author response: "A random number gen- erator to allocate into groups and from memory they were block randomised ac- cording to their VO2max"
Allocation concealment (selection bias)	Low risk	No details in manuscript Authors were contacted via email 17 May 2016 Author response: "All supplements were given in visually identical capsules double blind"
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double-blind
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Double-blind
Incomplete outcome data (attrition bias) All outcomes	Low risk	All participants completed the study with no adverse effects

Close 2006 (Continued)

Selective reporting (reporting bias)	High risk	No published protocol available All outcomes reported at all time points Adverse effects of antioxidant supplemen- tation were not reported
Other bias	Low risk	Participants were asked to refrain from using anti-inflammatory medication and other supplements for the duration of the study as well as any form of therapeutic in- tervention such as massage and ice

Cobley 2011

Methods	Randomised controlled trial (parallel design)	
Participants	Setting: Laboratory and Field; UK n = 14 recreationally trained males mean age 24.7 (SD 4.2) years (6 in each group) 2 participants dropped out for personal reasons Inclusion/exclusion criteria Recreationally trained was defined as participating in physical activity of an intermittent nature at least 3 times per week for at least 12 months. Prospective participants were excluded if they smoked or engaged in any course of supplementation or medication (e. g. antioxidant supplementation) that may have interfered with the study's results	
Interventions	Intervention N-acetylcysteine supplementation 50 mg/kg Placebo Water and cordial Duration 6 days	
Outcomes	 PRIMARY Delayed onset muscle soreness was assessed by a 12-point visual analogue scale where 0 is "no pain" and 12 is "intolerable pain". Participants were required to mark a point on the VAS that corresponded to their perception of total muscle soreness after performing a 90 degree squat SECONDARY Absolute muscle torque was determined in the dominant limb concentric quadriceps using a Isokinetic Dynamomter (Biodex Medical Systems, Shirely, NY). Concentric quadriceps torque was determined at 60, 180 and 300 rad/second. 3 maximal repetitions were performed at each speed with the greatest value attained being recorded Yo-Yo Intermittent Recovery Test Level 1. Involves the performance of consecutive 2 x 20 m shuttles separated by 10 seconds recovery intervals. Running velocity is dictated by audio beeps and increased by 0.5 km/hour throughout the test until volitional exhaustion ensues Loughborough intermittent Shuttle Test was completed in a well-ventilated indoor run- way. This consists of successive cycles of cruising at 95% VO2max (60 m), jogging at 	

Cobley 2011 (Continued)

	55% VO2max (60 m), walking (60 m) and maximally sprinting (20 m) between 2 pairs of timing lights placed 20 m apart in time with audio beeps for 15 minutes Side effects on a scale of 0 to 10
Exercise type	Loughborough intermittent Shuttle Test and Yo-Yo Intermittent Recovery Test Level 1
Sources of funding	None
Notes	N-acetylcysteine and placebo supplementation mixed in water Authors were contacted to request raw data for delayed onset muscle soreness, maxi- mal voluntary isometric contraction and performance data on 3 December 2013 and responded on 5 December 2013

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Pair-matched based on performance on the baseline test
Allocation concealment (selection bias)	Low risk	Not specified in manuscript Authors were contacted on 21 February 2017 and replied "treatment allocation was done in sealed opaque containers"
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double-blind
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Double-blind
Incomplete outcome data (attrition bias) All outcomes	Low risk	2 participants dropped out for personal rea- sons Attrition rate: 14.3%
Selective reporting (reporting bias)	Low risk	No published protocol available All outcomes reported at all time points
Other bias	Low risk	Participants were asked to refrain from using anti-inflammatory medication and other supplements for the duration of the study as well as any form of therapeutic in- tervention such as massage and ice

Connolly 2006

Methods	Randomised controlled trial (parallel design)
Participants	Setting: 2006, USA n = 24 healthy college males and females mean age 22 (SD 4) years Inclusion/exclusion criteria Without upper extremity injury, or previous known history of injury. Potential partic- ipants who indicated arm discomfort during any baseline assessments were excluded. Participants who reported habitually participating in a strenuous resistance-training pro- gramme involving elbow flexors, or unusual upper extremity activity were also excluded
Interventions	Intervention Vitamin C supplementation 1000 mg 3 times per day Placebo 3 x 50 mg per day of glucose Duration Supplements given 3 days before and 5 days after damaging exercise
Outcomes	PRIMARYDelayed onset muscle soreness assessed at the quadriceps by a 0 to 10 visual analogue scale where 0 is "no discomfort whatsoever" and 10 is "indicated extreme pain and discomfort"SECONDARYMaximal isometric strengthMuscle tenderness scores were assessed using a standard manual muscle myometer. Mea- surements were made just proximal to the distal tendon of the biceps. Force was applied via the probe through a 1 cm diameter head until the participant indicated pain or dis- comfort
Exercise type	40 maximal eccentric contractions of the elbow flexors (2 x 20)
Sources of funding	None
Notes	Authors were contacted on 30 October 2013 to request data for delayed onset muscle soreness and maximal voluntary isometric contraction but did not respond

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Randomly assigned (no details specified in the manuscript) Authors have been contacted with no re- sponse (19 May 2016)
Allocation concealment (selection bias)	Unclear risk	No details specified in manuscript Authors have been contacted with no re- sponse (19 May 2016)

Connolly 2006 (Continued)

Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double-blind
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Double-blind
Incomplete outcome data (attrition bias) All outcomes	Low risk	All participants completed the study
Selective reporting (reporting bias)	High risk	No published protocol available All outcomes reported at all time points Adverse effects of antioxidant supplemen- tation were not reported
Other bias	Low risk	Participants were asked to refrain from using anti-inflammatory medication and other supplements for the duration of the study as well as any form of therapeutic in- tervention such as massage and ice. Partici- pants who were exposed to any form of re- sistance training were also excluded

Connolly 2006a

Methods	Randomised controlled trial (cross-over design) Separated by a 14-day washout
Participants	Setting: laboratory; USA n = 16 men (training status not specified) Mean age vitamin C group 22.3 (SD 3.90) years Mean age placebo group 22.6 (SD 4.6) years Inclusion/exclusion criteria Not specified Authors were contacted via email on 30 October 2013 and again on 26 May 2016
Interventions	Intervention Freshly prepared tart cherry juice with commercially available apple juice. One 12 oz bottle of juice provided at least 600 mg phenolic compounds and at least 40 mg of anthocyanins. Each bottle contained approximately 50 to 60 cherries. 2 x 12 oz bottles consumed daily Placebo Unsweetened black cherry Kool-Aid with added sugar Duration 8 days with a 2-week washout

Connolly 2006a (Continued)

Outcomes	 PRIMARY Pain scores were obtained by asking participants to verbally rate their overall discomfort during active elbow flexion and extension with activities of daily living on a scale of 0 to 10 where 0 is "no discomfort whatsoever" and 10 is "extreme pain and discomfort" SECONDARY Maximal isometric strength was tested on a modified seated arm curl bench (preacher) with the upper arm supported by a padded bench in about 45 degrees shoulder flexion. Isometric strength was tested at 3 different elbow flexion angles: 130, 90 and 30 degrees Muscle tenderness scores were assessed using a standard manual muscle myometer. Measurements were made just proximal to the distal tendon of the biceps. Force was applied via the probe through a 1 cm diameter head until the participant indicated pain or discomfort
Exercise type	40 (2 x 20) maximal eccentric contraction of the elbow flexors using a modified preacher curl
Sources of funding	The study was funded by Cherrypharm Inc (West Hartford, Connecticut, USA) The authors of the study each have 2.5% equity in Cherrypharm Inc
Notes	Authors were contacted on 30 October 2013 to request data for delayed onset muscle soreness and maximal voluntary isometric contraction but did not respond

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	No details specified in the manuscript Authors were contacted via email on 30 Oc- tober 2013 and again on 26 May 2016
Allocation concealment (selection bias)	Unclear risk	No details specified in the manuscript Authors were contacted via email on 30 Oc- tober 2013 and again on 26 May 2016
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	No details specified in the manuscript Authors were contacted via email on 30 Oc- tober 2013 and again on 26 May 2016
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	No details provided
Incomplete outcome data (attrition bias) All outcomes	High risk	2 participants withdrew before completion; unclear which group they were in Attrition rate: 12.5%
Selective reporting (reporting bias)	High risk	No published protocol available All outcomes reported at all time points

Connolly 2006a (Continued)

		Adverse effects of antioxidant supplemen- tation were not reported
Other bias	Low risk	Participants were asked to refrain from using anti-inflammatory medication and other supplements for the duration of the study as well as any form of therapeutic in- tervention such as massage and ice. Partici- pants who were exposed to any form of re- sistance training were also excluded

Methods	Randomised controlled trial (parallel	Randomised controlled trial (parallel design)	
Participants	per week), non-smoking with no inju Mean age 38.1 (SD 11.1) years in pla	Setting: laboratory, Spain n = 20 male, healthy, moderately exercising (regular aerobic exercise for at least 4 hour per week), non-smoking with no injury Mean age 38.1 (SD 11.1) years in placebo group (n = 10) Mean age 32.7 (SD 12.3) years in curcumin group (n = 9)	
Interventions	to 200 mg curcumin twice daily Placebo Matched capsules Duration	Curcumin given as the Phytosome delivery system (Meriva) 1 g twice daily corresponding to 200 mg curcumin twice daily Placebo Matched capsules	
Outcomes	point visual analogue scale: 0 is "no p of 8 sites (anterior right thigh, poster	PRIMARY Delayed onset muscle soreness lower limbs when descending and climbing stairs (4- point visual analogue scale: 0 is "no pain" and 4 is "disabling pain"). Scores were a sum of 8 sites (anterior right thigh, posterior right thigh, anterior right leg, posterior right leg, anterior left thigh, posterior left thigh, anterior left leg, posterior left leg)	
Exercise type	Downhill running test on a treadmi threshold) for 45 minutes	Downhill running test on a treadmill at grade -10% at a constant speed (anaerobic threshold) for 45 minutes	
Sources of funding	Meriva, Giovanni Appendino is a con	Authors Stefano Togni and Fedrico are employees of Indena SpA the manufacturer of Meriva, Giovanni Appendino is a consultant to Indena SpA Statistical analysis assistance was funded by Indena	
Notes		Authors were contacted to request raw data for delayed onset muscle soreness on 18 February 2016 and responded on 18 February 2016	
Risk of bias			
Bias	Authors' judgement	Support f	or judgement

Drobnic 2014 (Continued)

Random sequence generation (selection bias)	Low risk	Randomised used computer software
Allocation concealment (selection bias)	Unclear risk	No details of safeguards. Although placebo- controlled, the sports medicine physicians performing the exercise test beforehand were not blinded
Blinding of participants and personnel (performance bias) All outcomes	High risk	"Study subjects and physicians perform- ing the radiologic and laboratory assess- ments were blinded to treatment, whereas the sports medicine physicians involved in exercise testing were not." It is not explained why the lattermost were not blinded
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	"Study subjects and physicians perform- ing the radiologic and laboratory assess- ments were blinded to treatment, whereas the sports medicine physicians involved in exercise testing were not." It is likely that the participants reporting DOMS were blinded but some uncertainty remains
Incomplete outcome data (attrition bias) All outcomes	Low risk	1 dropout by personal decision; 5% dropout rate
Selective reporting (reporting bias)	High risk	No published protocol available All outcomes reported at all time points Adverse effects of antioxidant supplemen- tation were not reported
Other bias	Low risk	Participants were asked to refrain from using anti-inflammatory medication and other supplements for the duration of the study Participants were familiarised with the pro- tocol and diet was standardised

Goldfarb 2011

Methods	Randomised controlled trial (parallel design)
Participants	Setting: laboratory; USA n = 44 healthy college aged men age range 18 to 35 years Mean age in the antioxidant group 23.8 (SEM 3.6) years (n = 21) Mean age in the placebo group 22.8 (SEM 0.7) years (n = 20)

Goldfarb 2011 (Continued)

	Inclusion/exclusion criteria All participants completed a medical history, diet, supplement and fitness questionnaire to determine eligibility. Participants were non-smokers, were not on anti-inflammatory drugs or on dietary supplements for at least 3 months and refrained from these substances throughout the study
Interventions	Intervention Fruit, vegetable and berry juice powder (7.5 mg beta-carotene, 276 mg vitamin C and 108 IU of vitamin E) (Juice Plus+, NSA, LLC, Collierville, TN) Placebo Microcrystalline cellulose capsules Participants were given a sealed container and were asked to take 6 capsules per day, 3 in the morning and 3 in the afternoon Duration 28 days
Outcomes	PRIMARY Delayed onset muscle soreness was measured at the elbow flexor with the arm rested using a visual linear scale ranging from 1 to 10 where 1 is "no pain" and 10 is "extreme pain" SECONDARY Maximal isometric strength was measured on a Biodex isokinetic dynamometer. Each participant performed 3 maximal isometric force contractions with their non-dominant and dominant arm elbow flexors each lasting 3 seconds with 60 seconds rest in between each effort Range of motion was assessed using a goniometer assessing the elbow flexors on both arms by asking participants to flex and extend their arms at the elbows
Exercise type	4 sets of 12 repetitions of eccentric actions of the elbow flexors
Sources of funding	The research study was partially supported by the NSA LLC and the University of North Carolina Greensboro
Notes	Authors were contacted on 25 November 2013 to request data for delayed onset muscle soreness, maximal voluntary isometric contraction and range of motion but did not respond

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Participants were randomised but no de- tails provided in the manuscript on how this was done Authors were contacted on 25 November 2013 with no reply

Goldfarb 2011 (Continued)

Allocation concealment (selection bias)	Unclear risk	No details in the manuscript Authors were contacted on 25 November 2013 via email with no reply
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double-blind
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Double-blind
Incomplete outcome data (attrition bias) All outcomes	Low risk	3 participants did not complete the study: 2 participants were from the placebo group and 1 participant was from the supplemen- tation group Attrition rate: 6.8%
Selective reporting (reporting bias)	High risk	No published protocol available All outcomes reported at all time points Adverse effects of antioxidant supplemen- tation were not reported
Other bias	Low risk	Participants were asked to refrain from using anti-inflammatory medication and other supplements for the duration of the study as well as any form of therapeutic in- tervention such as massage and ice. Partici- pants who were exposed to any form of re- sistance training were also excluded

He 2015

Methods	Randomised controlled trial (parallel design)
Participants	Setting: laboratory, USA n = 22 moderately trained males age range 18 to 25 years Mean age supplement group 20.5 (SD 2.3) years n = 11 Mean age placebo group 21.3 (SD 4.0) years n = 11 Inclusion/exclusion criteria Exclusion criteria included people who smoke, take any medication that would alter cardiovascular or metabolic function, have musculoskeletal limitations or use anti-in- flammatory drugs. People who supplemented with vitamin C and vitamin E or other antioxidants within 3 months prior to the study were excluded
Interventions	Intervention Capsules 100 mg vitamin C and 400 IU vitamin E ingested daily for 2 weeks Placebo

He 2015 (Continued)

	Maltodextrin capsules identical to supplement group Duration 17 days to 14 days before and 2 days after the downhill run
Outcomes	PRIMARY Delayed onset muscle soreness of the quadriceps, hamstrings, gluteus, gastrocnemius and tibialis anterior using a visual analogue scale of 0 "no pain" to 6 "unbearable pain"
Exercise type	40 minutes downhill running -10% grade at 65% to 70% VO2max
Sources of funding	Funded by Wastl Human Performance Laboratory, Donald L. Corrigan Professional Development Grant and Purdue Bilsland Strategic Initiative Fellowship
Notes	Compliance with supplementation was 99.4% as assessed by random capsule count Authors were contacted to request raw data for delayed onset muscle soreness on 24 February 2016 and responded on 25 February 2016

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computer generator
Allocation concealment (selection bias)	Low risk	Double-blind
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double-blind
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Double-blind
Incomplete outcome data (attrition bias) All outcomes	Low risk	All participants completed the study
Selective reporting (reporting bias)	High risk	No published protocol available All outcomes reported at all time points Adverse effects of antioxidant supplemen- tation were not reported
Other bias	Low risk	Participants were asked to refrain from using anti-inflammatory medication and other supplements

Herrlinger 2015

Methods	Randomised controlled trial (parallel design)
Participants	Setting: laboratory; USA n = 37 men between the ages of 18 and 35 years who were recreationally active High-dose (n = 12) mean age 24.33 (SEM 1.54) years Low-dose (n = 12) mean age 21.67 (SEM 1.12) years Placebo (n = 13) mean age 22.69 (SEM 1) years Inclusion/exclusion criteria Men who were recreationally active in both resistance and cardiovascular training yet not exercising for more that 6 hours per week were included. The training criteria required that participants be actively performing aerobic exercise and partaking in resistance training at least twice per week for a minimum of 3 months Participants were excluded who were actively engaged in eccentric muscle training, down- hill running, running more that 15 miles per week or presented with certain diseases or conditions such as HIV, hepatitis B and C, uncontrolled cardiovascular arrhythmias, chronic obstructive pulmonary disease, emphysema, diabetes, or unresolved orthopaedic concerns. Additional exclusion criteria included a body mass index of < 18 or > 30 kg/m ² , use of tobacco products within the previous 12 months, and regular consumption of medications or over-the-counter therapies that might affect inflammation such as: green or black tea, green or black tea supplements, cherry juice, vitamin E, vitamin C, aspirin, corticosteroids, anabolic steroids or NSAIDs
Interventions	 Intervention A blend of water-extracted black and green tea (<i>Camellia sinensis</i>) containing a minimum of 40% total polyphenols, 1.3% theaflavins, 5% to 8% epigallocatechin-3-gallate, 7% to 13% caffeine, and 600 ppm manganese. There were 3 groups in this study: Group 1: high-dose (2000 mg per day polyphenolic blend) n = 12 Group 2: low-dose (1000 mg per day polyphenolic blend) n = 12 Group 3: placebo n = 13 2 capsules twice per day were consumed Placebo 4 capsules per day of 500 mg microcrystalline cellulose excipient as 2 capsules twice per day were consumed Duration 13 weeks
Outcomes	Primary Muscle soreness was assessed using a 7-point Likert scale questionnaire for a variety of muscle groups including the gastrocnemius, hamstrings, quadriceps, gluteus maximus, lower back, abdominals and the whole body where 1 is "no pain" and 7 is "severe pain" Secondary Muscle strength All muscle strength tests were performed on a Biodex System 3 dynamometer (Biodex Medical Systems, Shirley, NY, USA). Participants performed 3 sets of quadriceps leg extensions on their dominant leg for 12 repetitions at 120 degrees per second
Exercise type	Downhill running on a treadmill consisted of running at a 10% decline for 40 minutes at a speed associated with 65% of VO2max

Herrlinger 2015 (Continued)

Sources of funding	Source of funding for the study was Kemin Foods, L.C. All authors were employed by the sponsor company and manufacturer of the polyphenol blend at the time of the clinical trial
Notes	The authors of Herrlinger 2015 were contacted on 3 February 2017 and again on 18 February 2017 for missing data (delayed onset muscle soreness and maximal voluntary isometric contraction maximal voluntary isometric contraction) as these were not available in the manuscript and could not be extracted from graphs. No response was received and this study was therefore included in the qualitative analysis but not the quantitative analysis

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Authors indicate random assignment to one of 3 groups (placebo, low-dose, high- dose), however methods to achieve ran- domisation were not indicated in the manuscript Authors contacted 3 February 2017 but no response was received
Allocation concealment (selection bias)	Low risk	No details in manuscript Authors contacted 3 February 2017 via email but no response was received
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	No details in manuscript Authors contacted 3 February 2017 via email but no response was received
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	No details provided
Incomplete outcome data (attrition bias) All outcomes	Low risk	From 39 participants randomised 37 com- pleted the intervention (12 each for low and high; 13 for placebo); 1 participant was withdrawn due to elevated creatine kinase during follow-up testing (high-dose group) and 1 participant was excluded due to < 80% compliance (low-dose group)
Selective reporting (reporting bias)	High risk	All outcomes reported at all time points Manuscripts states that participants were "contacted on a weekly basis by phone or email to ask about any adverse events" al- though adverse effects of antioxidant sup-

Herrlinger 2015 (Continued)

		plementation were not reported
Other bias	Low risk	Diet diaries performed prior to and during baseline testing, however diet was not mon- itored during or post-intervention. Pre-test meals not standardised for all participants however advice provided

Howatson 2009	
Methods	Randomised controlled trial (parallel design)
Participants	Setting: Field; UK n = 20 moderately trained male (13) and female (7) runners Mean age cherry juice group 37 (SD 13) years Mean age placebo group 38 (SD 5) years Inclusion/exclusion criteria 18 of the participants were accepted for, and completed, the 2008 London Marathon. All participants completed a health screening questionnaire and a written informed consent
Interventions	Intervention Tart cherry juice blend; 2 x 8 fl oz bottles per day. One bottle of the juice contained the equivalent of 50 to 60 cherries and provided at least 600 mg phenolic compounds, expressed as gallic acid equivalents, 32 g of carbohydrate and at least 40 mg of anthocyanins. One bottle in the morning and one in the afternoon Placebo Fruit flavoured concentrate mixed with 8 fl oz of water Duration 5 days before and 2 days after
Outcomes	 PRIMARY Delayed onset muscle soreness was determined using a 200 mm visual analogue scale where 0 is "no soreness" and 200 is "unbearably painful." The participant stood with the hands on hips and feet approximately shoulder width apart. The participant was then asked to squat down to 90 degrees (internal joint angle) rise to the start position and then indicate on the visual analogue scale the soreness felt in the lower limbs SECONDARY Maximum voluntary isometric contraction of the non-dominant knee extensors was determined using a strain gauge (MIE Medical Research Ltd, Leeds, UK). Participants were seated on a platform and the non-dominant ankle was attached to the strain gauge at an internal joint angle of 80 degrees (verified by a goniometer). Participants were given 3 submaximal trials, each separated by 1 minute. Each contraction lasted approximately 3 seconds and all participants were given standardised verbal encouragement throughout
Exercise type	Participants completed the 2008 London marathon. The environmental conditions on the day were barometric pressure: 758 mmHg; temperature: 7 degrees Celsius; wind speed: 4 km/h; relative humidity: 56%; there were intermittent showers throughout the day

Howatson 2009 (Continued)

	2 volunteers completed the marathon distance on similar terrain 14 days after the London Marathon	
Sources of funding	The authors thanked Dr Marco Cardinale from the British Olympic Association for procuring technical support and St Mary's University College Scholarship and Research Support Fund for financial support of the project	
Notes	-	
Risk of bias		
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	High risk	Pseudo-randomised based on predicted fin- ishing time. "We also attempted to balance the number of male and female participants in each group to account for possible sex differences"
Allocation concealment (selection bias)	Unclear risk	No details in manuscript Authors were contacted via email on 27 May 2016 Author reply: "allocation was based on sex and predicted finish time. So randomised, but stratified. ABBA style and treatments were given in identical containers"
Blinding of participants and personnel (performance bias) All outcomes	High risk	Not specified in manuscript Authors were contacted via email on 27 May 2016 Author reply: "Single blind"; thus the per- sonnel were not blinded
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Blinded for participants
Incomplete outcome data (attrition bias) All outcomes	Low risk	All the participants completed the study
Selective reporting (reporting bias)	High risk	No published protocol available All outcomes reported at all time points Adverse effects of antioxidant supplemen- tation were not reported
Other bias	Low risk	Participants were asked to keep a food diary and to refrain from taking supplements or taking part in strenuous exercise other than the marathon

Hutchinson 2016

Methods	Randomised controlled trial (paralle	el design)
Participants	Setting: laboratory; USA n = 16 college students (24 were originally recruited) Mean age blackcurrant group (n = 9, 7 female) 19.5 (SEM 0.3) years Mean age placebo group (n = 8, 6 female) 20.9 (SEM 0.9) years Inclusion/exclusion criteria Inclusion criteria included being untrained, moderately active, between the ages of 18 and 40 years. Exclusion criteria included a recent history of ankle, knee, hip or back pain that precluded squatting exercises, and the use of anti-inflammatory or analgesic drugs that would reduce pain	
Interventions	Intervention Commercially available blackcurrant nectar (CurrantC) was provided by CorpPharms (Staatsburg, NY). Each 16 oz bottle contained approximately 100 g of fruit, malvidin glucosides 193.25 mg, cyanidin glucosides 175.69 mg Placebo The placebo drink was produced by mixing black cherry Kool-Aid powder (Kraft, Ryrerbrook, NY, USA) with water Duration 8 days	
Outcomes	Primary Muscle soreness was assessed during a full range squat with no external weight using a 0 to 10 scale where 0 is "no soreness" and 10 is "extreme discomfort"	
Exercise type	Eccentric squatting session consisted of 3 sets of 10 repetitions of eccentric contractions using a bar weighted with 115% of the respective 1 repetition maximum	
Sources of funding	None	
Notes	-	
Risk of bias		
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Independent 3 rd party completed ran- domisation using random number genera- tion in Excel
Allocation concealment (selection bias)	Unclear risk	Not indicated in the manuscript Authors contacted on 3 February 2017 but no response was received
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double-blind; labels removed from bottles; neither personnel nor participants aware of contents

Hutchinson 2016 (Continued)

Blinding of outcome assessment (detection bias) All outcomes	Low risk	Double-blind
Incomplete outcome data (attrition bias) All outcomes	High risk	24 recruited, 16 completed the study (4 ill- ness; 3 injury; 1 removed due to undertak- ing resistance training prior to study)
Selective reporting (reporting bias)	High risk	All outcomes reported at all time points Adverse effects of antioxidant supplemen- tation were not reported
Other bias	Low risk	Diet not standardised during the trial however participants advised to maintain normal diet and avoid anti-inflammatory foods and drugs

Kaminski 1992

Methods	Randomised controlled trial (cross-over design)
Participants	Setting: laboratory; USA n = 25 healthy college students and college employees. Of the 25 original participants, 2 dropped out of the experiment, 3 were excluded for a variety of reasons (loss of capsule integrity, failure to properly maintain records, non-compliance with the experimental protocol), and 1 was removed for failure to develop delayed onset muscle soreness in either trial. Left with 19 participants (6 women and 13 men). Age rage 24 to 48 years Inclusion/exclusion criteria Participants were excluded from the study if they were older than 50 years, had a sensitivity to lactose, took analgesic or anti-inflammatory agents during the trials, participated in rigorous athletic training, had a current musculoskeletal ailment in the legs, or took ascorbic acid or riboflavin supplements within 3 weeks of the study
Interventions	Intervention Vitamin C 1000 mg as 3 capsules per day Placebo Lactose capsules Duration Vitamin C taken 3 days before and 7 days after exercise with a 3-week washout period
Outcomes	PRIMARY Delayed onset muscle soreness was monitored by self-reporting using a 10 cm continuous unmarked line as a visual analogue scale anchored with 1 "have no soreness" at one end and 10 "my soreness could not be any worse" at the other
Exercise type	Strenuous eccentric work of the plantar flexors of the calf

Kaminski 1992 (Continued)

Sources of funding	None
Notes	Participants were asked to refrain from using anti-inflammatory medication and other supplements for the duration of the study Authors were contacted to request raw data for delayed onset muscle soreness on 3 December 2013 and responded on 9 December 2013

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Randomised using a computer program
Allocation concealment (selection bias)	Unclear risk	No details provided in manuscript Authors were contacted via email on 14 May 2016 with no response
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double-blind
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Double-blind
Incomplete outcome data (attrition bias) All outcomes	High risk	6 participants dropped out and were ex- cluded for a variety of reasons Attrition rate: 24%
Selective reporting (reporting bias)	High risk	No published protocol available All outcomes reported at all time points Adverse effects of antioxidant supplemen- tation were not reported
Other bias	Low risk	Participants were asked to refrain from using anti-inflammatory medication and other supplements for the duration of the study

Kerksick 2009

Methods	Randomised controlled trial (parallel design)
Participants	Setting: laboratory; USA n = 30 healthy non-resistance trained men mean age 20 (SD 1.8) years Inclusion/exclusion criteria Non-resistance trained men defined as less than 1 workout per month over the last 6

Kerksick 2009 (Continued)

Bias	Authors' judgement	Support for judgement	
Risk of bias			
Notes		Authors were contacted on 2 November 2013 to request raw data for delayed onset muscle soreness and maximal voluntary isometric contraction and responded on 3 December 2013	
Sources of funding	Partial funding for the study was ing Association through GNC Nu Research Award for Darryn Willo award and indirect costs provided	10 sets of 10 repetitions at an isokinetic dynamometer; 1 minute rest between sets Partial funding for the study was provided by the National Strength and Condition- ing Association through GNC Nutritional Research Grant, a Baylor University Faculty Research Award for Darryn Willoughby, PhD and HHPR a graduate student research award and indirect costs provided by grants awarded to Richard Kreider, PhD through the Exercise and Sports Nutrition Laboratory while at Baylor university	
Exercise type	Biodex Medical Systems, Inc, NY a cycle ergometer for 10 minutes, was assessed by having participants eccentric fashion Peak dynamic torque was measured voluntary contractions over 5 sec in between each repetition. Partic effort throughout the entire 5-sec repetitions was regarded as peak is pleted at an angle of 90 degrees flo	Biodex Medical Systems, Inc, NY, USA). Prior to testing participants warmed up on a cycle ergometer for 10 minutes. Changes in dynamic strength of the knee extensors was assessed by having participants complete 10 maximal repetitions in a concentric and eccentric fashion Peak dynamic torque was measured in the dominant knee extensors, a total of 3 maximal voluntary contractions over 5 seconds duration were completed with 60 seconds rest in between each repetition. Participants were verbally encouraged to produce maximal effort throughout the entire 5-second period. The peak torque exerted throughout all 3 repetitions was regarded as peak isometric torque. All isometric repetitions were com- pleted at an angle of 90 degrees flexion	
Outcomes	analogue scale where 0 is "no sore SECONDARY	Delayed onset muscle soreness was assessed at the quadriceps along a 10 cm visual analogue scale where 0 is "no soreness" and 10 is "extreme soreness"	
Interventions	 2. 1800 mg epigallocatechin galla Placebo 1000 mg glucomannan Supplements were taken in the r 	 1800 mg N-acetyl-cysteine (NAC) 1800 mg epigallocatechin gallate (EGCG) Placebo 1000 mg glucomannan Supplements were taken in the morning on an empty stomach and compliance was monitored by making phone calls and participants bringing back empty bottles during next visit Duration 	
	contraindications to exercise accor	months. All participants were classified as low risk for cardiovascular disease with no contraindications to exercise according to the American College of Sports Medicine. No nutritional supplements (including multivitamins) were consumed at least 3 months prior to the study	

Kerksick 2009 (Continued)

Random sequence generation (selection bias)	High risk	Participants were matched in clusters ac- cording to age and body weight for assign- ment
Allocation concealment (selection bias)	Low risk	Clear capsules provided
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double-blind
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Double-blind
Incomplete outcome data (attrition bias) All outcomes	Low risk	A total of 3 participants did not complete the study; 2 participants withdrew from the study and 1 was excluded due to non-com- pliance Attrition rate: 10%
Selective reporting (reporting bias)	Low risk	No published protocol available All outcomes reported at all time points "No adverse outcomes were reported to the supplementation protocol"
Other bias	Low risk	Food records were obtained, participants were instructed to minimise foods high in quercetin and were asked to refrain from taking any other supplements or anti-in- flammatory medication or to engage in any other modality that could enhance recov- ery

Krotkiewski 1994

Methods	Randomised controlled trial (parallel design)
Participants	Setting: laboratory; Poland n = 50 male volunteers recruited from local paper 36 to the pollen group; mean age pollen extract group 35.1 (SEM 2.62) years 14 to the placebo group; mean age placebo group 35.1 (SEM 2.62) years Inclusion/exclusion criteria Inclusion criteria were absence of hypertension, diabetes, cardiovascular disease, organic brain disease, alcohol or drug dependence and any other deviation from good health, no physical training or permanent or intensive basis and the lack of any ongoing medication

Krotkiewski 1994 (Continued)

Interventions	Intervention Pollen extract; superoxide dismutase activity of approximately 30,000 units per gram/ Polbax (Allegon, Sweden) Placebo Placebo not specified Duration 4 weeks
Outcomes	PRIMARY Delayed onset muscle soreness, visual analogue scale (0 to 10 cm) where 0 is "no pain and discomfort" and 10 is "intense pain and discomfort."
Exercise type	A circuit exercise test which consisted of 10 minutes on the step up test, 30 minutes cycling at 70% VO2max followed by 10 minutes on the step test. 30 minutes of cycling at 60% VO2max followed by 10 minutes on the step test repeated twice
Sources of funding	The study was supported by the Swedish Sports Council and Askers Foundation
Notes	All the authors were contacted several times via email with no response. Maximal volun- tary strength data were not reported in the manuscript either in a graph or a table and delayed onset muscle soreness data were reported as a difference between the starting values therefore data could not be extracted Authors were contacted on 3 November 2016 to request data for delayed onset muscle soreness but did not respond

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	No details in manuscript 36 participants in experimental group and 14 in the placebo Authors contacted several times but did not respond
Allocation concealment (selection bias)	Unclear risk	No details in manuscript Authors contacted several times but did not respond
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Manuscript states: "tablets were given in a double blind manner"
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Double-blind

Krotkiewski 1994 (Continued)

Incomplete outcome data (attrition bias) All outcomes	Unclear risk	No details in manuscript It appears as if all participants completed the study Authors contacted several times but did not respond.
Selective reporting (reporting bias)	High risk	No protocol available All data reported at all time points Adverse effects of antioxidant supplemen- tation were not reported
Other bias	Unclear risk	Manuscript states: "All participants explic- itly asked to follow their habitual style of life, particularly with regards to diet and physical activity", but no details on whether participants were asked to refrain from NSAIDs or any other supplements
Kuehl 2010		
Methods	Randomised controlled trial (parallel design)	
Participants	Setting: field; USA n = 54 male (36) and female (18) runners participating in the Hood Coast Relay; mean age 35.8 (SD 9.6) years; 25 participant in the placebo group and 26 participants in the Cherry group Inclusion/exclusion criteria Inclusion criteria included an ability and willingness to abstain from anti-inflammatory or pain relieving drugs, and willingness to refrain from seeking any other treatment for symptoms of muscle damage until the competition of the study Exclusion criteria included recent use of pain management methods (including acupunc- ture, transcutaneous electrical nerve stimulation, topical medications/aesthetics, muscle relaxants, injections or systematic steroids). Women capable of becoming pregnant com- pleted a pregnancy test to rule out pregnancy prior to participation	
Interventions	Intervention Cherry juice 10.5 oz: 600 mg phenolic compounds, 40 mg anthocyanins, 40 to 50 cherries Placebo Unsweetened fruit punch with added sugar to match the cherry juice Duration 7 days before the race and 8 days during the race; total 15 days	
Outcomes	PRIMARY Delayed onset muscle soreness was assessed using a standard 100 mm visual analogue scale where 0 is "no pain" and 100 is "most severe pain." After finishing the race, participants completed the pain VAS for general soreness	

Kuehl 2010 (Continued)

Exercise type	Hood Coast Relay - 315 km. Each participant completed 3 running segments during the race with individual segments ranging from 5.6 (SD 2.5) km and an average total running distance of 26.3 (SD 2.5) km	
Sources of funding	No external funding was provided for this study. Cherrish Corporation (Seattle. WA) provided the cherry juice in the study	
Notes	2 x 335 bottles daily prior to race	
Risk of bias		
Bias	Authors' judgement Support for judgement	
Random sequence generation (selection bias)	Unclear risk	No details in manuscript Authors were contacted via email on 27 May 2016
Allocation concealment (selection bias)	Unclear risk	No details in manuscript Authors were contacted via email on 27 May 2016
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double-blind
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Double-blind
Incomplete outcome data (attrition bias) All outcomes	Low risk	3 participants dropped out (2 from exper- imental group and 1 from placebo due to NSAID use) Attrition rate: 6%
Selective reporting (reporting bias)	Low risk	Study protocol published in ClincalTrials. gov (NCT00733395) All outcomes published in study protocol were reported in the actual study All outcomes reported at all time points Tart cherry juice caused mild gastrointesti- nal distress in 1 participant
Other bias	Low risk	Participants were asked to refrain from using anti-inflammatory medication, any other supplements or seek any modality to reduce muscle soreness

Laupheimer 2014

Methods	Randomised controlled trial (parallel design)
Participants	Setting: field; UK n = 7 (experimental group of 3, placebo group of 4) well trained distance runners, age range 40 to 55 years Originally 8 (all males) were recruited but 1 participant in the experimental group was excluded because of a viral infection during the study Inclusion/exclusion criteria Inclusion criteria were male gender and age 20 to 55 years. The male gender and age were chosen to ensure a homogenous cohort and to optimise the safety of the use of resveratrol Exclusion criteria included a past medical history of chronic inflammatory medical con- ditions, muscle disorders or heart conditions, and a drug history of immune suppressants or anti-inflammatories
Interventions	Intervention 600 mg of resveratrol daily for 7 days and immediately before the marathon 2 x 100 mg tablets were taken 3 times daily Placebo Not specified Duration 9 days
Outcomes	PRIMARY General soreness on both legs; delayed onset muscle soreness, 10-point visual analogue scale: 0 "complete absence of pain" to 10 "indicating extreme soreness with noticeable pain and stiffness at all times"
Exercise type	Running the London marathon race in 2010
Sources of funding	None declared
Notes	Participants were asked not to alter their diet in any way and were not given any nutrition or hydration advice prior to the race Authors were contacted to request raw data for delayed onset muscle soreness on 18 February 2016 and responded on 18 February 2016

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computer block randomisation
Allocation concealment (selection bias)	Low risk	Double-blind Before randomisation 2 different sets of en- velopes had been prepared by an indepen- dent person not associated with the study

Laupheimer 2014 (Continued)

Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double-blind
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Double-blind
Incomplete outcome data (attrition bias) All outcomes	Low risk	All outcomes reported at all time points
Selective reporting (reporting bias)	Low risk	All outcomes reported at all time points "None of the seven participants reported any adverse effects during the study period or during the marathon itself"
Other bias	Low risk	Participants were asked not to alter their diet in any way and were not given any nutrition or hydration advice prior to the race Participants were instructed to avoid anti- inflammatory medication

Lynn 2015

Methods	Randomised controlled trial (single-blind, parallel design)
Participants	Setting: field; UK n = 21 (experimental group of 11, placebo group of 10; 2 participants were excluded from the bilberry group as they failed to report to the lab to provide follow-up data), recreationally trained runners, age range 18 to 55 years Inclusion/exclusion criteria Individuals with cardiovascular disease, diabetes, hypertension, gastrointestinal prob- lems, renal disease, musculoskeletal problems, regular antioxidant or NSAIDs use, and any food allergies were excluded from the study
Interventions	Intervention 2 x 200 mL of bilberry juice daily for 5 days before completing the Sheffield Half Marathon, on race day and for 2 days post-race Total phenol content per 200 mL serving was 744.14 \pm 81.75 mg (n = 3). and 80.04 \pm 3.51 mg (n = 3) of total anthocyanins Placebo Energy matched control drink Duration 8 days

Lynn 2015 (Continued)

Outcomes	PRIMARY Delayed onset muscle soreness, 200 mm visual analogue scale, rated after a squat to a 90 angle and returning to a standing position: 0 "complete absence of pain" to 200 "indicating extreme soreness with noticeable pain and stiffness at all times"
Exercise type	Sheffield half marathon
Sources of funding	The study was funded by Sheffield Hallam University
Notes	2 x 200 mL of bilberry juice was consumed 5 days before the race, on the day of, and up to 48 hours post race

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	No details in published abstract Authors confirmed via email on 3 February 2017 that a "random numbers generator" was employed
Allocation concealment (selection bias)	Unclear risk	No details in published abstract Authors described via email on 3 February 2017 that the "Study was single blind so in- vestigators knew which drink each partic- ipant got" and "drinks were given in non- labelled container" Adequate safeguards not reported
Blinding of participants and personnel (performance bias) All outcomes	High risk	No details in published abstract Authors described via email on 3 February 2017 that the "Study was single blind so in- vestigators knew which drink each partic- ipant got" and "drinks were given in non- labelled container" Not blinded
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Participants may have remained blinded but this is not confirmed
Incomplete outcome data (attrition bias) All outcomes	High risk	No details in published abstract Authors confirmed via email on 3 Febru- ary 2017 that "Of the 21 participants, we missed getting data from 2, one missed the post race sample, and on the last day one other person was missed - both were in the bilberry group"

Lynn 2015 (Continued)

Selective reporting (reporting bias)	Low risk	No published protocol All data available at all time points Personal communication: "None of the participants reported any adverse effects from consuming the Bilberry juice or the placebo"
Other bias	Low risk	Participants were asked to complete a food diary and were asked to refrain from using anti-inflammatory drugs or other supple- ments that could reduce soreness

McBride 1997

Methods	Randomised controlled trial (parallel design)	
Participants	Setting: laboratory; USA n = 12 males who were recreationally weight trained for at least 1 year Mean age placebo group 22.0 (SEM) 0.85 (n = 6) Mean age vitamin E group 21.17 (SEM) 0.65 (n = 6) Inclusion/exclusion criteria All participants were required to be recreationally weight trained with resistance training experience of at least 1 year. Participants had no medical problems (e.g. orthopaedic, endocrine, cardiovascular) that would confound the results of this investigation	
Interventions	Intervention 992 mg per day of vitamin E (1200 IU) Placebo Identical looking cellulose capsule - no detail on contents Duration 2 weeks	
Outcomes	PRIMARY Delayed onset muscle soreness, visual analogue scale (0 to 10 cm) where 0 is "no soreness" and 10 is "extremely sore"	
Exercise type	Heavy resistance exercise protocol	
Sources of funding	None	
Notes	1 capsule taken daily	
Risk of bias		
Bias	Authors' judgement Support for judgement	

McBride 1997 (Continued)

Random sequence generation (selection bias)	Unclear risk	No details in the manuscript Authors were contacted via email on 14 May 2016 but no response
Allocation concealment (selection bias)	Unclear risk	No details in the manuscript Authors were contacted via email on 14 May 2016 but no response
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	No details in the manuscript Authors were contacted via email on 14 May 2016 but no response
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	No details provided
Incomplete outcome data (attrition bias) All outcomes	Low risk	All participants completed the study
Selective reporting (reporting bias)	High risk	No published protocol available All outcomes reported at all time points Adverse effects of antioxidant supplemen- tation were not reported
Other bias	Unclear risk	Diet was controlled using food records, however no details on whether participants were asked to refrain from using anti-in- flammatory medication, any other supple- ments or seeking any modality to reduce muscle soreness
McCormick 2016		
Methods	Randomised, double-blind (cross-over design) 5-week washout period	
Participants	Setting: field/laboratory; Australia n = 9 highly-trained (elite) male water polo players from the Western Australian Institute of Sport Mean age 18.6 (SD 1.4) Inclusion/exclusion criteria Not specified - authors contacted on 4 February 2017 and a reply received 8 February 2017: "Participants had to be a part of the West Australian Institute of Sport Men's High Performance Water polo squad that attend daily training sessions. Participants were not taking any vitamin supplements (as per WAIS supplements policy). Maintained daily contact with the research group to ensure consumption of the prescribed supplement."	

McCormick 2016 (Continued)

Interventions	 Intervention 90 mL daily for 6 days of tart Montmorency Cherry Juice (<i>Prunus cerasus</i>) concentrate (Cherry Active, Sunbury, UK) diluted with water, such that each 30 mL serving was made up into a 200 mL beverage. Both the cherry juice and placebo were consumed in 2 doses each day; 200 mL before morning training, and 400 mL in the evening post training Placebo 3 different 'off the shelf' cordials: lime (Woolworths select lime cordial, Australia), cranberry (Bickford's cranberry juice cordial, Australia) and raspberry (Cottee's raspberry flavoured cordial, Australia). Cordials were mixed with food colouring and 480 mL of water in order to closely imitate the taste, colour and carbohydrate content Duration 6 days 	
Outcomes	Primary Delayed onset muscle soreness (delayed onset muscle soreness) was measured on a 0 to 10 scale in the upper body, upper legs, lower legs and overall body encompassing the anchor points of 0 (normal; without pain or stiffness) to 10 (very painful) Total quality of recovery was also recorded on a 6- to 20-point scale for the upper body, upper legs, lower legs and overall body, which encompassed the anchor points 6 (very, very poor recovery) to 20 (very, very good recovery) Secondary Swimming-based tests comprised of the in-water vertical jump test, 10 m sprint test, a repeat sprint test and the Water Polo Intermittent Shuttle Test	
Exercise type	A fixed training regimen for 6 days. All training (technical skill, weights, and swimming) performed during the 7-day trials was identical, and took place in the controlled environment of the indoor Water Polo pool or gymnasium	
Sources of funding	Manuscript states: "Funds received from the Australian Institute of Sport and the Aus- tralian Sports Commission"	
Notes	This study was only included in the qualitative analysis because the exercise paradigm was completely different to all the other studies included in this review. The other studies used an exercise paradigm where mechanical or whole body aerobic exercise was used to cause muscle damage and then a range of outcomes such as muscle soreness, muscle function, range of motion and performance were measured at various time points up to several days after exercise. However, participants in this study had a fixed daily training regimen for 5 continuous days performance, with outcomes being measured at the start and then throughout the trial. Thus the severity of muscle damage caused by the daily training regimen was not controlled	
Risk of bias		
Bias	Authors' judgement	Support for judgement

Random sequence generation (selection bias)	Low risk	Manuscript states: "randomised, double- blind, repeated measures, crossover de- sign". No specific details provided on how randomisation was completed Authors contacted on 4 February 2017 and response was received on 8 February 2017: "Each participant was assigned a partici- pant number and randomised by a number generator into two separate groups."
Allocation concealment (selection bias)	Low risk	No specific details provided on how ran- domisation was completed Authors contacted on 4 February 2017 and a response was received on 8 February 2017: "Fluids were prepared (by an inde- pendent researcher) in the absence of the athletes and researchers involved in the per- formance testing. PLA was made to look and taste the same as the CJ (specific prod- uct details within the manuscript). Bottles were then labelled with athlete names to ensure no mix-up."
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Manuscript states: "randomised, double- blind, repeated measures, crossover design"
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Double-blind
Incomplete outcome data (attrition bias) All outcomes	Low risk	No details in the manuscript Authors contacted on 4 February 2017 and a response was received on 8 February 2017: "Initial sample size was n=11 how- ever, two participants withdrew during the study due to injury. These participants were not included in the manuscript, leaving us with n=9."
Selective reporting (reporting bias)	High risk	No published protocol available All outcomes reported at all time points Adverse effects of antioxidant supplemen- tation were not reported
Other bias	Unclear risk	Manuscript states: "A limitation of this in- vestigation is that the anthocyanin concen- tration of both the commercial and placebo supplement used was not confirmed"

McCormick 2016 (Continued)

McFarlin 2016

Methods	Randomised controlled trial (parallel design)	
Participants	Setting: laboratory; USA n = 28 participants (40 in all) Mean age curcumin group (n = 16, 11 females) 20 (SD 1) years Mean age placebo group (n = 12, 7 females) 19 (SD 2) years "We experienced a 30% attrition/non-compliance"; it was not specified which group these participants withdrew from Inclusion/exclusion criteria Exclusion criteria included regular resistance training in the previous 6 months, leg mus- cle or orthopaedic condition, arthritis or other chronic inflammatory injury in the lower extremity, regular ingestion of curcumin containing foods, regular anti-inflammatory use, intake of curcumin supplementation in the pas 6 months and any other condition that would prohibit the completion of the lower body resistance exercise protocol	
Interventions	Intervention Curcumin supplementation (Longvida; Verdure Sciences Corp, Noblesville, IN) 400 mg per dose; total study dose 2400 mg Placebo 400 mg rice flour Duration 2 days prior to exercise, the day of and 3 days after exercise, total duration of 6 days	
Outcomes	PRIMARY Soreness was measured using a 10 cm visual analogue scale from 0 at one end "no pain" to 10 "severe pain" at the other end. Measures of soreness were made on the thigh (i. e. quadriceps). A gauge was applied using standard fore (20 to 30 N) over the distal, middle and proximal thigh in a seated position with the knee fully extended and relaxed The 3 ratings for each quadricep were added together	
Exercise type	6 sets of 10 repetition of the leg press exercise with a start load set at 110% of the estimated 1 repetition maximum	
Sources of funding	The study was partially funded by a grant from Verdure Sciences Corp (PI: McFarlin) and the National Strength and Conditioning Association to the University of North Texas	
Notes	Authors contacted on 4 February 2017 to request data for delayed onset muscle soreness but no reply was received	
Risk of bias		

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Manuscript states: "Stratified randomiza- tion (based on gender and initial strength) was used to assign participants to the treat- ment conditions to ensure similar numbers

McFarlin 2016 (Continued)

		of men and women and a balance based on initial muscle strength between conditions"
Allocation concealment (selection bias)	Unclear risk	No specific details provided on how ran- domisation was completed Authors contacted on 4 February 2017 but no reply was received
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Manuscript states: "Subjects were pro- vided supplements using a double-blind approach". However, no specific details were provided Authors contacted on 4 February 2017 but no reply was received
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Double-blind
Incomplete outcome data (attrition bias) All outcomes	High risk	Manuscript states: "we enrolled 20 subjects per group" and "In the case of the present study, no subjects asked to drop (sic), thus the key source of attrition was associated with lack of adherence to the study protocol or sample collection." This equates to 30% data loss and there was an uneven dropout rate between groups
Selective reporting (reporting bias)	High risk	No published protocol available All outcomes reported at all time points Adverse effects of antioxidant supplemen- tation were not reported
Other bias	Low risk	Manuscript states: "Exclusion criteria in- cluded: regular resistance training in the previous 6 months, leg muscle or ortho- pedic condition, arthritis or other chronic inflammatory injury in the lower extrem- ity, regular ingestion (N2 times per week) of curcumin containing foods, regular NSAID use (at least 3 of 7 days), intake of a curcumin supplement (within the past 6 months), and any other condition that would prohibit completion of the lower body resistance exercise protocol"

McLeay 2012

Methods	Randomised controlled trial (balanced randomised cross-over design) 30 day washout	
Participants	Setting: laboratory; New Zealand n = 10 healthy active females mean age 22 (SD 1) years Inclusion/exclusion criteria All participants were physically active and participated in this study. All participants were physically active and participated in recreational level resistance and aerobic-based exercise at least twice per week. All participants had at least 1 years' experience in training in this manner. Participants completed a Health Screening Questionnaire to exclude those who were at risk physically, culturally or religiously in following the protocol. Those who passed the questionnaire were asked to provide written consent	
Interventions	Intervention Blueberry smoothie 200 g blueberries 50 g banana + 200 mL apple juice. Per 100 mL, total phenolics 168 mg/gallic acid equ.; anthocyanins 96.6 mg; phenolic acid 26 mg, flavonoids 10.2 mg; vitamin C 45 mg; vitamin E 3 mg Placebo Smoothie 25 g dextrose 50 g banana + 200 mL apple juice Duration 4 days	
Outcomes	PRIMARY Delayed onset muscle soreness was recorded using a subjective 10-point scale where 0 is "no soreness" and 10 is "very, very painful." Participants were asked to step up (concentric muscle action) onto a 40 cm box then step down (eccentric muscular contraction) and the soreness was rated SECONDARY Muscle function was tested using an isokinetic dynamometer (Biodex Medical Systems Inc. 2004). Range of motion of the leg was set at 60 degrees for concentric and eccentric contractions and at 75 degrees for isometric contractions. The participants performed 5 maximal contractions of each type with each set separated by 2 minutes of recovery. Concentric and eccentric torque was measured at an angular velocity of 30 degrees per second	
Exercise type	3 sets of 100 eccentric repetitions of the quadriceps	
Sources of funding	Funded by an Institute of Food, Nutrition and Human Health Postgraduate Research Award, and the New Zealand Ministry of Science and Innovation, contract C06X0807 awarded to Plant and Food research Ltd	
Notes	Drinks consumed on day of exercise the again at 12 hours and 36 hours post-exercise	
Risk of bias		
Bias	Authors' judgement	Support for judgement

Random sequence generation (selection bias)	Low risk	Author response: "A table with vertically numbered cells 1-10 had either 'blueber- ries' or 'no blueberries' (4 of each) next to them. Names were then simply pulled from a hat and typed into these cells in drawn or- der. A simple method, yet allowed for ran- domised allocation of treatment."
Allocation concealment (selection bias)	High risk	No details in manuscript Authors were contacted on 27 May 2016 via email Author response: "Due to the form the treatment was given as (smoothie), we were unable to blind the study. Both control and blueberry smoothies were isocaloric how- ever. The study was a cross-over design and both treatment and leg of damage was ran- domised." Adequate safeguards not reported for the first phase; the second phase was pre- dictable
Blinding of participants and personnel (performance bias) All outcomes	High risk	Not blinded
Blinding of outcome assessment (detection bias) All outcomes	High risk	Probably not blinded
Incomplete outcome data (attrition bias) All outcomes	Low risk	All participants completed the study with no adverse effects
Selective reporting (reporting bias)	Low risk	No published protocol available All outcomes reported at all time points Manuscript states: "there were no reported adverse effects from the dietary interven- tion"
Other bias	Unclear risk	Participants were asked to complete a food diary but no detail on whether partici- pants were asked to refrain from using anti- inflammatory drugs or other supplements that could reduce soreness

McLeay 2012 (Continued)

Meamarbashi 2011

Wieamarbashi 2011		
Methods	Randomised controlled trial (parallel design)	
Participants	Setting: laboratory, Iran n = 20 male non-athletic university students mean age 18.2 (SD 0.4) years Inclusion/exclusion criteria Participants were selected based on fitness and health screening tests and recruited in a double-blind trial. Participants with history of any type of muscle injury, chronic inflammation, coagulation disorders, immune system impairment and cardiovascular problems were excluded. Participants were also excluded if they regularly participated in vigorous exercise in the previous 3 months	
Interventions	Intervention Purslane extract 1200 mg given as 2 x 600 mg capsules per day Placebo Lactose powder placebo capsules Duration 5 days	
Outcomes	corresponded to "no pain" and 6 to "unberto rate the discomfort in only the quadrice SECONDARY Knee range of motion - participants laid profully extended. The knee joint angle was deta landmarks to ensure alignment. Knee flexio maximally and voluntary flexed the knee Maximal knee extension isometric force was ter attached to an adjustable steel chain. P knee flexed at an angle of 90 degrees then the statement of the statement	essessed using a 0- to 6-point scale where 0 earably painful". Participants were requested ps and calf regions of the right leg one on an examination table with both knees termined by using a goniometer and universal n range was determined when the participant s evaluated using a computerised dynamome- articipant was seated on a special chair with he ankle was fixed by a special belt connected t, force-time data were recorded on a memory
Exercise type	7 sets of 5 minutes of continuous bench stepping exercise with 1 minute rest; 50 cm bench height	
Sources of funding	Financial support was received from the university postgraduate grant (no 11-4-899). University of Mohaghegh Ardabil, Iran	
Notes	2 capsules daily	
Risk of bias		
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	No details in the manuscript Authors were contacted by email on 25 May 2016 Response: "two groups had selection crite-

Meamarbashi 2011 (Continued)

		ria's and randomly selected by online pro- gram from a bigger group of volunteers"
Allocation concealment (selection bias)	Low risk	No details in the manuscript Authors were contacted by email on 25 May 2016 Response: "placebo and purslane were cap- sulated"
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double-blind
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Double-blind
Incomplete outcome data (attrition bias) All outcomes	Low risk	All participants completed the study
Selective reporting (reporting bias)	High risk	No published protocol available All outcomes reported at all time points Adverse effects of antioxidant supplemen- tation were not reported
Other bias	Low risk	Participants were asked to refrain from us- ing any supplements and anti-inflamma- tory drugs or other treatment that could re- duce soreness. Diet not controlled

Michailidis 2013

Methods	Randomised, double-blind (cross-over design) 6 weeks washout period
Participants	Setting: laboratory, Greece n = 10 male recreationally active Mean age 23.5 (SD 2.5) years Inclusion/exclusion criteria Participants were recreationally trained, as evidenced by their maximal oxygen consump- tion (O ₂ max) level (> 45 mL · kg-1 · min-1); had been engaged in systematic exercise ≥ 3 times/week for ≥ 12 months, and were non-smokers. Participants abstained from any vigorous physical activity and the consumption of caffeine, alcohol or performance- enhancing or antioxidant supplements and medications before (6 months) and during the exercise trials Exclusion criteria included a known NAC intolerance or allergy, a recent febrile illness and history of muscle lesion and lower limb trauma

Michailidis 2013 (Continued)

Interventions	Intervention 20 mg NAC/kg per day was administered orally (Uni-Pharma) in 3 daily dosages. NAC was dissolved in a 500 mL drink that contained water (375 mL), a sugar-free cordial (125 mL) and a 2 g low-calorie glucose/dextrose powder to improve palatability Placebo Placebo solution was formulated to be identical to the NAC solution, except for the NAC content Duration Supplement consumed immediately after muscle-damaging exercise and for 8 days post- exercise
Outcomes	PRIMARY Delayed onset of muscle soreness (delayed onset muscle soreness) was determined by palpation of the muscle belly and the distal region of the vastus medialis, vastus lateralis and rectus femoris after a squat. Perceived soreness was rated on a scale ranging from 1 (normal) to 10 (very, very sore) SECONDARY Maximal knee extensor eccentric peak torque at 60°/second on an isokinetic dynamome- ter (Isoforce)
Exercise type	300 eccentric unilateral repetitions (20 sets, 15 repetitions/set, 30-second rest between sets) with the quadriceps muscle group at a speed of 30°/second on an Isoforce (TUR Gmbh) isokinetic dynamometer
Sources of funding	Manuscript states: "Supported by departmental funding, a grant received by Bodosakis Foundation (Greece) for instrument purchase, and grant funding (CE-80739). APR was supported by a National Health and Medical Research Council Career Development Award, Australia."
Notes	Authors were contacted on 7 February 2017 to request data for delayed onset muscle soreness and maximal voluntary isometric contraction but did not respond

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	No details in manuscript Authors were contacted on 7 February 2017 but did not respond
Allocation concealment (selection bias)	Unclear risk	No details in manuscript Authors were contacted on 7 February 2017 but did not respond
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Manuscript states the design was double- blind

Michailidis 2013 (Continued)

Blinding of outcome assessment (detection bias) All outcomes	Low risk	Double-blind
Incomplete outcome data (attrition bias) All outcomes	High risk	Protocol states 20 individuals were enrolled and 12 completed. Manuscript states that 10 males completed the study
Selective reporting (reporting bias)	Low risk	Published protocol available (ClinicalTri- als.gov identifier: NCT01778309) All data reported at all time points Manuscript states: "Participants reported no adverse side effects attributed to NAC consumption"
Other bias	Unclear risk	5-day diet recalls (1 recall/day) were com- pleted before each trial and standardised between trials No information on NSAIDs

Nicol 2015

Methods	Randomised controlled trial (cross-over design) 14-day washout
Participants	Setting: laboratory; Australia n = 17 healthy men aged between 18 and 39 years 2 withdrew from the study following acceptance due to the inability to attend testing commitments Inclusion/exclusion criteria Participants were undertaking light to moderate regular physical activity including sports training but not doing lower limb resisted exercise
Interventions	Intervention 2.5 g of curcumin Placebo 2.5 g Avicel 105, an inert plant cellulose 5 capsules taken twice daily Duration 5 capsules were taken twice daily for 2.5 days prior to exercise, then 5 capsules twice daily for 2.5 days after exercise
Outcomes	Primary Muscle soreness using a 0 to 10 cm visual analogue scale where 0 is "no pain" and 10 is "severe pain". Pain was rated for a single leg squat, walking downstairs, passive strength of the gluteals and a single leg vertical jump Muscle tenderness was assessed using a Somedic pressure algometer (Somedic, Sollen- tuna, Sweden) at 4 standardised points

Nicol 2015 (Continued)

	Secondary Jump performance was measured by a single leg vertical squat jump. The jump and reach method using Vertec (Vertec, Vertec Sports Imports, Hilliard, OH)
Exercise type	Eccentric exercise protocol consisted of 7 sets of 1- eccentric single leg press repetitions on a leg press machine
Sources of funding	Manuscript states: "Funding from the Australian Institute of Sport"
Notes	Authors were contacted on 15 March 2016 to request raw data for delayed onset muscle soreness and counter-movement jump and they responded on 15 March 2016

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Manuscript states that the "randomiza- tion sequence was generated using a ran- dom numbers table (http://www.ramdom- izer.org)". Secondly: "Randomization was applied to both the order of treatment or placebo and to the sequence of right or left leg use within the unilateral crossover". It is known that the repeated bout effects can be observed in the non-exercised limb
Allocation concealment (selection bias)	Low risk	Manuscript states: "Allocation was con- cealed using sequentially numbered medi- cation. Investigators and participants were blinded by provision of the medications by AIS nursing staff according to the random- ization protocol."
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Manuscript states: "Investigators and par- ticipants were blinded by provision of the medications by AIS nursing staff according to the randomization protocol" and that "the participants reported that they could not distinguish between the treatment and placebo"
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Participants were blinded
Incomplete outcome data (attrition bias) All outcomes	Low risk	Manuscript states" "Two withdrew from the study following acceptance due to the inability to attend testing commitments, and no replacements were added due to re-

Nicol 2015 (Continued)

		source constraints." This equates to 11% attrition
Selective reporting (reporting bias)	High risk	No published protocol available All outcomes reported at all time points Adverse effects of antioxidant supplemen- tation were not reported
Other bias	Unclear risk	No information in the manuscript regard- ing food or using anti-inflammatory drugs or other supplements during the trial

Nie 2004

Bias	Authors' judgement	Support for judgement	
Risk of bias			
Notes	No detail on how the supplements	No detail on how the supplements were administered or whether it was a drink or capsule	
Sources of funding	None	None	
Exercise type	10 sets of 15 full-squat jumps wit	10 sets of 15 full-squat jumps with 10 kg weight imposed at the waist	
Outcomes	analogue scale where 0 is "comp noticeable pain and stiffness at a	PRIMARY Delayed onset muscle soreness was evaluated in the leg extensors using a 10 cm visual analogue scale where 0 is "complete absence of pain" and 10 is "extremely sore with noticeable pain and stiffness at all times and the muscle and leg are difficult to use". Perceived soreness was done during quadriceps extension	
Interventions	Duration Vitamin C taken 3 hours before	800 mg of vitamin C Placebo No details provided other than it was identical in appearance	
Participants	Mean age vitamin C group 16.7 Mean age placebo group 16.5 (SI Inclusion/exclusion criteria	n = 16 male junior basketball players (8 in each group) Mean age vitamin C group 16.7 (SD 0.3) years Mean age placebo group 16.5 (SD 0.2) years Inclusion/exclusion criteria Participants completed 4 to 5 training sessions a week with an average weekly training	
Methods	Randomised controlled trial (par	Randomised controlled trial (parallel design)	

Nie 2004 (Continued)

Random sequence generation (selection bias)	Unclear risk	No details in manuscript Authors were contacted via email on 26 May 2016 and responded on 27 May 2016: "distribute subjects by lot"
Allocation concealment (selection bias)	Unclear risk	No details in manuscript Authors were contacted via email on 26 May 2016 and responded on 27 May 2016 but did not understand the query
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double-blind
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Double-blind
Incomplete outcome data (attrition bias) All outcomes	Low risk	No details in manuscript Authors were contacted via email on 26 May 2016 and responded to say that all participants completed the study
Selective reporting (reporting bias)	High risk	No published protocol available All outcomes reported at all time points Adverse effects of antioxidant supplemen- tation were not reported
Other bias	Unclear risk	Diet was controlled 2 days before test- ing, however no details were provided on whether participants were instructed to avoid other supplements or anti-inflamma- tory drugs during the study

O'Connor 2013

Methods	Randomised controlled trial (parallel design)
Participants	Setting: laboratory; USA n = 40 untrained men (20) and women (20); age range 18 to 39 Placebo group (n = 20; 10 women) Antioxidant group (n = 2; 9 women) Inclusion/exclusion criteria Excluded were pregnant women, individuals engaged in vigorous activities on a regular basis (more than once per week on average during the prior month), those with con- traindications to exercise, those taking pain or prescription drugs (except for oral con- traceptives), and high consumers of 55 fruits, vegetables, drinks or chocolate products known to contain polyphenols (> 1 serving per day during the prior month)

O'Connor 2013 (Continued)

Interventions	Intervention Grape beverage - stilbenes (resveratrol = 1.75 mg/kg), catechins (catechin = 19.7 mg/kg, epicatechin = 12.6 mg/kg), anthocyanins (peonidin = 31.7 mg/kg, cyanidin = 125 mg/kg, malvidin = 145.2 mg/kg) and flavanols (quercetin = 32.6 mg/kg, kaempferol = 5.6 mg/kg, isorhamnetin = 6.8 mg/kg) Placebo A combination of starch, sugars, cellulose, acids, dipotassium phosphate, potassium citrate, grape flavouring and food dyes was used to create a placebo powder that matched the composition and caloric content of the grape powder as closely as possible but without any polyphenolic compounds Duration 45 days
Outcomes	 PRIMARY Delayed onset muscle soreness in the arm was rated in response to isometric strength measurement trials using a 100 mm visual analogue scale where 0 is "no pain" and 100 is "extreme pain" SECONDARY Range of motion Isometric strength of the elbow flexors at 90 degrees Maximal oxygen consumption performed on a treadmill
Exercise type	3 sets of 6 repetitions were performed using the non-dominant elbow flexors with a weight of 120% of concentric 1 RM
Sources of funding	Financial support for the study was provided by the California table Grape Commission
Notes	One serving of powder daily mixed with 236 mL of water

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	One investigator generated an allocation sequence using an online random number generator that created blocks of 2 with an allocation ratio of 1:1 to the conditions. A different investigator randomly assigned participants in blocks to their groups
Allocation concealment (selection bias)	Low risk	Opaque containers and a clip was placed on the nose
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double-blind: participants as well as re- searchers administering the intervention, assessing the outcomes and conducting the statistical analyses were blinded

O'Connor 2013 (Continued)

Blinding of outcome assessment (detection bias) All outcomes	Low risk	Double-blind
Incomplete outcome data (attrition bias) All outcomes	Low risk	All participants completed the study with no adverse effects
Selective reporting (reporting bias)	Low risk	No published protocol available All outcomes reported at all time points Manuscript states: "No adverse events oc- curred in response to beverage consump- tion"
Other bias	Low risk	Participants were asked to record food fre- quency and were asked to refrain from us- ing anti-inflammatory drugs or other sup- plements that could reduce soreness

O'Fallon 2012

Methods	Randomised controlled trial (parallel design)
Participants	Setting: laboratory, USA n = 30 sedentary adults (15 men and 15 women), age range 18 to 25 years Mean age placebo group men (n = 8) 19.5 (SD 1.1) years, mean age placebo group women (n = 7) 19.6 (SD 1.3) years Mean age supplement group men (n = 7) 20.9 (SD 1.8) years, mean age placebo group women (n = 8) 20.6 (SD 1.1) years Inclusion/exclusion criteria Participants were sedentary to recreationally active, naive to resistance training and resis- tance-type activities of the upper extremities for 6 months before participation, negative (by self-report) for family history of and current musculoskeletal or metabolic impair- ments, and not taking any dietary supplements
Interventions	Intervention First Strike Nutrition (Natick Soldier Centre, Natick MA) Bars with 1000 mg of Quercitin (Merck, SA Brazil) Placebo Placebo First Strike Nutrition Bar (Natick Soldier Centre, Natick MA) Duration 7 days
Outcomes	PRIMARY Delayed onset muscle soreness was assessed using a 100 mm visual analogue scale where 0 is "no soreness" and 100 is "unbearable pain" Elbow flexor SECONDARY Resting arm angle

O'Fallon 2012 (Continued)

	Upper arm swelling Isometric peak torque
Exercise type	24 eccentric contractions of the elbow flexors
Sources of funding	Funded by the US Army contract # W911QY-07-C-0001
Notes	1 bar twice daily for 7 days Authors were contacted to request raw data for delayed onset muscle soreness, range of motion and maximal voluntary isometric contraction on 3 November 2013 and responded on 3 December 2013

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Randomly assigned in a permuted block design
Allocation concealment (selection bias)	Unclear risk	No details in the manuscript Authors were contacted but no reply re- ceived
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double-blind
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Double-blind
Incomplete outcome data (attrition bias) All outcomes	Low risk	All participants completed the study with- out any adverse effects
Selective reporting (reporting bias)	High risk	No published protocol available All outcomes reported at all time points Adverse effects of antioxidant supplemen- tation were not reported
Other bias	Low risk	Food records were obtained, participants were instructed to minimise foods high in quercetin and were asked to refrain from taking any other supplements, anti-inflam- matory medication or engage in any other modality that could enhance recovery

Peschek 2014

Methods	Randomised controlled trial (cross-over design) Separated by a 21-day washout
Participants	Setting: laboratory, USA n = 8 well-trained male runners and triathletes age range 18 to 44 years Inclusion/exclusion criteria Inclusion criteria - currently training for at least 6 or more hours per week Exclusion criteria - lower body extremity injury in the past 6 months and/or were cur- rently taking chronic or daily doses of anti-inflammatory medication or nutritional sup- plements. Participants who had a history of a recent illness were also excluded from the study
Interventions	 Intervention 240 mL serving of carbohydrate protein beverage plus natural cocoa (350 mg flavanols) Placebo Placebo cocoa-based (processed with alkali) carbohydrate protein beverage (0 mg of flavanols) Duration Beverage consumed 1 and 2 hours into recovery after downhill running and primary and secondary outcomes measured for up to 2 days after exercise
Outcomes	 PRIMARY Delayed onset muscle soreness at the legs (10-point visual analogue scale: 0 is "no pain at all" and 10 is "unbearable pain") SECONDARY Muscle tenderness using a force algometer (Wagner Pain Test Model FPK Algometer) Muscle function - Quadricep Extension Performance - 5 km running time trial
Exercise type	Downhill running protocol at a -10% grade for 30 minutes at a speed equal to 70% of VO2 max
Sources of funding	Chocolate milk was provided by Darigold Co.
Notes	Drinks were 240 mL per serving and consumed 1 hour post-exercise and 2 hours post- exercise Authors were contacted on 18 February 2016 to request data for delayed onset muscle soreness, maximal voluntary isometric contraction and 5 km time trial but did not respond

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Randomised using a computer program
Allocation concealment (selection bias)	Low risk	Unmarked bottles

Peschek 2014 (Continued)

Blinding of participants and personnel (performance bias) All outcomes	High risk	Single-blind design thus personnel were not blinded
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Participants were blinded
Incomplete outcome data (attrition bias) All outcomes	Low risk	All participants completed the study with- out any adverse effects
Selective reporting (reporting bias)	High risk	All outcomes reported at all time points Adverse effects of antioxidant supplemen- tation were not reported
Other bias	Low risk	Participants were instructed to consume a similar diet during the period of testing and replicate diet during both trials. Partic- ipants were instructed to refrain from tak- ing anti-inflammatory medication

Phillips 2003

Methods	Randomised controlled trial (parallel design)
Participants	Setting: laboratory; USA n = 40 healthy, untrained, non-smoking males who were regularly involved with weight training mean; age 22.1 (SEM 3.9) years (16 in the antioxidant group and 19 in the placebo group) Inclusion/exclusion criteria During the screening process an extensive interview to clarify the extent and nature of each individual's exercise habits was conducted, specifically to ascertain whether or not a regular weight-training programme was a component thereof. Those participants not involved with a regular weight-training programme and with no prior history of injury to the biceps brachii or elbow region were included in the study
Interventions	Intervention Mixed antioxidant supplement (300 mg tocopherols, 800 mg docosahexaenoate, 300 mg flavonoids, of which was 100 mg hesperetin and 200 mg quercetin) Placebo Sunflower oil and rice powder capsules Duration 2 weeks of supplementation
Outcomes	PRIMARY Muscle soreness was measured using a visual analogue scale (0 to 10 cm) where 0 is "no pain" and 10 is "extreme pain". Soreness measures were subjectively evaluated through palpitation for oedema at the elbow and were performed by the same researcher through-

Phillips 2003 (Continued)

	out the study SECONDARY Range of motion was measured as active arm flexion from full extension using standard goniometry. Each range of motion value was obtained from an average of 3 measurements
Exercise type	3 sets of 10 repetitions at 80% of 1 RM of elbow flexor
Sources of funding	This research was supported with funding from Galileo Laboratories, Inc
Notes	Supplements were taken in the form of capsules (number of capsules per day not specified) Authors were contacted via email on 2 November 2013 and again on 3 December 2013 to request data for delayed onset muscle soreness and maximal voluntary isometric contraction but they did not respond

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Randomised; however, no details in the manuscript on how this was done Authors were contacted via email on 2 November 2013 and again on 3 December 2013 with no reply
Allocation concealment (selection bias)	Unclear risk	No details in the manuscript Authors were contacted via email on 2 November 2013 and again on 3 December 2013 with no reply
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double-blind
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Double-blind
Incomplete outcome data (attrition bias) All outcomes	High risk	5 participants were excluded from the study due to complications with the blood-draw- ing procedures, however it is unclear which group they were from Attrition rate = 12.5%
Selective reporting (reporting bias)	Low risk	No published protocol available All outcomes reported at all time points Manuscript states: "During the period of supplementation, there were no reported adverse events by any of the research sub- jects"

Phillips 2003 (Continued)

Other bias	Low risk	Participants were asked to refrain from us- ing any other supplements and medication for the duration of the study	
Shafat 2004			
Methods	Randomised controlled trial (p	parallel design)	
Participants	Mean age vitamin C group 25 Mean age placebo group 20.6 Inclusion/exclusion criteria All volunteers were moderately of resistance training exercise i	n = 12 moderately fit, active, non-smoking men Mean age vitamin C group 25 (SD 7.5) years Mean age placebo group 20.6 (SD 1.1) years	
Interventions	Intervention 500 mg vitamin C and 1200 I 400 IU each vitamin E Placebo Glucose Duration 37 days	500 mg vitamin C and 1200 IU vitamin E; 2 x 250 mg tablets of vitamin C + 3 tablets 400 IU each vitamin E Placebo Glucose Duration	
Outcomes	analogue scale for a total of 8 s sites on the posterior muscles of the relaxed muscle and rate so Results were summed for the 8 maximal muscle soreness by a SECONDARY Maximal voluntary concentric velocity of 0.5 rad/s 3 minutes on the Con-Trex dynamomete Isometric maximum voluntary of the knee extensors were mea were seated in the upright posi (Novatech, Hastings, UK). Ar digital information using an A shire, UK) and were recorded the strain gauge above the an For MVC, volunteers were ins	 PRIMARY Delayed onset muscle soreness was evaluated using a questionnaire employing a visual analogue scale for a total of 8 sites (6 sites on the anterior muscle of the upper leg and 2 sites on the posterior muscles of the upper leg). The participants were asked to palpate the relaxed muscle and rate soreness on a scale of 1 "normal" to 10 "very very sore". Results were summed for the 8 sites so that no soreness is indicated by a score of 8 and maximal muscle soreness by a score of 80 SECONDARY Maximal voluntary concentric torque for the knee extensors was measured at an angular velocity of 0.5 rad/s 3 minutes to and 3 minutes following the eccentric contraction bout on the Con-Trex dynamometer Isometric maximum voluntary contraction force (MVC) and electrically simulated force of the knee extensors were measured using a custom made isometric test rig. Volunteers were seated in the upright position with their leg connected to a pre-calibrated load cell (Novatech, Hastings, UK). Analogue signals from the strain gauge were converted to digital information using an A:D convertor (Powerlab 1400, ADInstruments, Oxford-shire, UK) and were recorded on a PC. The chair was adjusted to allow attachment of the strain gauge above the ankle with the knee at an angle of 1.57 rad (90 degrees). For MVC, volunteers were instructed to contract maximally for 3 seconds and verbally encouraged during their effort. 3 repetitions were performed, separated by 1 minute. 	
Exercise type	30 sets of 10 eccentric knee ex	tensions at a velocity of 0.52 rad s ^{-1}	

Shafat 2004 (Continued)

Sources of funding	None
Notes	-

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	No details in manuscript Authors were contacted via email on 26 May 2016 and responded on 5 June 2016: "Numbers were drawn out of a hat to de- termine a set allocation order which was balanced in numbers for treatment and placebo. As participants were recruited to the study, they were allocated to a group according to that random allocation order. "
Allocation concealment (selection bias)	Unclear risk	No details in manuscript Authors were contacted via email on 26 May 2016 and responded on 5 June 2016: "All volunteers were informed that they were being supplemented. All were sup- plied with identical labelled dispensers, containing capsules. However, the capsules were not identical in colour or size. We checked, informally, at the end of the test- ing to see if volunteers thought they were supplemented or controlled and they really had no idea which was which"
Blinding of participants and personnel (performance bias) All outcomes	High risk	Non-identical capsules; the personnel were not blinded
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Non-identical capsules; some risk of un- blinding
Incomplete outcome data (attrition bias) All outcomes	Low risk	All participants completed the study
Selective reporting (reporting bias)	High risk	No published protocol available All outcomes reported at all time points Adverse effects of antioxidant supplemen- tation were not reported

Shafat 2004 (Continued)

Other bias	Unclear risk	Participants that took supplements or smoked were excluded No details on whether participants were asked to refrain from using anti-inflamma- tory drugs or other treatment modalities that could reduce soreness
Silva 2008		
Methods	Randomised controlled trial (parallel design	n)
Participants	Setting: laboratory; Brazil n = 29 healthy, male university students mean age 21.3 (SD 4) years Inclusion/exclusion criteria Participants were non-smokers, did not take NAC or related supplements, had not participated in resistance training or any other form of structured exercise for at least 6 months, did not have a history of muscle lesion, and were not carriers of any disease that might compromise the results or be aggravated by physical exercise	
Interventions	Intervention N-acetylcysteine (NAC) 10 mg/kg of body mass in 3 groups as follows: Group 1: 21 days of N-acetylcysteine (NAC) 10 mg/kg of body mass n = 8 Group 2: 14 days of N-acetylcysteine (NAC) 10 mg/kg of body mass + placebo (14 days of NAC + 7 days of placebo) n = 8 Group 3: 21 days of placebo n = 9 Placebo Starch capsules Duration 21 days	
Outcomes	PRIMARY Delayed onset muscle soreness at the elbow flexor using a visual analogue scale (0 to 10 cm). Participants marked their subjective rating from 0 "without pain" to 10 "extreme pain"	
Exercise type	Elbow flexion and extension on the Scott bench at 80% 1 RM until exhaustion	
Sources of funding	The study was supported by grants from UNESC, CNPq and CAPES (Brazil)	
Notes	1 capsule per day for 14 days before the exercise protocol	
Risk of bias		
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	No details in the manuscript Authors were contacted via email on 24

Silva 2008 (Continued)

		May 2016 Author response: "We selected the individ- ual using a random number table. The par- ticipants were selected and they received a number. According with the random num- ber tables all individuals were included in the experimental or control groups."
Allocation concealment (selection bias)	Low risk	No details in the manuscript Authors were contacted via email on 24 May 2016 Author response: "Allocation concealment was ensured by the use of sequentially num- bered, dark and sealed envelopes. An inde- pendent colleague, blinded to the allocated treatment, did the selection and carried out the composition of groups."
Blinding of participants and personnel (performance bias) All outcomes	High risk	Single-blind; participants were blinded but the researchers were not
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Participants were blinded
Incomplete outcome data (attrition bias) All outcomes	High risk	4 participants withdrew for personal rea- sons Attrition rate: 14%
Selective reporting (reporting bias)	High risk	No published protocol available All outcomes reported at all time points Adverse effects of antioxidant supplemen- tation were not reported
Other bias	Unclear risk	Participants were non-smokers, did not take any other supplements and had not participated in resistance training or any form of structured exercise for 6 months No details on whether the participants used anti-inflammatory drugs for the duration of the study

Silva 2010

Methods	Randomised controlled trial (parallel design)
Participants	Setting: laboratory; Brazil n = 27 male university students mean age 25.5 (SD 4) years Inclusion/exclusion criteria All participants were non-smokers, were not taking vitamin E or any other antioxidant or related supplements, had not participated in resistance training or any other form of structured exercise for at least 6 months, did not have a history of muscular lesions, and were not carriers of any disease that might compromise the results or be aggravated by physical exercise
Interventions	Intervention 800 IU per day of D-a-tocopherol acetate (vitamin E); 1 capsule per day Placebo Starch capsules Duration 14 days before and 7 days after (total 21 days)
Outcomes	PRIMARY Muscle soreness of the biceps muscle was assessed using a 10 cm visual analogue scale where 0 is "no muscular soreness" and 10 is "maximum muscular soreness"
Exercise type	Elbow flexion and extension on the Scott bench at an intensity of 80% of 1 RM; 3 sets to exhaustion with 2 minutes recovery
Sources of funding	The research was supported by grants from CNPq/MCT (Brazil), CAPES/MEC (Brazil) and USESC (Brazil)
Notes	-

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	No details in manuscript Authors were contacted on 26 May 2016 via email Author response: "We selected the individ- ual using a random number table. The par- ticipants were selected and they received a number. According with the random num- ber tables all individuals were included in the experimental or control groups."
Allocation concealment (selection bias)	Low risk	No details in manuscript Authors were contacted on 26 May 2016 via email Author response: "Allocation concealment was ensured by the use of sequentially num-

Silva 2010 (Continued)

		bered, dark and sealed envelopes. An inde- pendent colleague, blinded to the allocated treatment, did the selection and carried out the composition of groups."
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double-blind
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Double-blind
Incomplete outcome data (attrition bias) All outcomes	High risk	6 participants withdrew from the study for personal reasons Attrition rate: 22%
Selective reporting (reporting bias)	High risk	No published protocol available All outcomes reported at all time points Adverse effects of antioxidant supplemen- tation were not reported
Other bias	Unclear risk	No data on food records reported Participants were instructed to refrain from taking supplements for the duration of the study but no details on anti-inflammatory medication

Su 2008

Methods	Randomised controlled trial (parallel design)
Participants	Setting: laboratory; China n = 16 athletes aged 18 to 20 years (8 males and 8 females) Mean age 18.9 (SD 0.8) years Inclusion/exclusion criteria A medical exam, including measurement of height, weight, blood pressure and electro- cardiogram was performed for each participant before the start of the study. No partici- pants had infectious diseases or were currently taking anti-inflammatory and anti-fatigue medicine during the study period
Interventions	Intervention 80 mg of allicin supplementation Placebo 80 mg maltodextrin Duration 2 weeks before and 2 days after running

Su 2008 (Continued)

Outcomes	PRIMARY Muscle soreness was assessed using the Borg CR-10 Scale where 0 is "no pain" and 10 is "maximal pain". At the beginning of the exercise test, participants were instructed to give CR-10 values
Exercise type	Downhill running on a treadmill at a grade of -10%
Sources of funding	No information in the manuscript Authors were contacted on 2 November 2013 and 3 December 2013 via email with no response
Notes	Supplements taken as capsules daily Authors were contacted on 2 November 2013 and 3 December 2013 via email to request data for delayed onset muscle soreness with no response

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	High risk	Participants were randomly assigned into an allicin or control group by sex and sports participation
Allocation concealment (selection bias)	Unclear risk	Not specified in the manuscript Authors were contacted on 2 November 2013 and 3 December 2013 via email with no response
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Not specified in the manuscript Authors were contacted on 2 November 2013 and 3 December 2013 via email with no response
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	No details provided
Incomplete outcome data (attrition bias) All outcomes	Low risk	All participants completed the study
Selective reporting (reporting bias)	High risk	No published protocol available All outcomes reported at all time points Adverse effects of antioxidant supplemen- tation were not reported
Other bias	Low risk	Participants were asked to maintain their normal dietary habits and avoid any form of antioxidant supplementation

Tanabe 2015

Methods	Randomised controlled trial (cross-over des 4-week washout period	ign)
Participants	Setting: laboratory; Japan n = 14 untrained young men mean age 23.5 (SD 2.4) years Inclusion/exclusion criteria Participants had not been involved in any regular resistance exercise training for the past year	
Interventions	Intervention 150 mg of curcumin in 6 capsules of 25 mg Placebo 150 mg of starch in 6 capsules of 25 mg eac Duration 1 hour before exercise and 12 hours after ex	ch
Outcomes	 Primary Muscle soreness was measured using a 100 mm visual analogue scale where 0 is "no pain" and 100 is "extremely sore." Soreness was measured upon palpitation of the upper arm and passively extending the elbow joint Secondary Range of motion was measured by actively extending the elbow joint maximally (extended elbow joint) and touching the shoulder of the same side with the hand (flexed elbow joint angle). The range of motion was defined by the difference between the 2 elbow joints. Each angle was measured by a goniometer 3 times and the mean of the 3 measures was used Maximum voluntary contraction of the exercised elbow flexors was measured using the isokinetic dynamometer in the same positioning as the eccentric exercise and the elbow joint angle was set at 90 degrees. 3 maximal isometric contractions were performed with a 30-second rest 	
Exercise type	2 bouts of eccentric exercise of the elbow flexors on a Biodex dynamometer (Biodex System 3, USA) using 1 arm for each bout separated by 4 weeks. Each exercise bout consisted of 50 maximal eccentric contractions of the elbow flexors at a velocity of 120 degrees per second	
Sources of funding	The study was supported by Theravalues Corporation, Japan	
Notes	Authors were contacted to request raw data for delayed onset muscle soreness, range of motion and maximal voluntary isometric contraction on 8 December 2017 and responded on 9 December 2017	
Risk of bias		
	Authors' judgement	Support for judgement

	, -	, -
Random sequence generation (selection bias)	Unclear risk	Manuscript states: "randomised, single- blinded" design was used; no additional de- tails in the manuscript

Tanabe 2015 (Continued)

		Authors were contacted via email on 5 February 2017 and responded on 8 Febru- ary 2017: "One investigator (YT) assigned and managed the order of dominant-non- dominant and active-placebo to be coun- terbalanced as described in manuscript."
Allocation concealment (selection bias)	Unclear risk	No details in manuscript Authors were contacted via email on 5 February 2017 and responded on 8 Febru- ary 2017: "The subjects were allocated be- fore the authors got any subject informa- tion (e.g., height, weight, day of birth etc) ."
Blinding of participants and personnel (performance bias) All outcomes	High risk	The study was a single-blinded design
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	No details provided
Incomplete outcome data (attrition bias) All outcomes	Low risk	Authors were contacted via email on 5 February 2017 and responded on 8 Febru- ary 2017: "all participants completed the study"
Selective reporting (reporting bias)	High risk	No published protocol available All outcomes reported at all time points Adverse effects of antioxidant supplemen- tation were not reported
Other bias	Low risk	Manuscript states: "Subjects maintained their normal food intake and lifestyle habits, but abstained from strenuous phys- ical activities, and did not take anti-inflam- matory drugs during the study period."

Theodorou 2011

Methods Ra	andomised controlled trial (parallel design)
n - M M In	etting: laboratory; Greece = 28 healthy, recreationally trained men Iean age placebo group 25.6 (SEM 1.2) Iean age vitamin C group 26.2 (SEM 1.5) nclusion/exclusion criteria Ien were recruited after advertising the study in the local media

Theodorou 2011 (Continued)

Interventions	Intervention 1g of vitamin C and 400 IU vitamin E Placebo Lactose Duration 11 weeks
Outcomes	PRIMARY Delayed onset muscle soreness was assessed using a squat using body weight with a 0 to 10 scale where 0 is "normal" and 10 is "very sore" SECONDARY Range of motion Isometric peak torque using an isokinetic dynamometer. Isometric knee extensor peak torque at 90 degrees knee flexion was measured. The average of the 3 best maximal voluntary contractions with the dominant leg was recorded
Exercise type	Knee extensions on an isokinetic dynamometer
Sources of funding	None: the authors had no personal or financial conflicts of interest
Notes	1 capsule per day

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	High risk	Participants were allocated based on age, BMI and maximum isometric torque into equal groups then a computer generator was used for the assignment into groups
Allocation concealment (selection bias)	Low risk	No details in manuscript Authors were emailed in 25 May 2016 via email to request this information Author response: "We used an independent person and a sealed opaque envelope for the allocation concealment."
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double-blind
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Double-blind
Incomplete outcome data (attrition bias) All outcomes	Low risk	All participants completed the study

Theodorou 2011 (Continued)

Selective reporting (reporting bias)	Unclear risk	Study protocol published (ClinicalTrials. gov: NCT01290458) All the outcomes published in the study protocol were measured in the actual study All outcomes reported at all time points However, adverse effects of antioxidant supplementation were not reported
Other bias	Unclear risk	Participants were asked to keep food records for 3 days before testing, however no details on whether participants were asked to refrain from using other supple- ments and anti-inflammatory medication

Thompson 2001

Methods	Randomised controlled trial (cross-over design) Separated by 14-day washout
Participants	Setting: laboratory, UK n = 9 male, habitually active, male university students Mean age 28.4 (SEM 1.3) years Inclusion/exclusion criteria Participants who smoked or took vitamin supplements were excluded from the study
Interventions	Intervention 1 g of vitamin C 2 hours before exercise Placebo Carbohydrate sports drink Duration Supplement consumed on day of test 2 hours before exercise with a 14-day washout
Outcomes	PRIMARY Delayed onset muscle soreness at the quadriceps using a 10-point (1 to 10 cm) visual analogue scale where 0 is "not sore" and 10 is "very very sore" SECONDARY Isometric flexion and extension
Exercise type	Loughborough Intermittent Shuttle Running Test - 90 minutes variable intensity run- ning over 20 m distance
Sources of funding	The authors acknowledged the financial support of SmithKline Beecham
Notes	Supplements were ingested in a drink
Risk of bias	

Thompson 2001 (Continued)

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Details not in the manuscript therefore au- thors were contacted (19 May 2016) "A third party independent from the in- vestigators generated a randomisation plan and held the sequence for allocation"
Allocation concealment (selection bias)	Unclear risk	Not reported in manuscript therefore au- thors were contacted (19 May 2016) No response received
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double-blind
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Double-blind
Incomplete outcome data (attrition bias) All outcomes	Low risk	All participants complete the study
Selective reporting (reporting bias)	High risk	No published protocol available All outcomes reported at all time points Adverse effects of antioxidant supplemen- tation were not reported
Other bias	Unclear risk	Vitamin C intake through diet was screened through weighed food records No detail on whether participants were asked to refrain from using supplements or anti-inflammatory medication

Thompson 2001a

Methods	Randomised controlled trial (parallel design)
Participants	Setting: laboratory; UK n = 16 physically active males (8 in the placebo group and 8 in the vitamin C group) Mean age vitamin C group 25 (SEM 2) years Mean age placebo group 23 (SEM 2) years Inclusion/exclusion criteria Participants who had smoked or took vitamin supplements were excluded from the study. All participants regularly took part in a variety of activities but were unfamiliar with the exercise protocol

Thompson 2001a (Continued)

Interventions	 Intervention Vitamin C supplementation; 1 g of vitamin C on day 1 followed by 400 mg/day divided into 2 doses for 12 days Placebo Lactose capsules Duration 13 days
Outcomes	PRIMARY Delayed onset muscle soreness at the quadriceps using a 10-point (0 to 10 cm) visual analogue scale where 0 is "not sore" and 10 is "very very sore" SECONDARY Isometric quadriceps muscle contraction. Muscle function was assessed in the flexors and extensors of both legs on an isokinetic dynamometer (CYBEX model 770, LUMEX, USA)
Exercise type	Loughborough Intermittent Shuttle Running Test - 90 minutes variable intensity run- ning over 20 m distance
Sources of funding	The study was financially supported by SmithKline Beecham UK
Notes	1 g given in a solution followed by 400 mg/day doses in capsule form

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Details not in the manuscript therefore au- thors were contacted (19 May 2016) "A third party independent from the in- vestigators generated a randomisation plan and held the sequence for allocation"
Allocation concealment (selection bias)	Unclear risk	Not reported in the manuscript therefore authors were contacted (19 May 2016) No response received
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double-blind
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Double-blind
Incomplete outcome data (attrition bias) All outcomes	Low risk	All the participants completed the study

Thompson 2001a (Continued)

Selective reporting (reporting bias)	High risk	No published protocol available All outcomes reported at all time points Adverse effects of antioxidant supplemen- tation were not reported
Other bias	Low risk	Participants who smoked or took vitamin supplements were excluded. No detail on whether participants kept food records or were instructed to refrain from taking sup- plements for the duration of the study and no details on avoiding anti-inflammatory medication

Thompson 2003

Methods	Randomised controlled trial (parallel design)
Participants	Setting: laboratory; UK n = 16 male university students (8 participants in each group) Mean age vitamin C group 23.6 (± SEM 1.4) years Mean age placebo group 24.3 (± SEM 1.7) years Inclusion/exclusion criteria Participants who smoked or took vitamin supplements were excluded from the investi- gation. All participants were habitually active in a variety of sports, although none were familiar with the exercise protocol used in the present study
Interventions	Intervention 200 mg vitamin C Placebo Carbohydrate sports drink Duration 3 days
Outcomes	PRIMARY Delayed onset muscle soreness was rated on a 10-point scale ranging from 1 "not sore" to 10 "very very sore." Soreness was assessed whilst the participants actively contracted the quadriceps SECONDARY Isometric quadriceps muscle contraction. Muscle function was assessed in the flexors and extensors of both legs on an isokinetic dynamometer (CYBEX model 770, LUMEX, USA)
Exercise type	Loughborough Intermittent Shuttle Running Test - 90 minutes variable intensity run- ning over 20 m distance
Sources of funding	The authors acknowledged the financial support of SmithKline Beecham, UK

Thompson 2003 (Continued)

Notes	Supplements were ingested in a drink daily		
Risk of bias			
Bias	Authors' judgement	Support for judgement	
Random sequence generation (selection bias)	Low risk	Details not in the manuscript therefore au- thors were contacted (19 May 2016) "A third party independent from the in- vestigators generated a randomisation plan and held the sequence for allocation"	
Allocation concealment (selection bias)	Unclear risk	Not reported in the manuscript therefore authors were contacted (19 May 2016) No response received	
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double-blind	
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Double-blind	
Incomplete outcome data (attrition bias) All outcomes	Low risk	All the participants completed the study	
Selective reporting (reporting bias)	High risk	No published protocol Data not reported for all outcomes Adverse effects of antioxidant supplemen- tation were not reported	
Other bias	Low risk	Participants were asked to record food fre- quency and to refrain from using anti-in- flammatory drugs or other supplements that could reduce soreness	

Thompson 2004

Methods	Randomised controlled trial (parallel design)
Participants	Setting: laboratory; UK n = 14 male university students Mean age vitamin C group 25.3 (SEM 1.4) years Mean age placebo group 22.6 (SEM 1.7) years Inclusion/exclusion criteria Participants who smoked or took vitamin supplements were excluded from the study. All participants regularly took part in a variety of activities but were unfamiliar with the

Thompson 2004 (Continued)

	exercise protocol used in the study
Interventions	Intervention 200 mg vitamin C Placebo 200 mg lactose Duration 14 days
Outcomes	PRIMARY Muscle soreness was assessed in the quadriceps using a 0 to 100 mm scale where 0 is "normal" and 100 is "very very sore". In order to activate the sensation of soreness, par- ticipants assessed soreness whilst actively contracting the leg extensors against resistance equivalent to 75% of each individual's one repetition maximum
Exercise type	30 minutes downhill running at -18% gradient
Sources of funding	None
Notes	No details on how many capsules were consumed per day Authors were contacted to request raw data for delayed onset muscle soreness on 3 November 2013 and responded on 4 November 2013

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Details not in the manuscript therefore au- thors were contacted (19 May 2016) "A third party independent from the in- vestigators generated a randomisation plan and held the sequence for allocation"
Allocation concealment (selection bias)	Unclear risk	Not reported in manuscript therefore au- thors were contacted (19 May 2016) No response received
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double-blind
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Double-blind
Incomplete outcome data (attrition bias) All outcomes	Low risk	All the participants completed the study

Thompson 2004 (Continued)

Selective reporting (reporting bias)	High risk	No published protocol available All outcomes reported at all time points Adverse effects of antioxidant supplemen- tation were not reported
Other bias	Unclear risk	Vitamin C intake through diet was screened through weighed food records No detail on whether participants were asked to refrain from using supplements or anti-inflammatory medication
Trombold 2010		
Methods	Randomised controlled trial (cross- Separated by a 14-day washout	over design)
Participants	Setting: laboratory; USA n = 16 healthy, non-smoking, recreationally active males, mean age 24 (SD 1.4) years Inclusion/exclusion criteria Participants were disqualified if they had participated in resistance exercise training of any kind in the previous 3 months, were currently participating in a formalised endurance training programme or had previous history of upper body injury. Other exclusion criteria included a recent weight change of more than 5 kg, history of hypertension, use of anti-inflammatory drugs, angiotensin converting enzyme inhibitors lipid-lowering medications or selective serotonin reuptake inhibitors	
Interventions	Intervention Pomegranate juice POM Wonderful 500 mL twice daily, 650 mg polyphenols, consisting of 95.5% ellagitannins, 3.5% ellagic acid and 1% anthocyanins Placebo 35 g carbohydrate + colouring and flavouring to match the pomegranate juice Duration 2 doses per day separated by 12 hours; 2 x 9-day treatment periods separated by a 14- day washout	
Outcomes	 PRIMARY Delayed onset muscle soreness of the elbow flexor muscles was determined before each isometric strength test using a 0 to 10 visual analogue scale where 0 is "no soreness" and 10 is "unbearable soreness". The rating was obtained before the measurement of strength while performing unloaded elbow flexion of the tested arm SECONDARY Maximal isometric strength in elbow extensors was performed on a modified preacher curl bench. Force was recorded using a load cell (LC101-500; Omega Engineering, Stamford, CT) secured to the ground using a galvanised steel cable and a strap secured to the waist of the participant. The participant performed 4 trials, 2 at both 150 degrees and 135 degrees of complete elbow extension, with a 180-second rest in between each trial. Strength was reported as the average of the peak values at angles 150 and 135 degrees of elbow flexion 	

Trombold 2010 (Continued)

Exercise type	2 sets of 20 maximal eccentric elbow flexion exercises
Sources of funding	The study was supported by a grant from POM Wonderful, L.L.C
Notes	2 doses of 480 mL of the drink consumed daily separated by 12 hours. Participants were reminded to take the products verbally and via email communication to consume the experimental supplements at the required times Authors were contacted to request raw data for delayed onset muscle soreness and maxi- mal voluntary isometric contraction on 2 November 2013 and responded on 5 Decem- ber 2013

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	No details in manuscript Authors were contacted on 26 May 2016 via email with no response
Allocation concealment (selection bias)	Unclear risk	No details in manuscript Authors were contacted on 26 May 2016 via email with no response
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double-blind
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Double-blind
Incomplete outcome data (attrition bias) All outcomes	Low risk	All participants completed the study
Selective reporting (reporting bias)	High risk	No published protocol available All outcomes reported at all time points Adverse effects of antioxidant supplemen- tation were not reported
Other bias	Low risk	Participants were asked to refrain from us- ing anti-inflammatory drugs or other sup- plements that could reduce soreness

Trombold 2011

Methods	Randomised controlled trial (cross-over design) Separated by a 14-day washout
Participants	Setting: laboratory; USA n = 17 healthy, non-smoking, resistance-trained males; mean age 21.9 (SD 2.4) years Inclusion/exclusion criteria The participants were required to have been weight training for at least the last 3 months, exercising both their upper and lower body, at least twice per week. Criteria for exclusion were a recent weight change of > 5 kg; history of hypertension; the prescience of major orthopaedic injury; use of anti-inflammatory drugs; over-the-counter pain medicine, vitamin or mineral supplements, angiotensin-converting enzyme inhibitors
Interventions	Intervention Pomegranate juice 250 mL POM Wonderful (LA, USA). Each bottle contained ap- proximately 1979 mg/L of tannins, 384 mg/L anthocyanins and 121 mg/L of ellagic derivatives Placebo 35 g carbohydrate + colouring and flavouring to match the pomegranate juice Duration 44 days; 15 days of supplementation with a 14-day washout
Outcomes	 PRIMARY Delayed onset muscle soreness of the elbow flexor and knee extensor muscles was determined before each isometric strength test using a 0- to 10-point visual analogue scale where 0 is "no soreness" and 10 is "unbearable soreness". The rating was obtained before the measurement of strength while performing unloaded elbow flexion and knee extension on the tested arm and leg SECONDARY Maximal isometric strength in elbows and knee extensors was performed on a modified preacher curl bench and modified knee extension machine respectively. The participant performed 4 trials at both 30 and 45 degrees above elbow extension and 45 and 90 degree below knee extension with 180-second rest in between each trial. Strength for both tests was reported as the average peak value of each joint angle
Exercise type	3 sets of 20 maximal eccentric elbow extensions on an isokinetic dynamometer
Sources of funding	The study was funded by POM Wonderful, L.L.C.
Notes	Supplement taken as 250 mL bottle twice daily separated by 12 hours. Participants were reminded to take the products verbally and via email communication to consume the experimental supplements at the required times Authors were contacted to request raw data for delayed onset muscle soreness and maxi- mal voluntary isometric contraction on 2 November 2013 and responded on 5 Decem- ber 2013
Risk of bias	
Bias	Authors' judgement Support for judgement

Trombold 2011 (Continued)

Random sequence generation (selection bias)	Unclear risk	No details in manuscript Authors were contacted on 26 May 2016 via email with no response
Allocation concealment (selection bias)	Unclear risk	No details in manuscript Authors were contacted on 26 May 2016 via email with no response
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double-blind
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Double-blind
Incomplete outcome data (attrition bias) All outcomes	Low risk	All participants completed the study
Selective reporting (reporting bias)	High risk	No published protocol available All outcomes reported at all time points Adverse effects of antioxidant supplemen- tation were not reported
Other bias	Low risk	Participants were asked to refrain from us- ing anti-inflammatory drugs or other sup- plements that could reduce soreness

BMI: body mass index EGCG: epigallocatechin gallate IU: international units NAC: N-acetyl-cysteine NSAID: non-steroidal anti-inflammatory drug PPT: pressure pain threshold RM: repetition maximum SD: standard deviation SE: standard deviation SEM: standard error SEM: standard error of the mean VAS: visual analogue scale

Characteristics of excluded studies [ordered by study ID]

Study	Reason for exclusion
Aalizadeh 2016	Although delayed onset muscle soreness is in the title, it was not measured Authors were contacted on 4 February 2017 to confirm
Al-Nawaiseh 2016	Examined antioxidants, ibuprofen, cold water immersion and whey protein at the same time compared to a placebo
Ammar 2016	Non-randomised study design
Arent 2010a	Delayed onset muscle soreness not measured
Askari 2012	Delayed onset muscle soreness not measured
Askari 2013	Delayed onset muscle soreness not measured
Babaei 2009	Delayed onset muscle soreness not measured
Bell 2014	Delayed onset muscle soreness not measured
Bloomer 2006	Delayed onset muscle soreness not measured
Bowtell 2011	Delayed onset muscle soreness not measured Tenderness was measured using a handheld algometer
Braakhuis 2014	Delayed onset muscle soreness not measured
Bunpo 2016	Delayed onset muscle soreness not measured
Carvalho-Peixoto 2015	Delayed onset muscle soreness not measured
Cavas 2004	Delayed onset muscle soreness not measured
Childs 2001a	Delayed onset muscle soreness not measured
Clifford 2017	Delayed onset muscle soreness not measured
Daneshvar 2013	Delayed onset muscle soreness not measured
Dawson 2002	Delayed onset muscle soreness not measured.
Eichenberger 2010	Delayed onset muscle soreness not measured
Fuster-Munoz 2016	Delayed onset muscle soreness not measured
Gaeini 2006	Delayed onset muscle soreness not measured

(Continued)

Gomez-Cabrera 2003	Delayed onset muscle soreness not measured
Hillman 2017	Tart cherry juice with whey protein No tart cherry juice only group
Itoh 2000	Delayed onset muscle soreness not measured.
Jakeman 1993	Delayed onset muscle soreness not measured
Jowko 2011	Delayed onset muscle soreness not measured
Jowko 2012	Delayed onset muscle soreness not measured
Jowko 2015	Delayed onset muscle soreness not measured
Kaikkonen 1998	Delayed onset muscle soreness not measured
Keong 2006	Delayed onset muscle soreness not measured
Kim 2013	Delayed onset muscle soreness not measured
Kingsley 2006	Supplementation used was not classed as an antioxidant
Kizaki 2015	Delayed onset muscle soreness not measured
Kon 2008	Delayed onset muscle soreness not measured
Kraemer 2007	Delayed onset muscle soreness not measured
Lafay 2009	Delayed onset muscle soreness not measured
Lamprecht 2009a	Delayed onset muscle soreness not measured
Leelarungrayub 2011	Delayed onset muscle soreness not measured
Lenn 2002	Antioxidant supplement was mixed with fish oils and antioxidant supplement alone not investigated
Levers 2015	Delayed onset muscle soreness not measured Tenderness was measured using a handheld algometer
Levers 2016	Delayed onset muscle soreness not measured Tenderness was measured using a handheld algometer
Louis 2010	Delayed onset muscle soreness not measured
Margaritis 2003	Delayed onset muscle soreness not measured

(Continued)

Mastaloudis 2006	Delayed onset muscle soreness not measured
Matsumoto 2005	Delayed onset muscle soreness not measured
McKenna 2006	Delayed onset muscle soreness not measured
Meamarbashi 2014	Delayed onset muscle soreness not measured
Meamarbashi 2016	Delayed onset muscle soreness not measured
Medved 2004	Delayed onset muscle soreness not measured
Meydani 1993	Delayed onset muscle soreness not measured
Mizuno 1997	Delayed onset muscle soreness not measured
Morillas-Ruiz 2005	Delayed onset muscle soreness not measured
NCT01555775	Antioxidant supplement compared to another dietary supplement (protein-carbohydrate supplement)
Nieman 2010	Delayed onset muscle soreness not measured
Olesen 2013	Delayed onset muscle soreness not measured
Ostman 2012	Delayed onset muscle soreness not measured
Panza 2016	Delayed onset muscle soreness not measured
Passerieux 2015	Delayed onset muscle soreness not measured
Paulsen 2014a	Delayed onset muscle soreness not measured
Petersen 2001	Delayed onset muscle soreness not measured
Pilaczynska-Szczesniak 2005	Delayed onset muscle soreness not measured
Roengrit 2014	Delayed onset muscle soreness not measured Tenderness was measured using a handheld algometer
Roengrit 2015	Delayed onset muscle soreness not measured Tenderness was measured using a handheld algometer
Romano-Ely 2006	Intervention was antioxidants and protein versus carbohydrate only Protein can reduce muscle soreness
Sacheck 2003	Delayed onset muscle soreness not measured

(Continued)

Sanchis-Gomar 2015	Delayed onset muscle soreness not measured
Santos 2016	Delayed onset muscle soreness not measured
Skarpanska-Stejnborn 2008	Delayed onset muscle soreness not measured.
Suzuki 2015	Delayed onset muscle soreness not measured
Taub 2015	Delayed onset muscle soreness not measured
Teixeira 2009a	Delayed onset muscle soreness not measured
Toscano 2015	Delayed onset muscle soreness not measured
Yarahmadi 2014	Delayed onset muscle soreness not measured
Yarahmadi 2014a	Delayed onset muscle soreness not measured
Yfanti 2010	Delayed onset muscle soreness not measured
Yfanti 2012	Delayed onset muscle soreness not measured
Zoppi 2006	Delayed onset muscle soreness not measured

Characteristics of ongoing studies [ordered by study ID]

NCT02281981

Trial name or title	The effects of repeated bouts of downhill running and curcumin supplementation on arterial stiffness during recovery
Methods	Randomised controlled trial (double-blind)
Participants	Setting: laboratory; USA n = 17 healthy, non-smoking, resistance-trained males; mean age 21.9 (SD 2.4) years Inclusion/exclusion criteria The participants were required to have been weight training for at least the last 3 months, exercising both their upper and lower body, at least twice per week. Criteria for exclusion were a recent weight change of > 5 kg; history of hypertension; the prescience of major orthopaedic injury; use of anti-inflammatory drugs; over-the-counter pain medicine, vitamin or mineral supplements, angiotensin-converting enzyme inhibitors
Interventions	Experimental Curcumin supplement 200 mg, curcuminoids, 7 days of supplementation in capsular form Placebo Sucrose, capsular

NCT02281981 (Continued)

Outcomes	PRIMARY Delayed onset muscle soreness (every 24 hours up to 72 hours post baseline); subjective analogue scale SECONDARY N/A
Starting date	November 2014
Contact information	Dr Jamie Burr, Assistant Professor, University of Prince Edward Island
Notes	ClinicalTrials.gov identifier: NCT02281981

N/A: not applicable SD: standard deviation

DATA AND ANALYSES

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Muscle soreness up to 6 hours; random-effects model	21	525	Std. Mean Difference (IV, Random, 95% CI)	-0.30 [-0.56, -0.04]
2 Muscle soreness at 24 hours; random-effects model	41	936	Std. Mean Difference (IV, Random, 95% CI)	-0.13 [-0.27, 0.00]
3 Muscle soreness at 48 hours; random-effects model	45	1047	Std. Mean Difference (IV, Random, 95% CI)	-0.24 [-0.42, -0.07]
4 Muscle soreness at 72 hours; random-effects model	28	657	Std. Mean Difference (IV, Random, 95% CI)	-0.19 [-0.38, -0.00]
5 Muscle soreness at 96 hours; random-effects model	17	436	Std. Mean Difference (IV, Random, 95% CI)	-0.05 [-0.29, 0.19]
6 Muscle soreness (follow-ups: 120, 144 and 168 hours); random-effects model	7		Std. Mean Difference (IV, Random, 95% CI)	Subtotals only
6.1 at 120 hours	4	128	Std. Mean Difference (IV, Random, 95% CI)	0.21 [-0.26, 0.69]
6.2 at 144 hours	1	20	Std. Mean Difference (IV, Random, 95% CI)	-0.23 [-1.11, 0.65]
6.3 at 168 hours	4	80	Std. Mean Difference (IV, Random, 95% CI)	-0.04 [-0.48, 0.41]
7 Muscle soreness up to 6 hours - all at same scale (0 to 10; worst pain)	21	525	Mean Difference (IV, Random, 95% CI)	-0.52 [-0.95, -0.08]
8 Muscle soreness at 24 hours - all at same scale (0 to 10; worst pain)	41	936	Mean Difference (IV, Random, 95% CI)	-0.17 [-0.42, 0.07]
9 Muscle soreness at 48 hours - all at same scale (0 to 10; worst pain)	45	1047	Mean Difference (IV, Random, 95% CI)	-0.41 [-0.69, -0.12]
10 Muscle soreness at 72 hours - all at same scale (0 to 10; worst pain)	28	657	Mean Difference (IV, Random, 95% CI)	-0.29 [-0.59, 0.02]
11 Muscle soreness at 96 hours - all at same scale (0 to 10; worst pain)	17	436	Mean Difference (IV, Random, 95% CI)	-0.03 [-0.43, 0.37]
12 Muscle soreness at 24 hours. Subgroup analysis by type of exercise (whole body aerobic vs. mechanically induced)	41	936	Std. Mean Difference (IV, Random, 95% CI)	-0.13 [-0.27, 0.00]
12.1 Whole body aerobic exercise	17	338	Std. Mean Difference (IV, Random, 95% CI)	-0.07 [-0.33, 0.18]
12.2 Mechanically induced	24	598	Std. Mean Difference (IV, Random, 95% CI)	-0.18 [-0.34, -0.01]
13 Muscle soreness at 48 hours. Subgroup analysis by type of exercise (whole body aerobic vs. mechanically induced)	45	1047	Std. Mean Difference (IV, Random, 95% CI)	-0.24 [-0.42, -0.07]

Comparison 1. Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies)

Antioxidants for preventing and reducing muscle soreness after exercise (Review)

Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

13.1 Whole body aerobic	17	349	Std. Mean Difference (IV, Random, 95% CI)	-0.12 [-0.47, 0.23]
exercise		<i></i>		
13.2 Mechanically induced	28	698	Std. Mean Difference (IV, Random, 95% CI)	-0.31 [-0.50, -0.12]
14 Muscle soreness at 24 hours.	40	920	Std. Mean Difference (IV, Fixed, 95% CI)	-0.13 [-0.26, 0.01]
Subgroup analysis by funding				
sources (funded by food				
company or provider of				
antioxidant supplements vs. not funded by food company				
or provider of antioxidant				
supplements)				
14.1 Company funding	17	427	Std. Mean Difference (IV, Fixed, 95% CI)	-0.11 [-0.31, 0.08]
14.2 Other funding	23	493	Std. Mean Difference (IV, Fixed, 95% CI)	-0.14 [-0.32, 0.05]
15 Muscle soreness at 48 hours.	44	1031	Std. Mean Difference (IV, Fixed, 95% CI)	-0.21 [-0.34, -0.09]
Subgroup analysis by funding	77	10,51	Std. Ivitali Difference (1V, 11xed, 7770 Cl)	-0.21 [-0.34, -0.07]
sources (funded by food				
company or provider of				
antioxidant supplements vs.				
not funded by food company				
or provider of antioxidant				
supplements)				
15.1 Company funding	18	443	Std. Mean Difference (IV, Fixed, 95% CI)	-0.19 [-0.38, 0.00]
15.2 Other funding	26	588	Std. Mean Difference (IV, Fixed, 95% CI)	-0.23 [-0.40, -0.06]
16 Muscle tenderness measured in	2		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
Newtons (all follow-up times)				
16.1 at 24 hours	2	52	Mean Difference (IV, Fixed, 95% CI)	-1.60 [-7.64, 4.45]
16.2 at 48 hours	2	52	Mean Difference (IV, Fixed, 95% CI)	-2.14 [-9.48, 5.19]
16.3 at 72 hours	2	52	Mean Difference (IV, Fixed, 95% CI)	-0.34 [-6.55, 5.86]
16.4 at 96 hours	2	52	Mean Difference (IV, Fixed, 95% CI)	-2.32 [-9.62, 4.99]
17 Muscle tenderness measured in	2		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
kg (all follow-up times)	1	20		0 (1 [1 (10 12
17.1 Up to 6 hours	1	20	Mean Difference (IV, Fixed, 95% CI)	-0.61 [-14.10, 12.
17.2 at 24 hours	2	36	Mean Difference (IV, Fixed, 95% CI)	88] 0.53 [-0.95, 2.01]
17.3 at 48 hours	2	36	Mean Difference (IV, Fixed, 95% CI)	0.52 [-1.08, 2.13]
17.4 at 72 hours	1	20	Mean Difference (IV, Fixed, 95% CI)	-1.03 [-13.01, 10.
17.4 at 72 nouis	1	20	Wear Difference (17, 11xed, 7570 Cf)	95]
17.5 at 96 hours	1	20	Mean Difference (IV, Fixed, 95% CI)	-1.39 [-15.12, 12.
	1	20	Wear Difference (17, 11, Ked, 757/6 Ci)	33]
18 30-second Wingate average	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
peak power output (W/kg)	-			
(post 7 days of intervention)				
19 20 m Sprint time (s)	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
19.1 at 24 hours	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
19.2 at 48 hours	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
19.3 at 120 hours	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
20 Maximal oxygen consumption	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
(mL/kg/min) (post 42 days of				
supplementation)				
21 Agility (seconds)	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
21.1 at 24 hours	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
21.2 at 48 hours	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]

21.3 at 72 hours	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
22 6 second sprint maximal power	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
(Watts) (all follow-up times)				
22.1 at 24 hours	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
22.2 at 48 hours	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
22.3 at 72 hours	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
23 Maximal voluntary isometric contraction measured as	15		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
percentage change from baseline				
23.1 Up to 6 hours	11	255	Mean Difference (IV, Fixed, 95% CI)	5.86 [3.29, 8.42]
23.2 at 24 hours	15	375	Mean Difference (IV, Fixed, 95% CI)	2.51 [0.99, 4.04]
23.3 at 48 hours	15	375	Mean Difference (IV, Fixed, 95% CI)	4.46 [2.94, 5.98]
23.4 at 72 hours	11	277	Mean Difference (IV, Fixed, 95% CI)	3.92 [0.88, 6.96]
23.5 at 96 hours	9	252	Mean Difference (IV, Fixed, 95% CI)	5.29 [3.65, 6.92]
23.6 at 168 hours	2	36	Mean Difference (IV, Fixed, 95% CI)	-7.96 [-15.96, 0.05]
24 Maximal voluntary isometric contraction measured in	6		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
Newton metres				
24.1 Up to 6 hours	3	84	Mean Difference (IV, Fixed, 95% CI)	-1.50 [-4.77, 1.76]
24.2 at 24 hours	6	148	Mean Difference (IV, Fixed, 95% CI)	-0.63 [-6.27, 5.01]
24.3 at 48 hours	6	148	Mean Difference (IV, Fixed, 95% CI)	0.80 [-5.46, 7.06]
24.4 at 72 hours	4	94	Mean Difference (IV, Fixed, 95% CI)	-3.62 [-11.91, 4.67]
24.5 at 96 hours	3	96	Mean Difference (IV, Fixed, 95% CI)	-4.65 [-16.21, 6.92]
24.6 at 120 hours	2	58	Mean Difference (IV, Fixed, 95% CI)	-5.89 [-19.14, 7.36]
24.7 at 168 hours	1	38	Mean Difference (IV, Fixed, 95% CI)	58.0 [13.57, 102.43]
25 Maximal voluntary isometric	6		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
contraction measured in				,
Newtons				
25.1 Up to 6 hours	4	73	Mean Difference (IV, Fixed, 95% CI)	6.50 [-55.11, 68.10]
25.2 at 24 hours	5	87	Mean Difference (IV, Fixed, 95% CI)	23.03 [-23.18, 69.
-	-			24]
25.3 at 48 hours	5	87	Mean Difference (IV, Fixed, 95% CI)	34.87 [-17.80, 87. 55]
25.4 at 72 hours	4	70	Mean Difference (IV, Fixed, 95% CI)	-5.11 [-73.42, 63. 19]
25.5 at 96 hours	1	20	Mean Difference (IV, Fixed, 95% CI)	-112.0 [-265.08, 41. 08]
25.6 at 168 hours	1	18	Mean Difference (IV, Fixed, 95% CI)	-225.0 [-534.90, 84. 90]
26 Maximal voluntary isometric contraction measured in	2		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
Newton metres per kg of body mass				
26.1 Up to 6 hours	2		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
26.2 at 24 hours	2		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
26.3 at 48 hours	2		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
26.4 at 72 hours	2		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
26.5 at 96 hours	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
26.6 at 120 hours	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
26.7 at 144 hours	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
26.8 at 168 hours	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
			(, , , , , , , , , , , , , , , , , , ,	

27 Maximal voluntary isometric contraction measured in kg	1		Std. Mean Difference (IV, Fixed, 95% CI)	Totals not selected
27.1 at 24 hours	1		Std. Mean Difference (IV, Fixed, 95% CI)	$0.0 \ [0.0, \ 0.0]$
27.2 at 48 hours	1		Std. Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
28 Range of motion (all follow-up times)	10		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
28.1 Up to 6 hours	6	163	Mean Difference (IV, Fixed, 95% CI)	-0.25 [-3.31, 2.81]
28.2 at 24 hours	9	259	Mean Difference (IV, Fixed, 95% CI)	1.03 [-0.91, 2.96]
28.3 at 48 hours	9	259	Mean Difference (IV, Fixed, 95% CI)	2.71 [0.39, 5.04]
28.4 at 72 hours	7	196	Mean Difference (IV, Fixed, 95% CI)	2.93 [-0.02, 5.87]
28.5 at 96 hours	6	158	Mean Difference (IV, Fixed, 95% CI)	0.79 [-1.26, 2.84]
28.6 at 120 hours	2	63	Mean Difference (IV, Fixed, 95% CI)	-0.34 [-2.43, 1.76]
28.7 at 168 hours	1	38	Mean Difference (IV, Fixed, 95% CI)	5.0 [2.77, 7.23]

Analysis I.I. Comparison I Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies), Outcome I Muscle soreness up to 6 hours; random-effects model.

Review: Antioxidants for preventing and reducing muscle soreness after exercise

Comparison: I Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies)

Outcome: I Muscle soreness up to 6 hours; random-effects model

Study or subgroup	Antioxidant		Placebo		Std. Mean Difference	Weight	Std. Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Random,95% CI		IV,Random,95% CI
Bloomer 2004	9	1.43 (0.9)	9	2.12 (0.84)		4.1 %	-0.75 [-1.72, 0.21]
Bloomer 2005	10	5.6 (3.7947)	10	4.2 (0.9487)		4.4 %	0.48 [-0.41, 1.38]
Bloomer 2007	7	4.35 (2.4605)	8	3.78 (2.2345)	_ <u>_</u>	3.8 %	0.23 [-0.79, 1.25]
Bryer 2006	10	1.8 (3.1623)	8	4.5 (3.1113)		4.0 %	-0.82 [-1.80, 0.16]
Close 2006	10	2.23 (2.98)	10	2.82 (0.89)		4.5 %	-0.26 [-1.14, 0.62]
Cobley 2011	6	2.8 (1.3)	6	2.6 (1.1)		3.4 %	0.15 [-0.98, 1.29]
Goldfarb 201 I	21	1.7 (1.833)	20	1.1 (1.3416)		6.0 %	0.36 [-0.25, 0.98]
He 2015 (1)	11	1.36 (0.92)	11	2.18 (1.25)		4.5 %	-0.72 [-1.59, 0.15]
Howatson 2009	10	115 (52)	10	115 (60)		4.5 %	0.0 [-0.88, 0.88]
Kaminski 1992 (2)	19	5 (2.7)	19	6.7 (2)		5.7 %	-0.70 [-1.36, -0.04]
Kerksick 2009 (3)	10	0.53 (0.88)	5	0.31 (0.56)		3.6 %	0.26 [-0.82, 1.34]
Kerksick 2009 (4)	10	0.33 (0.6)	5	0.31 (0.56)		3.6 %	0.03 [-1.04, 1.11]
Kuehl 2010	26	22.6 (12.6)	25	45.3 (20.5)		6.0 %	-1.32 [-1.93, -0.71]

-4 -2 0 2 4

Favours antioxidant Favours placebo

(Continued ...)

(Continued)
---	------------

							(
Study or subgroup	Antioxidant		Placebo		Std. Mean Difference	Weight	Std. Mean Difference	
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Random,95% CI		IV,Random,95% CI	
Lynn 2015	10	27.89 (26.32)	10	81.6 (46.17)		3.9 %	-1.37 [-2.37, -0.37]	
Meamarbashi 2011	10	1.5 (1.5)	10	2.5 (1.9)		4.4 %	-0.56 [-1.46, 0.34]	
Michailidis 2013	10	8.1 (0.8)	10	8.3 (0.6)		4.5 %	-0.27 [-1.15, 0.61]	
Nicol 2015 (5)	17	2(1)	17	(1.15)		5.4 %	0.91 [0.20, 1.62]	
Nie 2004	8	2.5 (1.1)	8	2.7 (1.6)		4.0 %	-0.14 [-1.12, 0.84]	
Su 2008	8	2.7 (3.1113)	8	5.1 (0.8485)		3.7 %	-1.00 [-2.05, 0.06]	
Tanabe 2015	14	1.3 (1.4)	14	1.4 (1.5)		5.2 %	-0.07 [-0.81, 0.67]	
Trombold 2010	16	3.7 (1.8)	16	4.8 (2.1)		5.4 %	-0.55 [-1.26, 0.16]	
Trombold 2011 (6)	17	1.94 (0.97)	17	2.56 (1.66)		5.6 %	-0.45 [-1.13, 0.24]	
otal (95% CI)	269		256		•	100.0 %	-0.30 [-0.56, -0.04]	
leterogeneity: Tau² = 0	0.20; Chi ² = 44.	53, df = 21 (P = 0	0.002); I ² =53	3%				
est for overall effect: Z	= 2.23 (P = 0.0)25)						
oct for cubarous diffor	ances Net and	eeble						

Test for subgroup differences: Not applicable

-4 -2 Favours antioxidant 0

2 4

Favours placebo

(1) Soreness at the thigh muscle

(2) 10 hrs post exercise

(3) NAC vs placebo

(4) EGCG vs placebo

(5) Single leg squat

(6) Soreness at elbow

Analysis I.2. Comparison I Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies), Outcome 2 Muscle soreness at 24 hours; random-effects model.

Review: Antioxidants for preventing and reducing muscle soreness after exercise

Comparison: I Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies)

Outcome: 2 Muscle soreness at 24 hours; random-effects model

Study or subgroup	Antioxidant N	Mean(SD)	Placebo N	Mean(SD)	Std. Mean Difference IV.Random,95% Cl	Weight	Std. Mean Difference IV,Random,95% Cl
Arent 2010	18	1.12 (1.4425)	18	2.09 (1.6971)		3.8 %	-0.60 [-1.27, 0.07]
Avery 2003	9	5.9 (3.6)	9	6 (3.9)		2.0 %	-0.03 [-0.95, 0.90]
Bailey 2011	20	5 (2)	18	5 (2)		4.1 %	0.0 [-0.64, 0.64]
Bell 2015	8	20.67 (27.6)	8	25 (19.7)	<u> </u>	1.8 %	-0.17 [-1.15, 0.81]
Bell 2016	8	60 (32.47)	8	93 (50.79)	.	1.7 %	-0.73 [-1.75, 0.29]
Bloomer 2004	9	3.54 (2.25)	9	4.2 (2.25)		2.0 %	-0.28 [-1.21, 0.65]
Bloomer 2005	10	5.7 (0.9487)	10	4.8 (0.9487)	.	2.0 %	0.9 [-0.02, .84]
Bloomer 2007	7	7.35 (1.217)	8	5.75 (2.4324)	<u> </u>	1.6 %	0.77 [-0.30, .83]
Bryer 2006	10	4.2 (2.2136)	8	6.2 (2.2627)	<u> </u>	1.8 %	-0.85 [-1.83, 0.13]
Close 2006	10	4.49 (2.29)	10	4.54 (2.83)		2.3 %	-0.02 [-0.90, 0.86]
Cobley 2011	6	3.2 (1)	6	3.1 (2.3)		1.4 %	0.05 [-1.08, 1.18]
Connolly 2006	12	2.54 (2.46)	12	2.75 (2.14)		2.7 %	-0.09 [-0.89, 0.71]
Connolly 2006a	14	3.7 (4.49)	4	4.3 (4.8642)		3.1 %	-0.12 [-0.87, 0.62]
Goldfarb 2011	21	2.6 (1.3748)	20	2.3 (1.7889)		4.4 %	0.19 [-0.43, 0.80]
He 2015 (1)	11	1.82 (1.25)	11	3.64 (2.01)		2.1 %	-1.05 [-1.95, -0.14]
Howatson 2009	10	91 (39)	10	82 (45)		2.2 %	0.20 [-0.67, 1.08]
Hutchinson 2016	8	2.44 (1.8385)	8	3 (1.7819)		1.8 %	-0.29 [-1.28, 0.69]
Kerksick 2009 (2)	10	2.84 (1.7)	5	3.58 (2.3)		1.5 %	-0.37 [-1.45, 0.72]
Kerksick 2009 (3)	10	2.14 (3.83)	5	3.58 (2.3)		1.5 %	-0.39 [-1.48, 0.69]
Krotkiewski 1994	36	3.9 (1.8)	14	2.7 (1.1225)		4.2 %	0.72 [0.08, 1.35]
Laupheimer 2014	3	4 (2.96)	4	6.25 (4.44)		0.7 %	-0.48 [-2.03, 1.06]
Lynn 2015	П	52.27 (37.57)	10	53 (36.38)		2.4 %	-0.02 [-0.88, 0.84]
McBride 1997	6	2.33 (1.9596)	6	3.25 (2.1556)		1.3 %	-0.41 [-1.56, 0.74]
McFarlin 2016	16	7.4 (3.6)	12	9.9 (3.1177)		2.9 %	-0.71 [-1.49, 0.06]

2 -4 -2 0 Favours antioxidant Favours placebo

4

(Continued . . .)

(... Continued)

					Std.		Std
Study or subgroup	Antioxidant		Placebo		Mean Difference	Weight	Mear Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Random,95% Cl		IV,Random,95% C
McLeay 2012 (4)	10	2.14 (1.73)	10	2.45 (2)		2.3 %	-0.16 [-1.04, 0.72
Meamarbashi 2011	10	1.8 (1.8)	10	3.2 (1.8)		2.1 %	-0.74 [-1.66, 0.17
Michailidis 2013	10	8.4 (0.4)	10	8.8 (0.4)		2.0 %	-0.96 [-1.89, -0.02
Nicol 2015 (5)	17	3.7 (1.32)	17	4.3 (1.98)		3.7 %	-0.35 [-1.03, 0.33
Nie 2004	8	6.2 (1.7)	8	6.7 (1.2)		1.8 %	-0.32 [-1.31, 0.67
O'Connor 2013	20	19.9 (21.4)	20	18.5 (14.3)		4.3 %	0.08 [-0.54, 0.70
O'Fallon 2012	15	36.03 (16.27)	15	39 (15.67)		3.3 %	-0.18 [-0.90, 0.54
Peschek 2014	8	41 (18)	8	46 (17)		1.8 %	-0.27 [-1.26, 0.72
Shafat 2004	6	9.5 (1.2)	6	10 (1.4)		1.3 %	-0.35 [-1.50, 0.79
Su 2008	8	6.2 (3.1113)	8	7.5 (1.6971)		1.8 %	-0.49 [-1.49, 0.51
Tanabe 2015	14	4.3 (2.5)	14	4.7 (1.9)		3.1 %	-0.17 [-0.92, 0.57
Theodorou 2011	14	3.36 (2.06)	14	2.79 (1.42)		3.1 %	0.31 [-0.43, 1.06
Thompson 2001	9	4 (3)	9	3 (3)	_ 	2.0 %	0.32 [-0.61, 1.25
Thompson 2001a (6)	8	50 (16.9706)	8	58 (16.9706)	.	1.8 %	-0.45 [-1.44, 0.55
Thompson 2003	8	6 (2.8284)	8	3 (2.8284)		1.6 %	1.00 [-0.06, 2.06
Thompson 2004	7	50.4 (20.37)	7	46.7 (24.07)	<u> </u>	1.6 %	0.16 [-0.89, 1.21
Trombold 2010	16	8 (2)	16	8.2 (1.9)		3.5 %	-0.10 [-0.79, 0.59
Trombold 2011 (7)	17	3.59 (2.03)	17	4.17 (1.62)		3.7 %	-0.3 [-0.99, 0.37
otal (95% CI)	488		448	4.17 (1.62)	•	3.7 % 100.0 %	-
Fotal (95% CI) leterogeneity: Tau ² = 0.01 est for overall effect: Z = 1	488 ; Chi ² = 42.93 1.94 (P = 0.05)	, df = 41 (P = 0.3	448			100.0 %	-
Fotal (95% CI) Heterogeneity: Tau ² = 0.01 Hest for overall effect: Z = 1 Hest for subgroup difference	488 ; Chi ² = 42.93 1.94 (P = 0.05) as: Not applica	, df = 41 (P = 0.3	448		-2 0 2 -2 antioxidant Favours plac	100.0 %	-0.31 [-0.99, 0.37
Total (95% CI) deterogeneity: Tau ² = 0.01 est for overall effect: Z = 1 est for subgroup difference (1) Soreness at the thigh m	488 ; Chi ² = 42.93 1.94 (P = 0.05) as: Not applica	, df = 41 (P = 0.3	448			100.0 %	-
Total (95% CI) deterogeneity: Tau ² = 0.01 est for overall effect: Z = 1 est for subgroup difference (1) Soreness at the thigh m	488 ; Chi ² = 42.93 1.94 (P = 0.05) as: Not applica	, df = 41 (P = 0.3	448			100.0 %	-
Trombold 2011 (7) Total (95% CI) Heterogeneity: Tau ² = 0.01 est for overall effect: Z = 1 est for subgroup difference (1) Soreness at the thigh m (2) EGCG vs placebo (3) NAC vs placebo	488 ; Chi ² = 42.93 1.94 (P = 0.05) as: Not applica	, df = 41 (P = 0.3	448			100.0 %	-
Total (95% CI) deterogeneity: Tau ² = 0.01 est for overall effect: Z = 1 est for subgroup difference (1) Soreness at the thigh m (2) EGCG vs placebo	488 ; Chi ² = 42.93 1.94 (P = 0.05) as: Not applica	, df = 41 (P = 0.3	448			100.0 %	-
Total (95% CI) deterogeneity: Tau ² = 0.01 est for overall effect: Z = 1 est for subgroup difference (1) Soreness at the thigh m (2) EGCG vs placebo (3) NAC vs placebo (4) 12 hrs post exercise	488 ; Chi ² = 42.93 1.94 (P = 0.05) as: Not applica	, df = 41 (P = 0.3	448			100.0 %	-
Fotal (95% CI) Heterogeneity: Tau ² = 0.01 Heterogeneity: Tau	488 ; Chi ² = 42.93 1.94 (P = 0.05) es: Not applica	, df = 41 (P = 0.3	448			100.0 %	-

Analysis I.3. Comparison I Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies), Outcome 3 Muscle soreness at 48 hours; random-effects model.

Review: Antioxidants for preventing and reducing muscle soreness after exercise

Comparison: I Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies)

Outcome: 3 Muscle soreness at 48 hours; random-effects model

Study or subgroup	Antioxidant		Placebo		Std. Mean Difference	Weight	Std. Mean Difference IV,Random,95% Cl
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Random,95% CI		
Arent 2010	18	0.88 (1.3576)	18	1.94 (1.9516)		2.8 %	-0.62 [-1.29, 0.05]
Avery 2003	9	4.9 (3.3)	9	5.1 (4.2)		2.1 %	-0.05 [-0.97, 0.87]
Bailey 2011	20	5 (2)	18	5 (2)	-	2.9 %	0.0 [-0.64, 0.64]
Beaton 2002a	9	8.8 (3.1)	7	7.5 (2)		1.9 %	0.46 [-0.55, 1.46]
Bell 2015	8	4.92 (22.5)	8	21.8 (18.72)		1.9 %	-0.31 [-1.30, 0.67]
Bell 2016	8	45 (27.82)	8	91 (56.08)		1.8 %	-0.98 [-2.04, 0.07]
Bloomer 2004	9	3.04 (2.4)	9	5.46 (3)		1.9 %	-0.85 [-1.82, 0.13]
Bloomer 2005	10	5.8 (2.5298)	10	4.8 (1.8974)	.	2.2 %	0.43 [-0.46, 1.32]
Bloomer 2007	7	7.07 (0.926)	8	6.25 (2.7436)	.	1.8 %	0.37 [-0.66, 1.39]
Bryer 2006	10	6.1 (2.2136)	8	7.5 (2.2627)		2.0 %	-0.60 [-1.55, 0.36]
Close 2006	10	4.34 (2.74)	10	5.59 (2.6)		2.1 %	-0.45 [-1.34, 0.44]
Cobley 201 I	6	2.9 (1.1)	6	2.4 (0.8)	·	1.6 %	0.48 [-0.68, 1.64]
Connolly 2006	12	2.25 (1.92)	12	2.75 (2.07)		2.4 %	-0.24 [-1.05, 0.56]
Connolly 2006a	14	3.3 (4.1158)	14	5 (4.49)	_+_	2.6 %	-0.38 [-1.13, 0.37]
Drobnic 2014	9	23.3 (7.9)	10	30.6 (7.9)		2.0 %	-0.88 [-1.84, 0.07]
Goldfarb 201 I	21	2.8 (2.7495)	20	3 (1.3416)		3.0 %	-0.09 [-0.70, 0.52]
He 2015 (1)	11	1.91 (1.14)	11	3.09 (1.58)		2.2 %	-0.82 [-1.70, 0.05]
Howatson 2009	10	58 (39)	10	46 (28)		2.2 %	0.34 [-0.55, 1.22]
Hutchinson 2016	8	2.75 (2.4324)	8	3.38 (2.1213)	-	1.9 %	-0.26 [-1.25, 0.72]
Kaminski 1992	19	3.7 (2.6)	19	5.4 (2.2)		2.9 %	-0.69 [-1.35, -0.03]
Kerksick 2009 (2)	10	3.49 (2.15)	5	5.51 (1.64)		1.6 %	-0.95 [-2.09, 0.20]
Kerksick 2009 (3)	10	3.3 (2.08)	5	5.51 (1.64)		1.6 %	-1.06 [-2.23, 0.10]
Krotkiewski 1994	36	2.95 (1.8)	4	1.1 (0.7483)		2.8 %	1.15 [0.49, 1.81]
Lynn 2015	10	24.6 (22.53)	10	17.7 (12.99)		2.2 %	0.36 [-0.53, 1.24]

-2 0 -4 Favours antioxidant Favours placebo

2

4

(Continued . . .)

(... Continued)

2 (2.1311)	N 6 12	Mean(SD) 2.75 (2.278) 12.5 (2.7713)	IV,Random,95% Cl	1.6 %	IV,Random,95% C -0.31 [-1.46, 0.83]
11.4 (3.2)		. ,		1.0 /0	-0.51 [-1.40, 0.05]
	IZ			2.5 %	-0.35 [-1.11, 0.40]
	10	. ,			
· /	10	3.35 (2.25)		2.2 %	0.20 [-0.68, 1.08]
()	10	3.3 (1.6)		1.8 %	-1.63 [-2.67, -0.59
		. ,			-2.87 [-4.20, -1.55
~ /					-0.39 [-1.07, 0.29
		. ,			0.15 [-0.83, 1.13
					0.05 [-0.57, 0.67
9.6 (21.86)	15	43.43 (17.7)		2.7 %	-0.19 [-0.90, 0.53
45 (20)	8	34 (24)		1.9 %	0.47 [-0.53, 1.47
10 (1.5)	6	10.3 (1.4)		1.6 %	-0.19 [-1.33, 0.94
5.83 (1)	4	5.43 (0.8)		1.5 %	0.39 [-0.82, 1.61
3.86 (0.7)	4	5.43 (0.8)		1.1 %	-2.00 [-3.50, -0.5
8 (2.6533)	10	6.2 (1.5811)		2.1 %	-1.04 [-1.97, -0.12
2 (4.5255)	8	8 (4.2426)		1.9 %	-0.39 [-1.38, 0.60
5.5 (2.1)	4	6 (2.2)		2.6 %	-0.23 [-0.97, 0.52
6.07 (2.4)	4	5.57 (1.5)	_ 	2.6 %	0.24 [-0.50, 0.99
3 (3)	9	3 (3)		2.1 %	0.0 [-0.92, 0.92
(.3 37)	8	47 (22.6274)		1.8 %	-0.74 [-1.76, 0.28
4 (2.8284)	8	3 (2.8284)	<u> </u>	1.9 %	0.33 [-0.65, 1.32
64.3 (16.4)	7	48.6 (27.24)		1.7 %	0.65 [-0.43, 1.74
8.1 (1.6)	16	8 (2.2)		2.7 %	0.05 [-0.64, 0.74
2.71 (2.11)	17	3.76 (1.68)		2.8 %	-0.54 [-1.22, 0.15
		17%	•	100.0 %	-0.24 [-0.42, -0.07
	8.9 (0.2) 3.32 (1.15) 5.1 (1.2) 8.6 (18.7) 2.6 (21.86) 4.5 (20) 10 (1.5) 5.83 (1) 3.86 (0.7) 3.86 (0.7) 3.2 (4.5255) 5.5 (2.1) 6.07 (2.4) 3 (3) (11.3137) 4 (2.8284) 4.3 (16.4) 8.1 (1.6) 2.71 (2.11) 4	8.9 (0.2) 10 8.2 (1.15) 17 5.1 (1.2) 8 8.6 (18.7) 20 2.6 (21.86) 15 45 (20) 8 10 (1.5) 6 5.83 (1) 4 3.86 (0.7) 4 3.86 (0.7) 4 3.86 (0.7) 4 6.07 (2.4) 14 6.07 (2.4) 14 3 (3) 9 (11.3137) 8 4 (2.8284) 8 .4.3 (16.4) 7 8.1 (1.6) 16 .271 (2.11) 17	8.9 (0.2) 10 9.5 (0.2) 3.32 (1.15) 17 4 (2.14) 5.1 (1.2) 8 4.9 (1.3) 8.6 (18.7) 20 17.7 (13.9) 4.6 (21.86) 15 43.43 (17.7) 45 (20) 8 34 (24) 10 (1.5) 6 10.3 (1.4) 5.83 (1) 4 5.43 (0.8) 3.86 (0.7) 4 5.43 (0.8) 3.86 (0.7) 4 5.43 (0.8) 3.86 (0.7) 4 5.43 (0.8) 3.86 (0.7) 4 5.43 (0.8) 3.86 (0.7) 4 5.43 (0.8) 3.83 (2.6533) 10 6.2 (1.5811) 2 (4.5255) 8 8 (4.2426) 5.5 (2.1) 14 6 (2.2) 6.07 (2.4) 14 5.57 (1.5) 3 (3) 9 3 (3) (11.3137) 8 47 (22.6274) 4 (2.8284) 8 3 (2.8284) 8.1 (1.6) 16 8 (2.2) 4.71 (2.11) 17 3.76 (1.68)	89 (0.2) 10 $9.5 (0.2)$ $322 (1.15)$ 17 $4 (2.14)$ $5.1 (1.2)$ 8 $4.9 (1.3)$ $8.6 (18.7)$ 20 $17.7 (13.9)$ $4.6 (21.86)$ 15 $43.43 (17.7)$ $45 (20)$ 8 $34 (24)$ $10 (1.5)$ 6 $10.3 (1.4)$ $5.83 (1)$ 4 $5.43 (0.8)$ $3.86 (0.7)$ 4 $5.43 (0.8)$ $2 (45255)$ 8 $8 (42426)$ $607 (2.4)$ 14 $6 (2.2)$ $607 (2.4)$ 14 $5.57 (1.5)$ $3 (3)$ 9 $3 (3)$ $4 (28284)$ 8 $3 (28284)$ $4 (28284)$ 8 $3 (28284)$ $4 (28284)$ 8 $3 (2.8284)$ $4 (28284)$ $8 (2.2)$ $4 (2.8284)$ $4.1 (1.6)$ 16 $8 (2.2)$ $4.7 (2.1 1)$ 17 $3.76 (1.68)$	89 (0.2) 10 $9.5 (0.2)$ $1.3 %$ $832 (1.15)$ 17 $4 (2.14)$ $28 %$ $5.1 (1.2)$ 8 $4.9 (1.3)$ $1.9 %$ $8.6 (18.7)$ 20 $17.7 (13.9)$ $30 %$ $8.6 (18.7)$ 20 $17.7 (13.9)$ $30 %$ $8.6 (18.7)$ 20 $17.7 (13.9)$ $2.7 %$ $45 (20)$ 8 $34 (24)$ $1.9 %$ $10 (1.5)$ 6 $10.3 (1.4)$ $1.6 %$ $5.83 (1)$ 4 $5.43 (0.8)$ $1.1 %$ $30 (26533)$ 10 $6.2 (1.5811)$ $2.1 %$ $2 (45255)$ 8 $8 (42426)$ $1.9 %$ $5.5 (2.1)$ 14 $6 (2.2)$ $2.6 %$ $3 (3)$ 9 $3 (3)$ $2.1 %$ $4 (28284)$ 8 $3 (28284)$ $1.9 %$ $4.3 (16.4)$ 7 $48.6 (27.24)$ $1.7 %$ $8.1 (1.6)$ 16 $8 (2.2)$ $2.7 %$ $8.1 (1.6)$ 16 $8 (2.2)$ $2.7 %$ $8.1 (1.6)$ 16 $8 (2.2)$

Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

(1) Soreness at the thigh muscle

(2) NAC vs placebo

- (3) EGCG vs placebo
- (4) 36 hours post exercise
- (5) Single leg squat
- (6) 14 days supplementation
- (7) 21 days supplementation
- (8) General soreness (0-100mm)
- (9) Soreness at elbow

Analysis I.4. Comparison I Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies), Outcome 4 Muscle soreness at 72 hours; random-effects model.

Review: Antioxidants for preventing and reducing muscle soreness after exercise

Comparison: I Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies)

Outcome: 4 Muscle soreness at 72 hours; random-effects model

Study or subgroup	Antioxidant N	Mean(SD)	Placebo N	Mean(SD)	Std. Mean Difference IV.Random,95% Cl	Weight	Std. Mean Difference IV,Random,95% Cl
Avery 2003	9	3.6 (4.5)	9	4.3 (5.1)		3.2 %	-0.14 [-1.06, 0.79]
Bell 2015	8	10.79 (15.48)	8	24.42 (28.14)		2.8 %	-0.57 [-1.57, 0.44]
Bell 2016	8	(8.4)	8	33 (25.19)		2.5 %	-1.11 [-2.18, -0.03]
Bloomer 2004	9	2.54 (2.94)	9	5.38 (3.3)		2.9 %	-0.87 [-1.84, 0.11]
Bloomer 2005	10	4.1 (2.2136)	10	3.3 (1.2649)		3.4 %	0.43 [-0.46, .3]
Bryer 2006	10	5 (2.5298)	8	5.8 (2.8284)		3.1 %	-0.29 [-1.22, 0.65]
Close 2006	10	2.96 (2.21)	10	3.24 (2.09)		3.4 %	-0.12 [-1.00, 0.75]
Cobley 2011	6	3.6 (1.5)	6	2.3 (2.4)		2.2 %	0.60 [-0.57, 1.77]
Connolly 2006	12	2.58 (2.07)	12	2.16 (1.93)		3.9 %	0.20 [-0.60, 1.01]
Connolly 2006a	14	2.2 (1.1225)	3	3 (1.5588)	<u> </u>	1.9 %	-0.64 [-1.91, 0.63]
Goldfarb 2011	21	1.8 (1.833)	20	2.4 (2.2361)		5.5 %	-0.29 [-0.90, 0.33]

-4 -2 0 2 4 Favours antioxidant Favours placebo

(Continued . . .)

(... Continued)

Study or subgroup	Antioxidant N	Mean(SD)	Placebo N	Mean(SD)	Std. Mean Difference IV,Random,95% Cl	Weight	(Continue) Std Mear Difference IV,Random,95% C
He 2015 (1)	11	0.82 (0.75)	11	1.73 (1.42)		3.4 %	-0.77 [-1.64, 0.10
Hutchinson 2016	8	1.38 (2.0082)	8	1.63 (1.3011)	<u> </u>	2.9 %	-0.14 [-1.12, 0.84
Kerksick 2009 (2)	10	3.23 (1.96)	5	4.35 (2.17)		2.4 %	-0.52 [-1.62, 0.58]
Kerksick 2009 (3)	10	2.61 (1.99)	5	4.35 (2.17)	<u> </u>	2.3 %	-0.80 [-1.92, 0.32
Krotkiewski 1994	36	1.6 (1.8)	4	0.5 (0.7483)		5.3 %	0.68 [0.05, 1.32
McFarlin 2016	16	4.4 (3.6)	12	5.2 (3.4641)		4.3 %	-0.22 [-0.97, 0.53
McLeay 2012 (4)	10	2.65 (1.44)	10	2.53 (1.6)	<u> </u>	3.4 %	0.08 [-0.80, 0.95
Michailidis 2013	10	8 (0.2)	10	8.5 (0.2)		2.1 %	-2.39 [-3.60, -1.19
O'Fallon 2012	15	31.2 (26.94)	15	30.9 (23.94)		4.6 %	0.01 [-0.70, 0.73
Phillips 2003	16	3.69 (9.52)	19	3.18 (7.4101)	-	5.0 %	0.06 [-0.61, 0.72
Tanabe 2015	14	4.8 (2.5)	4	5.2 (2.3)		4.3 %	-0.16 [-0.90, 0.58
Theodorou 2011	14	5.21 (1.67)	4	5.79 (1.67)		4.3 %	-0.34 [-1.08, 0.41
Thompson 2001	9	2 (1.2)	9	2 (1.2)	<u> </u>	3.2 %	0.0 [-0.92, 0.92
Thompson 2001a (5)	8	20 (14.1421)	8	8 (.3 37)	_ 	2.9 %	0.15 [-0.83, 1.13
Thompson 2003	8	3 (2.8284)	8	2 (1.1313)	_ 	2.8 %	0.44 [-0.56, 1.43
Thompson 2004	7	39.3 (20.63)	7	35.3 (25.39)		2.6 %	0.16 [-0.89, 1.21
Trombold 2010	16	5 (2.2)	16	5.9 (2.9)	-+-	4.7 %	-0.34 [-1.04, 0.36
Trombold 2011 (6)	17	1.64 (2.09)	17	2.41 (1.7)		4.9 %	-0.39 [-1.07, 0.28
			305		•	100.0 %	-0.19 [-0.38, 0.00
	352 7; Chi ² = 38.10	, df = 28 (P = 0.	$ 0\rangle; ^2 = 27\%$				
Heterogeneity: $Tau^2 = 0.07$ lest for overall effect: Z = 1	7; Chi ² = 38.10 2.01 (P = 0.04.	5)	10); I ² =27%		-4 -2 0 2 -4 urs antioxidant Favours plac	4 ebo	
leterogeneity: Tau ² = 0.07 est for overall effect: Z = est for subgroup differenc	7; Chi ² = 38.10 2.01 (P = 0.04. es: Not applica	5)	10); I ² =27%				
Heterogeneity: Tau ² = 0.07 Test for overall effect: Z = Test for subgroup difference (1) Soreness at the thigh r	7; Chi ² = 38.10 2.01 (P = 0.04. es: Not applica	5)	10); I ² =27%				
eterogeneity: Tau ² = 0.07 est for overall effect: Z = est for subgroup differenc (1) Soreness at the thigh r (2) NAC vs placebo	7; Chi ² = 38.10 2.01 (P = 0.04. es: Not applica	5)	10); I ² =27%				
Fotal (95% CI) Heterogeneity: Tau ² = 0.07 Test for overall effect: Z = Test for subgroup difference (1) Soreness at the thigh r (2) NAC vs placebo (3) EGCG vs placebo (4) 60 hrs post exercise	7; Chi ² = 38.10 2.01 (P = 0.04. es: Not applica	5)	10); I ² =27%				
Heterogeneity: Tau ² = 0.07 Test for overall effect: Z = Test for subgroup difference (1) Soreness at the thigh r (2) NAC vs placebo (3) EGCG vs placebo	7; Chi ² = 38.10 2.01 (P = 0.04: es: Not applica nuscle	5)	10); I ² =27%				

Analysis I.5. Comparison I Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies), Outcome 5 Muscle soreness at 96 hours; random-effects model.

Review: Antioxidants for preventing and reducing muscle soreness after exercise

Comparison: I Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies)

Outcome: 5 Muscle soreness at 96 hours; random-effects model

Study or subgroup A	Antioxidant		Placebo		Std. Mean Difference	Weight	Sto Mea Differenc
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Random,95% CI		IV,Random,95% (
Bloomer 2004	9	1.81 (1.5)	9	3.24 (2.04)		4.5 %	-0.76 [-1.73, 0.21
Bloomer 2005	10	3.7 (2.2136)	10	1.5 (1.2649)		4.5 %	1.17 [0.20, 2.13
Bryer 2006	10	3.5 (2.5298)	8	4.8 (2.5456)	.	4.7 %	-0.49 [-1.44, 0.46
Close 2006	10	1.46 (1.66)	10	1.3 (1.21)		5.2 %	0.11 [-0.77, 0.98
Cobley 2011	6	2.7 (1.4)	6	2.1 (2)		3.5 %	0.32 [-0.82, .46
Connolly 2006	12	1.66 (1.92)	12	0.71 (0.91)		5.7 %	0.61 [-0.21, 1.43
Connolly 2006a	14	1.2 (0.7483)	4	1.4 (1.1225)		6.6 %	-0.20 [-0.95, 0.54
Krotkiewski 1994	36	1.5 (1.8)	4	0.2 (0.7483)		7.9 %	0.81 [0.17, 1.45
McFarlin 2016	16	I (4)	12	2.4 (3.1177)		6.4 %	-0.37 [-1.13, 0.38
Michailidis 2013	10	5.2 (1.2)	10	5.6 (0.4)		5.1 %	-0.43 [-1.32, 0.46
O'Fallon 2012	15	8.54 (8.72)	15	16.04 (18.45)		6.9 %	0.13 [-0.59, 0.85
Silva 2008 (1)	8	1.67 (0.8)	4	1.84 (0.7)		3.2 %	-0.20 [-1.41, 1.00
Silva 2008 (2)	9	1.29 (0.5)	4	1.84 (0.7)	- _	3.0 %	-0.91 [-2.16, 0.34
Silva 2010	11	1.2 (1.6583)	10	2.3 (2.2136)		5.2 %	-0.54 [-1.42, 0.33
Tanabe 2015	14	2.9 (2.9)	14	3.4 (2.6)	_ _	6.6 %	-0.18 [-0.92, 0.57
Theodorou 2011	14	2.78 (1.25)	14	3.21 (1.48)		6.5 %	-0.30 [-1.05, 0.44
Trombold 2010	16	3.6 (2.3)	16	3.8 (2.1)		7.1 %	-0.09 [-0.78, 0.60
Trombold 2011 (3)	17	0.71 (1.49)	17	0.88 (0.86)		7.4 %	-0.14 [-0.81, 0.54
Total (95% CI)	237		199		•	100.0 %	-0.05 [-0.29, 0.19
leterogeneity: Tau ² = 0.08 est for overall effect: Z = (est for subgroup difference	0.41 (P = 0.6	8)); ² =3 9	6			

(1) 14 days supplementation

(2) 21 days supplementaton

(3) Soreness at elbow

Analysis 1.6. Comparison I Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies), Outcome 6 Muscle soreness (follow-ups: 120, 144 and 168 hours); random-effects model.

Review: Antioxidants for preventing and reducing muscle soreness after exercise

Comparison: I Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies)

Outcome: 6 Muscle soreness (follow-ups: 120, 144 and 168 hours); random-effects model

Study or subgroup	Antioxidant N	Mean(SD)	Placebo N	Mean(SD)	S Me Differer IV,Random,9	nce Weight	Std. Mean Difference IV,Random,95% Cl
I at 120 hours	24			0 - (0 - 27 - 42)	-		
Krotkiewski 1994	36	0.9 (1.2)	14	0.1 (0.3742)		- 29.6 %	0.75 [0.12, 1.39]
Michailidis 2013	10	3.5 (1)	10	3.8 (0.2)		19.7 %	-0.40 [-1.29, 0.49]
O'Fallon 2012	15	8.79 (11.09)	15	8.77 (16.45)		26.0 %	0.00 [-0.71, 0.72]
Theodorou 2011	14	1.64 (0.84)	14	1.43 (0.65)		24.7 %	0.27 [-0.47, 1.02]
Subtotal (95% CI) Heterogeneity: Tau ² = 0.0 Test for overall effect: Z = 2 at 144 hours		· · · · · ·	53 ² =39%		*	100.0 %	0.21 [-0.26, 0.69]
Michailidis 2013	10	2.4 (1.7)	10	2.7 (0.4)	-	100.0 %	-0.23 [-1.11, 0.65]
Subtotal (95% CI)	10		10		-	100.0 %	-0.23 [-1.11, 0.65]
Heterogeneity: not applica Test for overall effect: Z = 3 at 168 hours Michailidis 2013) 1.5 (0.8)	10	1.6 (0.6)		26.1 %	-0.14 [-1.01, 0.74]
Phillips 2003	16	0.68 (2.04)	19	0.68 (0.741)	_	45.5 %	0.0 [-0.67, 0.67]
	9			. ,			
Silva 2008 (1)		0.0001 (0.0001)	4	0 (0.0001)		14.5 %	0.0 [-1.18, 1.18]
Silva 2010 (2)	8	0.0001 (0.0001)	4	0 (0.0001)	Ī	14.0 %	0.0 [-1.20, 1.20]
Subtotal (95% CI) Heterogeneity: Tau ² = 0.0 Test for overall effect: Z =		· · · · ·	37 =0.0%			100.0 %	-0.04 [-0.48, 0.41]
					-4 -2 0	2 4	
				Favo	ours antioxidant F	avours placebo	
(I) 21 days supplementat	ton						
(2) 14 days supplementat	tion						

Analysis 1.7. Comparison I Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies), Outcome 7 Muscle soreness up to 6 hours - all at same scale (0 to 10; worst pain).

Review: Antioxidants for preventing and reducing muscle soreness after exercise

Comparison: I Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies)

Outcome: 7 Muscle soreness up to 6 hours - all at same scale (0 to 10; worst pain)

Study or subgroup A	Antioxidant	Mara (CD)	Placebo	Marca (CD)	Mean Difference IV,Random,95% CI	Weight	Mean Difference IV,Random,95% CI
Bloomer 2004	N 9	Mean(SD)	N 9	Mean(SD) 2.12 (0.84)	IV,Random,95% CI	6.4 %	-0.69 [-1.49, 0.11]
Bloomer 2005	10	5.6 (3.7947)	10	4.2 (0.9487)		2.3 %	1.40 [-1.02, 3.82]
Bloomer 2007	7	4.35 (2.4605)	8	3.77 (2.2345)	,	2.4 %	0.58 [-1.81, 2.97
Bryer 2006	10	0.89 (3.514)	8	3.89 (3.457)	<u>د ، </u>	1.5 %	-3.00 [-6.24, 0.24
Close 2006	10	2.23 (2.98)	10	2.82 (0.89)		3.2 %	-0.59 [-2.52, 1.34
Cobley 2011	6	2.33 (1.083)	6	2.17 (0.917)		5.3 %	0.16 [-0.98, 1.30
Goldfarb 2011	21	0.778 (2.037)	20	0.11 (1.491)		5.4 %	0.67 [-0.42, 1.76
He 2015 (1)		2.27 (1.533)	11	3.63 (2.083)		4.1 %	-1.36 [-2.89, 0.17]
Howatson 2009	10	5.75 (2.6)	10	5.75 (3)		2.3 %	0.0 [-2.46, 2.46
Kaminski 1992 (2)	19	5 (2.7)	19	6.7 (2)		4.2 %	-1.70 [-3.21, -0.19
Kerksick 2009 (3)	10	0.33 (0.6)	5	0.31 (0.56)	_ _	7.1 %	0.02 [-0.60, 0.64
Kerksick 2009 (4)	10	0.53 (0.88)	5	0.31 (0.56)		6.7 %	0.22 [-0.51, 0.95
Kuehl 2010	26	2.26 (1.26)	25	4.53 (2.05)		6.0 %	-2.27 [-3.21, -1.33
Lynn 2015	10	· · ·	10	4.08 (2.309)	•	3.8 %	
,	10	1.39 (1.316)		× /	<u> </u>		-2.69 [-4.34, -1.04]
Meamarbashi 2011		2.5 (2.5)	10	4.17 (3.167)		2.2 %	-1.67 [-4.17, 0.83]
Michailidis 2013	10	8.1 (0.8)	10	8.3 (0.6)		7.0 %	-0.20 [-0.82, 0.42]
Nicol 2015 (5)	17	2(1)	17	(1.15)		6.7 %	1.00 [0.28, 1.72]
Nie 2004	8	2.5 (1.1)	8	2.7 (1.6)		4.6 %	-0.20 [-1.55, 1.15]
Su 2008	8	2.7 (3.1113)	8	5.1 (0.8485)	←	2.6 %	-2.40 [-4.63, -0.17]
Tanabe 2015	14	1.3 (1.4)	14	1.4 (1.5)		5.5 %	-0.10 [-1.17, 0.97]
Trombold 2010	16	3.7 (1.8)	16	4.8 (2.1)		4.6 %	-1.10 [-2.46, 0.26]
Trombold 2011 (6)	17	1.94 (0.97)	17	2.56 (1.66)	-•-	6.0 %	-0.62 [-1.53, 0.29]
btal (95% CI) eterogeneity: Tau ² = 0.61 st for overall effect: Z = 2 st for subgroup difference	2.30 (P = 0.0	21)	256 0000 I); I ² =	66%	•	100.0 %	-0.52 [-0.95, -0.08]

Antioxidants for preventing and reducing muscle soreness after exercise (Review)

Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

- (1) Soreness at the thigh muscle
- (2) 10 hrs post exercise
- (3) EGCG vs placebo
- (4) NAC vs placebo
- (5) Single leg squat

(6) Soreness at elbow

Analysis I.8. Comparison I Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies), Outcome 8 Muscle soreness at 24 hours - all at same scale (0 to 10; worst pain).

Review: Antioxidants for preventing and reducing muscle soreness after exercise

Comparison: I Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies)

Outcome: 8 Muscle soreness at 24 hours - all at same scale (0 to 10; worst pain)

Study or subgroup	Antioxidant		Placebo		Mean Difference	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Random,95% CI	-	IV,Random,95% Cl
Arent 2010	18	1.12 (1.4425)	18	2.09 (1.6971)		3.9 %	-0.97 [-2.00, 0.06]
Avery 2003	9	5.9 (3.6)	9	6 (3.9)		0.5 %	-0.10 [-3.57, 3.37]
Bailey 2011	20	5 (2)	18	5 (2)		2.8 %	0.0 [-1.27, 1.27]
Bell 2015	8	1.03 (1.38)	8	1.25 (0.99)		3.2 %	-0.22 [-1.40, 0.96]
Bell 2016	8	3 (1.62)	8	4.65 (2.54)		1.2 %	-1.65 [-3.74, 0.44]
Bloomer 2004	9	3.54 (2.25)	9	4.2 (2.25)		1.2 %	-0.66 [-2.74, 1.42]
Bloomer 2005	10	5.7 (0.9487)	10	4.8 (0.9487)		5.1 %	0.90 [0.07, 1.73]
Bloomer 2007	7	7.35 (1.217)	8	5.75 (2.4324)		1.4 %	1.60 [-0.31, 3.51]
Bryer 2006	10	3.56 (2.45)	8	5.78 (2.51)	· · · · · · · · · · · · · · · · · · ·	1.0 %	-2.22 [-4.53, 0.09]
Close 2006	10	4.49 (2.29)	10	4.54 (2.83)		1.1 %	-0.05 [-2.31, 2.21]
Cobley 2011	6	2.67 (0.83)	6	2.58 (1.92)		1.8 %	0.09 [-1.58, 1.76]
Connolly 2006	12	2.54 (2.46)	12	2.75 (2.14)		1.5 %	-0.21 [-2.05, 1.63]
Connolly 2006a	14	3.7 (4.49)	14	4.3 (4.8642)	·	0.5 %	-0.60 [-4.07, 2.87]
Goldfarb 201 I	21	1.78 (1.53)	20	1.44 (1.99)		3.6 %	0.34 [-0.75, .43]

-4 -2 0 Favours antioxidant

2 4

Favours placebo

(Continued ...)

(... Continued)

Study or subgroup	Antioxidant		Placebo		Mean Difference	Weight	Mea Differenc
	N	Mean(SD)	N	Mean(SD)	IV,Random,95% CI	1.0.0/	IV,Random,95% (
He 2015 (1)	11	3.03 (2.08)	11	6.06 (3.35)		1.0 %	-3.03 [-5.36, -0.70
Howatson 2009	10	4.55 (1.95)	10	4.1 (2.25)		1.5 %	0.45 [-1.40, 2.3
Hutchinson 2016	8	2.44 (1.8385)	8	3 (1.7819)		1.6 %	-0.56 [-2.33, 1.2
Kerksick 2009 (2)	10	2.14 (3.83)	5	3.58 (2.3)	4 · · · ·	0.6 %	-1.44 [-4.55, 1.6
Kerksick 2009 (3)	10	2.84 (1.7)	5	3.58 (2.3)		1.1 %	-0.74 [-3.01, 1.5
Krotkiewski 1994	36	3.9 (1.8)	14	2.7 (1.1225)		5.1 %	1.20 [0.37, 2.0
Laupheimer 2014	3	4 (2.96)	4	6.25 (4.44)	• •	0.2 %	-2.25 [-7.74, 3.2
Lynn 2015	11	2.61 (1.88)	10	2.65 (1.82)		2.0 %	-0.04 [-1.62, 1.5
McBride 1997	6	2.33 (1.9596)	6	3.25 (2.1556)		1.0 %	-0.92 [-3.25, 1.4
McFarlin 2016	16	3.7 (1.8)	12	4.95 (1.559)		2.9 %	-1.25 [-2.50, 0.0
McLeay 2012 (4)	10	2.14 (1.73)	10	2.45 (2)		1.9 %	-0.31 [-1.95, 1.3
Meamarbashi 2011	10	3 (3)	10	5.33 (3)	←	0.8 %	-2.33 [-4.96, 0.3
Michailidis 2013	10	8.4 (0.4)	10	8.8 (0.4)		10.1 %	-0.40 [-0.75, -0.0
Nicol 2015 (5)	17	3.7 (1.32)	17	4.3 (1.98)	.	3.4 %	-0.60 [-1.73, 0.5
Nie 2004	8	6.2 (1.7)	8	6.7 (1.2)		2.3 %	-0.50 [-1.94, 0.9
O'Connor 2013	20	1.99 (2.14)	20	1.85 (1.43)		3.4 %	0.14 [-0.99, 1.2
O'Fallon 2012	15	3.6 (1.63)	15	3.9 (1.57)		3.3 %	-0.30 [-1.45, 0.8
Peschek 2014	8	4.1 (1.8)	8	4.6 (1.7)		1.7 %	-0.50 [-2.22, 1.2
Shafat 2004	6	0.28 (0.19)	6	0.21 (0.17)	-	11.7 %	0.07 [-0.13, 0.2
Su 2008	8	6.2 (3.1113)	8	7.5 (1.6971)		0.9 %	-1.30 [-3.76, 1.1
Tanabe 2015	14	4.3 (2.5)	14	4.7 (1.9)		1.9 %	-0.40 [-2.04, 1.2
Theodorou 2011	14	3.36 (2.06)	14	2.79 (1.42)	.	2.7 %	0.57 [-0.74, 1.8
Thompson 2001	9	3.333 (3.333)	9	2.22 (3.333)		→ 0.6 %	. [-1.97, 4.
Thompson 2001a (6)	8	5 (1.7)	8	5.8 (1.7)		1.8 %	-0.80 [-2.47, 0.8
Thompson 2003	8	5.56 (3.144)	8	2.22 (3.144)		↔ 0.6 %	3.34 [0.26, 6.4
Thompson 2004	7	5.04 (2.04)	7	4.67 (2.41)		1.0 %	0.37 [-1.97, 2.7
Trombold 2010	16	8 (2)	16	8.2 (1.9)		2.6 %	-0.20 [-1.55, 1.1
Trombold 2011 (7)	17	3.59 (2.03)	17	4.17 (1.62)		3.0 %	-0.58 [-1.81, 0.6
otal (95% CI)	488		448		•	100.0 %	-0.17 [-0.42, 0.07
eterogeneity: $Tau^2 = 0.1$ est for overall effect: Z = est for subgroup differen	1.39 (P = 0.17)	04); I ² =29%				
					-4 -2 0 2 rs antioxidant Favours	4 placebo	

(1) Soreness at the thigh muscle

- (2) NAC vs placebo
- (3) EGCG vs placebo
- (4) 12 hrs post exercise
- (5) Single leg squat
- (6) General soreness (0-100mm)
- (7) Soreness at elbow

-

Analysis I.9. Comparison I Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies), Outcome 9 Muscle soreness at 48 hours - all at same scale (0 to 10; worst pain).

Review: Antioxidants for preventing and reducing muscle soreness after exercise

Comparison: I Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies)

Outcome: 9 Muscle soreness at 48 hours - all at same scale (0 to 10; worst pain)

Study or subgroup	Antioxidant N	Mean(SD)	Placebo N	Mean(SD)	Mean Difference IV,Random,95% CI	Weight	Mean Difference IV,Random,95% Cl
Arent 2010	18	0.88 (1.3576)	18	1.94 (1.9516)		3.1 %	-1.06 [-2.16, 0.04]
Avery 2003	9	4.9 (3.3)	9	5.1 (4.2)		0.6 %	-0.20 [-3.69, 3.29]
Bailey 2011	20	5 (2)	18	5 (2)		2.6 %	0.0 [-1.27, 1.27]
Beaton 2002a	9	8.8 (3.1)	7	7.5 (2)		1.1 %	.30 [- .2 , 3.8]
Bell 2015	8	0.746 (1.126)	8	1.09 (0.936)		3.3 %	-0.34 [-1.36, 0.67]
Bell 2016	8	2.25 (1.391)	8	4.55 (2.804)	•	1.3 %	-2.30 [-4.47, -0.13]
Bloomer 2004	9	3.04 (2.4)	9	5.46 (3)	•	1.1 %	-2.42 [-4.93, 0.09]
Bloomer 2005	10	5.8 (2.5298)	10	4.8 (1.8974)		1.6 %	1.00 [-0.96, 2.96]
Bloomer 2007	7	7.07 (0.926)	8	6.25 (2.7436)		1.5 %	0.82 [-1.20, 2.84]
Bryer 2006	10	5.667 (2.46)	8	7.22 (2.514)		1.2 %	-1.56 [-3.87, 0.76]
Close 2006	10	4.34 (2.74)	10	5.59 (2.6)		1.2 %	-1.25 [-3.59, 1.09]
Cobley 2011	6	2.417 (0.917)	6	2 (0.667)		3.6 %	0.42 [-0.49, 1.32]
Connolly 2006	12	2.25 (1.92)	12	2.75 (2.07)		2.0 %	-0.50 [-2.10, 1.10]

0 -2 Favours antioxidant Favours placebo

2 4

-4

(Continued ...)

(.			Continued)
----	--	--	------------

Study or subgroup	Antioxidant		Placebo		Mean Difference	Weight	(Continued) Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Random,95% CI		IV,Random,95% CI
Connolly 2006a	14	3.3 (4.1158)	4	5 (4.49)	· · · · · · · · · · · · · · · · · · ·	0.7 %	-1.70 [-4.89, 1.49]
Drobnic 2014	9	7.281 (2.469)	10	9.56 (2.469)	•	1.3 %	-2.28 [-4.51, -0.06]
Goldfarb 2011	21	2 (3.055)	20	2.22 (1.491)		2.3 %	-0.22 [-1.68, 1.24]
He 2015 (1)	11	3.183 (1.9)	11	5.15 (2.633)		1.6 %	-1.97 [-3.89, -0.05]
Howatson 2009	10	2.9 (1.95)	10	2.3 (1.4)		2.2 %	0.60 [-0.89, 2.09]
Hutchinson 2016	8	2.75 (2.4324)	8	3.38 (2.1213)		1.3 %	-0.63 [-2.87, 1.61]
Kaminski 1992	19	3 (2.889)	19	4.89 (2.444)		1.9 %	-1.89 [-3.59, -0.19]
Kerksick 2009 (2)	10	3.3 (2.08)	5	5.51 (1.64)		1.6 %	-2.21 [-4.14, -0.28]
Kerksick 2009 (3)	10	3.49 (2.15)	5	5.51 (1.64)		1.6 %	-2.02 [-3.98, -0.06]
Krotkiewski 1994	36	2.95 (1.8)	4	1.1 (0.7483)		4.1 %	1.85 [1.14, 2.56]
Lynn 2015	10	1.23 (1.127)	10	0.89 (0.65)	_ 	3.8 %	0.35 [-0.46, 1.15]
McBride 1997	6	2 (2. 3)	6	2.75 (2.278)		1.1 %	-0.75 [-3.25, 1.75]
McFarlin 2016	16	5.7 (1.6)	12	6.25 (1.386)		3.0 %	-0.55 [-1.66, 0.56]
McLeay 2012 (4)	10	3.79 (1.88)	10	3.35 (2.25)		1.7 %	0.44 [-1.38, 2.26]
Meamarbashi 2011	10	2 (1.167)	10	5.5 (2.667)	←	1.7 %	-3.50 [-5.30, -1.70]
Michailidis 2013	10	8.9 (0.2)	10	9.5 (0.2)	-	5.4 %	-0.60 [-0.78, -0.42]
Nicol 2015 (5)	17	3.32 (1.15)	17	4 (2.14)		2.9 %	-0.68 [-1.83, 0.47]
Nie 2004	8	5.1 (1.2)	8	4.9 (1.3)		2.8 %	0.20 [-1.03, 1.43]
O'Connor 2013	20	1.86 (1.87)	20	1.77 (1.39)		3.2 %	0.09 [-0.93, .]
O'Fallon 2012	15	3.96 (2.186)	15	4.34 (1.77)		2.3 %	-0.38 [-1.81, 1.04]
Peschek 2014	8	4.5 (2)	8	3.4 (2.4)		1.3 %	1.10 [-1.06, 3.26]
Shafat 2004	6	0.278 (0.208)	6	0.32 (0.194)	+	5.3 %	-0.04 [-0.27, 0.19]
Silva 2008 (6)	9	3.86 (0.7)	4	5.43 (0.8)	<u> </u>	3.6 %	-1.57 [-2.48, -0.66]
Silva 2008 (7)	8	5.83 (1)	4	5.43 (0.8)	_	3.2 %	0.40 [-0.65, 1.45]
Silva 2010	11	3.8 (2.6533)	10	6.2 (1.5811)	← →→	1.7 %	-2.40 [-4.25, -0.55]
Su 2008	8	6.2 (4.5255)	8	8 (4.2426)	•	0.4 %	-1.80 [-6.10, 2.50]
Tanabe 2015	14	5.5 (2.1)	4	6 (2.2)		2.0 %	-0.50 [-2.09, 1.09]
Theodorou 2011	14	6.07 (2.4)	4	5.57 (1.5)		2.2 %	0.50 [-0.98, 1.98]
Thompson 2001	9	2.222 (3.333)	9	2.22 (3.333)		0.8 %	0.0 [-3.08, 3.08]
Thompson 2001a (8)	8	3.3 (1.131)	8	4.7 (2.263)		1.8 %	-1.40 [-3.15, 0.35]
Thompson 2003	8	3.333 (3.143)	8	2.22 (3.143)		0.8 %	. [-1.97, 4.19]

-2 0 2

4

-4

Favours antioxidant Favours placebo

(Continued . . .)

Antioxidants for preventing and reducing muscle soreness after exercise (Review) Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

148

(.			Continued)
----	--	--	------------

							(Continued
Study or subgroup	Antioxidant		Placebo		Mean Difference	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Random,95% CI		IV,Random,95% C
Thompson 2004	7	6.43 (1.64)	7	4.86 (2.724)		— I.2 %	1.57 [-0.79, 3.93]
Trombold 2010	16	8.1 (1.6)	16	8 (2.2)		2.5 %	0.10 [-1.23, 1.43]
Trombold 2011 (9)	17	2.71 (2.11)	17	3.76 (1.68)		2.6 %	-1.05 [-2.33, 0.23]
Total (95% CI) Heterogeneity: Tau ² = 0.3 Test for overall effect: Z = Test for subgroup differen	= 2.76 (P = 0.005	58)	498 0001); I ² =6	54%	•	100.0 %	-0.41 [-0.69, -0.12]
				-4	-2 0 2	4	
					antioxidant Favours		
(1) Soreness at the thigh	muscle						
(2) EGCG vs placebo							
(3) NAC vs placebo							
(4) 36 hours post exercis	se						
(5) Single leg squat							
(6) 21 days supplementat	tion						
(7) 14 days supplementat	tion						
(8) General soreness (0-	100mm)						
(9) Soreness at elbow							
(7) Solelless at elbow							

Analysis 1.10. Comparison I Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies), Outcome 10 Muscle soreness at 72 hours - all at same scale (0 to 10; worst pain).

Review: Antioxidants for preventing and reducing muscle soreness after exercise

Comparison: I Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies)

Outcome: 10 Muscle soreness at 72 hours - all at same scale (0 to 10; worst pain)

Study or subgroup	Antioxidant		Placebo		Mean Difference	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Random,95% CI	-	IV,Random,95% CI
Avery 2003	9	3.6 (4.5)	9	4.3 (5.1)	· · · · · · · · · · · · · · · · · · ·	0.5 %	-0.70 [-5.14, 3.74]
Bell 2015	8	0.54 (0.774)	8	1.22 (1.407)		5.3 %	-0.68 [-1.79, 0.43]
Bell 2016	8	0.55 (0.421)	8	1.65 (1.26)		6.8 %	-1.10 [-2.02, -0.18]
Bloomer 2004	9	2.54 (2.94)	9	5.38 (3.3)	•	1.0 %	-2.84 [-5.73, 0.05]
Bloomer 2005	10	4.1 (2.2136)	10	3.3 (1.2649)		3.1 %	0.80 [-0.78, 2.38]
Bryer 2006	10	4.44 (2.811)	8	5.33 (3.143)		1.1 %	-0.89 [-3.68, 1.90]
Close 2006	10	2.96 (2.21)	10	3.24 (2.09)		2.3 %	-0.28 [-2.17, 1.61]
Cobley 2011	6	3 (1.25)	6	1.92 (2)		2.3 %	1.08 [-0.81, 2.97]
Connolly 2006	12	2.58 (2.07)	12	2.16 (1.93)	·	3.0 %	0.42 [-1.18, 2.02]
Connolly 2006a	14	2.2 (1.1225)	3	3 (1.5588)		2.3 %	-0.80 [-2.66, .06]
Goldfarb 2011	21	0.89 (2.037)	20	1.56 (2.485)		3.8 %	-0.67 [-2.06, 0.72]
He 2015 (1)	11	1.37 (1.25)	11	2.88 (2.367)		3.1 %	-1.51 [-3.09, 0.07]
Hutchinson 2016	8	1.38 (2.0082)	8	1.63 (1.3011)		2.8 %	-0.25 [-1.91, 1.41]
Kerksick 2009 (2)	10	2.61 (1.99)	5	4.35 (2.17)		1.6 %	-1.74 [-4.01, 0.53]
Kerksick 2009 (3)	10	3.23 (1.96)	5	4.35 (2.17)		1.6 %	-1.12[-3.38, 1.14]
Krotkiewski 1994	36	1.6 (1.8)	4	0.5 (0.7483)		9.2 %	1.10 [0.39, 1.81]
McFarlin 2016	16	4.4 (3.6)	12	5.2 (3.4641)		1.2 %	-0.80 [-3.44, .84]
McLeay 2012 (4)	10	2.65 (1.44)	10	2.53 (1.6)		4.0 %	0.12[-1.21, 1.45]
Michailidis 2013	10	8 (0.2)	10	8.5 (0.2)	-	17.1 %	-0.50 [-0.68, -0.32]
O'Fallon 2012	15	3.12 (2.694)	15	3.09 (2.394)		2.4 %	0.03 [-1.79, 1.85]
Phillips 2003	16	3.69 (9.52)	19	3.18 (7.4101)	· · · · · · · · · · · · · · · · · · ·	0.3 %	0.5 [-5.22, 6.24]
Tanabe 2015	14	4.8 (2.5)	14	5.2 (2.3)		2.5 %	-0.40 [-2.18, 1.38]
Theodorou 2011	14	4.68 (1.856)	4	5.32 (1.856)		3.8 %	-0.64 [-2.01, 0.73]
Thompson 2001	9	1.11 (1.333)	9	1.11 (1.333)		4.6 %	0.0 [-1.23, 1.23]

-4 -2 0 2 4

Favours antioxidant Favours placebo

(Continued ...)

						Mean		Mear
Study or subgroup	Antioxidant N	Mean(SD)	Placebo N	Mean(SD)		erence om,95% Cl	Weight	Difference IV,Random,95% C
Thompson 2001a (5)	8	2 (1.41421)	8	I.8 (I.I3I37)			4.4 %	0.20 [-1.05, 1.45
Thompson 2003	8	2.222 (3.143)	8	1.11 (1.257)			1.5 %	1.11 [-1.23, 3.46
, Thompson 2004	7	3.93 (2.063)	7	3.53 (2.539)			1.4 %	0.40 [-2.02, 2.82
Trombold 2010	16	5 (2.2)	16	5.9 (2.9)			2.5 %	-0.90 [-2.68, 0.88
Trombold 2011 (6)	17	1.64 (2.09)	17	2.41 (1.7)			4.3 %	-0.77 [-2.05, 0.5]
Fotal (95% CI)	352		305		•		100.0 %	-0.29 [-0.59, 0.02
Heterogeneity: Tau ² = 0.1 Fest for overall effect: Z = Fest for subgroup difference	I.86 (P = 0.06	2)	9); I ² =27%					
						. <u>.</u>		
				Favo	-4 -2 urs antioxidant	0 2 4 Favours place	t ebo	
(1) Soreness at the thigh	muscle							
(2) EGCG vs placebo								
(3) NAC vs placebo								
(4) 60 hrs post exercise								
., .	00 N							
(5) General soreness (0-1	00mm)							
(6) Soreness at elbow								

Analysis I.I.I. Comparison I Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies), Outcome 11 Muscle soreness at 96 hours - all at same scale (0 to 10; worst pain).

Review: Antioxidants for preventing and reducing muscle soreness after exercise

Comparison: I Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies)

Outcome: II Muscle soreness at 96 hours - all at same scale (0 to 10; worst pain)

Study or subgroup	Antioxidant N	Mean(SD)	Placebo N	Mean(SD)	Mean Difference IV,Random,95% CI	Weight	Mean Difference IV,Random,95% CI
Bloomer 2004	9	1.81 (1.5)	9	3.24 (2.04)		3.9 %	-1.43 [-3.08, 0.22]
Bloomer 2005	10	3.7 (2.2136)	10	1.5 (1.2649)		4.2 %	2.20 [0.62, 3.78]
Bryer 2006	10	2.78 (2.8108889)	8	4.22 (2.83)	••	1.9 %	-1.44 [-4.07, 1.18]
Close 2006	10	1.46 (1.66)	10	1.3 (1.21)		5.5 %	0.16[-1.11, 1.43]
Cobley 201 I	6	1.55 (1.27)	6	(1.82)	.	3.6 %	0.55 [-1.23, 2.33]
Connolly 2006	12	1.66 (1.92)	12	0.71 (0.91)		5.8 %	0.95 [-0.25, 2.15]
Connolly 2006a	14	1.2 (0.7483)	14	1.4 (1.1225)		8.9 %	-0.20 [-0.91, 0.51]
Krotkiewski 1994	36	1.5 (1.8)	14	0.2 (0.7483)		8.9 %	1.30 [0.59, 2.01]
McFarlin 2016	16	(4)	12	2.4 (3.1177)	••	1.9 %	-1.40 [-4.04, 1.24]
Michailidis 2013	10	5.2 (1.2)	10	5.6 (0.4)		8.4 %	-0.40 [-1.18, 0.38]
O'Fallon 2012	15	1.85 (1.87)	15	1.6 (1.85)		5.2 %	0.25 [-1.09, 1.58]
Silva 2008 (1)	8	1.67 (0.8)	4	1.84 (0.7)		7.7 %	-0.17 [-1.05, 0.71]
Silva 2008 (2)	9	1.29 (0.5)	4	1.84 (0.7)		8.5 %	-0.55 [-1.31, 0.21]
Silva 2010	11	1.2 (1.6583)	10	2.3 (2.2136)		3.8 %	-1.10 [-2.79, 0.59]
Tanabe 2015	14	2.9 (2.9)	14	3.4 (2.6)		2.9 %	-0.50 [-2.54, 1.54]
Theodorou 2011	14	1.98 (1.39)	14	2.46 (1.64)		6.2 %	-0.48 [-1.60, 0.65]
Trombold 2010	16	3.6 (2.3)	16	3.8 (2.1)		4.4 %	-0.20 [-1.73, 1.33]
Trombold 2011 (3)	17	0.71 (1.49)	17	0.88 (0.86)		8.1 %	-0.17 [-0.99, 0.65]
Total (95% CI) Heterogeneity: Tau ² = 0 Test for overall effect: Z Test for subgroup differe	= 0.13 (P = 0.13)	39)	199); I ² =5 I%		•	100.0 %	-0.03 [-0.43, 0.37]
 I4 days supplement 	tation			 Favour	4 -2 0 2 · s antioxidant Favours plac	4 ebo	
(2) 21 days supplement							
., ,	laton						
(3) Soreness at elbow							

Antioxidants for preventing and reducing muscle soreness after exercise (Review) Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Analysis 1.12. Comparison I Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies), Outcome 12 Muscle soreness at 24 hours. Subgroup analysis by type of exercise (whole body aerobic vs. mechanically induced).

Review: Antioxidants for preventing and reducing muscle soreness after exercise

Comparison: I Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies)

Outcome: 12 Muscle soreness at 24 hours. Subgroup analysis by type of exercise (whole body aerobic vs. mechanically induced)

					Std. Mean		Std. Mean
Study or subgroup	Antioxidant		Placebo		Difference	Weight	Difference
	N	Mean(SD)	Ν	Mean(SD)	IV,Random,95% CI		IV,Random,95% C
I Whole body aerobic exe Bailey 2011	ercise 20	5 (2)	18	5 (2)		4.1 %	0.0 [-0.64, 0.64 -
,		()					
Bell 2015	8	20.67 (27.6)	8	25 (19.7)		1.8 %	-0.17 [-1.15, 0.81]
Bell 2016	8	60 (32.47)	8	93 (50.79)		1.7 %	-0.73 [-1.75, 0.29]
Close 2006	10	4.49 (2.29)	10	4.54 (2.83)		2.3 %	-0.02 [-0.90, 0.86]
Cobley 2011	6	3.2 (1)	6	3.1 (2.3)		1.4 %	0.05 [-1.08, 1.18]
He 2015 (1)	11	1.82 (1.25)	11	3.64 (2.01)		2.1 %	-1.05 [-1.95, -0.14]
Howatson 2009	10	91 (39)	10	82 (45)		2.2 %	0.20 [-0.67, 1.08]
Krotkiewski 1994	36	3.9 (1.8)	14	2.7 (1.1225)		4.2 %	0.72 [0.08, 1.35]
Laupheimer 2014	3	4 (2.96)	4	6.25 (4.44)		0.7 %	-0.48 [-2.03, 1.06]
Lynn 2015	11	52.27 (37.57)	10	53 (36.38)	<u> </u>	2.4 %	-0.02 [-0.88, 0.84]
Meamarbashi 2011	10	1.8 (1.8)	10	3.2 (1.8)		2.1 %	-0.74 [-1.66, 0.17]
Peschek 2014	8	41 (18)	8	46 (17)	<u> </u>	1.8 %	-0.27 [-1.26, 0.72]
Su 2008	8	6.2 (3.1113)	8	7.5 (1.6971)	- _	1.8 %	-0.49 [-1.49, 0.51]
Thompson 2001	9	4 (3)	9	3 (3)	-	2.0 %	0.32 [-0.61, 1.25]
Thompson 2001a (2)	8	50 (16.9706)	8	58 (16.9706)	_	1.8 %	-0.45 [-1.44, 0.55]
Thompson 2003	8	6 (2.8284)	8	3 (2.8284)		1.6 %	1.00 [-0.06, 2.06]
Thompson 2004	7	50.4 (20.37)	7	46.7 (24.07)		1.6 %	0.16 [-0.89, 1.21]
Subtotal (95% CI)	181		157		+	35.5 %	-0.07 [-0.33, 0.18]
Heterogeneity: Tau ² = 0.0 [°] Test for overall effect: Z =			8); I ² =24%	5			
2 Mechanically induced							
Arent 2010	18	1.12 (1.4425)	18	2.09 (1.6971)		3.8 %	-0.60 [-1.27, 0.07]
Avery 2003	9	5.9 (3.6)	9	6 (3.9)	<u> </u>	2.0 %	-0.03 [-0.95, 0.90]
Bloomer 2004	9	3.54 (2.25)	9	4.2 (2.25)	<u> </u>	2.0 %	-0.28 [-1.21, 0.65]

Favours antioxidant Favours placebo

(Continued . . .)

(... Continued)

Study or subgroup	Antioxidant N	Maan (SD)	Placebo N	Maan(CD)	Std. Mean Difference IV,Random,95% CI	Weight	Sto Mea Differenc
Bloomer 2005	10	Mean(SD) 5.7 (0.9487)	10	Mean(SD) 4.8 (0.9487)		2.0 %	IV,Random,95% (0.91 [-0.02, 1.84
Bloomer 2007	7	7.35 (1.217)	8	5.75 (2.4324)	<u> </u>	1.6 %	0.77 [-0.30, 1.83
Bryer 2006	10	4.2 (2.2136)	8	6.2 (2.2627)		1.8 %	-0.85 [-1.83, 0.13
, Connolly 2006	12	2.54 (2.46)	12	2.75 (2.14)		2.7 %	-0.09 [-0.89, 0.71
, Connolly 2006a	14	3.7 (4.49)	14	4.3 (4.8642)		3.1 %	-0.12 [-0.87, 0.62
Goldfarb 201 I	21	2.6 (1.3748)	20	2.3 (1.7889)		4.4 %	0.19 [-0.43, 0.80
Hutchinson 2016	8	2.44 (1.8385)	8	3 (1.7819)		1.8 %	-0.29 [-1.28, 0.69
Kerksick 2009 (3)	10	2.14 (3.83)	5	3.58 (2.3)		1.5 %	-0.39 [-1.48, 0.69
Kerksick 2009 (4)	10	2.84 (1.7)	5	3.58 (2.3)		1.5 %	-0.37 [-1.45, 0.72
McBride 1997	6	2.33 (1.9596)	6	3.25 (2.1556)		1.3 %	-0.41 [-1.56, 0.74
McFarlin 2016	16	7.4 (3.6)	12	9.9 (3.1177)		2.9 %	-0.71 [-1.49, 0.06
McLeay 2012 (5)	10	2.14 (1.73)	10	2.45 (2)		2.3 %	-0.16 [-1.04, 0.72
Michailidis 2013	10	8.4 (0.4)	10	8.8 (0.4)		2.0 %	-0.96 [-1.89, -0.02
Nicol 2015 (6)	17	3.7 (1.32)	17	4.3 (1.98)		3.7 %	-0.35 [-1.03, 0.3
Nie 2004	8	6.2 (1.7)	8	6.7 (1.2)		1.8 %	-0.32 [-1.31, 0.6
O'Connor 2013	20	19.9 (21.4)	20	18.5 (14.3)		4.3 %	0.08 [-0.54, 0.7
		. ,		. ,			-
O'Fallon 2012	15	36.03 (16.27)	15	39 (15.67)		3.3 %	-0.18 [-0.90, 0.5
Shafat 2004	6	9.5 (1.2)	6	10 (1.4)		1.3 %	-0.35 [-1.50, 0.7
Tanabe 2015	14	4.3 (2.5)	14	4.7 (1.9)	<u> </u> .	3.1 %	-0.17 [-0.92, 0.5
Theodorou 2011	14	3.36 (2.06)	14	2.79 (1.42)		3.1 %	0.31 [-0.43, 1.0
Trombold 2010	16	8 (2)	16	8.2 (1.9)		3.5 %	-0.10 [-0.79, 0.5
Trombold 2011 (7)	17	3.59 (2.03)	17	4.17 (1.62)		3.7 %	-0.31 [-0.99, 0.3
Subtotal (95% CI) leterogeneity: Tau ² = 0.0; C est for overall effect: $Z = 2$			291); I ² =0.0%		•	64.5 %	-0.18 [-0.34, -0.01
Total (95% CI) leterogeneity: Tau ² = 0.01; est for overall effect: Z = 1 est for subgroup difference	.94 (P = 0.05	2)	*		•	100.0 %	-0.13 [-0.27, 0.00

(1) Soreness at the thigh muscle

- (2) General soreness (0-100mm)
- (3) NAC vs placebo
- (4) EGCG vs placebo
- (5) 12 hrs post exercise
- (6) Single leg squat
- (7) Soreness at elbow

Analysis 1.13. Comparison I Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies), Outcome 13 Muscle soreness at 48 hours. Subgroup analysis by type of exercise (whole body aerobic vs. mechanically induced).

Review: Antioxidants for preventing and reducing muscle soreness after exercise

Comparison: I Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies)

Outcome: 13 Muscle soreness at 48 hours. Subgroup analysis by type of exercise (whole body aerobic vs. mechanically induced)

Study or subgroup	Antioxidant N	Mean(SD)	Placebo N	Mean(SD)	Std. Mean Difference IV,Random,95% Cl	Weight	Std. Mean Difference IV,Random,95% Cl
I Whole body aerobic ex	ercise						
Bailey 2011	20	5 (2)	18	5 (2)	-	2.9 %	0.0 [-0.64, 0.64]
Bell 2015	8	14.92 (22.51)	8	21.8 (18.72)		1.9 %	-0.31 [-1.30, 0.67]
Bell 2016	8	45 (27.82)	8	91 (56.08)		1.8 %	-0.98 [-2.04, 0.07]
Close 2006	10	4.34 (2.74)	10	5.59 (2.6)		2.1 %	-0.45 [-1.34, 0.44]
Cobley 2011	6	2.9 (1.1)	6	2.4 (0.8)		1.6 %	0.48 [-0.68, 1.64]
Drobnic 2014	9	23.3 (7.9)	10	30.6 (7.9)		2.0 %	-0.88 [-1.84, 0.07]
He 2015 (1)	11	1.91 (1.14)	11	3.09 (1.58)		2.2 %	-0.82 [-1.70, 0.05]
Howatson 2009	10	58 (39)	10	46 (28)	_ 	2.2 %	0.34 [-0.55, 1.22]
Krotkiewski 1994	36	2.95 (1.8)	14	1.1 (0.7483)		2.8 %	1.15 [0.49, 1.81]
Lynn 2015	10	24.6 (22.53)	10	17.7 (12.99)	_ -	2.2 %	0.36 [-0.53, 1.24]
Meamarbashi 2011	10	1.2 (0.7)	10	3.3 (1.6)		1.8 %	-1.63 [-2.67, -0.59]

Favours antioxidant

-2 0

2 4

Favours placebo

-4

(Continued ...)

Study or subgroup	Antioxidant N		Placebo		Std. Mean		Std. Mean
	N				Difference	Weight	Difference
		Mean(SD)	N	Mean(SD)	IV,Random,95% CI		IV,Random,95% CI
Peschek 2014	8	45 (20)	8	34 (24)		1.9 %	0.47 [-0.53, 1.47]
Su 2008	8	6.2 (4.5255)	8	8 (4.2426)		1.9 %	-0.39 [-1.38, 0.60]
Thompson 2001	9	3 (3)	9	3 (3)		2.1 %	0.0 [-0.92, 0.92]
Thompson 2001a (2)	8	33 (.3 37)	8	47 (22.6274)		1.8 %	-0.74 [-1.76, 0.28]
Thompson 2003	8	4 (2.8284)	8	3 (2.8284)	_ 	1.9 %	0.33 [-0.65, 1.32]
Thompson 2004	7	64.3 (16.4)	7	48.6 (27.24)	<u> </u>	1.7 %	0.65 [-0.43, 1.74]
Subtotal (95% CI)	186		163		•	34.7 %	-0.12 [-0.47, 0.23]
Heterogeneity: $Tau^2 = 0.32$			$00 00); ^2 =$	59%			
Test for overall effect: Z = 2 Mechanically induced	0.66 (P = 0.51))					
Arent 2010	18	0.88 (1.3576)	18	1.94 (1.9516)		2.8 %	-0.62 [-1.29, 0.05]
Avery 2003	9	4.9 (3.3)	9	5.1 (4.2)		2.1 %	-0.05 [-0.97, 0.87]
Beaton 2002a	9	8.8 (3.1)	7	7.5 (2)		1.9 %	0.46 [-0.55, 1.46]
Bloomer 2004	9	3.04 (2.4)	9	5.46 (3)	_	1.9 %	-0.85 [-1.82, 0.13]
Bloomer 2005	10	5.8 (2.5298)	10	4.8 (1.8974)	<u>+</u>	2.2 %	0.43 [-0.46, 1.32]
Bloomer 2007	7	7.07 (0.926)	8	6.25 (2.7436)	_ 	1.8 %	0.37 [-0.66, 1.39]
Bryer 2006	10	6.1 (2.2136)	8	7.5 (2.2627)		2.0 %	-0.60 [-1.55, 0.36]
Connolly 2006	12	2.25 (1.92)	12	2.75 (2.07)		2.4 %	-0.24 [-1.05, 0.56]
Connolly 2006a	14	3.3 (4.1158)	4	5 (4.49)		2.6 %	-0.38 [-1.13, 0.37]
Goldfarb 2011	21	2.8 (2.7495)	20	3 (1.3416)		3.0 %	-0.09 [-0.70, 0.52]
Hutchinson 2016	8	2.75 (2.4324)	8	3.38 (2.1213)		1.9 %	-0.26 [-1.25, 0.72]
Kaminski 1992	19	3.7 (2.6)	19	5.4 (2.2)		2.9 %	-0.69 [-1.35, -0.03]
Kerksick 2009 (3)	10	3.49 (2.15)	5	5.51 (1.64)		1.6 %	-0.95 [-2.09, 0.20]
Kerksick 2009 (4)	10	3.3 (2.08)	5	5.51 (1.64)		1.6 %	-1.06 [-2.23, 0.10]
McBride 1997	6	2 (2.1311)	6	2.75 (2.278)		1.6 %	-0.31 [-1.46, 0.83]
McFarlin 2016	16	11.4 (3.2)	12	12.5 (2.7713)		2.5 %	-0.35 [-1.11, 0.40]
McLeay 2012 (5)	10	3.79 (1.88)	10	3.35 (2.25)	_ <u></u>	2.2 %	0.20 [-0.68, 1.08]
Michailidis 2013	10	8.9 (0.2)	10	9.5 (0.2)	<u>← </u>	1.3 %	-2.87 [-4.20, -1.55]
Nicol 2015 (6)	17	3.32 (1.15)	17	4 (2.14)	-+	2.8 %	-0.39 [-1.07, 0.29]
Nie 2004	8	5.1 (1.2)	8	4.9 (1.3)	_ <u>_</u>	1.9 %	0.15 [-0.83, 1.13]
O'Connor 2013	20	18.6 (18.7)	20	17.7 (13.9)	+	3.0 %	0.05 [-0.57, 0.67]
O'Fallon 2012	15	39.6 (21.86)	15	43.43 (17.7)		2.7 %	-0.19 [-0.90, 0.53]

-4 -2 0 2

4

Favours antioxidant Favours placebo

(Continued . . .)

(... Continued)

Antioxidants for preventing and reducing muscle soreness after exercise (Review) Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. 156

					Std.		Sto
Study or subgroup	Antioxidant		Placebo		Mean Difference	Weight	Mear Difference
, , , , , , , , , , , , , , , , , , , ,	Ν	Mean(SD)	Ν	Mean(SD)	IV,Random,95% CI		IV,Random,95% C
Shafat 2004	6	10 (1.5)	6	10.3 (1.4)		1.6 %	-0.19 [-1.33, 0.94
Silva 2008 (7)	8	5.83 (1)	4	5.43 (0.8)	,	1.5 %	0.39 [-0.82, 1.61
Silva 2008 (8)	9	3.86 (0.7)	4	5.43 (0.8)		1.1 %	-2.00 [-3.50, -0.5
Silva 2010	11	3.8 (2.6533)	10	6.2 (1.5811)	<u> </u>	2.1 %	-1.04 [-1.97, -0.12
Tanabe 2015	14	5.5 (2.1)	14	6 (2.2)		2.6 %	-0.23 [-0.97, 0.52
Theodorou 2011	14	6.07 (2.4)	14	5.57 (1.5)		2.6 %	0.24 [-0.50, 0.99
Trombold 2010	16	8.1 (1.6)	16	8 (2.2)	<u> </u>	2.7 %	0.05 [-0.64, 0.74
Trombold 2011 (9)	17	2.71 (2.11)	17	3.76 (1.68)		2.8 %	-0.54 [-1.22, 0.15
Subtotal (95% CI)	363		335		•	65.3 %	-0.31 [-0.50, -0.12
deterogeneity: $Tau^2 = 0.$			4); I ² =34%				
est for overall effect: Z = Total (95% CI)		7)					
leterogeneity: Tau ² = 0. lest for overall effect: Z = lest for subgroup differen	2.72 (P = 0.006	, df = 46 (P = 0.00		47%	•	100.0 %	-0.24 [-0.42, -0.07
est for overall effect: Z = est for subgroup differen	7; $Chi^2 = 86.34$, 2.72 (P = 0.006 ces: $Chi^2 = 0.88$, df = 46 (P = 0.00	0029); l ² =4	-4	-2 0 2 antioxidant Favours play	4	-0.24 [-0.42, -0.07
est for overall effect: Z =	7; Chi ² = 86.34, 2.72 (P = 0.006 ces: Chi ² = 0.88 muscle	, df = 46 (P = 0.00	0029); l ² =4	-4		4	-0.24 [-0.42, -0.07
est for overall effect: Z = est for subgroup differen (1) Soreness at the thigh	7; Chi ² = 86.34, 2.72 (P = 0.006 ces: Chi ² = 0.88 muscle	, df = 46 (P = 0.00	0029); l ² =4	-4		4	-0.24 [-0.42, -0.07
est for overall effect: Z = est for subgroup differen [1] Soreness at the thigh [2] General soreness (0-	7; Chi ² = 86.34, 2.72 (P = 0.006 ces: Chi ² = 0.88 muscle	, df = 46 (P = 0.00	0029); l ² =4	-4		4	-0.24 [-0.42, -0.07
est for overall effect: Z = est for subgroup differen (1) Soreness at the thigh (2) General soreness (0- (3) NAC vs placebo	7; Chi ² = 86.34, 2.72 (P = 0.00 <i>c</i> ces: Chi ² = 0.88 muscle	, df = 46 (P = 0.00	0029); l ² =4	-4		4	-0.24 [-0.42, -0.07
est for overall effect: Z = est for subgroup differen (1) Soreness at the thigh (2) General soreness (0- (3) NAC vs placebo (4) EGCG vs Placebo	7; Chi ² = 86.34, 2.72 (P = 0.00 <i>c</i> ces: Chi ² = 0.88 muscle	, df = 46 (P = 0.00	0029); l ² =4	-4		4	-0.24 [-0.42, -0.07
est for overall effect: Z = est for subgroup differen (1) Soreness at the thigh (2) General soreness (0- (3) NAC vs placebo (4) EGCG vs Placebo (5) 36 hours post exercis	7; Chi ² = 86.34, 2.72 (P = 0.006 ces: Chi ² = 0.88 muscle 100mm)	, df = 46 (P = 0.00	0029); l ² =4	-4		4	-0.24 [-0.42, -0.07
 (1) Soreness at the thigh (2) General soreness (0- (3) NAC vs placebo (4) EGCG vs Placebo (5) 36 hours post exercise (6) Single leg squat 	7; Chi ² = 86.34, 2.72 (P = 0.00¢ ces: Chi ² = 0.88 muscle 100mm)	, df = 46 (P = 0.00	0029); l ² =4	-4		4	-0.24 [-0.42, -0.07

Analysis 1.14. Comparison I Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies), Outcome 14 Muscle soreness at 24 hours. Subgroup analysis by funding sources (funded by food company or provider of antioxidant supplements vs. not funded by food company or provider of antioxidant supplements).

Review: Antioxidants for preventing and reducing muscle soreness after exercise

Comparison: I Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies)

Outcome: 14 Muscle soreness at 24 hours. Subgroup analysis by funding sources (funded by food company or provider of antioxidant supplements vs. not funded by food company or provider of antioxidant supplements)

Study or subgroup	Antioxidants N	Mean(SD)	Placebo N	Mean(SD)	Std. Mean Difference IV,Fixed,95% Cl	Weight	Std. Mean Difference IV,Fixed,95% Cl
Company funding							
Arent 2010	18	1.12 (1.4425)	18	2.09 (1.6971)		3.9 %	-0.60 [-1.27, 0.07]
Bailey 2011	20	5 (2)	18	5 (2)		4.3 %	0.0 [-0.64, 0.64]
Bell 2015	8	20.67 (27.6)	8	25 (19.7)		1.8 %	-0.17 [-1.15, 0.81]
Bell 2016	8	60 (32.47)	8	93 (50.79)		1.7 %	-0.73 [-1.75, 0.29]
Bloomer 2005	10	5.7 (0.9487)	10	4.8 (0.9487)		2.0 %	0.91 [-0.02, 1.84]
Bloomer 2007	7	7.35 (1.217)	8	5.75 (2.4324)		1.5 %	0.77 [-0.30, 1.83]
Connolly 2006a	14	3.7 (4.49)	4	4.3 (4.8642)		3.2 %	-0.12 [-0.87, 0.62]
Kerksick 2009 (I)	10	2.84 (1.7)	5	3.58 (2.3)		1.5 %	-0.37 [-1.45, 0.72]
Kerksick 2009 (2)	10	2.14 (3.83)	5	3.58 (2.3)		1.5 %	-0.39 [-1.48, 0.69]
McFarlin 2016	16	7.4 (3.6)	12	9.9 (3.1177)		2.9 %	-0.71 [-1.49, 0.06]
O'Connor 2013	20	19.9 (21.4)	20	18.5 (14.3)		4.6 %	0.08 [-0.54, 0.70]
Peschek 2014	8	41 (18)	8	46 (17)		1.8 %	-0.27 [-1.26, 0.72]
Tanabe 2015	14	4.3 (2.5)	4	4.7 (1.9)		3.2 %	-0.17 [-0.92, 0.57]
Thompson 2001	9	4 (3)	9	3 (3)		2.0 %	0.32 [-0.61, 1.25]
Thompson 2001a (3)	8	50 (16.9706)	8	58 (16.9706)		1.8 %	-0.45 [-1.44, 0.55]
Thompson 2003	8	6 (2.8284)	8	3 (2.8284)		1.6 %	1.00 [-0.06, 2.06]
Trombold 2010	16	8 (2)	16	8.2 (1.9)		3.6 %	-0.10 [-0.79, 0.59]
Trombold 2011 (4)	17	3.59 (2.03)	17	4.17 (1.62)	_	3.8 %	-0.3 [-0.99, 0.37]
abtotal (95% CI) eterogeneity: Chi ² = 19.92, st for overall effect: $Z = 1.1$ Other funding		0.28); I ² = I 5%	206		•	46.7 %	-0.11 [-0.31, 0.08]

(Continued ...)

St Mea Differenc IV,Fixed,95% (Weight	Std. Mean Difference IV,Fixed,95% Cl	Mean(SD)	Placebo N	Mean(SD)	Antioxidants N	Study or subgroup
-0.03 [-0.95, 0.90	2.0 %		6 (3.9)	9	5.9 (3.6)	9	Avery 2003
-0.28 [-1.21, 0.65	2.0 %		4.2 (2.25)	9	3.54 (2.25)	9	Bloomer 2004
-0.85 [-1.83, 0.13	1.8 %		6.2 (2.2627)	8	4.2 (2.2136)	10	Bryer 2006
-0.02 [-0.90, 0.86	2.3 %		4.54 (2.83)	10	4.49 (2.29)	10	Close 2006
0.05 [-1.08, 1.18	1.4 %		3.1 (2.3)	6	3.2 (1)	6	Cobley 2011
-0.09 [-0.89, 0.71	2.7 %		2.75 (2.14)	12	2.54 (2.46)	12	Connolly 2006
0.19 [-0.43, 0.80	4.6 %	+	2.3 (1.7889)	20	2.6 (1.3748)	21	Goldfarb 2011
-1.05 [-1.95, -0.14	2.1 %		3.64 (2.01)	11	1.82 (1.25)	11	He 2015 (5)
0.20 [-0.67, 1.08	2.3 %		82 (45)	10	91 (39)	10	Howatson 2009
-0.29 [-1.28, 0.69	1.8 %	·	3 (1.7819)	8	2.44 (1.8385)	8	Hutchinson 2016
0.72 [0.08, 1.35	4.3 %		2.7 (1.1225)	14	3.9 (1.8)	36	Krotkiewski 1994
-0.48 [-2.03, 1.06	0.7 %	•	6.25 (4.44)	4	4 (2.96)	3	Laupheimer 2014
-0.02 [-0.88, 0.84	2.4 %		53 (36.38)	10	52.27 (37.57)	11	Lynn 2015
-0.41 [-1.56, 0.74	1.3 %		3.25 (2.1556)	6	2.33 (1.9596)	6	, McBride 1997
-0.16 [-1.04, 0.72	2.3 %		2.45 (2)	10	2.14 (1.73)	10	McLeay 2012 (6)
-0.74 [-1.66, 0.17	2.1 %		3.2 (1.8)	10	1.8 (1.8)	10	Meamarbashi 2011
-0.96 [-1.89, -0.02	2.0 %		8.8 (0.4)	10	8.4 (0.4)	10	Michailidis 2013
-0.35 [-1.03, 0.33	3.8 %		4.3 (1.98)	17	3.7 (1.32)	17	Nicol 2015 (7)
-0.32 [-1.31, 0.67	1.8 %	.	6.7 (1.2)	8	6.2 (1.7)	8	Nie 2004
-0.18 [-0.90, 0.54	3.4 %		39 (15.67)	15	36.03 (16.27)	15	O'Fallon 2012
-0.35 [-1.50, 0.79	1.3 %		10 (1.4)	6	9.5 (1.2)	6	Shafat 2004
0.31 [-0.43, 1.06	3.1 %		2.79 (1.42)	14	3.36 (2.06)	14	Theodorou 2011
0.16 [-0.89, 1.21	1.6 %		46.7 (24.07)	7	50.4 (20.37)	7	Thompson 2004
-0.14 [-0.32, 0.05	53.3 %	•		234	$(143) \cdot 1^2 = 2\%$	259	Subtotal (95% CI) leterogeneity: $Chi^2 = 22$.
					0.15),1 =2/6		est for overall effect: $Z =$
-0.13 [-0.26, 0.01	100.0 %	•		440), I ² =0.0%)	I.86 (P = 0.063)	Fotal (95% CI) Heterogeneity: Chi ² = 42. Fest for overall effect: Z = Fest for subgroup difference

(1) EGCG vs placebo

(2) NAC vs placebo

- (3) General soreness (0-100mm)
- (4) Soreness at elbow
- (5) Soreness at the thigh muscle
- (6) 12 hrs post exercise
- (7) Single leg squat

Analysis 1.15. Comparison I Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies), Outcome 15 Muscle soreness at 48 hours. Subgroup analysis by funding sources (funded by food company or provider of antioxidant supplements vs. not funded by food company or provider of antioxidant supplements).

Review: Antioxidants for preventing and reducing muscle soreness after exercise

Comparison: I Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies)

Outcome: 15 Muscle soreness at 48 hours. Subgroup analysis by funding sources (funded by food company or provider of antioxidant supplements vs. not funded by food company or provider of antioxidant supplements)

Study or subgroup	Antioxidants N	Mean(SD)	Placebo N	Mean(SD)	Std. Mean Difference IV,Fixed,95% Cl	Weight	Std. Mean Difference IV,Fixed,95% Cl
I Company funding							
Arent 2010	18	0.88 (1.3576)	18	1.94 (1.9516)		3.6 %	-0.62 [-1.29, 0.05]
Bailey 2011	20	5 (2)	18	5 (2)		4.0 %	0.0 [-0.64, 0.64]
Beaton 2002a	9	8.8 (3.1)	7	7.5 (2)		1.6 %	0.46 [-0.55, 1.46]
Bell 2015	8	14.92 (22.51)	8	21.8 (18.72)		1.6 %	-0.31 [-1.30, 0.67]
Bell 2016	8	45 (27.82)	8	91 (56.08)		1.4 %	-0.98 [-2.04, 0.07]
Bloomer 2005	10	5.8 (2.5298)	10	4.8 (1.8974)		2.0 %	0.43 [-0.46, 1.32]
Bloomer 2007	7	7.07 (0.926)	8	6.25 (2.7436)	.	1.5 %	0.37 [-0.66, 1.39]
Connolly 2006a	14	3.3 (4.1158)	4	5 (4.49)		2.9 %	-0.38 [-1.13, 0.37]
Kerksick 2009 (I)	10	3.49 (2.15)	5	5.51 (1.64)		1.2 %	-0.95 [-2.09, 0.20]
Kerksick 2009 (2)	10	3.3 (2.08)	5	5.51 (1.64)		1.2 %	-1.06 [-2.23, 0.10]
					-4 -2 0 2	4	

-4 -2 Favours antioxidants

Favours placebo

(Continued . . .)

(Contir M Differe	Weight	Std. Mean Difference		Placebo		Antioxidants	Study or subgroup
IV,Fixed,95%	vveigni	IV,Fixed,95% CI	Mean(SD)	N	Mean(SD)	Antioxidants	study or subgroup
-0.35 [-1.11, 0.4	2.8 %		12.5 (2.7713)	12	11.4 (3.2)	16	McFarlin 2016
0.05 [-0.57, 0.6	4.2 %		17.7 (13.9)	20	18.6 (18.7)	20	O'Connor 2013
0.47 [-0.53, 1.4	1.6 %		34 (24)	8	45 (20)	8	Peschek 2014
-0.23 [-0.97, 0.5	2.9 %		6 (2.2)	14	5.5 (2.1)	14	Tanabe 2015
0.0 [-0.92, 0.9	1.9 %		3 (3)	9	3 (3)	9	Thompson 2001
-0.74 [-1.76, 0.2	1.5 %		47 (22.6274)	8	33 (11.3137)	8	Thompson 2001a (3)
0.33 [-0.65, 1.3	1.6 %		3 (2.8284)	8	4 (2.8284)	8	Thompson 2003
0.05 [-0.64, 0.7	3.3 %		8 (2.2)	16	8.1 (1.6)	16	Trombold 2010
-0.54 [-1.22, 0.1	3.4 %		3.76 (1.68)	17	2.71 (2.11)	17	Trombold 2011 (4)
-0.19 [-0.38, 0.0	44.4 %	•		213		230	Subtotal (95% CI)
							Heterogeneity: Chi ² = 19. Fest for overall effect: Z = 2 Other funding
-0.05 [-0.97, 0.8	1.9 %		5.1 (4.2)	9	4.9 (3.3)	9	Avery 2003
-0.85 [-1.82, 0.1	1.7 %	- _	5.46 (3)	9	3.04 (2.4)	9	Bloomer 2004
-0.60 [-1.55, 0.3	1.8 %		7.5 (2.2627)	8	6.1 (2.2136)	10	Bryer 2006
-0.45 [-1.34, 0.4	2.0 %		5.59 (2.6)	10	4.34 (2.74)	10	Close 2006
0.48 [-0.68, 1.6	1.2 %	.	2.4 (0.8)	6	2.9 (1.1)	6	Cobley 201 I
-0.24 [-1.05, 0.5	2.5 %		2.75 (2.07)	12	2.25 (1.92)	12	Connolly 2006
-0.88 [-1.84, 0.0	1.8 %	- _	30.6 (7.9)	10	23.3 (7.9)	9	Drobnic 2014
-0.09 [-0.70, 0.5	4.3 %	_	3 (1.3416)	20	2.8 (2.7495)	21	Goldfarb 2011
-0.82 [-1.70, 0.0	2.1 %	- _	3.09 (1.58)	11	1.91 (1.14)	11	He 2015 (5)
0.34 [-0.55, 1.2	2.1 %		46 (28)	10	58 (39)	10	Howatson 2009
-0.26 [-1.25, 0.7	1.7 %		3.38 (2.1213)	8	2.75 (2.4324)	8	Hutchinson 2016
-0.69 [-1.35, -0.0	3.7 %		5.4 (2.2)	19	3.7 (2.6)	19	Kaminski 1992
1.15 [0.49, 1.8	3.7 %		1.1 (0.7483)	14	2.95 (1.8)	36	Krotkiewski 1994
0.36 [-0.53, 1.2	2.1 %	_ 	17.7 (12.99)	10	24.6 (22.53)	10	Lynn 2015
-0.31 [-1.46, 0.8	1.2 %		2.75 (2.278)	6	2 (2.1311)	6	McBride 1997
0.20 [-0.68, 1.0	2.1 %		3.35 (2.25)	10	3.79 (1.88)	10	McLeay 2012 (6)
-1.63 [-2.67, -0.5	1.5 %		3.3 (1.6)	10	1.2 (0.7)	10	Meamarbashi 2011
-2.87 [-4.20, -1.5	0.9 %		9.5 (0.2)	10	8.9 (0.2)	10	Michailidis 2013
-0.39 [-1.07, 0.2	3.5 %		4 (2.14)	17	3.32 (1.15)	17	Nicol 2015 (7)

-4

Favours antioxidants Favours placebo

(Continued . . .)

Antioxidants for preventing and reducing muscle soreness after exercise (Review) Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. 161

Study or subgroup	Antioxidants		Placebo		Std. Mean Difference	Weight	(Continue Sto Mea Differenc
study of subgroup	Antioxidants	Mean(SD)	N	Mean(SD)	IV,Fixed,95% CI	A AGISUL	IV,Fixed,95% C
Nie 2004	8	5.1 (1.2)	8	4.9 (1.3)	_ 	1.7 %	0.15 [-0.83, 1.13
O'Fallon 2012	15	39.6 (21.86)	15	43.43 (17.7)	-+-	3.1 %	-0.19 [-0.90, 0.53
Shafat 2004	6	10 (1.5)	6	10.3 (1.4)	<u> </u>	1.2 %	-0.19 [-1.33, 0.94
Silva 2008 (8)	9	3.86 (0.7)	4	5.43 (0.8)		0.7 %	-2.00 [-3.50, -0.5
Silva 2008 (9)	8	5.83 (1)	4	5.43 (0.8)	 +	1.1 %	0.39 [-0.82, 1.61
Silva 2010	11	3.8 (2.6533)	10	6.2 (.58)	- _	1.9 %	-1.04 [-1.97, -0.12
Theodorou 2011	4	6.07 (2.4)	14	5.57 (1.5)		2.9 %	0.24 [-0.50, 0.99
Thompson 2004	7	64.3 (16.4)	7	48.6 (27.24)		1.4 %	0.65 [-0.43, 1.74
Subtotal (95% CI)	311		277		•	55.6 %	-0.23 [-0.40, -0.06
Heterogeneity: $Chi^2 = 67$.		0.00002); $ ^2 = 6 $	0/				
	2.66 (P = 0.0079)		/0				
Fotal (95% CI) Heterogeneity: Chi ² = 86. Test for overall effect: Z = Test for subgroup difference	3.29 (P = 0.0010	9) 0.00021); I ² =48 0)	490 %	-4 Favours a	-2 0 2 antioxidants Favours pl	4	-0.21 [-0.34, -0.09
Fotal (95% CI) Heterogeneity: Chi ² = 86. Fest for overall effect: Z =	541 23, df = 45 (P = 3.29 (P = 0.0010	9) 0.00021); I ² =48 0)	490 %			4	-0.21 [-0.34, -0.09
Total (95% CI) Heterogeneity: Chi ² = 86. Test for overall effect: Z = Test for subgroup difference (1) NAC vs placebo	541 23, df = 45 (P = 3.29 (P = 0.0010 tes: Chi ² = 0.10,	9) 0.00021); I ² =48 0)	490 %			4	-0.21 [-0.34, -0.09
Fotal (95% CI) Heterogeneity: Chi ² = 86. Test for overall effect: Z = Test for subgroup difference (1) NAC vs placebo (2) EGCG vs placebo (3) General soreness (0-1)	541 23, df = 45 (P = 3.29 (P = 0.0010 tes: Chi ² = 0.10,	9) 0.00021); I ² =48 0)	490 %			4	-0.21 [-0.34, -0.09
Total (95% CI) Heterogeneity: Chi ² = 86. Test for overall effect: Z = Test for subgroup difference (1) NAC vs placebo (2) EGCG vs placebo	541 23, df = 45 (P = 3.29 (P = 0.0010 ces: Chi ² = 0.10,	9) 0.00021); I ² =48 0)	490 %			4	-0.21 [-0.34, -0.09
Fotal (95% CI) Heterogeneity: Chi ² = 86. Test for overall effect: Z = Test for subgroup difference (1) NAC vs placebo (2) EGCG vs placebo (3) General soreness (0-1 (4) Soreness at elbow	541 23, df = 45 (P = 3.29 (P = 0.0010 res: Chi ² = 0.10, 00mm) muscle	9) 0.00021); I ² =48 0)	490 %			4	-0.21 [-0.34, -0.09
Fotal (95% CI) Heterogeneity: Chi ² = 86. Test for overall effect: Z = Test for subgroup difference (1) NAC vs placebo (2) EGCG vs placebo (3) General soreness (0-1 (4) Soreness at elbow (5) Soreness at the thigh	541 23, df = 45 (P = 3.29 (P = 0.0010 res: Chi ² = 0.10, 00mm) muscle	9) 0.00021); I ² =48 0)	490 %			4	-0.21 [-0.34, -0.09
Fotal (95% CI) Heterogeneity: Chi ² = 86. Test for overall effect: Z = Test for subgroup difference (1) NAC vs placebo (2) EGCG vs placebo (3) General soreness (0-1 (4) Soreness at elbow (5) Soreness at the thigh (6) 36 hours post exercise	541 23, df = 45 (P = 3.29 (P = 0.0010 ces: Chi ² = 0.10, 00mm) muscle	9) 0.00021); I ² =48 0)	490 %			4	-0.21 [-0.34, -0.09

Antioxidants for preventing and reducing muscle soreness after exercise (Review) Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Analysis 1.16. Comparison I Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies), Outcome 16 Muscle tenderness measured in Newtons (all follow-up times).

Review: Antioxidants for preventing and reducing muscle soreness after exercise

Comparison: I Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies)

Outcome: 16 Muscle tenderness measured in Newtons (all follow-up times)

Study or subgroup	Antioxidants N	Mean(SD)	Placebo N	Mean(SD)	Mean Difference IV,Fixed,95% Cl	Weight	Mean Difference IV,Fixed,95% CI
l at 24 hours							
Connolly 2006	12	33.9 (10.64)	12	35.2 (10.64)	+	50.5 %	-1.30 [-9.81, 7.21]
Connolly 2006a	14	-11.9 (11.5991)	4	-10 (11.5991)	+	49.5 %	-1.90 [-10.49, 6.69]
Subtotal (95% CI)	26		26		•	100.0 %	-1.60 [-7.64, 4.45]
Heterogeneity: $Chi^2 = 0.0$	01, df = 1 (P = 0	.92); I ² =0.0%					
Test for overall effect: Z =	= 0.52 (P = 0.60)						
2 at 48 hours Connolly 2006	12	33.9 (21.3)	12	35.2 (10.6)	-	29.7 %	-1.30 [-14.76, 12.16]
7				· · · ·			2
Connolly 2006a	14	- 3. (3.844)	14	-10.6 (9.3541)		70.3 %	-2.50 [-11.25, 6.25]
Subtotal (95% CI) Heterogeneity: $Chi^2 = 0.0$	26 D2, df = 1 (P = 0	.88); l ² =0.0%	26		•	100.0 %	-2.14 [-9.48, 5.19]
Test for overall effect: Z =							
3 at 72 hours							
Connolly 2006	12	37.2 (11.9)	12	37.2 (11.9)	-	42.5 %	0.0 [-9.52, 9.52]
Connolly 2006a	14	-7.5 (11.5991)	4	-6.9 (10.4766)	-	57.5 %	-0.60 [-8.79, 7.59]
Subtotal (95% CI) Heterogeneity: $Chi^2 = 0.0$	26	.93): I ² =0.0%	26		•	100.0 %	-0.34 [-6.55, 5.86]
Test for overall effect: Z =	,	,					
4 at 96 hours							
Connolly 2006	12	38.6 (11.7)	12	41.9 (13.3)	-	53.2 %	-3.30 [-13.32, 6.72]
Connolly 2006a	14	-6.2 (13.8441)	14	-5 (14.9666)	-	46.8 %	-1.20 [-11.88, 9.48]
Subtotal (95% CI)	26		26		•	100.0 %	-2.32 [-9.62, 4.99]
Heterogeneity: $Chi^2 = 0.0$	08, df = 1 (P = 0	.78); I ² =0.0%					
Test for overall effect: Z =	= 0.62 (P = 0.53)						

-100 -50 0 Favours placebo

0 50 100 Favours antioxidant

Analysis 1.17. Comparison I Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies), Outcome 17 Muscle tenderness measured in kg (all follow-up times).

Review: Antioxidants for preventing and reducing muscle soreness after exercise

Comparison: I Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies)

Outcome: 17 Muscle tenderness measured in kg (all follow-up times)

Subtotal (95% CI) 10 10 Heterogeneity: not applicable Test for overall effect: $Z = 0.09$ (P = 0.93) 2 at 24 hours Close 2006 10 13.52 (12.1431) 10 Peschek 2014 8 5.9 (1.2) 8 Subtotal (95% CI) 18 18 Heterogeneity: Chi ² = 0.05, df = 1 (P = 0.81); l ² = 0.0% 10 14.075 (14.9576) 10 Peschek 2014 8 6 (1.6) 8 8 Subtotal (95% CI) 18 18 18 Heterogeneity: Chi ² = 0.04, df = 1 (P = 0.84); l ² = 0.0% 10 14.075 (14.9576) 10 Peschek 2014 8 6 (1.6) 8 8 Subtotal (95% CI) 18 18 18 Heterogeneity: Chi ² = 0.04, df = 1 (P = 0.84); l ² = 0.0% 18 18 Heterogeneity: Chi ² = 0.04, df = 1 (P = 0.84); l ² = 0.0% 18 18 Heterogeneity: Chi ² = 0.04, df = 1 (P = 0.84); l ² = 0.0% 18 18 Heterogeneity: Chi ² = 0.04, df = 1 (P = 0.84); l ² = 0.0% 14.075 (14.9576) 10 Test for overall effect: Z = 0.64 (P = 0.52) 4 at 72 hours 10 10	Mean(SD) 4.67 (14.5149) 11.85 (9.8347) 5.4 (1.8) 2.33 (13.3132) 5.5 (1.7)	IV,Fixed,95% CI	100.0 % 100.0 % 2.3 % 97.7 % 100.0 % 1.7 % 98.3 % 100.0 %	
Close 20061014.055 (16.2225)10Subtotal (95% CI)1010Heterogeneity: not applicableTest for overall effect: $Z = 0.09 (P = 0.93)$ 2 at 24 hoursClose 20061013.52 (12.1431)10Peschek 201485.9 (1.2)8Subtotal (95% CI)18Heterogeneity: Chi ² = 0.05, df = 1 (P = 0.81); l ² = 0.0%Test for overall effect: $Z = 0.70 (P = 0.49)$ 3 at 48 hoursClose 2006101014.075 (14.9576)10Peschek 201486 (1.6)8Subtotal (95% CI)18Heterogeneity: Chi ² = 0.04, df = 1 (P = 0.84); l ² = 0.0%Test for overall effect: $Z = 0.64 (P = 0.52)$ 4 at 72 hours	11.85 (9.8347) 5.4 (1.8)		100.0 % 2.3 % 97.7 % 100.0 % I.7 % 98.3 %	-0.61 [-14.10, 12.88 1.67 [-8.02, 11.36 0.50 [-1.00, 2.00 0.53 [-0.95, 2.01] 1.75 [-10.66, 14.16 0.50 [-1.12, 2.12
Subtotal (95% CI) 10 10 Heterogeneity: not applicable Test for overall effect: $Z = 0.09$ (P = 0.93) 2 at 24 hours Close 2006 10 13.52 (12.1431) 10 Peschek 2014 8 5.9 (1.2) 8 Subtotal (95% CI) 18 18 Heterogeneity: Chi ² = 0.05, df = 1 (P = 0.81); l ² = 0.0% 10 14.075 (14.9576) 10 Peschek 2014 8 6 (1.6) 8 8 18 Heterogeneity: Chi ² = 0.04, df = 1 (P = 0.84); l ² = 0.0% 18 18 18 Heterogeneity: Chi ² = 0.04, df = 1 (P = 0.84); l ² = 0.0% 18 18 Heterogeneity: Chi ² = 0.04, df = 1 (P = 0.84); l ² = 0.0% 18 18 Heterogeneity: Chi ² = 0.04, df = 1 (P = 0.84); l ² = 0.0% 18 18 Heterogeneity: Chi ² = 0.04, df = 1 (P = 0.84); l ² = 0.0% 13 14 Peschek 2014 8 6 (1.6) 8 Subtotal (95% CI) 18 18 18 Heterogeneity: Chi ² = 0.04, df = 1 (P = 0.84); l ² = 0.0% 14 14 14 10 Yet hours Yet hours Yet hours 14 16 16	11.85 (9.8347) 5.4 (1.8)		100.0 % 2.3 % 97.7 % 100.0 % I.7 % 98.3 %	-0.61 [-14.10, 12.88 1.67 [-8.02, 11.36 0.50 [-1.00, 2.00 0.53 [-0.95, 2.01] 1.75 [-10.66, 14.16 0.50 [-1.12, 2.12
Heterogeneity: not applicable Test for overall effect: $Z = 0.09 (P = 0.93)$ 2 at 24 hours Close 2006 10 13.52 (12.1431) 10 Peschek 2014 8 5.9 (1.2) 8 Subtotal (95% CI) 18 18 Heterogeneity: Chi ² = 0.05, df = 1 (P = 0.81); l ² = 0.0% Test for overall effect: $Z = 0.70 (P = 0.49)$ 3 at 48 hours Close 2006 10 14.075 (14.9576) 10 Peschek 2014 8 6 (1.6) 8 Subtotal (95% CI) 18 18 Heterogeneity: Chi ² = 0.04, df = 1 (P = 0.84); l ² = 0.0% Test for overall effect: $Z = 0.64 (P = 0.52)$ 4 at 72 hours	5.4 (1.8)		2.3 % 97.7 % 100.0 % I.7 % 98.3 %	1.67 [-8.02, 11.36 0.50 [-1.00, 2.00 0.53 [-0.95, 2.01 1.75 [-10.66, 14.16 0.50 [-1.12, 2.12
Test for overall effect: $Z = 0.09$ (P = 0.93) 2 at 24 hours Close 2006 10 13.52 (12.1431) 10 Peschek 2014 8 5.9 (1.2) 8 Subtotal (95% CI) 18 18 Heterogeneity: Chi ² = 0.05, df = 1 (P = 0.81); l ² = 0.0% Test for overall effect: $Z = 0.70$ (P = 0.49) 3 at 48 hours Close 2006 10 14.075 (14.9576) 10 Peschek 2014 8 6 (1.6) 8 Subtotal (95% CI) 18 18 Heterogeneity: Chi ² = 0.04, df = 1 (P = 0.84); l ² = 0.0% 18 18 Heterogeneity: Chi ² = 0.04, df = 1 (P = 0.84); l ² = 0.0% Test for overall effect: $Z = 0.64$ (P = 0.52) 4 at 72 hours	5.4 (1.8)		97.7 % 100.0 % 1.7 % 98.3 %	0.50 [-1.00, 2.00 0.53 [-0.95, 2.01 1.75 [-10.66, 14.16 0.50 [-1.12, 2.12
2 at 24 hours Close 2006 10 13.52 (12.1431) 10 Peschek 2014 8 5.9 (1.2) 8 Subtotal (95% CI) 18 18 Heterogeneity: Chi ² = 0.05, df = 1 (P = 0.81); l ² = 0.0% Test for overall effect: $Z = 0.70$ (P = 0.49) 3 at 48 hours Close 2006 10 14.075 (14.9576) 10 Peschek 2014 8 6 (1.6) 8 Subtotal (95% CI) 18 18 Heterogeneity: Chi ² = 0.04, df = 1 (P = 0.84); l ² = 0.0% Test for overall effect: $Z = 0.64$ (P = 0.52) 4 at 72 hours	5.4 (1.8)		97.7 % 100.0 % 1.7 % 98.3 %	0.50 [-1.00, 2.00 0.53 [-0.95, 2.01 1.75 [-10.66, 14.16 0.50 [-1.12, 2.12
Close 20061013.52 (12.1431)10Peschek 201485.9 (1.2)8Subtotal (95% CI)1818Heterogeneity: Chi² = 0.05, df = 1 (P = 0.81); 1² = 0.0%1818Test for overall effect: Z = 0.70 (P = 0.49)3 at 48 hours10Close 20061014.075 (14.9576)10Peschek 201486 (1.6)8Subtotal (95% CI)1818Heterogeneity: Chi² = 0.04, df = 1 (P = 0.84); 1² = 0.0%18Test for overall effect: Z = 0.64 (P = 0.52)4 at 72 hours	5.4 (1.8)		97.7 % 100.0 % 1.7 % 98.3 %	0.50 [-1.00, 2.00 0.53 [-0.95, 2.01 1.75 [-10.66, 14.16 0.50 [-1.12, 2.12
Peschek 2014 8 5.9 (1.2) 8 Subtotal (95% CI) 18 18 Heterogeneity: Chi ² = 0.05, df = 1 (P = 0.81); l ² = 0.0% 18 18 Test for overall effect: Z = 0.70 (P = 0.49) 3 at 48 hours 10 14.075 (14.9576) 10 Peschek 2014 8 6 (1.6) 8 8 18 Subtotal (95% CI) 18 18 18 Heterogeneity: Chi ² = 0.04, df = 1 (P = 0.84); l ² = 0.0% 18 18 Heterogeneity: Chi ² = 0.04, df = 1 (P = 0.52) 4 at 72 hours 10	5.4 (1.8)		97.7 % 100.0 % 1.7 % 98.3 %	0.50 [-1.00, 2.00 0.53 [-0.95, 2.01 1.75 [-10.66, 14.16 0.50 [-1.12, 2.12
Subtotal (95% CI) 18 18 Heterogeneity: $Chi^2 = 0.05$, $df = 1$ (P = 0.81); $l^2 = 0.0\%$ Test for overall effect: $Z = 0.70$ (P = 0.49) 3 at 48 hours Close 2006 10 14.075 (14.9576) 10 Peschek 2014 8 6 (1.6) 8 Subtotal (95% CI) 18 18 Heterogeneity: $Chi^2 = 0.04$, $df = 1$ (P = 0.84); $l^2 = 0.0\%$ Test for overall effect: $Z = 0.64$ (P = 0.52) 4 at 72 hours 10 10	12.33 (13.3132)		100.0 % 1.7 % 98.3 %	0.53 [-0.95, 2.01 1.75 [-10.66, 14.16 0.50 [-1.12, 2.12
Heterogeneity: $Chi^2 = 0.05$, $df = 1$ (P = 0.81); $l^2 = 0.0\%$ Test for overall effect: Z = 0.70 (P = 0.49) 3 at 48 hours Close 2006 10 14.075 (14.9576) 10 Peschek 2014 8 6 (1.6) 8 Subtotal (95% CI) 18 18 Heterogeneity: $Chi^2 = 0.04$, $df = 1$ (P = 0.84); $l^2 = 0.0\%$ Test for overall effect: Z = 0.64 (P = 0.52) 4 at 72 hours	, ,		1.7 % 98.3 %	1.75 [-10.66, 14.16 0.50 [-1.12, 2.12
Test for overall effect: $Z = 0.70$ (P = 0.49) 3 at 48 hours Close 2006 10 14.075 (14.9576) 10 Peschek 2014 8 6 (1.6) 8 Subtotal (95% CI) 18 18 Heterogeneity: Chi ² = 0.04, df = 1 (P = 0.84); l ² = 0.0% Test for overall effect: $Z = 0.64$ (P = 0.52) 4 at 72 hours	, ,		98.3 %	0.50 [-1.12, 2.12
Close 20061014.075 (14.9576)10Peschek 201486 (1.6)8Subtotal (95% CI)1818Heterogeneity: $Chi^2 = 0.04$, $df = 1$ (P = 0.84); $l^2 = 0.0\%$ 18Test for overall effect: Z = 0.64 (P = 0.52)4 at 72 hours	, ,		98.3 %	0.50 [-1.12, 2.12
Peschek 2014 8 6 (1.6) 8 Subtotal (95% CI) 18 18 Heterogeneity: Chi ² = 0.04, df = 1 (P = 0.84); l ² = 0.0% 18 Test for overall effect: Z = 0.64 (P = 0.52) 4 at 72 hours	, ,	•	98.3 %	0.50 [-1.12, 2.12
Subtotal (95% CI) 18 18 Heterogeneity: Chi ² = 0.04, df = I (P = 0.84); I ² = 0.0% Test for overall effect: Z = 0.64 (P = 0.52) 4 at 72 hours	(۱./)	Ī		-
Heterogeneity: $Chi^2 = 0.04$, $df = 1$ (P = 0.84); $l^2 = 0.0\%$ Test for overall effect: Z = 0.64 (P = 0.52) 4 at 72 hours			100.0 %	0.52 [-1.08, 2.13
	15.22 (12.3961)	-	100.0 %	-1.03 [-13.01, 10.95
Subtotal (95% CI) 10 10		+	100.0 %	-1.03 [-13.01, 10.95
Heterogeneity: not applicable Test for overall effect: Z = 0.17 (P = 0.87) 5 at 96 hours	17.97 (14.3251)	-	100.0 %	-1.39 [-15.12, 12.33
		I		-
Subtotal (95% CI) 10 10 Heterogeneity: not applicable Iteration			100.0 %	-1.39 [-15.12, 12.33
	-100 Favor		100 antioxidant	

Analysis 1.18. Comparison I Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies), Outcome 18 30-second Wingate average peak power output (W/kg) (post 7 days of intervention).

Review: Antioxidants for preventing and reducing muscle soreness after exercise

Comparison: I Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies)

Outcome: 18 30-second Wingate average peak power output (W/kg) (post 7 days of intervention)

Study or subgroup	Antioxidants		Placebo			Mean rence	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Fixe	1,95% CI	IV,Fixed,95% CI
Arent 2010	18	10.9 (4.1578)	18	10.6 (5.0912)	-	-	0.30 [-2.74, 3.34]
					-50 -25 C Favours placebo	25 Favours a	50 ntioxidants

Analysis 1.19. Comparison I Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies), Outcome 19 20 m Sprint time (s).

Review: Antioxidants for preventing and reducing muscle soreness after exercise

Comparison: I Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies)

Outcome: 19 20 m Sprint time (s)

Study or subgroup	Antioxidants N	Mean(SD)	Placebo N	Mean(SD)	Mean Difference IV,Fixed,95% CI	Mean Difference IV,Fixed,95% CI
at 24 hours Cobley 2011	6	3.2 (0.21)	6	3.61 (0.18)		-0.41 [-0.63, -0.19]
2 at 48 hours Cobley 201 I	6	3.41 (0.15)	6	3.71 (0.23)		-0.30 [-0.52, -0.08]
3 at 120 hours Cobley 2011	6	3.36 (0.16)	6	3.66 (0.25)		-0.30 [-0.54, -0.06]
				E.	-1 -0.5 0 0.5 I avours antioxidants Favours place	bo
				Fa	avours antioxidants Favours place	DO

Analysis 1.20. Comparison I Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies), Outcome 20 Maximal oxygen consumption (mL/kg/min) (post 42 days of supplementation).

Review: Antioxidants for preventing and reducing muscle soreness after exercise

Comparison: I Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies)

Outcome: 20 Maximal oxygen consumption (mL/kg/min) (post 42 days of supplementation)

Study or subgroup	Antioxidants		Placebo			Dif	Me feren			Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)		IV,Fix	ed,95	5% CI		IV,Fixed,95% CI
O'Connor 2013	20	43 (9.3)	20	42.8 (9.6)		-	t			0.20 [-5.66, 6.06]
						1	-		-	
					-50	-25	0	25	50	
				Fa	wours ant	ioxidants		Favours	placebo	

Analysis 1.21. Comparison I Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies), Outcome 21 Agility (seconds).

Review: Antioxidants for preventing and reducing muscle soreness after exercise

Comparison: I Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies)

Outcome: 21 Agility (seconds)

Study or subgroup	Antioxidants		Placebo		Mean Difference	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Fixed,95% CI	IV,Fixed,95% CI
I at 24 hours						
Bell 2016	8	2.42 (0.17)	8	2.41 (0.17)		0.01 [-0.16, 0.18]
2 at 48 hours						
Bell 2016	8	2.38 (0.1)	8	2.43 (0.17)	- _	-0.05 [-0.19, 0.09]
3 at 72 hours						
Bell 2016	8	2.35 (0.12)	8	2.37 (0.18)		-0.02 [-0.17, 0.13]
-					-0.5 -0.25 0 0.25 0.1	5
				Fa	avours antioxidants Favours place	

Analysis 1.22. Comparison I Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies), Outcome 22 6 second sprint maximal power (Watts) (all follow-up times).

Review: Antioxidants for preventing and reducing muscle soreness after exercise

Comparison: I Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies)

Outcome: 22 6 second sprint maximal power (Watts) (all follow-up times)

Study or subgroup	Antioxidants		Placebo		Mean Difference	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Fixed,95% CI	IV,Fixed,95% CI
I at 24 hours						
Bell 2015	8	865 (256)	8	826 (191)	_ 	39.00 [-182.33, 260.33]
2 at 48 hours						
Bell 2015	8	908 (293)	8	858 (199)		50.00 [-195.44, 295.44]
3 at 72 hours						
Bell 2015	8	911 (272)	8	858 (184)	_ 	53.00 [-174.56, 280.56]

-1000 -500 0 500 1000

Favours placebo Favours antioxidants

Analysis 1.23. Comparison I Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies), Outcome 23 Maximal voluntary isometric contraction measured as percentage change from baseline.

Review: Antioxidants for preventing and reducing muscle soreness after exercise

Comparison: I Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies)

Outcome: 23 Maximal voluntary isometric contraction measured as percentage change from baseline

Study or subgroup	Antioxidant		Placebo		Mean Difference	Weight	Mean Difference
	N	Mean(SD)	N	Mean(SD)	IV,Fixed,95% CI		IV,Fixed,95% CI
I Up to 6 hours		50 (10 0)	_	50 (15 0)			
Beaton 2002a	9	50 (19.2)	7	53 (15.3)		2.3 %	-3.00 [-19.91, 13.91]
Bloomer 2004	9	63.08 (24.3)	9	56.05 (21.3)		1.5 %	7.03 [-14.08, 28.14]
Bryer 2006	10	62.3 (42.0583)	8	59.1 (28.2843)		0.6 %	3.20 [-29.41, 35.81]
Close 2006 (1)	10	83.3 (10.1193)	10	80.8 (17.7088)	+-	4.1 %	2.50 [-10.14, 15.14]
Goldfarb 2011	21	71.1 (20.1633)	20	64.4 (23.2551)	+	3.7 %	6.70 [-6.65, 20.05]
Meamarbashi 2011	10	112.6 (7)	10	105.8 (6.9)	-	17.8 %	6.80 [0.71, 12.89]
Shafat 2004	6	76.8 (6)	6	66.1 (4.2)	-	19.2 %	10.70 [4.84, 16.56]
Tanabe 2015	14	-33 (8)	14	-40 (9)	-	16.6 %	7.00 [0.69, 3.3]
Thompson 2001a (2)	8	85 (2.8284)	8	79 (.3 37)		10.1 %	6.00 [-2.08, 14.08]
Trombold 2010	16	71.5 (7.3)	16	72.8 (10)	-	17.9 %	-1.30 [-7.37, 4.77]
Trombold 2011 (3)	17	75.4 (13.3)	17	64.9 (16.9)	-	6.3 %	10.50 [0.28, 20.72]
Subtotal (95% CI)	130		125		•	100.0 %	5.86 [3.29, 8.42]
Heterogeneity: $Chi^2 = 10$.		,					
Test for overall effect: Z = 2 at 24 hours	4.47 (P < 0.00	001)					
Beaton 2002a	9	71.1 (26.9)	7	78.8 (15.4)		0.5 %	-7.70 [-28.65, 13.25]
Bloomer 2004	9	82.08 (20.4)	9	83.46 (12)		1.0 %	-1.38 [-16.84, 14.08]
Bryer 2006	10	72.3 (41.4258)	8	70.1 (39.8808)		0.2 %	2.20 [-35.52, 39.92]
Close 2006 (4)	10	75.3 (18.6574)	10	75.7 (13.914)	+	1.1 %	-0.40 [-14.83, 14.03]
Connolly 2006	12	-34 (21.7)	12	-26.3 (20.6)		0.8 %	-7.70 [-24.63, 9.23]
Connolly 2006a	14	89 (11.225)	14	70 (7.4833)	+	4.7 %	19.00 [11.93, 26.07]
Goldfarb 2011	21	60.2 (16.039)	20	60.5 (18.3358)	+	2.1 %	-0.30 [-10.87, 10.27]
Herrlinger 2015 (5)	12	97 (3.4641)	13	94 (3.6056)	-	30.4 %	3.00 [0.23, 5.77]
Herrlinger 2015 (6)	12	93 (3.4641)	13	94 (3.6056)	-	30.4 %	-1.00 [-3.77, 1.77]
Meamarbashi 2011	10	28.67 (7)	10	34.88 (6.9)	-	6.3 %	-6.21 [-12.30, -0.12]

-100 -50 0 50 100

Favours placebo Favours antioxidants

(Continued ...)

Study or subgroup	Antioxidant N	Mean(SD)	Placebo N	Mean(SD)	Mean Difference IV,Fixed,95% Cl	Weight	Mea Differenc IV,Fixed,95% (
Shafat 2004	6	85.9 (5.8)	6	73.3 (4.6)	■	6.6 %	12.60 [6.68, 18.52
Tanabe 2015	14	-32 (14)	14	-40 (8)		3.3 %	8.00 [-0.45, 16.45
Thompson 2001 (7)	9	85 (12)	9	96 (15)		1.5 %	-11.00 [-23.55, 1.55
Thompson 2001 (7)		92 (8.4853)	8	. ,		1.5 %	12.00 [0.57, 23.43
	8	· · · ·		80 (14.1421)			-
Trombold 2010	16	77.3 (11.8)	16	75.7 (11.3)		3.6 %	1.60 [-6.41, 9.6
Trombold 2011 (9)	17	90.8 (9.9)	17	85.2 (8.9)		5.8 %	5.60 [-0.73, 11.93
Subtotal (95% CI)	189		186		ľ	100.0 %	2.51 [0.99, 4.04
Heterogeneity: Chi ² = 58.8 Fest for overall effect: Z = 3							
at 48 hours	5.25 (1 - 0.00	(12)					
Beaton 2002a	9	92.4 (28.8)	7	86.5 (17.4)	_ 	0.4 %	5.90 [-16.91, 28.7
Bloomer 2004	9	86.32 (16.8)	9	83.05 (13.8)	<u> </u>	1.1 %	3.27 [-10.93, 17.42
Bryer 2006	10	75.3 (50.9127)	8	73.1 (39.8808)		0.1 %	2.20 [-39.75, 44.1
Close 2006 (10)	10	80. (3.9 4)	10	77 (24.3495)	<u> </u>	0.8 %	3.10 [-14.28, 20.48
Connolly 2006	12	-31.7 (23.4)	12	-20.4 (22.3)		0.7 %	-11.30 [-29.59, 6.9
Connolly 2006a	14	93 (14.9666)	14	74 (7.4833)		3.0 %	19.00 [10.23, 27.7
Goldfarb 2011	21	62.8 (20.6216)	20	63.1 (18.3358)	+	1.6 %	-0.30 [-12.23, 11.6
Herrlinger 2015 (11)	12	98 (3.4641)	13	92 (3.6056)	-	30.0 %	6.00 [3.23, 8.7
Herrlinger 2015 (12)	12	94 (3.4641)	13	92 (3.6056)	-	30.0 %	2.00 [-0.77, 4.7
Meamarbashi 2011	10	28.67 (7)	10	33.88 (6.9)	-	6.2 %	-5.21 [-11.30, 0.8
Shafat 2004	6	90.2 (3.8)	6	83.6 (5.2)	-	8.7 %	6.60 [1.45, 11.7
Tanabe 2015	14	-28 (9)	14	-40 (13)	-	3.4 %	12.00 [3.72, 20.2
Thompson 2001 (13)	9	89 (12)	9	96 (15)	_+_	1.5 %	-7.00 [-19.55, 5.5
Thompson 2001a (14)	8	92 (8.4853)	8	84 (14.1421)	+	1.8 %	8.00 [-3.43, 19.4
Trombold 2010	16	85.4 (10.1)	16	78.3 (10.1)		4.7 %	7.10 [0.10, 14.1
Trombold 2011 (15)	17	95 (9.3)	17	87.4 (9.1)	-	6.0 %	7.60 [1.41, 13.7
Subtotal (95% CI)	189		186		,	100.0 %	4.46 [2.94, 5.98
Heterogeneity: $Chi^2 = 36.9$,					
Test for overall effect: $Z = \frac{1}{2}$	5.76 (P < 0.00	001)					
at 72 hours Bloomer 2004	9	84.76 (14.7)	9	84.7 (17.4)	-	4.2 %	0.06 [-14.82, 14.94
Bryer 2006	10	79.1 (41.4258)	8	78.3 (31.3955)		0.8 %	0.80 [-32.85, 34.4
Close 2006 (16)		84.9 (10.7517)	10	84.7 (21.1873)	<u> </u>	4.3 %	0.20 [-14.53, 14.93

Favours placebo Favours antioxidants

(Continued . . .)

(... Continued)

Antioxidants for preventing and reducing muscle soreness after exercise (Review) Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

169

Me Differen	Weight	Mean Difference		Placebo		Antioxidant	Study or subgroup
IV,Fixed,95%		IV,Fixed,95% Cl	Mean(SD)	Ν	Mean(SD)	Ν	
-14.20 [-33.37, 4.9]	2.5 %	_	-17.6 (20.6)	12	-31.8 (26.9)	12	Connolly 2006
14.00 [5.23, 22.7	12.1 %	-	82 (7.4833)	14	96 (14.9666)	14	Connolly 2006a
1.50 [-7.79, 10.7	10.7 %	+	69.8 (15.6525)	20	71.3 (14.6642)	21	Goldfarb 2011
14.00 [3.10, 24.9	7.8 %	-=-	-35 (17)	14	-21 (12)	14	Tanabe 2015
-12.00 [-23.43, -0.5	7.1 %	-=-	105 (9)	9	93 (15)	9	Thompson 2001 (17)
3.00 [-11.27, 17.2	4.5 %		93 (5.6569)	8	96 (19.799)	8	Thompson 2001a (18)
4.90 [-0.54, 10.3	31.3 %	-	84 (7.8)	16	88.9 (7.9)	16	Trombold 2010
3.40 [-4.53, 11.3	14.7 %	+	93.4 (11.9)	17	96.8 (11.7)	17	Trombold 2011 (19)
3.92 [0.88, 6.96	100.0 %	•		137		140	Subtotal (95% CI)
					,	,	Heterogeneity: $Chi^2 = 20.2$ Test for overall effect: $Z = 3$ 5 at 96 hours
-4.30 [-13.88, 5.2	2.9 %		88.27 (12.6)	9	83.97 (7.5)	9	Bloomer 2004
2.20 [-37.59, 41.9	0.2 %		86. (39.3 5)	8	88.3 (46.8017)	10	Bryer 2006
-1.40 [-13.91, 11.1	1.7 %	-	94.4 (11.7004)	10	93 (16.4438)	10	Close 2006 (20)
-15.60 [-36.67, 5.4	0.6 %	- ,	-11.1 (23.6)	12	-26.7 (28.8)	12	Connolly 2006
8.00 [8.20, 27.8	2.8 %		87 (11.225)	14	105 (14.9666)	14	Connolly 2006a
3.00 [0.23, 5.7	34.7 %	-	93 (3.6056)	13	96 (3.4641)	12	Herrlinger 2015 (21)
9.00 [6.23, 11.7	34.7 %	-	93 (3.6056)	13	102 (3.4641)	12	Herrlinger 2015 (22)
16.00 [5.60, 26.4	2.5 %		-31 (13)	14	-15 (15)	14	Tanabe 2015
0.90 [-4.02, 5.8	11.0 %	+	90.4 (7.3)	16	91.3 (6.9)	16	Trombold 2010
4.10 [-1.36, 9.5	8.9 %	-	95.6 (7.5)	17	99.7 (8.7)	17	Trombold 2011 (23)
5.29 [3.65, 6.92	100.0 %	•		126	,		Subtotal (95% CI) Heterogeneity: $Chi^2 = 32.0$ Test for overall effect: Z = 0
5.70 [-11.38, 22.7	22.0 %	_ _	88.5 (13.5)	7	94.2 (21.2)	9	5 at 168 hours Beaton 2002a
-11.80 [-20.86, -2.7	78.0 %		102.2 (11.3842)		90.4 (9.1706)		Close 2006 (24)
-7.96 [-15.96, 0.05		•	10212 (1113012)	17	, o (, , co)	19	Subtotal (95% CI)
					,		Heterogeneity: $Chi^2 = 3.15$ Test for overall effect: Z =

(... Continued)

Antioxidants for preventing and reducing muscle soreness after exercise (Review) Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

170

(1) Concentrique quad torque at 1.04 rad/s

- (2) Left flexor
- (3) Isometric strength during elbow flexion
- (4) Concentrique quad torque at 1.04 rad/s
- (5) high dose vs. placebo
- (6) Low dose vs. placebo
- (7) left flexor
- (8) left elbow flexors
- (9) Isometric strength during elbow flexion
- (10) Concentrique quad torque at 1.04 rad/s
- (11) high dose vs. placebo
- (12) low dose vs. placebo
- (13) left flexor
- (14) left elbow flexors
- (15) Isometric strength during elbow flexion
- (16) Concentrique quad torque at 1.04 rad/s
- (17) left flexor
- (18) left elbow flexors
- (19) Isometric strength during elbow flexion
- (20) Concentrique quad torque at 1.04 rad/s
- (21) low dose vs. placebo
- (22) high dose vs. placebo
- (23) Isometric strength during elbow flexion
- (24) Concentrique quad torque at 1.04 rad/s

Analysis I.24. Comparison I Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies), Outcome 24 Maximal voluntary isometric contraction measured in Newton metres.

Review: Antioxidants for preventing and reducing muscle soreness after exercise

Comparison: I Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies)

Outcome: 24 Maximal voluntary isometric contraction measured in Newton metres

Mear Difference IV,Fixed,95% C	Weight	Mean Difference IV,Fixed,95% CI	Mean(SD)	Placebo N	Mean(SD)	Antioxidant N	Study or subgroup
			. ,				I Up to 6 hours
10.00 [-23.47, 43.47	1.0 %		259 (46)	18	269 (59)	20	Bailey 2011 (1)
.7 [-8.44, .86	10.3 %	+	28.56 (14.46)	15	30.27 (13.9)	15	O'Fallon 2012
-2.00 [-5.46, 1.46	88.7 %		85 (4)	8	83 (3)	8	Thompson 2003
-1.50 [-4.77, 1.76]	100.0 %	•		41		43	Subtotal (95% CI)
					,	,	Heterogeneity: Chi ² = 0.9 Test for overall effect: Z = 2 at 24 hours
6.00 [-33.12, 45.12	2.1 %	<u> </u>	276 (57)	18	282 (66)	20	Bailey 2011 (2)
2.91 [-25.31, 31.13	4.0 %		131 (33.56)	10	33.9 (30.78)	10	McLeay 2012 (3)
-6.07 [-18.66, 6.52	20.1 %	-	34.37 (18.94)	15	28.3 (16.13)	15	O'Fallon 2012
8.10 [-15.43, 31.63	5.7 %		141.5 (21.6)	8	149.6 (26.2)	8	Peschek 2014
-2.57 [-29.34, 24.20	4.4 %	_	196.93 (39.32)	4	194.36 (32.65)	14	Theodorou 2011
0.0 [-7.07, 7.07	63.7 %	-	84 (8.4853)	8	84 (5.6569)	8	Thompson 2003
-0.63 [-6.27, 5.01	100.0 %	•		73			Subtotal (95% CI) Heterogeneity: $Chi^2 = 1.4$ Test for overall effect: Z = 3 at 48 hours
-11.00 [-49.79, 27.79	2.6 %	<u> </u>	292 (57)	18	281 (65)	20	Bailey 2011 (4)
21.48 [-11.18, 54.14	3.7 %		140.25 (43.58)	10	161.73 (29.63)	10	McLeay 2012 (5)
-8.77 [-21.08, 3.54	25.9 %	-	37.95 (19.62)	15	29.18 (14.37)	15	O'Fallon 2012
18.20 [-6.25, 42.65	6.6 %		4 .4 (5.3)	8	159.6 (31.8)	8	Peschek 2014
5.21 [-23.77, 34.19	4.7 %	<u> </u>	167.43 (46.51)	14	172.64 (29.95)	14	Theodorou 2011
2.00 [-6.32, 10.32	56.6 %	-	83 (8.4853)	8	85 (8.4853)	8	Thompson 2003
0.80 [-5.46, 7.06	100.0 %	•		73	,		Subtotal (95% CI) Heterogeneity: Chi ² = 6.: Test for overall effect: Z = 4 at 72 hours

(Continued . . .)

(... Continued)

Study or Julgroup Anisolization Practicle Difference Weight Difference N Mexrc(SD) N Mexrc(SD) Model(SF) CL Model(SF) CL <td< th=""><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th>(Continued)</th></td<>								(Continued)
N Mean(SD) N Man(SD) IV/Feed/9% CI IV/Feed/9% CI Md.exy 2012 (6) 10 168.52 (6.77) 10 164.93 (0.052) 7.6 % 3.59 [-3.61, 3.64] O'Falon 2012 15 33.26 (13.85) 15 41.31 (22.68) 38.0 % -46.05 [-21.50, 54.0] Theodorou 2011 14 164.29 (29.11) 14 176 (38.15) 109.9 % -46.05 [-1.63, 13.43] Theomyon 2003 8 88 (14.1421) 47 100.0 % -3.62 [-11.91, 4.67] Heterogenetry Ch ² = 1.56, df = 3 (P = 0.37); P = 0.0%; Te tor overall effect Z = 0.80 (P = 0.33) 38.8 (14.1421) 47 100.0 % -3.62 [-11.91, 4.67] Balley 2011 (7) 20 32.8 (71.1) 18 298 (57) 8.0 % 3000 [-1.076, 707.6] O'Falon 2012 15 36.16 (71.4) 15 44.25 (20.01) 75.2 % -8.10 [-2.14.3, 5.23] Theodorou 2011 14 186.29 (37.15) 100.0 % -4.65 [-1.62.1, 6.92] Heterogenety: Ch ² = 3.04, eff = 2 (P = 0.22); P = 3.48 100.0 % -5.89 [-1.9.14, 7.36] Subtocal (95% C1)	Study or subgroup	Antioxidant		Placebo			Weight	Mean Difference
O'Falon 2011 15 33.26 (136) 15 41.31 (22.6) 38.0 % -4.65 [-21.05, 4.0 % Theadorou 2011 14 164.29 (29.11) 14 176 (88.15) 10.9 % -11.71 [-3.68, 13.43] Thempson 2003 8 89 (11.3137) 8 88 (14.1421) 43.6 % 1.00 (-11.55, 13.55) Suboral (95% CI) 47 47 100.0 % -3.62 [-11.91, 4.67] These companies (CR) = 1.56, df = 3.0 / = 0.67); P = 0.00X 18 298 (57) 8.0 % 20.00 (-10.76, 70.76) Suboral (95% CI) 49 47 100.0 % -3.62 [-11.91, 4.67] Theodorou 2011 14 180.5 (37.15) 14 186.22 (9.11) 16.7 % 5.77 [-3405, 22.47] Suboral (95% CI) 49 47 100.0 % -4.65 [-16.21, 6.92] 16.7 % 5.79 [-3405, 22.47] Suboral (95% CI) 29 47 100.0 % -5.89 [-19.14, 7.36] Heterogenety: CR) = 20.0, df = [P = 0.35); P = 0.0% 18 21.8 (41.86) 22.1 % -5.15 [-33.33, 23.03] Suboral (95% CI) 20 38 (66) 18 278 (73) 100.0 % 58.00 [13.57, 102.43] The	,	Ν	Mean(SD)	Ν	Mean(SD)	IV,Fixed,95% CI	0	IV,Fixed,95% CI
Theodorou 2011 14 16429 (29.11) 14 176 (38.15) 109 % -11.71 [-34.85, 13.45] Thompson 2003 8 89 (11.3137) 8 88 (14.1421) 43.6 % 100 0 % -3.62 [-11.91, 4.67] Subtratel (95% CI) 47 47 100.0 % -3.62 [-11.91, 4.67] 100.0 % -3.62 [-11.91, 4.67] The for overall effect: Z = 0.86 (P = 0.39) 5 34.9 6 hours 167 % 5.79 [-3405, 22.47] O'Fallon 2012 15 36.15 (17.14) 15 44.25 (2001) 75.2 % -8.10 [-21.43, 22.3] Theodorou 2011 14 186 (27.15) 14 186.29 (37.11) 100.0 % -4.65 [-16.21, 6.92] Subtratel (95% CI) 49 47 100.0 % -4.65 [-16.21, 6.92] 11.41 Theodorou 2011 14 196.71 (33.8) 14 201.86 (41.86) 22.1 % -5.15 [-33.33, 23.03] Subtratel (95% CI) 29 29 100.0 % 58.00 [13.57, 102.43] 100.0 % 58.00 [13.57, 102.43] Tech coveral effect: Z = 0.87 (P = 0.08) 20 38 278 (73) 100.0 % 58.00 [13.57, 102.43] 100.0 % 58.00 [13.57, 102.43]	McLeay 2012 (6)	10	168.52 (26.77)	10	164.93 (40.52)	-	7.6 %	3.59 [-26.51, 33.69]
Thompson 2003 8 89 (11.3137) 8 88 (14.1421) 43.6 % 1.00 [-11.55, 1355] Subtotal (95% CI) 47 47 100.0 % -3.62 [-11.91, 4.67] Heterogeneity: Chill = 156, df = 3 (P = 0.67); P = 0.06; 18 298 (57) 80 % 3000 [-10.76, 70.76] Subtotal (95% CI) 20 328 (71) 18 298 (57) 80 % 3000 [-10.76, 70.76] O'Falen 2012 15 36.15 (17.14) 15 44.25 (20.01) 75.2 % -8.10 [-21.43, 52.3] Theodorou 2011 14 180.5 (37.15) 14 186.29 (39.11) 16.7 % -5.79 [-34.05, 22.47] Subtotal (95% CI) 49 47 100.0 % -4.65 [-1.6.21, 6.92] 11.400.0 % -4.65 [-1.6.21, 6.92] Theodorou 2011 14 196.71 (32.8) 14 201.86 (41.86) 77.9 % -6.10 [-21.12, 892] Theodorou 2012 15 399.6 (16.6) 15 46.06 (24.6) 77.9 % -6.10 [-21.12, 892] Theodorou 2016 19 20 30.6 (61.86) 29 100.0 % 58.00 [13.57, 102.43] Heterogeneity: Chill 0.0 3.6 (66) 18 278 (73	O'Fallon 2012	15	33.26 (13.85)	15	41.31 (22.68)	-	38.0 %	-8.05 [-21.50, 5.40]
Subtrail (95% CI) 47 47 Heterogeneity: Ch ² = 1.56, df = 3 (P = 0.57); F = 0.0% 100.0 % -3.62 [-11.91, 4.67] Baley 2011 (7) 20 328 (71) 18 298 (57) 8.0 % 3000 [-10.76, 70.76] O'Fallen 2012 15 36.15 (17.14) 15 44.25 (2001) 75.2 % -8.10 [-21.43, 52.3] Theodorou 2011 14 1805 (37.15) 14 186.29 (39.11) 16.7 % -5.79 [-3405, 22.47] Subtroat (95% CI) 49 47 100.0 % -4.65 [-16.21, 6.92] -4.65 [-16.21, 6.92] Subtroat (95% CI) 49 47 100.0 % -4.65 [-16.21, 6.92] -4.65 [-16.21, 6.92] Subtroat (95% CI) 29 47 100.0 % -5.89 [-19.14, 7.36] Theodorou 2011 14 196.71 (33.8) 14 20.186 (41.86) 22.1 % -5.15 [-33.33, 23.03] Subtroat (95% CI) 20 336 (66) 18 278 (73) 100.0 % 58.00 [13.57, 102.43]	Theodorou 2011	14	64.29 (29.11)	14	176 (38.15)		10.9 %	- .7 [-36.85, 3.43]
teterogenety: Ch ² = 1.56, df = 3 (P = 0.67); P = 0.0% tet for overall effect: Z = 0.86 (P = 0.39) i at 96 hours Bailey 2011 (7) 20 328 (71) 18 298 (57) 80 % 3000 [-10.76, 70.76] O'Fallon 2012 15 36.15 (17.14) 15 44.25 (20.01) 75.2 % -8.10 [-2.143, 52.3] Theodorou 2011 14 1805 (37.15) 14 186.29 (39.11) 16.7 % -5.79 [-34.05, 22.47] Heterogenety: Ch ² = 3.04, df = 2 (P = 0.22); P = 34% Test for overall effect: Z = 0.79 (P = 0.43) i 1 20 hours O'Fallon 2012 15 39.96 (16.6) 15 46.06 (24.6) 77.9 % -6.10 [-2.1.12, 89.2] Theodorou 2011 14 196.71 (33.8) 14 201.86 (41.86) 22.1 % -5.15 [-33.33, 23.03] Nubtotal (95% CI) 29 29 Heterogenety: Ch ² = 0.00, df = 1 (P = 0.95); P = 0.0% Test for overall effect: Z = 0.87 (P = 0.38) 'at 168 hours Bailey 2011 (8) 20 336 (66) 18 278 (73) -0 100 0 % 58.00 [13.57, 102.43] Heterogenety: not applicable Test for overall effect: Z = 2.56 (P = 0.011) -200 -100 0 100 200 Faours pittedor Faours pittedor (1) Extension (3) 12 hrs post (4) Extension (3) 12 hrs post (4) Extension (5) 36 hours post. (6) 60 hrs post. (7) Extension	Thompson 2003	8	89 (11.3137)	8	88 (14.1421)	+	43.6 %	1.00 [-11.55, 13.55]
Test Groverall effect: Z = 0.86 (P = 0.39) Bailey 2011 (7) 20 328 (71) 18 298 (57) 80.% 30.00 [-10.76, 70.76] O'Fallon 2012 15 36.15 (17.14) 15 44.25 (2001) 75.2 % 8.10 [-2.143, 523] Theodorou 2011 14 180.5 (37.15) 14 186.29 (39.11) 16.7 % -5.79 [-3.405, 22.47] Subtrati (95% C1) 49 47 Heterogeneity: Ch ² = 3.04, df = 2 (P = 0.22); P = 34% Test for overall effect: Z = 0.79 (P = 0.43) 6 at 120 hours O'Fallon 2012 15 39.96 (16.6) 15 46.06 (24.6) 77.9 % -6.10 [-2.1.2, 89.2] Theodorou 2011 14 196.71 (33.8) 14 201.86 (41.86) 22.1 % -5.15 [-3.33, 23.03] Subtrati (95% C1) 29 29 Heterogeneity: Ch ² = 0.00, df = 1 (P = 0.95); P = 0.0% Test for overall effect: Z = 0.27 (P = 0.38) Tat 1.68 hours Bailey 2011 (8) 20 33.6 (6.6) 18 278 (73) Subtrati (95% C1) 20 18 Heterogeneity: not applicable Test for overall effect: Z = 2.56 (P = 0.011) -2.00 -100 0 100 200 Facuurs placebo (1) Extension (2) Extension (3) 12 hrs post (4) Extension (5) 36 hours post (6) 60 hrs post (7) Extension	Subtotal (95% CI)	47		47		•	100.0 %	-3.62 [-11.91, 4.67]
Crallon 2012 15 36.15 (17.14) 15 44.25 (2001) 752 % -8.10 [-21.43, 523] Theodorou 2011 14 1805 (37.15) 14 186.29 (39.11) 167 % -5.79 [-34.05, 22.47] Subtoal (95% CI) 49 47 100.0 % -4.65 [-16.21, 6.92] 167 % -5.79 [-34.05, 22.47] Subtoal (95% CI) 49 47 100.0 % -4.65 [-16.21, 6.92] 100.0 % -4.65 [-16.21, 6.92] Theodorou 2011 14 196.71 (33.8) 14 201.86 (41.86) 77.9 % -6.10 [-21.12, 892] Theodorou 2011 14 196.71 (33.8) 14 201.86 (41.86) 77.9 % -6.10 [-21.12, 892] Subtoal (95% CI) 29 29 100.0 % -5.89 [-19.14, 7.36] 100.0 % -5.89 [-19.14, 7.36] Tet for overall effect Z = 0.87 (P = 0.38) 7 100.0 % 58.00 [13.57, 102.43] - Subtoal (95% CI) 20 18 200 -100 0 100.0 % 58.00 [13.57, 102.43] Heterogeneity: not applicable - - - 100.0 % 58.00 [13.57, 102.43] (1) Extension (2) 12 hrs post (4) 5	Test for overall effect: Z =							
Theodorou 2011 14 180.5 (37.15) 14 186.29 (39.11) 16.7 % -5.79 [-34.05, 22.47] Subtoal (95% CI) 49 47 100.0 % -4.65 [-16.21, 6.92] Heterogeneity: Ch ² = 3.04, df = 2 (P = 0.22); P = 0.43) 54 120 hours 07alon 2012 15 39.96 (16.6) 15 46.06 (24.6) 77.9 % -6.10 [-21.12, 89.2] Theodorou 2011 14 196.71 (33.8) 14 20.186 (41.86) 22.1 % -5.15 [-33.33, 23.03] Subtoal (95% CI) 29 29 100.0 % -5.89 [-19.14, 7.36] Heterogeneity: Ch ² = 0.07 (P = 0.38) 7 100.0 % 58.00 [13.57, 102.43] 7 at 168 hours 7 100.0 % 58.00 [13.57, 102.43] Subtoal (95% CI) 20 18 100.0 % 58.00 [13.57, 102.43] -terogeneity: not applicable 7 7 * 100.0 % 58.00 [13.57, 102.43] -terogeneity: not applicable 7 7 * 100.0 % 58.00 [13.57, 102.43] -terogeneity: not applicable 7 * 100.0 % 58.00 [13.57, 102.43] * -terogeneity: not applicable * <td< td=""><td>Bailey 2011 (7)</td><td>20</td><td>328 (71)</td><td>18</td><td>298 (57)</td><td></td><td>8.0 %</td><td>30.00 [-10.76, 70.76]</td></td<>	Bailey 2011 (7)	20	328 (71)	18	298 (57)		8.0 %	30.00 [-10.76, 70.76]
Subtoral (95% CI) 49 47 Heterogeneity: Chi ² = 304, df = 2 (P = 0.22); l ² = 34% 100.0 % -4.65 [-16.21, 6.92] Fettorogeneity: Chi ² = 304, df = 2 (P = 0.22); l ² = 34% 100.0 % -4.65 [-16.21, 6.92] O'Talion 2012 15 39.96 (16.6) 15 46.06 (24.6) 77.9 % -6.10 [-2.1.2, 8.92] Theodorou 2011 14 196.71 (33.8) 14 201.86 (41.86) 22.1 % -5.15 [-333.3, 23.03] Subtoral (95% CI) 29 29 100.0 % -5.89 [-19.14, 7.36] Heterogeneity: Chi ² = 0.00; df = 1 (P = 0.95); l ² = 0.0% 18 278 (73) 100.0 % 58.00 [13.57, 102.43] Subtoral (95% CI) 20 18 278 (73) 100.0 % 58.00 [13.57, 102.43] Subtoral (95% CI) 20 18 100.0 % 58.00 [13.57, 102.43] Heterogeneity: not applicable 100.0 % 58.00 [13.57, 102.43] 100.0 % 58.00 [13.57, 102.43] -200 -100 100 200 Favours placebo Favours antioodarts (1) Extension (2) 24 historation (3) 24 historation (5) 36 hours post (6) 60 hist post (7) Extension	O'Fallon 2012	15	36.15 (17.14)	15	44.25 (20.01)	-	75.2 %	-8.10 [-21.43, 5.23]
Heterogeneity: $Ch^2 = 3.04$, $df = 2 (P = 0.22)$; $l^2 = 34\%$ Test for overall effect: $Z = 0.79 (P = 0.43)$ Sat 120 hours O'Fallon 2012 15 39.96 (16.6) 15 46.06 (24.6) T7.9 % -6.10 [-2.1.12, 82.92] Theodorou 2011 14 196.71 (33.8) 14 201.86 (41.86) Subtocal (95% CI) 29 29 Heterogeneity: $Ch^2 = 0.00$, $df = 1 (P = 0.95)$; $l^2 = 0.0\%$ Test for overall effect: $Z = 0.87 (P = 0.38)$ 7 at 168 hours Bailey 2011 (8) 20 336 (66) 18 278 (73) Subtocal (95% CI) 20 18 Heterogeneity: not applicable Test or overall effect: $Z = 2.56 (P = 0.011)$ Favours placebo (1) Extension (2) Extension (3) 12 hrs post (4) Extension (5) 36 hours post (6) 60 hrs post (7) Extension	Theodorou 2011	14	180.5 (37.15)	14	186.29 (39.11)		16.7 %	-5.79 [-34.05, 22.47]
S at 120 hours O'Fallon 2012 15 39.96 (16.6) 15 46.06 (24.6) Theodorou 2011 14 196.71 (33.8) 14 201.86 (41.86) 22.1 % -5.15 [-33.33, 23.03] Subtotal (95% CI) 29 29 100.0 % -5.89 [-19.14, 7.36] Heterogeneity: Chi ² = 0.087 (P = 0.38) 7at 168 hours Bailey 2011 (8) 20 336 (66) 18 278 (73) Subtotal (95% CI) 20 18 Heterogeneity: not applicable Test for overall effect: Z = 2.56 (P = 0.011) -200 -100 0 100 200 Favours placebo Favours antioxidants (1) Extension (2) Extension (3) 12 hrs post (4) Extension (5) 36 hours post (6) 60 hrs post (7) Extension	Heterogeneity: $Chi^2 = 3.0$)4, df = 2 (P =		47		•	100.0 %	-4.65 [-16.21, 6.92]
Theodorou 2011 14 196.71 (33.8) 14 201.86 (41.86) 22.1 % -5.15 [-33.33, 23.03] Subtocal (95% CI) 29 29 100.0 % -5.89 [-19.14, 7.36] Heterogeneity: Chi ² = 0.00, df = 1 (P = 0.95); l ² = 0.0% 7a1 (8 hours 100.0 % -5.89 [-19.14, 7.36] Tai 168 hours 3ailey 2011 (8) 20 336 (66) 18 278 (73) 100.0 % 58.00 [13.57, 102.43] Subtocal (95% CI) 20 18 100.0 % 58.00 [13.57, 102.43] 100.0 % 58.00 [13.57, 102.43] Veterogeneity: not applicable Test for overall effect: Z = 2.56 (P = 0.011) 100 200 Favours placebo Favours antioxidants (1) Extension (2) Extension (3) 12 hrs post 100.0 % 58.00 [13.57, 102.43] 100.0 % 58.00 [13.57, 102.43] (6) 60 hrs post (7) Extension (7) Extensio	6 at 120 hours	,	3)					
Subtocal (95% CI) 29 29 Heterogeneity: Chi ² = 0.00, df = 1 (P = 0.95); l ² = 0.0% Test for overall effect: Z = 0.87 (P = 0.38) 7 at 168 hours Bailey 2011 (8) 20 336 (66) 18 Peterogeneity: not applicable Test for overall effect: Z = 2.56 (P = 0.011) -200 -100 -200 -100 -200 -100 -200 -100 Ferrors antioxidants (1) Extension -200 (2) Extension -312 (3) 12 hrs post -40 (4) Extension -536 (P = 0.01 - 0.00) (5) 36 hours post -60 + 0.00 (6) 60 hrs post -70 + 0.00 (7) Extension -70 + 0.00		15	. ,	15				-6.10 [-21.12, 8.92]
Heterogeneity: Ch ² = 0.00, df = 1 (P = 0.95); l ² = 0.0%. Test for overall effect: Z = 0.87 (P = 0.38) 7 at 168 hours Bailey 2011 (8) 20 336 (66) 18 278 (73) Subtotal (95% CI) 20 18 Heterogeneity: not applicable Test for overall effect: Z = 2.56 (P = 0.011) -200 -100 0 100 200 Favours placebo Favours placebo Favours antioxidants (1) Extension (2) Extension (3) 12 hrs post (4) Extension (5) 36 hours post (6) 60 hrs post (7) Extension	Theodorou 2011	14	196.71 (33.8)	14	201.86 (41.86)		22.1 %	-5.15 [-33.33, 23.03]
Heterogeneity: not applicable Test for overall effect: Z = 2.56 (P = 0.011) -200 -100 0 100 200 Favours placebo Favours antioxidants (1) Extension (2) Extension (3) 12 hrs post (4) Extension (5) 36 hours post (5) 36 hours post (6) 60 hrs post (7) Extension	Test for overall effect: Z = 7 at 168 hours	= 0.87 (P = 0.3	8)	18	278 (73)	-#-	100.0 %	58.00 [13.57, 102.43]
Heterogeneity: not applicable Test for overall effect: Z = 2.56 (P = 0.011) -200 -100 0 100 200 Favours placebo Favours antioxidants (1) Extension (2) Extension (3) 12 hrs post (4) Extension (5) 36 hours post (5) 36 hours post (6) 60 hrs post (7) Extension	, , ,		336 (66)		278 (73)			
 (1) Extension (2) Extension (3) 12 hrs post (4) Extension (5) 36 hours post (6) 60 hrs post (7) Extension 	Heterogeneity: not applica	able)				200	50.00 [15.57, 102.15]
(3) 12 hrs post (4) Extension (5) 36 hours post (6) 60 hrs post (7) Extension	(1) Extension				Favo	purs placebo Favours an	tioxidants	
(4) Extension (5) 36 hours post (6) 60 hrs post (7) Extension	(2) Extension							
(4) Extension (5) 36 hours post (6) 60 hrs post (7) Extension	(3) 12 hrs post							
(5) 36 hours post (6) 60 hrs post (7) Extension								
(6) 60 hrs post (7) Extension	. ,							
(7) Extension	.,							
	., .							
	(8) Extension							

Analysis 1.25. Comparison I Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies), Outcome 25 Maximal voluntary isometric contraction measured in Newtons.

Review: Antioxidants for preventing and reducing muscle soreness after exercise

Comparison: I Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies)

Outcome: 25 Maximal voluntary isometric contraction measured in Newtons

Study or subgroup A	ntioxidant N	Mean(SD)	Placebo N	Mean(SD)	Mean Difference IV,Fixed,95% Cl	Weight	Mean Difference IV,Fixed,95% CI
I Up to 6 hours							
Avery 2003 (1)	9	1750 (450)	9	1853 (600)		1.6 %	-103.00 [-592.99, 386.99]
Bloomer 2005 (2)	10	510 (126.4911)	10	660 (252.9822)		12.3 %	-150.00 [-325.30, 25.30]
Bloomer 2007	7	772 (253.9921)	8	775 (195.1615)	_	7.1 %	-3.00 [-234.72, 228.72]
Howatson 2009	10	310 (88)	10	276 (69)	=	79.0 %	34.00 [-35.31, 103.31]
Subtotal (95% CI)	36		37		+	100.0 %	6.50 [-55.11, 68.10]
Heterogeneity: $Chi^2 = 3.86$,	df = 3 (P =	= 0.28); I ² =22%					
Test for overall effect: $Z = 0$.	21 (P = 0.8	34)					
2 at 24 hours Bell 2015	8	632.67 (86.65)	8	657.2 (98.95)	-	25.7 %	-24.53 [-115.67, 66.61]
		× /			_	23.7 %	
Bell 2016	8	601 (126.26)	8	553 (60.22)	Γ		48.00 [-48.93, 144.93]
Bloomer 2005 (3)	10	450 (205.548)	10	615 (189.7367)		7.1 %	-165.00 [-338.38, 8.38]
Bloomer 2007	7	996 (232.8261)	8	971 (130.1076)		5.6 %	25.00 [-169.62, 219.62]
Howatson 2009	10	387 (94)	10	313 (74)	-	38.8 %	74.00 [-0.15, 148.15]
Subtotal (95% CI)	43		44		•	100.0 %	23.03 [-23.18, 69.24]
Heterogeneity: $Chi^2 = 7.63$, Test for overall effect: $Z = 0$.		,					
3 at 48 hours							
Bell 2015	8	620.67 (118.07)	8	635.2 (85.58)	-	27.2 %	-14.53 [-115.58, 86.52]
Bell 2016	8	638 (136.46)	8	584 (58.65)		26.2 %	54.00 [-48.92, 156.92]
Bloomer 2005 (4)	10	480 (189.7367)	10	605 (221.3594)		8.5 %	-125.00 [-305.70, 55.70]
Bloomer 2007	7	1039 (325.4274)	8	889 (164.0488)		3.9 %	50.00 [- 6.53, 4 6.53]
Howatson 2009	10	435 (109)	10	349 (96)	-	34.2 %	86.00 [-4.02, 176.02]
Subtotal (95% CI)	43		44		•	100.0 %	34.87 [-17.80, 87.55]
Heterogeneity: $Chi^2 = 6.01$,	df = 4 (P =	= 0.20); I ² =33%					
Test for overall effect: $Z = 1$.	30 (P = 0.1	9)					
4 at 72 hours	0		0			(7 0/	
Avery 2003 (5)	9	1550 (150)	9	1750 (375)	-	6.7 %	-200.00 [-463.87, 63.87]

(Continued . . .)

Study or subgroup	Antioxidant N	Mean(SD)	Placebo N	Mean(SD)	Mean Difference IV,Fixed,95% CI	Weight	(Continued) Mean Difference IV,Fixed,95% Cl
Bell 2015	8	665.22 (137.91)	8	641 (87.86)	-	36.3 %	24.22 [-89.09, 137.53]
Bell 2016	8	641 (137.85)	8	610 (55.17)	-	44.1 %	31.00 [-71.89, 133.89]
Bloomer 2005 (6)	10	545 (252.9822)	10	655 (173.9253)		12.9 %	-110.00 [-300.28, 80.28]
Subtotal (95% CI)	35		35		+	100.0 %	-5.11 [-73.42, 63.19]
Heterogeneity: Chi ² = 3. Test for overall effect: Z 5 at 96 hours Bloomer 2005 (7)	= 0.15 (P = 0.8	,	10	652 (189.7367)	-	100.0 %	-112.00 [-265.08, 41.08]
Subtotal (95% CI) Heterogeneity: not applie Test for overall effect: Z	able	. ,	10		•		-112.00 [-265.08, 41.08]
6 at 168 hours Avery 2003 (8)	9	1600 (150)	9	1825 (450)		100.0 %	-225.00 [-534.90, 84.90]
Subtotal (95% CI) Heterogeneity: not applie Test for overall effect: Z	cable	5)	9		-	100.0 %	-225.00 [-534.90, 84.90]
					00 -500 0 500 ours placebo Favours a	1000 ntioxidants	
(I) Isometric squat							
(2) Muscle isometric for	rce						
(3) Muscle isometric for	rce						

(4) Muscle isometric force

(5) Isometric squat

(6) Muscle isometric force

(7) Muscle isometric force

(8) Isometric squat

Analysis 1.26. Comparison I Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies), Outcome 26 Maximal voluntary isometric contraction measured in Newton metres per kg of body mass.

Review: Antioxidants for preventing and reducing muscle soreness after exercise

Comparison: I Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies)

Outcome: 26 Maximal voluntary isometric contraction measured in Newton metres per kg of body mass

Study or subgroup	Antioxidant		Placebo		Mean Difference	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Fixed,95% CI	IV,Fixed,95% CI
l Up to 6 hours Kerksick 2009 (1)	10	2.01 (0.4237)	5	1.98 (0.6325)		0.03 [-0.58, 0.64]
Kerksick 2009 (2)	10	2.4 (0.6641)	5	1.98 (0.6325)		0.42 [-0.27, 1.11]
		. ,		. ,		
Michailidis 2013 (3)	10	1.9 (0.1)	10	1.75 (0.1)		0.15 [0.06, 0.24]
2 at 24 hours Kerksick 2009 (4)	10	2.14 (0.6325)	5	2 (0.5376)		0.14 [-0.47, 0.75]
Kerksick 2009 (5)	10	1.98 (0.3162)	5	2 (0.5376)		-0.02 [-0.53, 0.49]
Michailidis 2013	10	1.85 (0.1)	10	1.4 (0.1)		0.45 [0.36, 0.54]
3 at 48 hours						
Kerksick 2009 (6)	10	1.98 (0.4111)	5	2.14 (0.6325)		-0.16 [-0.77, 0.45]
Kerksick 2009 (7)	10	2.24 (0.6325)	5	2.14 (0.6325)		0.10 [-0.58, 0.78]
Michailidis 2013	10	1.6 (0.1)	10	1.2 (0.05)		0.40 [0.33, 0.47]
4 at 72 hours						
Kerksick 2009 (8)	10	2.48 (0.6325)	5	2.28 (0.6325)		0.20 [-0.48, 0.88]
Kerksick 2009 (9)	10	2.24 (0.4111)	5	2.28 (0.6325)		-0.04 [-0.65, 0.57]
Michailidis 2013	10	1.8 (0.1)	10	1.5 (0.1)		0.30 [0.21, 0.39]
5 at 96 hours Michailidis 2013	10	1.95 (0.15)	10	1.75 (0.05)	-	0.20 [0.10, 0.30]
6 at 120 hours Michailidis 2013	10	2.15 (0.15)	10	2.1 (0.1)		0.05 [-0.06, 0.16]
7 at 144 hours Michailidis 2013	10	2.35 (0.2)	10	2.45 (0.1)		-0.10 [-0.24, 0.04]
8 at 168 hours Michailidis 2013	10	2.5 (0.2)	10	2.7 (0.2)		-0.20 [-0.38, -0.02]
					-1 -0.5 0 0.5 I Favours placebo Favours antic	

Antioxidants for preventing and reducing muscle soreness after exercise (Review)

Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

(1) EGCG vs placebo (only half group shown here)

(2) NAC vs placebo (only half group shown here)

(3) 2 hrs post

(4) NAC vs placebo (only half group shown here)

(5) EGCG vs placebo (only half group shown here)

(6) EGCG vs placebo (only half group shown here)

(7) NAC vs placebo (only half group shown here)

(8) NAC vs placebo (only half group shown here)

(9) EGCG (only half group shown here)

Analysis 1.27. Comparison I Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies), Outcome 27 Maximal voluntary isometric contraction measured in kg.

Review: Antioxidants for preventing and reducing muscle soreness after exercise

Comparison: I Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies)

Outcome: 27 Maximal voluntary isometric contraction measured in kg

Study or subgroup	Antioxidant		Placebo		Std. Mean Difference	Std. Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Fixed,95% CI	IV,Fixed,95% CI
l at 24 hours O'Connor 2013	20	6.3 (2.7)	20	5.7 (2.3)		0.23 [-0.39, 0.86]
2 at 48 hours O'Connor 2013	20	6.7 (3)	20	6.2 (2.5)		0.18 [-0.44, 0.80]
					-4 -2 0 2 4 Favours placebo Favours antioxidan	ts

Analysis 1.28. Comparison I Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies), Outcome 28 Range of motion (all follow-up times).

Review: Antioxidants for preventing and reducing muscle soreness after exercise

Comparison: I Antioxidant supplementation vs. placebo for delayed onset muscle soreness (all studies)

Outcome: 28 Range of motion (all follow-up times)

Study or subgroup An	ntioxidants N	Mean(SD)	Placebo N	Mean(SD)	Mean Difference IV,Fixed,95% Cl	Weight	Mean Difference IV,Fixed,95% CI
I Up to 6 hours							
Bailey 2011 (1)	20	106 (8)	18	106 (6)		46.9 %	0.0 [-4.47, 4.47]
Bloomer 2004 (2)	9	76.69 (7.5)	9	83.15 (11.7)		11.4 %	-6.46 [-15.54, 2.62]
Bryer 2006 (3)	10	8 (0.75 7)	8	116.7 (9.3338)		10.9 %	1.30 [-7.99, 10.59]
Goldfarb 2011 (4)	21	117 (46.284)	20	2 (28.1745)		- 1.7 %	-4.00 [-27.33, 19.33]
Meamarbashi 2011 (5)	10	129 (5)	10	128.7 (9.7)		20.5 %	0.30 [-6.46, 7.06]
Tanabe 2015	14	6 (4)	14	2 (4)		8.7 %	4.00 [-6.37, 14.37]
Subtotal (95% CI) Heterogeneity: Chi ² = 2.69, df = Test for overall effect: Z = 0.16 (1 2 at 24 hours		5); I ² =0.0%	79		•	100.0 %	-0.25 [-3.31, 2.81]
Bailey 2011 (6)	20	106 (10)	18	105 (10)		9.2 %	1.00 [-5.37, 7.37]
Bloomer 2004 (7)	9	86.22 (16.8)	9	82.3 (20.1)		→ I.3 %	3.92 [-13.19, 21.03]
Bryer 2006 (8)	10	0 (.3842)	8	103.3 (8.7681)		4.3 %	6.70 [-2.61, 16.01]
Connolly 2006a (9)	4	-4.29 (4.3029)	4	-4.78 (6.1737)		24.0 %	0.49 [-3.45, 4.43]
Goldfarb 2011 (10)	21	3 (39.8684)	20	113 (40.6964)		→ 0.6 %	0.0 [-24.68, 24.68]
Meamarbashi 2011 (11)	10	127.3 (5.4)	10	122.4 (10.6)		6.9 %	4.90 [-2.47, 2.27]
O'Connor 2013 (12)	20	114 (9)	20	118 (9)		12.0 %	-4.00 [-9.58, 1.58]
Tanabe 2015	4	7 (2)	4	3 (0)		5.6 %	4.00 [-4.18, 12.18]
Theodorou 2011 (13)	14	117.7 (2.49)	14	116.6 (5.61)		36.1 %	1.10 [-2.12, 4.32]
Subtotal (95% CI) Heterogeneity: Chi ² = 6.30, df = Test for overall effect: Z = 1.04 (I); ² =0.0%	127		•	100.0 %	1.03 [-0.91, 2.96]
3 at 48 hours Bailey 2011 (14)	20	105 (11)	18	106 (10)		12.1 %	-1.00 [-7.68, 5.68]
	20		9	77.87 (16.8)		→ 2.7 %	12.68 [-1.40, 26.76]
Bloomer 2004 (15)	9	90.55 (13.5)					

Favours placebo

Favours antioxidants

(Continued ...)

		Mean					
Mean Difference	Weight	Difference		Placebo		Antioxidants	Study or subgroup
IV,Fixed,95% C		IV,Fixed,95% CI	Mean(SD)	Ν	Mean(SD)	Ν	
1.32 [-3.73, 6.37]	21.2 %		-6.27 (6.1737)	4	-4.95 (7.4085)	14	Connolly 2006a (17)
1.00 [-21.74, 23.74]	1.0 %		5 (32.1994) 🔶	20	116 (41.7014)	21	Goldfarb 2011 (18)
7.70 [1.01, 14.39]	12.1 %		123.1 (8.9)	10	30.8 (6.1)	10	Meamarbashi 2011 (19)
-6.00 [-11.96, -0.04]	15.2 %		121 (8)	20	5 ()	20	O'Connor 2013 (20)
4.00 [-4.59, 12.59]	7.3 %		4 (0)	14	118 (13)	14	Tanabe 2015
3.30 [-2.27, 8.87]	17.4 %		108.6 (8.86)	4	.9 (5.88)	14	Theodorou 2011 (21)
2.71 [0.39, 5.04]	100.0 %	•		127		132	Subtotal (95% CI)
					01); I ² =61%		Heterogeneity: Chi ² = 20.6: Test for overall effect: Z = 2 4 at 72 hours
10.20 [0.08, 20.32]	8.5 %		80.84 (12.6)	9	91.04 (9)	9	Bloomer 2004 (22)
8.00 [-0.18, 16.18]	13.0 %		109 (8.2024)	8	117 (9.4868)	10	Bryer 2006 (23)
0.66 [-3.73, 5.05]	45.0 %		-5.11 (4.939)	14	-4.45 (6.7724)	14	Connolly 2006a (24)
5.00 [-18.19, 28.19]	1.6 %		117 (39.802)	20	122 (35.7441)	21	Goldfarb 2011 (25)
-3.30 [-25.03, 18.43]	1.8 %		159.3 (31.3) 🗕	19	156 (33.8)	16	Phillips 2003 (26)
5.00 [-4.74, 14.74]	9.1 %		114 (15)	14	9()	14	Tanabe 2015 (27)
1.20 [-5.23, 7.63]	21.0 %		107.9 (8.09)	14	109.1 (9.24)	14	Theodorou 2011 (28)
2.93 [-0.02, 5.87]	100.0 %	•		98		98	Subtotal (95% CI)
						.95 (P = 0.051)	Heterogeneity: $Chi^2 = 5.28$, Test for overall effect: $Z = 1$ 5 at 96 hours
0.0 [-3.53, 3.53]	33.6 %		102 (6)	18	102 (5)	20	Bailey 2011 (29)
0.0 [-3.33, 3.35]	5.3 %		87.57 (9.6)	9	92.08 (9.6)	9	Bloomer 2004 (30)
4.51 [-4.36, 13.38]					110 (((400)	10	Bryer 2006 (31)
4.5 [-4.36, 3.38]	13.6 %		116 (5.374)	8	119 (6.6408)	10	
4.51 [-4.36, 13.38] 3.00 [-2.55, 8.55]	13.6 % 27.0 %		116 (5.374) -2.47 (4.3029)	8	-1.81 (6.1737)	10	Connolly 2006a (32)
4.51 [-4.36, 13.38] 3.00 [-2.55, 8.55] 0.66 [-3.28, 4.60]		 			. ,		, , ,
4.51 [-4.36, 13.38] 3.00 [-2.55, 8.55] 0.66 [-3.28, 4.60] 6.00 [-2.15, 14.15]	27.0 %	 	-2.47 (4.3029)	14	-1.81 (6.1737)	14	Connolly 2006a (32)
4.51 [-4.36, 13.38] 3.00 [-2.55, 8.55] 0.66 [-3.28, 4.60] 6.00 [-2.15, 14.15] -2.90 [-8.32, 2.52]	27.0 % 6.3 % 14.2 %	 	-2.47 (4.3029)	4 4	-1.81 (6.1737) 122 (11) 112.7 (7.22)	4 4 4 81 df = 5 (P = 0.4	Connolly 2006a (32) Tanabe 2015 (33)
	27.0 % 6.3 % 14.2 %		-2.47 (4.3029)	14 14 14	-1.81 (6.1737) 122 (11) 112.7 (7.22)	4 4 4 81 df = 5 (P = 0.4	Connolly 2006a (32) Tanabe 2015 (33) Theodorou 2011 (34) Subtotal (95% CI) Heterogeneity: Chi ² = 4.83, Test for overall effect: Z = C
4.51 [-4.36, 13.38] 3.00 [-2.55, 8.55] 0.66 [-3.28, 4.60] 6.00 [-2.15, 14.15] -2.90 [-8.32, 2.52] 0.79 [-1.26, 2.84]	27.0 % 6.3 % 14.2 % 100.0 %	 •	-2.47 (4.3029) 116 (11) 115.6 (7.42)	14 14 14 77	-1.81 (6.1737) 122 (11) 112.7 (7.22) 4); 1 ² =0.0%	4 4 4 df = 5 (P = 0.4 .76 (P = 0.45)	Connolly 2006a (32) Tanabe 2015 (33) Theodorou 2011 (34) Subtotal (95% CI) Heterogeneity: Chi ² = 4.83, Test for overall effect: Z = C 6 at 120 hours

(Continued . . .)

Antioxidants for preventing and reducing muscle soreness after exercise (Review) Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

179

(... Continued)

(... Continued)

Study or subgroup	Antioxidants		Placebo		Diff	Mean erence	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Fixe	ed,95% Cl		IV,Fixed,95% CI
Test for overall effect: $Z = C$	0.31 (P = 0.75)							
7 at 168 hours								
Bailey 2011 (37)	20	108 (4)	18	103 (3)			100.0 %	5.00 [2.77, 7.23]
Subtotal (95% CI) Heterogeneity: not applicab	20		18			•	100.0 %	5.00 [2.77, 7.23]
Test for overall effect: $Z = 4$.)						
	х.	,		1			1	
				-20	-10	0 10	20	
				Favoi	urs placebo	Favours an	itioxidants	

(1) knee extensors and flexors

- (2) elbow flexors
- (3) elbow flexors
- (4) elbow flexors
- (5) knee flexion
- (6) knee extensors and flexors
- (7) elbow flexors
- (8) elbow flexors
- (9) relaxed elbow angle
- (10) elbow flexors
- (11) knee flexion
- (12) elbow flexors
- (13) knee flexion
- (14) knee extensors and flexors
- (15) elbow flexors
- (16) elbow flexors
- (17) relaxed elbow angle
- (18) elbow flexors
- (19) knee flexion
- (20) elbow flexors
- (21) knee flexion
- (22) elbow flexors
- (23) elbow flexors
- (24) relaxed elbow angle
- (25) elbow flexors
- (26) Active arm flexion
- (27) elbow flexors
- (28) knee flexion
- (29) knee extensors and flexors
- (30) elbow flexors
- (31) elbow flexors
- (32) relaxed elbow angle
- (33) elbow flexors
- (34) knee flexion

(35) Active arm flexion

ADDITIONAL TABLES

Table 1. Antioxidant supplements tested in the included trials

Study ID	Antiox- idant (type: Ex; Vit; Whole)*	Dose**	Form taken	Regimen	Started: before exercise	Duration
Arent 2010	Ex: black tea ex- tract; theaflavin	700 mg/day	Capsule	4 capsules daily	9 days	11 days
Avery 2003	Vit: vitamin E	992 mg (1200 IU)/day	Capsule	Not known (daily)	21 days	31 days
Bailey 2011	plement: vi-	400 mg vitamin C 268 mg vitamin E etc	Capsule	1 capsule daily	42 days	6 weeks
Beaton 2002a	Vit: vitamin E	1200 IU	Capsule	?	30 days	30 days
Bell 2015	Whole: tart cherry	9.2 mg/mL an- thocyanins	Drink	30 mL twice daily	3 days	8 days
Bell 2016	Whole: tart cherry	73.5 mg/L to- tal anthocyanin content	Drink	30 mL twice daily	4 days	7 days
Bloomer 2004	Vit: vitamin C, E and selenium	268 mg vitamin E 1 g vitamin C 90 μg selenium	Capsule	3 capsules daily	14 days	18 days
Bloomer 2005	Ex: astaxanthin	4 mg astaxanthin 480 mg lutein	Capsule	2 capsules daily	21 days	25 days
Bloomer 2007	Vit: vitamin C and E	1000 mg of vita- min C 378 mg vitamin E	Capsule	2 capsules daily	14 days	14 days
Bryer 2006	Vit: vitamin C	3 g/day vitamin C	Capsule	3 capsules daily	14 days	18 days
Close 2006	Vit: vitamin C	1 g/day vitamin C	?	?	0 days (day of ex- ercise)	14 days

Table 1.	Antioxidant	supplements	tested in the	e included trials	(Continued)
----------	-------------	-------------	---------------	-------------------	-------------

Cobley 2011	Ex: N-acetyl-cysteine	50 mg/kg/day	Powder dissolved in water	50 mg/kg/day once daily dissolved in 500 mL water	1 hour	6 days
Connolly 2006	Vit: vitamin C	1 g/day vitamin C	Capsule	3 capsules daily	3 days	8 days
Connolly 2006a	Whole: cherry	600 mg phenolic compounds 40 mg antho- cyanins	Drink	2 x 12 oz bottle daily	4 days	8 days
Drobnic 2014	Ex: curcumin	400 mg/day cur- cumin	Capsule	2 capsules daily	2 days	5 days
Goldfarb 2011	Ex: Juice Plus powder	 7.5 mg beta- carotene 276 mg vitamin C 108 IU of vita- min E 	Capsule	6 capsules daily	4 days	8 days
He 2015	Vit: vitamin C and vitamin E	100 mg of vita- min C 268 mg (400 IU) of vitamin E	Capsule	?	14 days	17 days
Herrlinger 2015	Ex: black and green tea	High-dose = 2000 mg per day polypheno- lic blend Low- dose = 1000 mg per day polyphe- nolic blend	Capsule	4 capsules daily	91 days	91 days
Howatson 2009	Whole: cherry	600 mg phenolic compounds ex- pressed as gallic acid equivalents, 32 g of carbohy- drate and at least 40 mg of antho- cyanins	Drink	2 x 8 fl oz bottles per day	5 days	7 days
Hutchinson 2016	Whole: black- currant nectar	193.25 mg/day of malvidin glu- cosides	Drink	16 oz bottle per day	8 days	8 days

		175.69 mg/day of cyanidin glu- cosides				
Kaminski 1992	Vit: vitamin C	1 g/day vitamin C	Capsule	3 capsules daily	3 days	10 days
Kerksick 2009	Ex: N-acetyl- cysteine and epi- gallocatechin gallate (EGCG)	1800 mg/day N- acetyl-cysteine (NAC) 1800 mg/day epigallo- catechin gallate (EGCG)	Drink	3	14 days	14 days
Krotkiewski 1994	Ex: pollen ex- tract	30,000 units per gram of Polbax	?	?	28 days	28 days
Kuehl 2010	Whole: cherry	600 mg phenolic compounds 40 mg antho- cyanins	Drink	2 x 335 mL bot- tles daily	7 days	15 days
Laupheimer 2014	Ex: resveratrol	600 mg/day of resveratrol	Capsules	6 capsules daily	7 days	9 days
Lynn 2015	Whole: bilberry juice	Total phenol content per 200 mL serving was 744.14 \pm 81.75 mg (n = 3) and 80.04 \pm 3.51 mg (n = 3) of total anthocyanins	Drink	2 x 200 mL daily	5 days	8 days
McBride 1997	Vit: vitamin E	992 mg/day of vitamin E (1200 IU)	Capsules	1 capsule daily	14 days	14 days
McCormick 2016	Whole: cherry	9.117 mg/mL anthocyanins	Drink	90 mL daily (2 x 30 mL)	6 days	6 days
McFarlin 2016	Ex: curcumin	400 mg/day cur- cumin	Capsules	Capsules	2 days	6 days
McLeay 2012	Whole: blue- berry smoothie	Per 100 mL: to- tal phenolics 168 mg/gallic acid equ.; antho-	Drink	200 g blueber- ries, 50 g banana + 200 mL apple juice daily	0 days (day of ex- ercise)	4 days

		cyanins 96.6 mg; phenolic acid 26 mg, flavonoids 10.2 mg; vitamin C 45 mg; vitamin E 3 mg				
Meamarbashi 2011	Ex: purslane ex- tract	1200 mg/day purslane extract	Capsules	2 capsules daily	3 days	5 days
Michailidis 2013	Vit: N-acetyl- cysteine	20 mg/ kg/day N-acetyl- cysteine	Drink	3 x 500 mL drink daily	0 days (day of ex- ercise)	9 days
Nicol 2015	Ex: curcumin	2.5 g/day of cur- cumin	Capsules	10 capsules daily (2 x 5 capsules)	2.5 days	5 days
Nie 2004	Vit: vitamin C	800 mg/day vita- min C	Capsules	?	3 hours	2 days
O'Connor 2013	Whole: grape juice	1.75 mg/kg resveratrol 19.7 mg/kg cate- chin 12.6 mg/kg 31.7 mg/kg pe- onidin 125 mg/kg cyanidin 145.2 mg/kg 32.6 mg/kg quercetin 5.6 mg/kg kaempferol 6.8 mg/kg isorhamnetin	Drink (dissolved powder)	1 serving of pow- der daily mixed with 236 mL of water	45 days	50 days
O'Fallon 2012	Ex: quercetin	1000 mg/day quercetin	Bar	2 bars daily	7 days	7 days
Peschek 2014	Whole: cocoa	350 mg/day fla- vanols	Drink	240 mL daily	0 days (day of ex- ercise)	3 days
Phillips 2003	Ex: mixed an- tioxidants	300 mg/day to- copherols 800 mg/day do- cosahexaenoate 300 mg/	Capsules	Vi- tamin E: 1 cap- sule; docosahex- aenoate: 3 cap- sules; flavonoids:	14 days	14 days

		day flavonoids of which was 100 mg hes- peretin and 200 mg quercetin		3 capsules		
Shafat 2004	Vit: vitamin C + vitamin E	500 mg/day vita- min C 992 mg/ day (1200 IU/ day) vitamin E	Capsules	?	?	37 days
Silva 2008	Ex: N-acetyl- cysteine	10 mg/kg/day of body mass N- acetyl-cysteine	Capsules	1 capsule daily	14 days	21 days
Silva 2010	Vit: vitamin E	536 mg/day (800 IU/ day) vitamin E	Capsules	1 capsule daily	14 days	21 days
Su 2008	Ex: allicin	80 mg/day al- licin	Capsules	Capsules	14 days	16 days
Tanabe 2015	Ex: curcumin	150 mg/day cur- cumin	Capsules	6 capsules daily	0 days (day of ex- ercise; 1 hour be- fore)	1 day
Theodorou 2011	Vit: vitamin C + vitamin E	1 g/day vitamin C 268 mg/ day (1200 IU/ day) vitamin E	Capsules	1 capsule daily	28 days	77 days
Thompson 2001	Vit: vitamin C	1 g/day vitamin C	Drink	?	0 days (day of exercise; 2 hours before)	1 day
Thompson 2001a	Vit: vitamin C	1 g/day of vita- min C on day 1 followed by 400 mg/day divided into 2 doses for 12 days		1 g given in a so- lution followed by 400 mg/day doses in capsules	14 days	14 days
Thompson 2003	Vit: vitamin C	200 mg/day vita- min C	Drink	Daily drink	0 days (day of ex- ercise)	3 days
Thompson 2004	Vit: vitamin C	200 mg/day vita- min C	Drink	Daily drink	14 days	14 days

Trombold 2010	Whole: pomegranate juice	650 mg/ day polyphenols, consisting of 95. 5% ellagitannins, 3. 5% ellagic acid and 1% antho- cyanins	Drink	960 mL per day (as 2 x 480 mL drinks)	9 days	32 days
Trombold 2011	Whole: pomegranate juice	3958 mg/L of tannins 768 mg/L antho- cyanins 242 mg/L of el- lagic derivatives	Drink	500 mL per day (as 2 x 250 mL drinks)	15 days	44 days

* Types: Extract, mixed or other (e.g. amino-acid derivative) antioxidants; Vitamin; and Whole natural food source.

** Every study included in this review used a dose higher than the recommended daily amount.

Study ID	Outcome measure	Score (higher = worse)	Timing post-exercise	Data extraction
Arent 2010	Muscle soreness during a squat	VAS (0 to 10 cm)	24, 48 hours	Text (SDs from SEs)
Avery 2003	Muscle soreness during shoulder abduction, shoulder hori- zontal adduction and hip flexion (unloaded squat)	VAS (0 to 10 cm)	24, 48, 72 hours	Text
Bailey 2011	General soreness at the quadriceps	VAS (1 to 10 cm)	24, 48 hours	Text
Beaton 2002a	General soreness at the quadriceps	VAS (0 to 10 cm)	48 hours	Text
Bell 2015	Muscle soreness during a squat	VAS (0 to 200 mm)	24, 48, 72 hours	Raw data provided by the authors
Bell 2016	Muscle soreness during a squat	VAS (0 to 200 mm)	24, 48, 72 hours	Raw data provided by the authors

Table 2. Details of measurement of muscle soreness in the included trials	Table 2.	2. Details of measurement of muscle soreness in the includ	ed trials
---	----------	--	-----------

Bloomer 2004	Active movement of el- bow flexion or extension, as well as following light palpitation by the investi- gators	VAS (0 to 10 cm)	0, 2, 6, 24, 48, 72, 96 hours	Raw data provided by the authors Immediate pain data used for the up to 6 hours anal- ysis
Bloomer 2005	Dominant leg during knee extension	VAS (0 to 10 cm)	0, 10, 24, 48, 72, 96 hours	Raw data provided by the authors Immediate pain data used for the up to 6 hours anal- ysis
Bloomer 2007	Performance of 2 (con- centric-eccentric) repeti- tions of the barbell bench press exercise using a stan- dard 20 kg barbell	VAS (0 to 10 cm)	0, 24, 48 hours	Raw data provided by the authors Immediate pain data used for the up to 6 hours anal- ysis
Bryer 2006	Delayed onset muscle soreness was assessed in a rested position and in re- sponse to palpation on the muscle of the arms	VAS (1 to 10 cm)	0, 4, 24, 48, 72, 96 hours	Text (SDs from SEs) Immediate pain data used for the up to 6 hours anal- ysis
Close 2006	Delayed onset mus- cle soreness was measured at the gastrocnemius, an- terior tibialis, hamstrings, quadriceps, gluteals (both sides) and lower back muscles	VAS (0 to 10 cm)	0, 24, 48, 72, 96, 168, 336 hours	Raw data provided by the authors Immediate pain data used for the up to 6 hours anal- ysis
Cobley 2011	Total muscle soreness af- ter performing a 90 degree squat	VAS (0 to 12 cm)	0, 24, 48, 50, 72, 96, 98 hours	Raw data provided by the authors Immediate pain data used for the up to 6 hours anal- ysis
Connolly 2006	General delayed onset muscle soreness assessed at the quadriceps	VAS (0 to 10 cm)	24, 48, 72, 96 hours	Text
Connolly 2006a	Pain scores were obtained by asking participants to verbally rate their overall discomfort during active elbow flexion and exten- sion	VAS (0 to 10 cm)	24, 48, 72, 96 hours	Text (SDs from SEs)

Table 2. Details of measurement of muscle soreness in the included trials (Continued)

 Table 2. Details of measurement of muscle soreness in the included trials
 (Continued)

Drobnic 2014	Muscle soreness during descending and climbing stairs. The following 8 sites were measured: ante- rior right thigh, posterior right thigh, anterior right leg, posterior right leg, an- terior left thigh, poste- rior left thigh, anterior left leg, posterior left leg and added together for a total score	VAS (0 to 4)	48 hours	Raw data provided by the authors
Goldfarb 2011	Delayed onset muscle soreness was measured at the elbow flexor with the arm rested	VAS (1 to 10 cm)	0, 2, 6, 24, 48, 72 hours	Text (SDs from SEs) Immediate pain data used for the up to 6 hours anal- ysis
He 2015	Delayed onset mus- cle soreness of the quadri- ceps, hamstrings, gluteus, gastrocnemius and tibialis anterior	VAS (0 to 6)	0, 24, 48, 72 hours	Raw data provided by the authors Immediate pain data used for the up to 6 hours anal- ysis
Herrlinger 2015	Soreness was assessed in a variety of muscle groups including the gastrocne- mius, hamstrings, quadri- ceps, gluteus maximus, lower back, abdominals and the whole body	Likert (0 to 7)	24, 48, 72, 96 hours	The authors of Herrlinger 2015 were contacted on 2 February 2017 and again on 18February 2017 for missing data as these were not available in the manuscript and could not be extracted from graphs. No response was received and this study was there- fore included in the quali- tative analysis but not the quantitative analysis
Howatson 2009	Squat down to 90 degrees (internal joint angle) rise to the start position	VAS (0 to 200 mm)	0, 24, 48 hours	Text Immediate pain data used for the up to 6 hours anal- ysis
Hutchinson 2016	Full range squat with no external weight	VAS (0 to 10 cm)	24, 48, 72 hours	Text (SDs from SEs)
Kaminski 1992	General delayed onset muscle soreness was mon- itored by self-reporting	VAS (1 to 10 cm)	0, 10, 24, 48, 58, 72, 96 hours	Raw data provided by the authors

Table 2. Details of measurement of muscle soreness in the included trials (Continued)

				Immediate pain data used for the up to 6 hours anal- ysis
Kerksick 2009	Delayed onset muscle soreness was assessed at the quadriceps	VAS (0 to 10 cm)	6, 24, 48 hours	Raw data provided by the authors 6 hours post-exercise data used for the up to 6 hours analysis
Krotkiewski 1994	General soreness	VAS (0 to 10 cm)	24, 48, 72, 96, 120 hours	Text (SDs from SEs)
Kuehl 2010	General soreness in the legs	VAS (0 to 100 mm)	0 hours	Text Immediate pain data used for the up to 6 hours anal- ysis
Laupheimer 2014	General soreness in both legs	VAS (0 to 10 cm)	24 hours	Raw data provided by the authors
Lynn 2015	Squat to a 90 angle and re- turning to a standing po- sition	VAS (0 to 200 mm)	0, 24, 48 hours	Text Immediate pain data used for the up to 6 hours anal- ysis
McBride 1997	General soreness	VAS (0 to 10 cm)	24, 48 hours	Text (SDs from SEs)
McCormick 2016	Upper body, upper legs, lower legs and overall body	VAS (0 to 10 cm)	24, 48, 72, 96, 120, 144 hours	This study was only in- cluded in the qualitative analysis because the exer- cise paradigm was com- pletely different to all the other studies included in this review
McFarlin 2016	Muscle soreness measured using a gauge. Pressure was applied using stan- dard force (20 to 30 N) over the distal, middle and proximal thigh in a seated position with the knee fully extended and relaxed. The 3 ratings for each quadricep were added together	VAS (0 to 10 cm)	24, 48, 72, 96 hours	Text (SDs from SEs)

Table 2. Details of measurement of muscle soreness in the included trials (C	_ontinuea)
--	------------

McLeay 2012	Step up (concentric mus- cle action) onto a 40 cm box then step down (ec- centric muscular contrac- tion) and the soreness was rated	VAS (0 to 10 cm)	24, 48, 72 hours	Text
Meamarbashi 2011	Participants were requested to rate the general discomfort in only the quadriceps and calf re- gions of the right leg	VAS (0 to 6)	0, 24, 48 hours	Text Immediate pain data used for the up to 6 hours anal- ysis
Michailidis 2013	Palpation of the muscle belly and the distal region of the vastus medialis, vas- tus lateralis and rectus femoris after a squat	VAS (1 to 10 cm)	0, 2, 24, 48, 72, 96, 120, 144, 168 hours	Text Immediate pain data used for the up to 6 hours anal- ysis
Nicol 2015	Pain was rated for single leg squat, walking down- stairs, passive strength of the gluteals and single leg vertical jump	VAS (0 to 10 cm)	0, 24, 48 hours	Raw data provided by the authors Immediate pain data used for the up to 6 hours anal- ysis
Nie 2004	Perceived soreness was done during quadriceps extension	VAS (0 to 10 cm)	0, 24, 48 hours	Text Immediate pain data used for the up to 6 hours anal- ysis
O'Connor 2013	Delayed on- set muscle soreness in the arm was rated in response to isometric strength mea- surement	VAS (0 to 100 mm)	24, 48 hours	Text
O'Fallon 2012	Delayed on- set muscle soreness at the elbow flexor	VAS (0 to 100 mm)	24, 48, 72, 96, 120 hours	Raw data provided by the authors
Peschek 2014	Delayed onset muscle soreness at the legs	VAS (0 to 10 cm)	24, 48 hours	Text
Phillips 2003	Soreness measures were subjectively evalu- ated through palpitation for oedema at he elbow	VAS (0 to 10 cm)	72, 168 hours	Text (SDs from SEs)

 Table 2. Details of measurement of muscle soreness in the included trials
 (Continued)

Shafat 2004	Delayed onset mus- cle soreness was evaluated using a questionnaire em- ploying a visual analogue scale for a total of 8 sites (6 sites on the anterior mus- cle of the upper leg and 2 sites on the posterior mus- cles of the upper leg). The participants were asked to palpate the relaxed muscle and rate soreness	VAS (1 to 10 cm) (x 8): 8 to 80 score	24, 48 hours	Text
Silva 2008	Delayed on- set muscle soreness at the elbow flexor	VAS (0 to 10 cm)	48, 96, 168 hours	Text
Silva 2010	Muscle soreness of the bi- ceps muscle was assessed	VAS (0 to 10 cm)	48, 96, 168 hours	Text (SDs from SEs)
Su 2008	At the beginning of the exercise test, participants were instructed to give CR-10 values	Borg CR (0-10)	0, 24, 48 hours	Text (SDs from SEs) Immediate pain data used for the up to 6 hours anal- ysis
Tanabe 2015	Palpitation of the upper arm and passively extend- ing the elbow joint	VAS (0 to 100 mm)	0, 24. 48, 72, 96 hours	Raw data provided by the authors Immediate pain data used for the up to 6 hours anal- ysis
Theodorou 2011	Squat using body weight	VAS (0 to 10 cm)	24, 48, 72, 96, 120 hours	Text
Thompson 2001	Actively contracted the quadriceps	VAS (1 to 10 cm)	24, 48, 72 hours	Text (SDs from SEs) ; there are no decimal places; where SE = 0, we have put this as 0.4 (SD = 1.2)
Thompson 2001a	Actively contracted the quadriceps	VAS (0 to 100 mm)	24, 48, 72 hours	Text (SDs from SEs)
Thompson 2003	Actively contracted the quadriceps	VAS (1 to 10 cm)	24, 48, 72 hours	Text (SDs from SEs) ; there are no decimal places; where SE = 0, we have put this as 0.4 (SD = 1.1313)

Table 2. Details of measurement of muscle soreness in the include	ed trials	(Continued)
---	-----------	-------------

Thompson 2004	Actively contracting the leg extensors against resis- tance equivalent to 75% of each individual's 1 rep- etition maximum	VAS (0 to 10 cm)	24, 48, 72 hours	Raw data provided by the authors
Trombold 2010	Unloaded elbow flexion of the tested arm	VAS (0 to 10 cm)	2, 24, 48, 72, 96 hours	Raw data provided by the authors 2 hours post-exercise data used for the up to 6 hours analysis
Trombold 2011	Unloaded elbow flexion and knee extension on the tested arm and leg	VAS (0 to 10 cm)	2, 24, 48, 72, 96 hours	Raw data provided by the authors 2 hours post-exercise data used for the up to 6 hours analysis

SD: standard deviation SE: standard error

VAS: visual analogue scale

Follow-up times (post-exercise)	No. studies	No. participants	SMD (95% CI)
Up to 6 hours	21	525	-0.31 (-0.49 to -0.13)
24 hours	41	936	-0.13 (-0.26 to -0.00)
48 hours	45	1047	-0.22 (-0.34 to -0.09)
72 hours	28	657	-0.17 (-0.33 to -0.02)
96 hours	17	436	-0.04 (-0.23 to 0.16)
120 hours	4	128	0.25 (-0.12 to 0.61)
144 hours	1	20	-0.23 (-1.11 to 0.65)
168 hours	4	80	-0.04 (-0.48 to 0.41)

Table 3. Muscle soreness sensitivity analyses: fixed-effect model

CI: confidence interval

SMD: standardised mean difference

Follow-up times	All studies		Parallel group studies only		
(post-exercise)	No. studies	SMD (95% CI)	No. studies	SMD (95% CI)	
Up to 6 hours	21	-0.30 (-0.56 to -0.04)	15	-0.35 (-0.67 to -0.03)	
24 hours	41	-0.13 (-0.27 to 0.00)	32	-0.08 (-0.25 to 0.08)	
48 hours	45	-0.24 (-0.42 to -0.07)	34	-0.19 (-0.40 to 0.01)	
72 hours	28	-0.19 (-0.38 to -0.00)	22	-0.11 (-0.30 to 0.08)	
96 hours	17	-0.05 (-0.29 to 0.19)	12	0.01 (-0.33 to 0.34)	

Table 4. Muscle soreness sensitivity analyses: removal of cross-over trials

Table produced independently of the authors by Newton Opiyo and checked by Helen Handoll

APPENDICES

Appendix I. Search strategies

CENTRAL (Wiley Online Library)

#1 MeSH descriptor: [Exercise] explode all trees (18173)

#2 MeSH descriptor: [Exercise Test] this term only (7428)

#3 MeSH descriptor: [Physical Exertion] this term only (3598)

#4 (#1 or #2 or #3) (25438)

#5 MeSH descriptor: [Muscle, Skeletal] this term only and with qualifier(s): [Drug effects - DE, Physiopathology - PP] (2094)

#6 MeSH descriptor: [Muscle Contraction] this term only and with qualifier(s): [Drug effects - DE, Physiopathology - PP] (640)

#7 MeSH descriptor: [Muscle Cramp] this term only (150)

#8 MeSH descriptor: [Spasm] this term only (191)

#9 MeSH descriptor: [Muscle Rigidity] this term only (61)

#10 MeSH descriptor: [Sprains and Strains] this term only (326)

#11 MeSH descriptor: [Muscle Weakness] this term only (303)

#12 MeSH descriptor: [Creatine Kinase] this term only and with qualifier(s): [Blood - BL] (970)

#13 (#5 or #6 or #7 or #8 or #9 or #10 or #11 or #12) (4397)

#14 #4 and #13 (1134)

#15 (exercise and (muscle* near/2 (damage* or injur*))):ti,ab,kw (579)

#16 (sore* near/3 musc*):ti,ab,kw (561)

#17 (DOMS or EIMD):ti,ab,kw (190)

#18 (#14 or #15 or #16 or #17) (1772)

#19 MeSH descriptor: [Antioxidants] explode all trees (3991)

#20 MeSH descriptor: [Ascorbic Acid] explode all trees (1721)

#21 MeSH descriptor: [Tocopherols] explode all trees (448)

#22 MeSH descriptor: [Vitamin A] explode all trees (1706)

#23 MeSH descriptor: [Vitamin E] explode all trees (2122) #24 MeSH descriptor: [beta Carotene] explode all trees (741) #25 MeSH descriptor: [Oxidants] explode all trees (455) #26 MeSH descriptor: [Oxidation-Reduction] explode all trees (2133) #27 MeSH descriptor: [Reactive Oxygen Species] this term only and with qualifier(s): [Antagonists & inhibitors - AI] (7) #28 MeSH descriptor: [Peroxides] explode all trees and with qualifier(s): [Antagonists & inhibitors - AI] (11) #29 MeSH descriptor: [Ubiquinone] this term only (355) #30 MeSH descriptor: [Phenol] this term only (66) #31 MeSH descriptor: [Glutathione] this term only (580) #32 MeSH descriptor: [Glutathione Peroxidase] this term only (402) #33 MeSH descriptor: [Curcumin] this term only (100) #34 MeSH descriptor: [Flavonoids] explode all trees (2148) #35 (antioxidant* or anti-oxidant*):ti,ab,kw (7674) #36 "vitamin c" or ascorbic acid:ti,ab,kw (3913) #37 "vitamin E" or alpha-tocopherol or beta-tocopherol or gamma-tocopherol or tocopherol*:ti,ab,kw (4630) #38 (betacarotene or beta carotene or carotene or carotenoid*):ti,ab,kw (2083) #39 (n-acetyl cysteine or n-acetylcysteine or n-acetyl-l-cysteine or acetylcysteine):ti,ab,kw (1441) #40 (superoxide dismutase or SOD or dehydroepiandrosterone or glutathione or coenzyme q10 or astaxanthin or zeaxanthin or lycopene or pentoxifylline or polyphenol* or pycnogenol* or flavonoid* or selenium or anthocyanin*):ti,ab,kw (8882) #41 (#19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29 or #30 or #31 or #32 or #33 or #34 or #35 or #36 or #37 or #38 or #39 or #40) (23501) #42 (#18 and #41) (194) MEDLINE (Ovid Web) 1 Exercise/ or Exercise Test/ or Physical Exertion/ (178530) 2 Muscle, Skeletal/de, pp [Drug Effects, Physiopathology] (25164) 3 Muscle Contraction/de, pp [Drug Effects, Physiopathology] (37380) 4 Muscle Cramp/ or Spasm/ or Muscle Rigidity/ or "Sprains and Strains"/ or Muscle Weakness/ (22384) 5 Creatine Kinase/bl [Blood] (14287) 6 or/2-5 (95850) 7 and/1,6 (4164) 8 (exercise and (muscle* adj2 (damage* or injur*))).tw. (2188) 9 (sore* adj3 musc*).tw. (1635) 10 (DOMS or EIMD).tw. (629) 11 or/7-10 (6846) 12 exp Antioxidants/ (397449) 13 exp Ascorbic Acid/ or exp Tocopherols/ or exp Vitamin A/ or exp Vitamin E/ or beta Carotene/ (106065) 14 exp Oxidants/ (109419) 15 exp Oxidation-Reduction/ (219323) 16 Reactive Oxygen Species/ai [Antagonists & Inhibitors] (1156) 17 exp Peroxides/ai [Antagonists & Inhibitors] (1602) 18 Ubiquinone/ or Phenol/ or Glutathione/ or Glutathione Peroxidase/ or Curcumin/ or exp Flavonoids/ (162838) 19 (antioxidant* or anti-oxidant*).tw. (153352) 20 ("vitamin c" or ascorbic acid).tw. (42561) 21 ("vitamin E" or alpha-tocopherol or beta-tocopherol or gamma-tocopherol or tocopherol*).tw. (38259) 22 (betacarotene or beta carotene or carotene or carotenoid*).tw. (25604) 23 (n-acetyl cysteine or n-acetylcysteine or n-acetyl-l-cysteine or acetylcysteine).tw. (16312) 24 (superoxide dismutase or SOD or dehydroepiandrosterone or glutathione or coenzyme q10 or astaxanthin or zeaxanthin or lycopene or pentoxifylline or polyphenol* or pycnogenol* or flavonoid* or selenium or anthocyanin*).tw. (241246) 25 or/12-24 (908015) 26 and/11,25 (701) 27 Randomized controlled trial.pt. (446926)

28 Controlled clinical trial.pt. (91808)
29 randomized.ab. (387435)
30 placebo.ab. (183299)
31 Drug therapy.fs. (1928982)
32 randomly.ab. (270638)
33 trial.ab. (405897)
34 groups.ab. (1669773)
35 or/27-34 (3968345)
36 exp Animals/ not Humans/ (4312930)
37 35 not 36 (3428779)
38 and/26,37 (302)

Embase (Ovid Web)

1 Exercise/ or Exercise Test/ (308139) 2 Skeletal Muscle/ (110436) 3 Muscle Contraction/ (68260) 4 Muscle Cramp/ or Spasm/ or Muscle Rigidity/ or Sprain/ or Muscle Weakness/ (66779) 5 Creatine Kinase/ (43734) 6 2 or 3 or 4 or 5 (267718) 7 1 and 6 (24273) 8 (exercise and (muscle* adj2 (damage* or injur*))).tw. (2372) 9 (sore* adj3 musc*).tw. (1733) 10 (DOMS or EIMD).tw. (662) 11 7 or 8 or 9 or 10 (26382) 12 exp antioxidant/ (185205) 13 exp Ascorbic Acid/ or exp Tocopherol/ or exp Retinol/ or Beta Carotene/ (167284) 14 exp Oxidizing Agent/ (226287) 15 exp Oxidation Reduction Reaction/ (86850) 16 Reactive Oxygen Metabolite/ (130471) 17 exp Peroxide/ (40960) 18 Ubiquinone/ or Phenol/ or Glutathione/ or Glutathione peroxidise/ or Curcumin/ or exp Flavonoid/ (242322) 19 (antioxidant* or anti-oxidant*).tw. (202054) 20 ("vitamin C" or ascorbic acid).tw. (49233) 21 ("vitamin E" or alpha-tocopherol or beta-tocopherol or gamma-tocopherol or tocopherol*).tw. (43945) 22 (betacarotene or beta carotene or carotene or carotenoid*).tw. (28360) 23 (n-acetyl cysteine or n-acetylcysteine or n-acetyl-l-cysteine or acetylcysteine).tw. (20567) 24 (superoxide dismutase or SOD or dehydroepiandrosterone or glutathione or coenzyme q10 or astaxanthin or zeaxanthin or lycopene or pentoxifylline or polyphenol* or pycnogenol* or flavonoid* or selenium or anthocyanin*).tw. (294093) 25 or/12-24 (897856) 26 11 and 25 (1859) 27 Randomized controlled trial/ (476005) 28 Clinical trial/ (1026775) 29 Controlled clinical trial/ (470380) 30 Randomization/ (84507) 31 Single blind procedure/ (29183) 32 Double blind procedure/ (139527) 33 Crossover procedure/ (54944) 34 Placebo/ (327195) 35 Prospective study/ (396959) 36 ((clinical or controlled or comparative or placebo or prospective* or randomi#ed) adj3 (trial or study)).tw. (995276) 37 (random* adj7 (allocat* or allot* or assign* or basis* or divid* or order*)).tw. (246237)

38 ((singl* or doubl* or trebl* or tripl*) adj7 (blind* or mask*)).tw. (200629)

39 (cross?over* or (cross adj1 over*)).tw. (86814)
40 ((allocat* or allot* or assign* or divid*) adj3 (condition* or experiment* or intervention* or treatment* or therap* or control* or group*)).tw. (330995)
41 RCT.tw. (23208)
42 or/27-41 (2480033)
43 Case Study/ or Abstract Report/ or Letter/ (1091413)
44 42 not 43 (2427252)
45 26 and 44 (476)

SPORTDiscus (Ebsco)

S1 DE "EXERCISE" OR DE "EXERCISE tests" (84,781) S2 (((((DE "MYALGIA") OR (DE "DELAYED onset muscle soreness")) OR (DE "MUSCLE cramps")) OR (DE "MUSCLE rigidity")) OR (DE "SPRAINS")) OR (DE "MUSCLE weakness") (4,207) S3 (DE "SKELETAL muscle") (1,747) S4 DE "MUSCLE contraction" (10,331) S5 DE "CREATINE kinase" (1,275) S6 S2 OR S3 OR S4 OR S5 (16,480) S7 S1 AND S6 (3,922) S8 TX (exercise and (muscle* n2 (damage* or injur*))) (2,482) S9 TX sore* n3 musc* (2,055) S10 TX DOMS or EIMD (1,006) S11 S7 OR S8 OR S9 OR S10 (7,601) S12 DE "ANTIOXIDANTS" (2,399) S13 (DE "VITAMIN C") OR (DE "VITAMIN E") OR (DE "VITAMIN A") (1,531) S14 DE "OXIDATION-reduction reaction" (280) S15 DE "FREE radicals (Chemistry)" (485) S16 ((DE "UBIQUINONES") OR (DE "PHENOLS")) OR (DE "GLUTATHIONE") (612) S17 TI (antioxidant* or anti-oxidant*) OR AB (antioxidant* or anti-oxidant*) (4,527) S18 TI ("vitamin c" or ascorbic acid) OR AB ("vitamin c" or ascorbic acid) (1,367) S19 TI ("vitamin E" or alpha-tocopherol or beta-tocopherol or gamma-tocopherol or tocopherol*) OR AB ("vitamin E" or alphatocopherol or beta-tocopherol or gamma-tocopherol or tocopherol*) (1,049) S20 TI (betacarotene or beta carotene or carotene or carotenoid*) OR AB (betacarotene or beta carotene or carotene or carotenoid*) (788) S21 TI (n-acetyl cysteine or n-acetyl-l-cysteine or acetyl-lysteine) OR AB (n-acetyl cysteine or n-acetylcysteine or n-acetyl-l-cysteine or acetylcysteine) (178) S22 TI (superoxide dismutase or SOD or dehydroepiandrosterone or glutathione or coenzyme q10 or astaxanthin or zeaxanthin or lycopene or pentoxifylline or polyphenol* or pycnogenol* or flavonoid* or selenium or anthocyanin*) OR AB (superoxide dismutase or SOD or dehydroepiandrosterone or glutathione or coenzyme q10 or astaxanthin or zeaxanthin or lycopene or pentoxifylline or polyphenol* or pycnogenol* or flavonoid* or selenium or anthocyanin*) (3,919) S23 S12 OR S13 OR S14 OR S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22 (9,624) S24 S11 AND S23 (312) S25 TX ((clinic* N3 trial) or (controlled N3 trial) or (comparative N3 trial) or (placebo N3 trial) or (prospective N3 trial) or (randomi? ed N3 trial)) or TX ((clinic* N3 study) or (controlled N3 study) or (comparative N3 study) or (placebo N3 study) or (prospective N3 study) or (randomi?ed N3 study)) (74,987) S26 (random* N7 allot*) or (random* N7 assign*) or (random* N7 basis*) or (random* N7 divid*) or (random* N7 order*) (10,503) S27 TX ((singl* N7 blind*) or (doubl* N7 blind*) or (trebl* N7 blind*) or (tripl* N7 blind*)) or TX ((singl* N7 mask*) or (doubl* N7 mask*) or (trebl* N7 mask*) or (tripl* N7 mask*)) (6,354) S28 TX (cross#over*) or TX (cross N1 over*) (5,072) S29 TX randomi?ed control* trial* (12,817) S30 TX ((allocat* N3 condition*) or (allocat* N3 experiment*) or (allocat* N3 intervention*) or (allocat* N3 treatment*) or (allocat* N3 therap*) or (allocat* N3 control*) or (allocat* N3 group*)) or TX ((allot* N3 condition*) or (allot* N3 experiment*) or (allot*

N3 intervention*) or (allot* N3 treatment*) or (allot* N3 therap*) or (allot* N3 control*) or (allot* N3 group*)) or TX ((assign* N3

condition*) or (assign* N3 experiment*) or (assign* N3 intervention*) or (assign* N3 treatment*) or (assign* N3 therap*) or (assign* N3 control*) or (assign* N3 group*)) or TX ((divid* N3 condition*) or (divid* N3 experiment*) or (divid* N3 intervention*) or (divid* N3 treatment*) or (divid* N3 therap*) or (divid* N3 control*) or (divid* N3 group*)) (11,741) S31 TX placebo* (9,181) S32 S25 or S26 or S27 or S28 or S29 or S30 or S31 (93,140) S33 (S26 or S28 or S30 or S25 or S27 or S29 or S31) AND (S24 AND S32) (117)

Appendix 2. WHO International Clinical Trials Registry Platform

1. musc* AND oxidative OR musc* AND antioxidant OR musc* AND exercis* AND supplement* 2. exercis* AND oxidative OR exercis* AND antioxidant OR exercis* AND vitamin Total = 282

Appendix 3. ClinicalTrials.gov

1. muscle AND (oxidative OR antioxidant) AND exercise Total = 162

CONTRIBUTIONS OF AUTHORS

Mayur Ranchordas identified the research idea for the review, wrote the protocol, extracted the data, wrote the review and is the guarantor.

David Rogerson assisted with drafting the protocol and data extraction.

Hora Soltani provided feedback on the draft protocol and review.

Joseph Costello assisted with data analysis and drafted the final review.

DECLARATIONS OF INTEREST

Mayur Ranchordas co-authored one of the included studies (Lynn 2015). Decisions on inclusion of this study, the 'Risk of bias' assessment and data extraction were undertaken by other review authors (JC, DR), who had no involvement in the study.

David Rogerson: none known.

Hora Soltani: none known.

Joseph Costello: none known.

SOURCES OF SUPPORT

Internal sources

- Sheffield Hallam University, UK.
- University of Portsmouth, UK.

External sources

• No sources of support supplied

DIFFERENCES BETWEEN PROTOCOL AND REVIEW

Since publication of the protocol (Ranchordas 2012), we made the following changes.

We updated the Background to reflect current evidence on the potential negative effects of antioxidant supplementation (in particularly long-term use) by impairing exercise adaptations.

In Types of outcome measures, we stipulated that trials that did not record muscle soreness (pain) would be excluded. We included a new primary outcome (subjective recovery) and we elevated adverse effects, originally listed as a secondary outcome, to primary outcome status.

Linked with this was our selection of outcome measures for presentation in Summary of findings for the main comparison. This included limiting the measurement of DOMS to five follow-up periods up to 96 hours.

In Subgroup analysis and investigation of heterogeneity, we removed the subgroup analysis "Type of antioxidants supplement (antioxidants supplements vs. antioxidants-enriched food)". This is because we realised that it was not possible to categorise studies into 'antioxidant supplement' or 'antioxidant-enriched food' as they usually belonged to both categories; for example, tart cherry juice is an antioxidant-enriched food but it is also an antioxidant supplement containing vitamins such as vitamin C.

We merged two previous subgroup comparisons on types of exercise ("Normal sporting activities and laboratory induced DOMS"; "Exercise that requires high oxygen consumption (e.g. running, cycling) and exercise that requires low oxygen consumption (e.g. eccentric exercise in one arm)") as the comparison of "whole body aerobic exercise" versus "mechanical exercise" captured both of these.

We included an additional subgroup analysis on sources of funding where we compared DOMS for studies that were funded by a food company or provider of antioxidant supplements versus studies that were not funded by a food company or provider of antioxidant supplements.

We could not compare the subgroup analysis 'timing of exercise' because of insufficient studies in the 'supplementation after exercise' group.

In Sensitivity analysis, we modified the sensitivity analysis testing the effects of high risk of selection bias to include also trials at unclear risk of selection bias, relating to random sequence generation, allocation concealment or both. Additional sensitivity analysis to explore the effects of excluding cross-over studies on the pooled data for muscle soreness at five time periods were conducted at screening by the Cochrane Editorial Unit.